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  by	  a	  decrease	  in	  F-­‐actin	  in	  TBS	  cells.	  	  
Figure	  R	  25.	  TBS	  cells	  are	  more	  sensitive	  to	  Cytochalasin	  B	  treatment.	  
Figure	  R	  26.	  The	  lack	  of	  Luzp1	  is	  accompanied	  by	  a	  decrease	  in	  F-­‐actin	  in	  Shh-­‐LIGHT2	  cells.	  	  
Figure	  R	  27.	  A	  reduction	  in	  LUZP1	  is	  linked	  to	  a	  decrease	  in	  F-­‐actin	  in	  cells	  upon	  starvation.	  	  
Figure	  R	  28.	  Luzp1	  depleted	  cells	  are	  more	  sensitive	  to	  Cytochalasin	  B	  treatment.	  	  
Figure	  R	  29.	  Truncated	  SALL1	  leads	  to	  LUZP1	  destabilization	  and	  degradation.	  	  
Figure	  R	  30.	  LUZP1	  interacts	  with	  actin-­‐related	  proteins.	  
Figure	  R	  31.	  LUZP1	  interacts	  with	  centrosome-­‐related	  proteins.	  
Figure	  R	  32.	  Luzp1-­‐/-­‐	  cells	  show	  aberrant	  cilia	  frequency	  and	  length.	  	  
Figure	  R	  33.	  Luzp1	  expression	  is	  sufficient	  to	  repress	  ciliogenesis	  in	  TBS	  cells.	  	  
Figure	  R	  34.	  Luzp1-­‐/-­‐	  cells	  display	  aberrant	  Shh	  signalling.	  
Figure	  R	  35.	  Luzp1-­‐/-­‐	  cells	  display	  multiple	  centrioles.	  
Figure	  R	  36.	  Increased	  apoptosis	  in	  Luzp1-­‐/-­‐	  cells.	  
Figure	  R	  37.	  Luzp1-­‐/-­‐	  cells	  exhibit	  cell	  division	  defects.	  	  
Figure	  R	  38.	  Defects	  in	  F-­‐actin	  formation	  in	  Luzp1-­‐/-­‐	  cells.	  	  
Figure	  R	  39.	  Luzp1-­‐/-­‐	  cells	  display	  cell	  migration	  defects.	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Figure	  D	  1.	  F-­‐actin	  formation	  dynamics	  in	  Luzp1-­‐/-­‐	  cells.	  	  
Figure	   D	   2.	   Final	   model.	   The	   presence	   of	   truncated	   SALL1	   underlies	   cilia	   and	   actin	  
malformations	  in	  TBS	  through	  the	  sequestration	  of	  key	  regulatory	  factors	  CCP110,	  CEP97	  
and	  LUZP1.	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  List	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  proteins	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  by	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  at	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  in	  the	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  subproteome	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  to	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Abstract	  
	  
Townes-­‐Brocks	   Syndrome	   (TBS)	   is	   characterized	   by	   a	   spectrum	   of	  
malformations	  in	  digits,	  ears	  and	  kidneys.	  These	  anomalies	  overlap	  with	  those	  seen	  
in	   a	   growing	   number	   of	   genetic	   syndromes	   linked	   to	   defects	   in	   the	   formation	   or	  
function	   of	   the	   primary	   cilia,	   collectively	   known	   as	   ciliopathies.	   TBS	   is	   caused	   by	  
mutations	  in	  the	  gene	  encoding	  the	  transcriptional	  repressor	  SALL1	  and	  is	  associated	  
with	   the	  presence	  of	   a	   truncated	  protein,	  which	   localizes	   to	   the	   cytoplasm.	   In	   this	  
Thesis,	  we	  studied	  the	  hypothesis	  that	  SALL1	  mutations	  might	  cause	  TBS	  by	  means	  
beyond	   its	   transcriptional	   capacity.	  We	  hypothesized	   that	   TBS	  might	   be	   caused	  by	  
defects	  in	  cilia	  formation	  and/or	  function	  through	  its	  dominant	  interaction	  with	  cilia-­‐
related	   proteins.	   In	   fact,	   TBS	   patient-­‐derived	   fibroblasts,	   a	   CRISPR/Cas9-­‐generated	  
model	   cell	   line	   and	   TBS-­‐modeled	   mouse	   embryonic	   fibroblasts,	   display	   cilia	   at	   a	  
higher	   frequency	  compared	  to	  wild-­‐type	  controls.	  Furthermore,	  TBS-­‐like	  cells	   show	  
changes	   in	   cilia	   length	   and	   disassembly	   rates,	   accompanied	   by	   aberrant	   Sonic	  
hedgehog	  (Shh)	  signalling	  transduction.	  By	  using	  proximity	  proteomics,	  we	  identified	  
two	  main	   ciliogenesis	   suppressors,	   CCP110	   (Centriolar	   coiled-­‐coil	   protein,	   110	   KD)	  
and	  CEP97	  (Centrosomal	  protein,	  97	  KD),	  and	  a	  novel	  cilia	  and	  actin-­‐related	  protein	  
named	   LUZP1	   (Leucine	   zipper	   protein	   1)	   as	   interactors	   of	   TBS-­‐causing	   truncated	  
SALL1	  protein.	  The	  higher	  rate	  of	  ciliogenesis	  detected	   in	  TBS-­‐derived	  fibroblasts	   is	  
consistent	  with	  an	  observed	  reduction	  in	  CCP110,	  CEP97	  and	  LUZP1	  protein	  levels	  at	  
the	  mother	  centriole	  (MC)	  compared	  to	  controls.	  In	  addition,	  we	  demonstrated	  that	  
LUZP1	   localizes	   to	   the	  centrosome,	  actin	   cytoskeleton,	  and	  midbody.	  CRISPR/Cas9-­‐
mediated	   loss	   of	   LUZP1	   in	   mouse	   fibroblasts	   changed	   actin	   dynamics	   and	   cell	  
migration,	  while	  facilitating	  ciliogenesis	  and	  altering	  Sonic	  Hedgehog	  signaling.	  Given	  
its	  localization	  to	  both	  actin	  stress	  fibers	  and	  the	  centrosome,	  LUZP1	  might	  be	  a	  key	  
factor	  for	  integrating	  cytoskeletal	  changes	  to	  cilia	  formation	  and	  function.	  	  
These	   results	   indicate	   that	   truncated	   proteins	   arising	   from	   certain	   SALL1	  
mutations	   can	   disrupt	   cilia	   formation	   and	   function.	   Therefore,	   TBS	   might	   be	  
considered	   as	   a	   ciliopathy-­‐like	   disease	   opening	   a	   possibility	   for	   pharmacological	  
intervention	  by	  cilia/cytoskeletal	  modulators.	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Resumen	  
	  
El	   síndrome	   de	   Townes-­‐Brocks	   (TBS)	   se	   caracteriza	   por	   un	   espectro	   de	  
malformaciones	   en	   los	   dedos,	   orejas	   y	   riñones.	   Estos	   síntomas	   coinciden	   con	   los	  
observados	   en	   los	   síndromes	   genéticos	   relacionados	   con	   defectos	   en	   la	   formación	  
y/o	   función	  de	   los	   cilios	  primarios,	   conocidos	   colectivamente	  como	  ciliopatías.	   TBS	  
está	  causado	  por	  mutaciones	  en	  el	  gen	  que	  codifica	  el	  represor	  transcripcional	  SALL1	  
que	   mayoritariamente	   dan	   lugar	   a	   una	   proteína	   truncada	   que	   se	   localiza	   en	   el	  
citoplasma.	  Los	  estudios	  sobre	  TBS	  se	  han	  centrado	  tradicionalmente	  en	  los	  defectos	  
que	  la	  proteína	  SALL1	  truncada	  podría	  ocasionar	  en	  el	  núcleo	  a	  nivel	  transcripcional.	  
Sin	  embargo,	  en	  este	  trabajo	  estudiamos	  la	  hipótesis	  de	  que	  dicha	  proteína	  truncada	  
podría	  interferir	  con	  la	  formación	  o	  señalización	  de	  los	  cilios	  debido	  a	  su	  interacción	  
dominante	   negativa	   con	   proteínas	   ciliares	   o	   del	   centrosoma.	   De	   hecho,	   tanto	  
fibroblastos	  derivados	  de	  pacientes	  de	  TBS,	  como	  una	  línea	  celular	  modelo	  generada	  
mediante	  tecnología	  CRISPR	  /	  Cas9	  y	  fibroblastos	  embrionarios	  del	  modelo	  de	  TBS	  en	  
ratón,	   muestran	   mayor	   frecuencia	   de	   ciliación	   en	   comparación	   con	   los	   controles.	  
Además,	  las	  células	  modelo	  de	  TBS	  muestran	  una	  mayor	  longitud	  de	  cilios	  y	  retrasos	  
en	  el	  desemblaje	  de	  los	  mismos,	  acompañados	  por	  una	  transducción	  aberrante	  de	  la	  
señalización	   por	   la	   vía	   Sonic	   Hedgehog	   (Shh).	   Mediante	   el	   uso	   de	   proteómica	   de	  
proximidad,	   identificamos	   interactores	   de	   la	   proteína	   SALL1	   truncada	   en	   los	  
pacientes	  de	  TBS.	  Entre	  ellos,	  encontramos	  a	  dos	  de	  los	  principales	  supresores	  de	  la	  
ciliogénesis,	   CCP110	   (Centriolar	   coiled-­‐coil	   protein,	   110	   KD)	   y	   CEP97	   (Centrosomal	  
protein,	  97	  KD),	  y	  a	  LUZP1	  (Leucine	  zipper	  protein	  1),	  una	  proteína	  no	  muy	  estudiada	  
que	  interacciona	  con	  el	  citoesqueleto	  de	  actina	  y	  el	  centrosoma	  .	  La	  mayor	  tasa	  de	  
ciliogénesis	  detectada	  en	   los	   fibroblastos	  derivados	  de	  TBS	  es	   consistente	   con	  una	  
reducción	   en	   los	   niveles	   de	   las	   proteínas	   CCP110,	   CEP97	   y	   LUZP1	   en	   el	   centriolo	  
madre	  (MC)	  en	  comparación	  con	  los	  controles.	  Además,	  demostramos	  que	  LUZP1	  se	  
localiza	   en	   el	   centrosoma,	   en	   el	   citoesqueleto	   de	   actina	   y	   en	   el	   cuerpo	  medio	   (o	  
midbody).	  Las	  células	  knocked-­‐out	  de	  LUZP1	  que	  generamos	  mediante	  la	  tecnología	  
CRISPR-­‐Cas9	  mostraron	  una	  ciliogénesis	  prematura	  y	  alteraciones	  en	  la	  señalización	  
por	   Shh,	   la	   dinámica	   de	   actina,	   y	   la	   división	   y	   migración	   celular.	   Estos	   hallazgos	  
apoyan	  la	  hipótesis	  de	  que	  LUZP1	  podría	  ser	  un	  factor	  clave	  en	  la	  integración	  de	  los	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cambios	   del	   citoesqueleto	   de	   actina	   y	   la	   función/formación	   de	   los	   cilios,	   procesos	  
que	  se	  encuentran	  alterados	  en	  TBS.	  Estos	   resultados	   indican	  que	   las	   truncaciones	  
en	  SALL1	  pueden	  afectar	  la	  formación	  y	  función	  de	  los	  cilios.	  Por	  lo	  tanto,	  TBS	  podría	  
considerarse	   como	   una	   ciliopatías,	   abriendo	   las	   posibilidades	   de	   intervención	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1.1	  Townes-­‐Brocks	  Syndrome	  (TBS)	  
Townes-­‐Brocks	  Syndrome	  (TBS,	  MIM:	  107480)	  is	  a	  rare	  genetic	  disease	  with	  a	  
stimated	  prevalence	  of	  1	  per	  350,000	  live	  births.	  TBS	  is	  characterized	  by	  these	  major	  
features:	   imperforate	   anus,	   dysplastic	   ears,	   and	   thumb	   malformations	   such	   as	  
triphalangeal	   thumbs,	   duplication	   of	   the	   thumb	   (preaxial	   polydactyly)	   and	   thumb	  
hypoplasia	  (Figure	  I	  1)	  (Powell	  and	  Michaelis,	  1999).	  	  
	  
	  
TBS	   is	   also	   frequently	   associated	   with	   other	   minor	   features	   such	   as	  
sensorineural	   and/or	   conductive	   hearing	   impairment,	   foot	   malformations,	   renal	  
impairment	   including	   end-­‐stage	   renal	   disease	   or	   polycystic	   kidneys,	   together	   with	  
genitourinary	  malformations	   and	   congenital	   heart	  disease	   (Table	   I	   1).	  Although	   less	  
common,	   radius	   hypoplasia	   and	   cleft/lip	   palate	   are	   also	   observed	   (Kohlhase,	   1993).	  
Figure	   I	   1.	   Classical	   symptoms	   of	   Townes-­‐Brocks	   Syndrome.	   TBS	   individuals	   exhibit	   polydactyly	   in	  
hands	   (A,B)	   and	   dysplastic	   ears	   (D,	   compare	   to	   normal	   ear	   in	  C).	   TBS	   individuals	  might	   also	   exhibit	  
preauricular	  and	  cheek	  tags	  (E).	  Pictures	  after	  (Kohlhase	  et	  al.,	  1998;	  Powell	  and	  Michaelis,	  1999).	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The	  diagnosis	  of	   TBS	   is	   established	  by	   the	  presence	  of	   three	  major	   features.	   If	   only	  
two	  major	   features	  are	  present,	   the	  presence	  of	  minor	   features	  and	  the	  absence	  of	  
atypical	  features	  further	  support	  the	  diagnosis.	  
	  
1.1.1	  TBS	  is	  caused	  by	  mutations	  in	  SALL1	  
TBS	   is	  an	  autosomal	  dominant	  genetic	  disease	  caused	  by	  mutations	   in	  SALL1	  
(Spalt-­‐like	  1,	  MIM:	  602218)	  (Botzenhart	  et	  al.,	  2007;	  Kohlhase	  et	  al.,	  1998),	  one	  of	  the	  
four	  members	  of	  the	  SALL	  gene	  family	  in	  vertebrates.	  In	  Drosophila,	  SALL	  factors	  are	  
implicated	   in	  the	  formation	  of	  the	  wing	  via	  control	  of	  cell	  differentiation	   in	   imaginal	  
discs,	  trachea,	  sensory	  organs	  and	  the	  nervous	  system	  (Cantera	  et	  al.,	  2002;	  de	  Celis	  
and	  Barrio,	  2000;	  de	  Celis	   and	  Barrio,	  2009).	   In	   the	  wing,	   SALLs	   control	   growth	  and	  
patterning	   by	   transcriptionally	   regulating	   downstream	   genes	   (Barrio	   and	   de	   Celis,	  
2004;	   de	   Celis	   and	   Barrio,	   2000).	   SALL1	   encodes	   a	   zinc-­‐finger	   transcription	   factor	  
linked	   to	   chromatin-­‐mediated	   repression	   (de	   Celis	   and	   Barrio,	   2009).	   SALL	   proteins	  
are	  characterized	  by	  the	  presence	  of	  stereotypical	  pairs	  of	  zinc	  finger	  domains	  along	  
Table	   I	   1.	  Major,	  minor	  and	  atypical	   features	   in	  Townes-­‐Brocks	   Syndrome.	  The	  diagnosis	  of	   TBS	   is	  
established	   by	   the	   presence	   of	   three	   major	   features.	   If	   only	   two	   major	   features	   are	   present,	   the	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the	  protein	   (Figure	   I	  2),	  which	  are	   thought	   to	  mediate	   interactions	  with	  DNA	  via	  an	  
AT-­‐rich	  sequence	  (Netzer	  et	  al.,	  2006).	  In	  vertebrates,	  the	  N-­‐terminal	  region	  of	  SALL1	  
mediates	   transcriptional	   repression	   via	   the	   interaction	   with	   the	   nucleosome	  
remodeling	   deacetylase	   (NuRD)	   complex	   through	   a	   conserved	   12	   amino	   acid	  
sequence	   (Kiefer	   et	   al.,	   2002).	   Another	   important	   N-­‐terminal	   motif	   is	   a	   conserved	  
polyglutamine	   domain	   involved	   in	   dimerization	   with	   itself	   or	   other	   SALL	   family	  
members	  (Sweetman	  et	  al.,	  2003).	  
Dominant	   genetic	   syndromes	   are	   often	   caused	   by	   a	   gain-­‐of-­‐function	   or	  
dominant-­‐negative	   effect	   of	   the	   underlying	   mutant	   proteins.	   More	   than	   50	   point-­‐
mutations	  were	  described	   that	   cause	  premature	   stop	   codons	  by	   frame	   shifts,	   short	  
insertions	  or	  deletions,	  mainly	   in	  a	  hot-­‐spot	   region	   located	  between	   the	  N-­‐terminal	  
part	   of	   the	   protein	   and	   the	   second	   zinc-­‐finger	   pair	   (Botzenhart	   et	   al.,	   2007;	  
Botzenhart	  et	  al.,	  2005;	  Kohlhase	  et	  al.,	  1998)	  (Figure	  I	  2).	  In	  addition,	  three	  different	  
deletions,	  including	  most	  part	  of	  the	  SALL1	  coding	  region,	  have	  been	  reported	  in	  TBS	  
patients	  (Borozdin	  et	  al.,	  2006;	  Miller	  et	  al.,	  2012).	  	  
Figure	  I	  2.	  Schematic	  representation	  of	  SALL1	  protein.	  Schematic	  representation	  of	  the	  SALL1	  protein	  
and	   localization	   of	   the	   mutations	   identified	   (upward	   and	   downward	   symbols).	   Zinc	   fingers	   are	  
indicated	  as	  colored	  ovals.	  (17)	   indicates	  that	  the	  c.826C>T	  mutation	  had	  been	  found	  in	  15	  sporadic	  
and	  2	   familial	   cases,	   including	  one	   individual	   studied	   in	   this	  work.	  At	  position	  c.1115,	   two	  different	  
nonsense	  mutations	   had	   been	   detected	   (2),	   and	   the	  mutation	   c.1403_1404insG	  was	   found	   in	   two	  
unrelated	  families	  (2).	  All	  other	  mutations	  have	  been	  found	  only	  once.	  The	  red	  horizontal	  bar	  marks	  
the	   refined	   “hot	   spot	   region”	   and	   the	  blue	  bar	   assigns	   the	   glutamine	   rich	  domain.	   Positions	  of	   the	  




	   32	  
1.1.2	  TBS	  is	  not	  caused	  by	  haploinsufficency	  
Many	  TBS-­‐causing	  SALL1	  mutations	  could	  result	  in	  truncated	  proteins	  that	  lack	  
some	   or	   all	   the	   zinc	   finger	   pairs	   that	   are	   thought	   to	   mediate	   chromatin/DNA	  
interactions,	  but	  retain	  the	  N-­‐terminal	  domain.	  Previous	  studies	  have	  addressed	  the	  
expression	  of	  mutant	  SALL1	  gene,	  showing	  that	  mutant	  mRNA	  transcripts	  are	  stable	  
and	   resistant	   to	  nonsense-­‐mediated	  decay	   (Furniss	  et	  al.,	  2007).	  Truncated	  proteins	  
causing	  TBS	  are	  able	  to	  interact	  with	  the	  NuRD	  complex	  and	  to	  form	  multimers	  with	  
themselves,	  with	  full-­‐length	  (FL)	  SALL1	  (SALL1FL)	  or	  with	  other	  SALL	  proteins	  (Lauberth	  
et	  al.,	  2007).	  Inappropriate	  protein	  interactions	  of	  truncated	  SALL1	  may	  underlie	  TBS	  
symptoms	  (Kiefer	  et	  al.,	  2003).	  This	  possibility	  is	  supported	  by	  animal	  models	  of	  TBS,	  
where	  Sall1+/-­‐	   and	  Sall1-­‐/-­‐	  mice	   fail	   to	   show	  TBS-­‐like	  phenotypes	   (Kiefer	  et	  al.,	   2003;	  
Kiefer	   et	   al.,	   2008;	  Nishinakamura	  et	   al.,	   2001),	   discarding	  haploinsufficiency	   as	   the	  
most	   plausible	   cause	   of	   the	   disease.	   Only	   when	   murine	   Sall1	   is	   altered	   to	   mimic	  
human	  mutations	  (i.e.	  to	  generate	  a	  truncated	  protein	  in	  a	  single	  copy),	  mice	  display	  
TBS	   symptoms	   such	  as	  hearing	   loss	   and	  anus	  and	   limb	  malformations	   (Kiefer	   et	   al.,	  
2003).	  The	  etiology	  of	  the	  disease	  thus	  depends	  on	  the	  presence	  of	  a	  truncated	  SALL1	  
protein,	  which	   localizes	   to	   the	  nucleus	  and	  cytoplasm,	   in	   contrast	   to	  SALL1FL,	  which	  
resides	  primarily	   in	   the	  nucleus	   (Sato	  et	  al.,	  2004).	  Elucidating	   the	   role	  of	   truncated	  
SALL1	  and	   its	  possible	   interference	  with	  SALL1FL	  and	  other	  factors	  would	  fill	  a	  major	  
gap	  in	  our	  understanding	  of	  TBS.	  
	  
1.2	  The	  primary	  cilia	  
Intriguingly,	  some	  of	  the	  features	  shown	  in	  TBS	   individuals	  match	  those	  seen	  
in	  a	  growing	  number	  of	  diseases	  linked	  to	  the	  formation	  and	  function	  of	  primary	  cilia,	  
collectively	   called	   ciliopathies	   (Figure	   I	   3).	   Depending	   on	   the	   underlying	   mutation,	  
ciliopathies	  present	  a	  spectrum	  of	  overlapping	  phenotypes	  such	  as	  polycystic	  kidneys,	  
hearing	   loss,	   limb	  defects	  and	  mental	   retardation,	  among	  others	   (Hildebrandt	  et	  al.,	  
2011).	   These	   coincidental	   features	   could	   suggest	   similar	  molecular	   causes	   between	  
ciliopathies	  and	  TBS,	  but	  a	  characterization	  of	  primary	  cilia	  formation	  and	  function	  has	  
not	  been	  reported	  for	  cells	  derived	  from	  TBS	  individuals.	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1.2.1	  Cilia	  structure	  and	  formation	  
Cilia	  are	  microtubule-­‐based	  organelles	  that	  emerge	  from	  centriole-­‐containing	  
basal	   bodies.	   Centrioles	   together	   with	   their	   surrounding	   matrix,	   the	   pericentriolar	  
material,	   form	   the	   centrosome	   (Figure	   I	   4A).	   Once	   anchored	   to	   the	   plasma	  
membrane,	  centrioles	  behave	  as	  basal	  bodies	  giving	  rise	  to	  two	  different	  kinds	  of	  cilia:	  
motile	  cilia	   (or	   flagella)	   (Figure	   I	  4B)	  or	   immotile	  cilia	   (or	  primary	  cilia)	   (Figure	   I	  4C).	  
Cilia	  assembly	  and	  disassembly	  are	  accurately	  coordinated	  during	  the	  cell	  cycle	  (Gilula	  
and	  Satir,	  1972;	  Sorokin,	  1962).	  Centrosomal	  duplication	  starts	  during	  the	  S-­‐phase	  of	  
the	   cell	   cycle	   when	   procentrioles	   form	   at	   the	   proximal	   end	   of	   both	   mother	   and	  
daughter	  centrioles	   (Figure	   I	  5).	   In	   the	  G2-­‐phase	  the	  procentrioles	  elongate,	  mature	  
and	   during	  mitosis	   they	  migrate	   to	   polar	   ends	   of	   the	   cell	   to	   nucleate	   and	   organise	  
microtubules	  
Figure	   I	  3.	  Overlapping	  defects	  between	  ciliopathies	  and	  TBS.	  Different	  organ	  systems	  or	   tissues	  are	  
affected	   in	   diverse	   ciliopathies.	   Phenotypic	   manifestations	   of	   the	   disease	   in	   each	   organ	   are	   shown.	  
Ciliopathies	  that	  are	  caused	  primarily	  by	  defects	   in	  motile	  cilia	  are	  shown	   in	  orange,	   those	  that	  result	  
from	  defects	  in	  non-­‐motile	  (primary)	  cilia	  are	  shown	  in	  blue	  and	  those	  associated	  with	  defects	  in	  both	  
types	  of	  cilia	  are	  shown	  in	  green.	  TBS	  symptoms	  overlapping	  with	  those	  of	  ciliopathies	  are	  marked	  with	  
a	   green	   tick	   according	   to	   (Kohlhase,	   1993).	   NPHP,	   nephronophthisis;	   PKD,	   polycystic	   kidney	   disease.	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to	  form	  the	  mitotic	  spindle.	  The	  centrioles	  attach	  to	  chromosomes	  and	  have	  a	  role	  in	  
their	  segregation	   in	  the	  process	  of	  mitosis.	  Each	  of	  the	  newly	  formed	  daughter	  cells	  
retains	   one	   of	   the	   centrosomes	   following	   cytokinesis.	   Only	   upon	   completion	   of	  
mitosis	  and	  cytokinesis,	  mainly	  in	  G0	  phase,	  the	  centrosomes	  are	  free	  to	  mature	  into	  
the	   basal	   body	   and	   form	   primary	   cilia	   (Rezabkova	   et	   al.,	   2016).	   However,	   some	  
reports	  described	  the	  presence	  of	  cilia	  throughout	  the	  cell	  cycle	  with	  the	  exception	  of	  
Figure	  I	  4.	  Centrosome	  and	  cilia	  structure.	  (A)	  Centrosome	  and	  cilia	  are	  composed	  of	  centrioles.	  Each	  
centrosome	   comprises	   a	   mother	   and	   daughter	   centriole	   in	   a	   barrel-­‐shaped	   configuration	   and	  
surrounded	   by	   a	   matrix	   of	   proteins	   called	   the	   pericentriolar	   material	   (PCM).	   The	   older	   centriole	  
(mother)	  has	   subdistal	  appendages,	  where	  microtubules	  are	  docked,	  and	  distal	  appendages,	  which	  
are	   important	   for	  docking	   to	   the	  plasma	  membrane.	   Satellites	   are	   granular	   structures	   surrounding	  
the	  centrosome	  that	  are	  implicated	  in	  the	  trafficking	  of	  material	  involved	  in	  centriole	  assembly.	  Once	  
anchored	   to	   the	   plasma	   membrane,	   the	   centriole,	   called	   the	   basal	   body	   at	   this	   point,	   starts	  
nucleating	  cilia.	  The	  skeleton	  of	  cilia,	  known	  as	  the	  axoneme,	  is	  composed	  either	  of	  nine	  microtubule	  
doublets	   with	   no	   dynein	   arms	   or	   central	   pair	   (as	   in	   most	   immotile	   cilia)	   or	   of	   nine	   microtubule	  
doublets	  with	  dynein	  arms	  and	  a	  central	  microtubule	  pair	  (as	  in	  most	  motile	  cilia).	  The	  distal	  part	  of	  
the	  basal	  body	  is	  the	  transition	  zone,	  where	  the	  outer	  tubule	  stops	  growing.	  During	  centriole	  to	  basal	  
body	   differentiation,	   the	   acquisition	   of	   specialised	   structures,	   such	   as	   rootlets,	   basal	   feet	   and	  
transitional	   fibers,	  provides	  mechanical	   support	   to	   the	  cilia,	  anchoring	   the	  basal	  body	   to	   the	  apical	  
cytoskeleton	   and	   serving	   as	   platforms	   for	   the	   docking	   of	   ciliary	   components,	   respectively.	   Image	  
adapted	   from	   (Bettencourt-­‐Dias	  et	  al.,	  2011).	   (B)	   Scanning	  electron	  micrograph	  showing	  numerous	  
motile	   cilia	   protruding	   from	   epithelial	   cells	   of	   a	  mouse	   trachea.	   (C)	   Scanning	   electron	  micrograph	  
showing	  solitary	  primary	  cilia	  (white	  arrowheads)	  projecting	  from	  mouse	  renal	  epithelial	  cells	   lining	  
the	  nephron.	  Scale	  bar	  =	  5µm.	  Modified	  after	  (Green	  and	  Mykytyn,	  2010).	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mitosis	   (Dingemans,	  1969;	  Fonte	  et	  al.,	   1971;	  Ford	  et	  al.,	   2018)	   suggesting	   they	  are	  
actively	  assembled	  and	  disassembled	  in	  response	  to	  mitotic	  signals.	  	  
A.	  Key	  steps	  in	  cilia	  initiation	  
The	   initiation	   of	   primary	   cilia	   formation	   (or	   ciliogenesis)	   is	   the	   basal	   body	  
consisting	  of	  a	  mother	   (MC)	  and	  a	  daughter	  centriole	   (DC).	  The	  basal	  body	  matures	  
and	   becomes	   surrounded	   by	   the	   pericentriolar	   material	   composed	   of	   specialized	  
Figure	   I	   5.	   The	   centrosome	   cell	   cycle.	  During	   S	   phase	  both	  mother	   (M)	   and	  daughter	   (D)	   centrioles	  
form	  procentrioles.	  During	  G2	  the	  procentrioles	  elongate	  and	  mature	  and	  upon	  transition	  into	  mitosis	  
(M	  phase)	  they	  separate	  to	  form	  the	  spindle	  poles	  leading	  to	  equal	  division	  of	  the	  genetic	  material.	  In	  
G0/G1	  the	  centrioles	  are	  able	  to	  mature,	   form	  the	  basal	  body	  and	  assemble	  a	  primary	  cilium.	   Image	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proteins	  that	  attach	  directly	  to	  the	  centrioles	  or	  nearby	  as	  satellite	  structures.	  During	  
maturation,	   the	   centrioles	   also	   migrate	   to	   the	   plasma	   membrane	   where	   the	   MC	  
“docks”.	   This	   membrane-­‐associated	   MC	   acquires	   three	   characteristic	   features:	  
rootlets,	  basal	  feet	  and	  transition	  fibers,	  serving	  the	  last	  ones	  as	  connection	  between	  
the	   centriole	   and	   the	   plasma	   membrane	   (Anderson,	   1972).	   During	   the	   process	   of	  
docking,	   before	   the	   centrosome	   becomes	   fully	   associated	   with	   the	   plasma	  
membrane,	  the	  distal	  tip	  of	  the	  MC	  recruits	  and	  docks	  small	  vesicles	  originating	  from	  
the	  Golgi	  apparatus	  that	  fuse	  to	  form	  a	  cap	  known	  as	  the	  ciliary	  vesicle	  (Figure	  I	  6).	  
	  
Microtubules	   start	   to	   elongate	   from	   the	   centriole	   and	   invaginate	   the	   vesicle	  
into	   a	   mushroom	   shape,	   known	   as	   the	   ciliary	   bud.	   The	   microtubules	   continue	   to	  
elongate	   forming	   the	   ciliary	   sheath.	   Eventually	   the	   ciliary	   sheath	   fuses	   with	   the	  
plasma	  membrane	  allowing	  the	  primary	  cilium	  to	  emerge	  from	  the	  cell	  covered	  in	  the	  
ciliary	   membrane	   (Sorokin,	   1962).	   Cilia	   continue	   to	   elongate	   and	   become	   highly	  
specialized	   with	   proteins	   trafficking	   along	   the	   microtubules	   and	   transmembrane	  
proteins	   become	   embedded	   in	   the	   ciliary	   membrane.	   Cilia	   assembly	   is	   tightly	  
Figure	   I	   6.	   Schematic	   illustration	   of	   primary	   cilia	   formation.	  Golgi-­‐derived	   vesicles	   dock	  with	   distal	  
appendages	  to	  form	  the	  ciliary	  vesicle	  and	  begin	  axonemal	  elongation.	  The	  ciliary	  sheath	  surrounding	  
the	  growing	  axoneme	  fuses	  with	  the	  plasma	  membrane	  to	  form	  the	  primary	  cilium.	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controlled	   through	   a	   balance	   of	   essential	   proteins	   (e.g.
elements	   contributing	   to	   structure	   and	   transport	   to/from/inside	   the	   cilia)	   and	  
negative	  regulators.	  	  
	  
B.	  The	  cilia	  negative	  regulators	  CCP110	  and	  CEP97	  
Two	  of	  the	  most	  relevant	  proteins	  in	  the	  process	  of	  cilia	  formation	  are	  CCP110	  
and	   CEP97.	   Removal	   of	   these	   inhibitory	   capping	   proteins	   from	   the	   MC	   has	   been	  
proposed	   as	   a	   key	   initiator	   of	   ciliogenesis	   (Bettencourt-­‐Dias	   and	   Carvalho-­‐Santos,	  
2008;	   Bettencourt-­‐Dias	   et	   al.,	   2011;	   Kobayashi	   et	   al.,	   2011;	   Sanchez	   and	   Dynlacht,	  
2016;	  Tsang	  and	  Dynlacht,	  2013).	  Previous	  studies	  demonstrated	  that	  TTBK2,	  MARK4,	  
and	  Centrin2	  are	  required	  for	  CCP110	  and	  CEP97	  depletion	  (Goetz	  et	  al.,	  2012;	  Kuhns	  
et	   al.,	   2013;	   Prosser	   and	   Morrison,	   2015)	   and	   some	   miRNAs	   affect	   ciliogenesis	   by	  
controlling	  the	  expression	  levels	  of	  CCP110	  (Cao	  et	  al.,	  2012;	  Song	  et	  al.,	  2014).	  It	  has	  
been	   recently	   demonstrated	   that	   the	   ubiquitin-­‐proteasome	   system	   controls	   serum-­‐
starvation-­‐induced	   CEP97	   degradation	   leading	   to	   CCP10	   removal	   and	   ciliogenesis	  
(Nagai	  et	  al.,	  2018).	  Their	   results	  showed	  that	  both	  CCP110	  and	  CEP97	  are	  required	  
for	  their	  co-­‐recruitment	  to	  the	  centrioles	  and	  that	  CEP97	  appears	  to	  play	  a	  dominant	  
role	  in	  controlling	  the	  stability	  of	  the	  CCP10-­‐CEP97	  complex	  on	  the	  centrioles.	  While	  
some	  studies	  demonstrated	  that	  removal	  of	  CCP110	  was	  sufficient	  to	  induce	  ectopic	  
cilia	   formation	   (Spektor	   et	   al.,	   2007;	   Tsang	   et	   al.,	   2008),	   others	   reported	   that	   its	  
depletion	   promoted	   abnormal	   elongation	   of	   non-­‐docked	   centriolar	   microtubules	  
(Franz	  et	  al.,	  2013;	  Schmidt	  et	  al.,	  2009).	  A	   recent	  publication	  suggested	  a	  dual	  and	  
context-­‐dependent	   role	   of	   CCP110	   in	   cilia	   formation	   relying	   on	   the	   proteins	  
interacting	  with	  CCP110	  in	  a	  determined	  subcellular	  environment	  (Yang	  et	  al.,	  2016).	  	  
	  
1.2.2	  Primary	  cilia	  function	  	  
As	   previously	   mentioned,	   cilia	   within	   the	   mammalian	   body	   are	   generally	  
classified	   as	   either	   motile	   or	   primary.	   Motile	   cilia	   are	   mainly	   responsible	   for	  
generating	   flow	  or	  movement	  and	   include	   respiratory	   cilia,	  ependymal	   cilia,	  oviduct	  
cilia	  and	  sperm	  flagella.	  On	  the	  other	  hand,	  non-­‐motile	  or	  primary	  cilia	  are	  present	  in	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most	  vertebrate	  cells	  (Wheatley,	  1995)	  and	  function	  principally	  as	  sensory	  organelles.	  
However,	  these	  functional	  classifications	  are	  not	  mutually	  exclusive,	  as	  some	  types	  of	  
primary	   cilia	   on	   the	   embryonic	   node	   are	   motile	   and	   generate	   flow	  
across	  the	  node	  establishment	  of	  the	  left	  right	  asymmetry	  axis	  and	  motile	  respiratory	  
cilia	  also	  possess	  sensory	  functions	  (Bloodgood,	  2010;	  Nonaka	  et	  al.,	  1998;	  Shah	  et	  al.,	  
2009).	  Further,	  primary	  cilia	  lack	  radial	  spokes	  and	  the	  central	  axoneme	  surrounding	  
the	  central	  microtubule	  pair	  present	  in	  motile	  cilia	  (Satir	  and	  Christensen,	  2008).	  
	  
A.	  Primary	  cilia-­‐mediated	  signalling:	  Shh	  pathway	  
Significant	   advances	   have	   revealed	   the	   crucial	   role	   of	   primary	   cilia	   in	   cell	  
signalling,	  polarity	  and	  protein	  trafficking.	  During	  development,	  several	  key	  pathways	  
(Hedgehog,	   Wnt,	   TGFbeta)	   are	   dependent	   or	   influenced	   by	   primary	   cilia	   function.	  
Specifically,	   the	   vertebrate	   Sonic	   Hedgehog	   (Shh)	   pathway	   is	   crucial	   for	   vertebrate	  
digit	  patterning	  and	  fully	  dependent	  on	  primary	  cilia	  (Huangfu	  et	  al.,	  2003;	  Yin	  et	  al.,	  
2009).	  	  
The	  generally	  accepted	  model	  of	  Shh	  signalling	  in	  mammals	  is	  summarized	  in	  
Figure	   I	   7.	   In	   unstimulated	   cells,	   the	   inhibitory	   transmembrane	   receptor,	   Patched1	  
(Ptch1),	   localises	  at	   the	  base	  of	   the	  cilium.	  Here	   it	  exerts	  a	   repressive	  effect	  on	   the	  
seven-­‐pass	  transmembrane	  protein	  Smoothened	  (Smo)	  that	  is	  found	  in	  vesicles	  in	  the	  
cytoplasm	   (Rohatgi	   et	   al.,	   2007).	   In	   this	   inactivated	   state,	   members	   of	   the	   glioma-­‐
associated	  oncogene	   (Gli)	   family	   are	  bound	   to	   Suppressor	  of	   Fused	   (SuFu),	  which	   is	  
thought	  to	  inhibit	  their	  nuclear	  translocation	  (Ding	  et	  al.,	  1999).	  In	  addition,	  some	  Gli	  
proteins	  are	  proteolytically	  processed	   into	  short	   repressor	   forms	   (Gli-­‐R),	  which	   then	  
translocate	   to	   the	   nucleus	   where	   they	   directly	   repress	   transcription	   of	   Shh-­‐target	  
genes	   (Wang	  et	  al.,	  2000a).	  This	  proteolytic	  processing	   is	   initiated	  by	   the	  activity	  of	  
protein	   kinase	   A	   (PKA)	   which	   targets	   it	   for	   proteosomal	   degradation	   (Wang	   et	   al.,	  
2000b).	  The	  Gli-­‐SuFu	  complex	  is	  trafficked	  through	  the	  ciliary	  axoneme	  but	  it	  has	  been	  
suggested	   that	   PKA	   activity	   on	   Gli	   occurs	   at	   the	   basal	   body	   after	   its	   exit	   from	   the	  
cilium	  (Tuson	  et	  al.,	  2011).	   In	   the	  unstimulated	  state,	   the	  kinesin	  Kif7	  has	  also	  been	  
shown	   to	   localise	  at	   the	  basal	  body	  where	   it	   is	   thought	   to	   form	  a	   complex	  with	  Gli	  
proteins	   and	   promote	   the	   formation	   of	   Gli-­‐R	   and	   limit	   their	   accumulation	   in	   the	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axoneme	   (Liem	   et	   al.,	   2009).	   Upon	   activation,	   the	   binding	   of	   the	   Shh	   ligand	   to	   the	  
transmembrane	   receptor	   Ptch1	   abolishes	   the	   inhibitory	   effect	   of	   Ptch1	   on	   Smo.	  
Following	  the	  loss	  of	  Ptch1	  activity,	  Smo	  is	  enriched	  in	  the	  cilia	  where,	  through	  SuFu	  
inhibition,	   it	   is	  able	   to	   transduce	  a	   signal	  via	  Gli	   transcription	   factors	   to	   the	  nucleus	  
that	   initiate	   expression	   of	   Shh	   target	   genes.	   Kif7	   also	   translocates	   into	   the	   cilia	  
axoneme	  and	  promotes	  the	  accumulation	  of	  SuFu	  and	  Gli	   in	   the	  cilia	   tip	   (Goetz	  and	  
Anderson,	   2010).	   There	   are	   three	   Gli	   transcription	   factors,	   Gli1-­‐3,	   where	   Gli1	  
functions	  as	  a	  constitutive	  activator	  (Hynes	  et	  al.,	  1997;	  Liu	  et	  al.,	  2005).	  In	  contrast,	  
Gli2	   and	  Gli3	  have	  an	  N-­‐terminal	   transcriptional	   repressor	  domain	  and	  a	  C-­‐terminal	  
transcription	   activator	   domain.	   The	   translocation	   of	   Smo	   to	   the	   cilia	   leads	   to	   the	  
Figure	  I	  7.	  The	  Hedgehog	  signalling	  pathway.	  In	  the	  ‘Off’	  state,	  Ptch1	  is	  found	  at	  the	  base	  of	  primary	  
cilia	   and	   has	   a	   repressive	   effect	   on	   Smo	   present	   in	   cytoplasmic	   vesicles.	   SuFu	   acts	   as	   an	   inhibitor,	  
preventing	   the	   nuclear	   translocation	   of	   Gli.	   Gli	   protein	   is	   also	   proteolytically	   processed	   into	   short	  
repressor	   forms	   (Gli-­‐R)	   through	  protein	  kinase	  A	   (PKA)	   to	   repress	  Shh	   target	  gene	   transcription.	  Kif7	  
forms	  a	  complex	  with	  Gli	  to	  prevent	  its	  accumulation	  in	  the	  cilia	  axoneme.	  In	  the	  ‘On’	  state,	  Shh	  can	  
bind	  to	  Ptch1	  to	  release	  its	  repression	  on	  Smo.	  This	  allows	  Smo,	  Kif7,	  Gli	  and	  Sufu	  to	  accumulate	  in	  the	  
primary	  cilia.	  Smo	  inhibits	  the	  action	  of	  SuFu	  and	  active	  Gli.	  Gli-­‐A	  is	  able	  to	  translocate	  to	  the	  nucleus	  
to	  activate	  Shh	  target	  gene	  transcription.	  Image	  adapted	  from	  (Goetz	  &	  Anderson,	  2010).	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proteolytic	  events	  that	  convert	  Gli3	  from	  a	  repressor	  (Gli3-­‐R)	   into	  an	  activator	  (Gli3-­‐
A),	  promoting	  the	  activation	  of	  Shh	  target	  genes	  (Huangfu	  and	  Anderson,	  2006;	  Pan	  et	  
al.,	   2006).	   Two	   such	   genes	   are	   Gli1	   and	   Ptch1,	   encoding	   the	   Shh	   receptor	   and	   a	  
transcriptional	  activator,	  respectively.	  
	  
The	  trafficking	  of	  these	  multiprotein	  complexes	  through	  primary	  cilia	  is	  tightly	  
regulated	   by	   several	   anterograde	   and	   retrograde	   systems	   called	   the	   intraflagellar	  
transport	   (IFT)	  machinery	   (Behal	   and	   Cole,	   2013;	   Pigino	   et	   al.,	   2009).	  Mutations	   in	  
genes	  that	  encode	  IFT	  proteins	  deregulate	  Shh	  signalling	  and	  result	  in	  limb	  formation	  
and	  neural	  tube	  closure	  defects,	  similar	  phenotypes	  to	  those	  observed	  in	  mutations	  of	  
genes	  encoding	  Shh	  pathway	   components	   (Cabrera	  et	   al.,	   2004;	  Corbit	   et	   al.,	   2005;	  
Haycraft	  et	  al.,	  2005).	  
B.	  Shh	  function	  as	  a	  morphogen	  
Shh	   acts	   both	   as	   a	   mitogen	   by	   influencing	   cell	   proliferation	   and	   as	   a	  
morphogen,	   inducing	   distinct	   molecular	   responses	   at	   distinct	   concentrations	  
(McMahon	  et	  al.,	  2003).	  The	  best	  understood	  functions	  of	  Shh	  as	  a	  morphogen	  are	  in	  
the	   patterning	   of	   the	   neural	   tube	   and	   limb	   bud.	   During	   mouse	   development,	   the	  
expression	  of	  Shh	  in	  the	  notochord	  of	  the	  developing	  neural	  tube	  results	  in	  a	  gradient	  
of	  Shh	   (highest	   at	   the	   notochord	   and	   the	   floor	   plate,	   FP)	   determining	   the	   different	  
ventral	   neuron	   fates	   in	   a	   gradient	   and	   time-­‐dependent	  manner	   (Figure	   I	   8A)	   (Ribes	  
and	  Briscoe,	  2009;	  Wong	  and	  Reiter,	  2008).	  As	  a	  consequence,	  dorsal	  neural	  subtypes	  
are	  largely	  expanded	  into	  the	  ventral	  neural	  tube	  in	  Shh	  deficient	  mutants	  (Chiang	  et	  
al.,	  1996).	  The	  neural	  tube	  is	  formed	  from	  an	  initially	  flat	  sheet	  of	  neuroepithelial	  cells	  
whose	  edges	  roll	  up	  and	  fuse	  to	  form	  a	  tube	  in	  aprocess	  termed	  neural	  tube	  closure.	  
(Colas	   and	   Schoenwolf,	   2001).	   Together	  with	   the	   planar	   cell	   polarity/Wnt	   pathway,	  
the	   Shh	   pathway,	   which	   relies	   on	   the	   presence	   of	   functional	   cilia,	   regulates	   neural	  
tube	   closure	   and	   patterning	   (Campbell,	   2003;	   Copp,	   2005;	   Fuccillo	   et	   al.,	   2006).	  
Another	   well-­‐characterized	   example	   of	   Shh	   activity	   is	   its	   role	   in	   the	   limb	   bud	  
patterning,	  where	  its	  expression	  in	  the	  zone	  of	  polarizing	  activity	  (ZPA)	  establishes	  an	  
anterior	   to	   posterior	   concentration	   and	   temporal	   gradient	   specifying	   digit	   type	   and	  
number	  (Figure	  I	  8B).	  Cells	  localized	  in	  the	  close	  proximity	  of	  the	  ZPA	  are	  exposed	  to	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higher	   concentrations	   of	   Shh	   for	   a	   longer	   period	   of	   time	   and	   are	   specified	   to	   form	  
digit	  #5	  (little	  finger).	  In	  contrast,	  cells	  at	  the	  anterior	  side	  are	  exposed	  to	  low	  Shh	  and	  
are	  specified	  to	  form	  digit	  #1	  (thumb).	  Shh-­‐/-­‐	  mutants	  form	  only	  a	  single	  digit	  (Chiang	  
et	  al.,	  2001).	  
Figure	   I	   8.	  Hedgehog	  gradients	  during	  development.	   (A)	  During	  neural	   tube	  development,	   Shh	   is	  
secreted	  from	  the	  floor	  plate	  (FP)	  and	  the	  notochord	  to	  stablish	  a	  ventral	  [V]	  to	  dorsal	  concentration	  
gradient	   leading	   to	   a	   spatially	   restricted	   expression	   profile	   of	   various	   transcription	   factors.	   The	  
unique	  combination	  of	  transcription	  factors	  leads	  to	  the	  formation	  of	  neural	  progenitor	  cells	  along	  
the	   dorsal/ventral	   axis,	   which	   generates	   V0-­‐V3	   interneurons	   and	   motorneurons	   (MN).	   (B)	   The	  
production	   of	   Shh	   in	   the	   zone	   of	   polarizing	   activity	   (ZPA)	   establishes	   a	   posterior	   to	   anterior	  
concentration	  gradient	  specifying	  digit	  identity	  and	  number	  in	  the	  developing	  vertebrate	  limb	  bud.	  
Not	   only	   the	   spatial,	   but	   also	   temporal	   establisment	   of	   the	   Shh	   gradient	   is	   important.	   Figure	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1.2.3	  Primary	  Cilia	  and	  human	  disease	  	  
Ciliopathies	   are	   a	   group	   of	   phenotypically	   heterogeneous	   diseases	   that	   can	  
affect	   almost	   all	   organs,	   reflecting	   the	  near	   ubiquity	   of	   primary	   cilia	   in	   human	   cells	  
and	  highlighting	  the	  important	  functions	  of	  this	  organelle	  in	  diverse	  cell	  types.	  It	  has	  
been	  predicted	  that	  over	  100	  known	  conditions	  fall	  into	  this	  category	  with	  only	  a	  few	  
studied	  to	  date.	  The	  characteristic	  spectrum	  of	  overlapping	  phenotypes	  in	  ciliopathies	  
that	   include	   polydactyly,	   cystic-­‐fibrotic	   kidney,	   congenital	   heart	   diseases,	   skeletal	  
anomalies,	   situs	   inversus,	   retinal	   degeneration,	   brain	   problems	   and	   hepatic	   fibrosis	  
are	  caused	  by	  mutations	  that	   lead	  to	  cilia	  formation	  or	  function	  defects	  (Figure	  I	  3).	  
Due	  to	  the	  overlapping	  with	  TBS	  and	  their	  recurrence	  in	  the	  disease,	  polydactyly	  and	  
polycystic	   kidney	   disease	   and	   their	   association	   with	   primary	   cilia	   will	   be	   further	  
explained.	  
A.	  Polydactyly	  
Importantly,	   defective	   Shh	   signalling	   can	   explain	   several	   of	   the	   phenotypes	  
that	   characterize	   the	   ciliopathies	   such	   as	   polydactyly.	   It	   has	   been	   reported	   that	  
ablation	  of	  the	  IFT	  kinesin	  Kif3a	  in	  the	  developing	  limb	  leads	  to	  aberrant	  Shh	  signalling	  
and	   results	   in	  polydactyly	  and	  altered	  digit	  patterning	   (Haycraft	  et	  al.,	   2007).	  When	  
Kif7,	  another	  kinesin	  required	  for	  generating	  Shh	  signalling	  response,	  is	  depleted	  mice	  
display	  phenotypes	  such	  as	  polydactyly	  that	  are	  associated	  with	  compromised	  Gli3-­‐R	  
function.	  The	  role	  of	  Gli	  genes	  in	  development	  was	  first	  revealed	  by	  the	  discovery	  of	  
deleterious	  mutations	  of	  GLI3	   in	   several	  human	  congenital	  malformations,	   including	  
Pallister-­‐Hall	   syndrome	   (Kang	   et	   al.,	   1997),	  mainly	   characterized	   by	   polydactyly	   and	  
craniofacial	   features.	   Loss-­‐of-­‐function,	   as	   well	   as	   dominant-­‐negative	   mutations	   in	  
GLI2,	  have	  also	  been	   identified	   in	  patients	  with	  holoprosencephaly-­‐like	  features	  and	  
pituitary	   anomalies	  but	  not	  with	   limb	  defects	   (Roessler	   et	   al.,	   2003;	  Roessler	   et	   al.,	  
2005).	   However,	  GLI1	   mutations	   have	   not	   yet	   been	   reported	   in	   human	   congenital	  
malformations.	  Of	  note,	  polydactyly	  and	  triphalangeal	  thumb	  are	  also	  present	  in	  TBS	  
patients	   and	   in	   the	   TBS	   model	   adult	   mice	   Sall1tg/tg	   (Figure	   I	   9).	   These	   genotype-­‐
phenotype	  correlations	  and	  molecular	  analyses	  demonstrate	   the	  crucial	   role	  of	  Shh,	  
and	  by	  extension,	  the	  primary	  cilia	  function	  and	  regulation	  in	  limb	  development.	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B.	  Polycystic	  kidney	  disease	  
One	  of	   the	   first	  diseases	   to	  be	   related	   to	  dysfunctional	  primary	  cilia	  was	   the	  
polycystic	   kidney	   disease	   (PKD)	   when	   the	   gene	   encoding	   the	   Ift88/Tg737/Polaris	  
protein	  in	  the	  Oak	  Ridge	  Polycystic	  Kidney	  mouse	  (ORPK	  mouse,	  or	  currently	  named	  
Ift88Tg737Rpw)	   was	   mutated.	   Both	   in	   Chlamydomonas	   and	   in	   mice,	   Ift88	   mutants	  
showed	  defective	  ciliogenesis	  (Moyer	  et	  al.,	  1994;	  Pazour	  et	  al.,	  2002).	  In	  the	  case	  of	  
the	  mouse	  kidney,	  cilia	  were	  also	  abnormally	  short	  or	  missing,	  which	  suggested	  that	  
PKD	   was	   a	   cilia-­‐related	   disease	   (Pazour	   et	   al.,	   2000).	   The	   resultant	   phenotype	  
resembles	  that	  of	  human	  autosomal	  recessive	  polycystic	  kidney.	  	  
Primary	   cilia	   project	   from	   the	   apical	   surface	   of	   epithelial	   cells	   along	   the	  
nephron	  tubule	  and	  collecting	  ducts,	   in	  contact	  with	  urine	  flow.	   In	  the	  adult	  kidney,	  
Figure	  I	  9.	  Limb	  defects	  in	  TBS	  individuals	  and	  model	  mice.	  (a,d)	  Patients	  exhibit	  preaxial	  polydactyly	  
(a)	   and	   triphalangeal	   thumb	   (d).	   (b,c,e,f)	   These	   defects	   are	   also	   found	   in	   mice	   homozygous	   for	   a	  
mutated	  Sall1	  transgene	  in	  the	  limb,	  Sall1tg/tg	  (b,e),	  but	  not	  in	  littermate	  controls	  Sall1+/+	  	  (c,f).	  Taken	  
and	  reprinted	  in	  (Kiefer,	  Robbins,	  Barina,	  Zhang,	  &	  Rauchman,	  2008)	  with	  permission	  from	  (Powell	  &	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cilia	   act	   as	   sensory	   antennae	   that	   respond	   to	   modifications	   of	   urine	   flow,	  
composition,	   and	   osmolality	   by	   modulating	   important	   intracellular	   signalling	  
pathways.	  For	  instance,	  polycystin-­‐1	  and	  −2,	  the	  two	  proteins	  mutated	  in	  autosomal-­‐
dominant	   polycystic	   kidney	   diseases	   (ADPKD),	   were	   found	   to	   regulate	   urine-­‐flow	  
dependent	   signalling	   pathways,	   such	   as	   Shh	   (Saigusa	   and	   Bell,	   2015).	   Likewise,	  
mutations	   in	   ciliary	   proteins	   such	   as	   inversin	   or	   nephrocystin-­‐3,	   which	   cause	  
nephronophthisis	  (NPH),	  alter	  the	  balance	  between	  canonical	  and	  non-­‐canonical	  Wnt	  
pathways	  that	  is	  crucial	  to	  regulate	  the	  correct	  polarity	  of	  epithelial	  tubular	  cells,	  thus	  
explaining	  the	  pathogenesis	  of	  cyst	  formation	  (Lienkamp	  et	  al.,	  2012).	   In	  contrast	  to	  
polycystic	  kidney	  disease	  that	  typically	  presents	  enlarged	  kidneys	  and	  massive	  cysts,	  
nephronophthisis	   (NPHP)	  rather	  presents	  shrunken,	  or	  normal	  sized,	  fibrotic	  kidneys	  
and	   small	   cysts	   at	   the	   cortico-­‐medullary	   junction.	   The	   renal	   phenotype	   of	   NPHP	  
frequently	  occurs	   in	  a	  syndromic	  manner	  and	   is	  accompanied	  by	  anomalies	   in	  other	  
organ	  systems,	  specifically	  retinal	  degeneration,	  cerebellar	  vermis	  hypoplasia,	  hepatic	  
fibrosis,	   skeletal	   anomalies,	   ectodermal	   dysplasia,	   brain	   malformations,	   and	  
neurological	   impairment.	   Of	   note,	   numerous	   small	   and,	   on	   occasion,	   large	   cysts	  
covered	  the	  kidney	  surface	  of	  some	  TBS	  model	  adult	  mice	  (Figure	  I	  10)	  (Kiefer	  et	  al.,	  
2003).	  All	  these	  data	  imply	  that	  there	  is	  a	  connexion	  between	  ciliary	  dysfunction	  and	  
cystic	  kidney	  disease.	  
	  
	  
Figure	   I	  10.	  Kidney	  defects	   in	   the	  TBS	  model	  mice	  Sall1+/Δ.	   Some	  Sall1+/Δ	  mice	  showed	  cystic	  and	  
hypoplastic	   kidneys	   with	   dilated	   renal	   tubules	   (B)	   that	   were	   never	   observed	   in	   their	   wild-­‐type	  
littermates	  Sall1+/+	  (A).	  Figure	  taken	  from	  (Kiefer	  et	  al.,	  2003).	  	  
	  
Introduction	  
	   45	  
	  
1.3	  The	  actin	  cytoskeleton	  
Actin	   is	  one	  of	   the	  most	  abundant	  proteins	   in	   cells	  and	  plays	   crucial	   roles	   in	  
cytokinesis	   during	   cell	   division,	   protrusion	   of	   the	   leading	   edge	   of	   motile	   cells	   and	  
maintaining	   the	   physical	   integrity	   of	   the	   cell	   (Pollard	   and	   Cooper,	   2009).	   Its	  
implication	  in	  primary	  cilia	  dynamics	  is	  an	  emerging	  trend	  in	  the	  field.	  
	  
1.3.1	  Actin	  structure,	  assembly	  and	  dissasembly	  
Actin	  monomers	  (glomerular	  or	  g-­‐actin)	  polymerize	  into	  dimmers,	  trimers	  and	  
finally	  double	  helical	  polymers	  with	  all	  of	  the	  subunits	  oriented	  in	  the	  same	  direction	  
to	  form	  filamentous	  actin	  (F-­‐actin)	  (Figure	  I	  11A).	  	  
	   Based	  on	  decoration	  with	  myosin	  heads,	  one	  end	  of	  the	  filament	  is	  called	  the	  
barbed	   end	   and	   the	   other,	   the	   pointed	   end.	   Myosin	   and	   many	   other	   proteins	   act	  
synergistically	  to	  regulate	  every	  aspect	  of	  actin	  dynamics.	  These	  proteins	  (i.e	  profilin)	  
maintain	  a	  pool	  of	  unpolymerized	  actin	  monomers	  to	  grow	  filaments	  when	  needed,	  
nucleate	   actin	   filaments,	   promote	   elongation,	   terminate	   the	   elongation	   of	   actin	  
Figure	   I	  11.	  Actin	  polimerization.	   (A)	  Actin	  monomers	   (g-­‐actin)	  combine	  to	   form	  dimers	  and	  trimers,	  
which	  can	  elongate	  rapidly	  from	  both	  its	  ‘barbed’	  and	  ‘pointed’	  ends	  to	  give	  rise	  to	  filamentous	  actin	  
(F-­‐actin).Figure	   adapted	   from	   (Amann	   &	   Pollard,	   2001).	   (B)	   Arp2/3	   complex	   nucleates	   a	   new	   actin	  
filament	   (daughter	   filament)	   growing	   from	   its	   barbed	   end	   at	   a	   70°	   angle	   from	   the	  mother	   filament.	  
Figure	  adapted	  from	  (Amann	  &	  Pollard,	  2001).	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filaments	   by	   capping,	   sever	   actin	   filaments,	   and	   crosslink	   filaments	   into	   tertiary	  
structures.	  	  
Two	   factors	   that	   appear	   to	   play	   an	   essential	   role	   in	   regulating	   actin	  
polymerization	   are	   the	   Arp2/3	   complex	   and	   ADF/cofilin,	   thereafter	   referred	   to	   as	  
cofilin.	   The	   spontaneous	   nucleation	   of	   filaments	   by	   actin	  monomers	   is	   unfavorable	  
and	   profilin	   suppresses	   nucleation.	   As	   a	   consequence,	   cells	   use	   other	   proteins	   to	  
initiate	  new	  actin	   filaments	   such	  as	   the	  Arp2/3	   complex.	  On	   the	  other	  hand,	   cofilin	  
promotes	  the	  actin	  severing	  that	  leads	  to	  actin	  turnover.	  	  
A.	  The	  Arp2/3	  complex	  
The	   Arp2/3	   complex	   consists	   of	   two	   actin-­‐related	   proteins,	   Arp2	   and	   Arp3,	  
together	  with	  five	  other	  protein	  subunits	  (Machesky	  et	  al.,	  1994).	  The	  Arps	  prime	  the	  
new	   filament	   formed	   as	   a	   branch	   of	   an	   existing	   actin	   filament	   called	   the	   mother	  
filament	   (Rouiller	   et	   al.,	   2008)	   (Figure	   I	   11B).	   The	   complex	   assembles	   networks	   of	  
branched	  actin	  filaments	  (Mullins	  et	  al.,	  1998)	  for	  cellular	  motility	  (Pollard	  and	  Borisy,	  
2003)	   and	   endocytosis	   (Weinberg	   and	   Drubin,	   2012).	   To	   be	   activated,	   the	   Arp2/3	  
complex	   requires	   proteins	   called	   nucleation-­‐promoting	   factors	   to	   favor	   the	  
conformational	   change	   and	   the	   formation	   of	   a	   daughter	   filament	   (Machesky	   et	   al.,	  
1999).	   Nucleation-­‐promoting	   factors	   (Campellone	   and	   Welch,	   2010)	   include	   the	  
Wiskott-­‐Aldrich	   syndrome	   protein	   (WASP)	   and	   related	   proteins	   with	   V	   motifs	   that	  
bind	   actin	   monomers,	   and	   CA	   motifs	   that	   bind	   Arp2/3	   complex	   (Marchand	   et	   al.,	  
2001).	   Another	   nucleation-­‐promoting	   factor,	   cortactin,	   stabilizes	   actin	   filament	  
branches	   (Weaver	   et	   al.,	   2001),	   while	   tropomyosin	   bound	   to	   the	   mother	   filament	  
inhibits	  branch	  formation	  (Blanchoin	  et	  al.,	  2001).	  	  
B.	  Cofilin	  
Hydrolysis	   of	   the	   ATP	   bound	   to	   polymerized	   actin	   and	   dissociation	   of	   the	  
phosphate	  prepare	   the	   filament	   for	   disassembly.	   The	  main	  player	   to	   promote	   actin	  
filament	  turnover	  and	  F-­‐actin	  severing	  is	  cofilin,	  a	  small	  protein	  that	  binds	  ADP-­‐actin	  
monomers	   and	   filaments	  with	   higher	   affinity	   than	  ATP-­‐actin	   and	   that	   is	   inactivated	  
when	  phosphorylated	   (Blanchoin	   and	   Pollard,	   1999).	   Actin	   filaments	   saturated	  with	  
cofilin	   are	   very	   stable	   (Andrianantoandro	   and	   Pollard,	   2006).	   On	   the	   other	   hand,	  
filaments	   sparsely	   occupied	   with	   cofilin	   are	   severed	   rapidly	   because	   of	   instability	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between	  parts	  of	  the	  filament	  with	  different	  flexibilities	  (Elam	  et	  al.,	  2013a;	  Elam	  et	  
al.,	  2013b;	  Ngo	  et	  al.,	  2015).	  Sparse	  occupancy	  occurs	  constantly	  during	  the	  turnover	  
of	   actin	   filaments,	   given	   that	   older	   parts	   are	   converted	   to	  ADP-­‐actin	   and	   then	  bind	  
cofilin.	   Severing	   by	   cofilin	   promotes	   turnover	   and	   filaments	   can	   regrow	   (Bravo-­‐
Cordero	  et	  al.,	  2013),	  but	  many	  are	  likely	  to	  be	  capped	  at	  their	  barbed	  ends.	  	  
The	  organization	  of	   the	  F-­‐actin	   (as	  well	  as	   the	  microtubule)	  network	  and	  the	  
formation	  of	  cell–matrix	  adhesions	  in	  response	  to	  extracellular	  stimuli	  are	  controlled	  
by	   small	   GTPases	   of	   the	   Rho	   family	   (Etienne-­‐Manneville	   and	   Hall,	   2002).	   In	   their	  
activated	  GTP-­‐bound	  state,	  Rho	  GTPases	  can	  activate	  multiple	  downstream	  effector	  
pathways.	   Both	  Rac1	   and	  RhoA	  GTPases	  have	  been	   reported	   to	   activate	   a	   pathway	  
that	  results	  in	  the	  inhibition	  of	  cofilin	  through	  phosphorylation	  at	  Ser3	  (Edwards	  et	  al.,	  
1999;	  Maekawa	  et	  al.,	  1999),	  but	  Rac1	  is	  mostly	  linked	  to	  lamellipodia	  extension	  and	  
the	  formation	  of	  nascent	  adhesions,	  whereas	  RhoA	  stimulates	  stress	  fiber	  formation	  
and	  maturation	  of	  cell–matrix	  adhesions	  (Rottner	  et	  al.,	  1999).	  The	  activation	  of	  the	  
Arp2/3	  complex	  downstream	  of	  Rac	   initiates	  actin	  polymerization	  (Figure	  R	  12).	  The	  
increase	   in	   polymerized	   actin	   stimulates	   the	   phosphatase	   activity	   of	   the	   slingshot	  
homologue	   1	   phosphatase,	   SSH1,	   leading	   to	   cofilin	   dephosphorylation	   and	  
consequential	  increase	  in	  its	  severing	  action.	  Active	  actin	  depolymerization	  by	  cofilin	  
can	   then	   free	   up	   actin	   monomers	   for	   Arp2/3-­‐dependent	   polymerization	   and	   a	  
dynamic	  actin	  turnover	  of	  actin	  remodeling	  is	  achieved	  (Chiu	  et	  al.,	  2010).	  
	  
1.3.2	  The	  role	  of	  actin	  cytoskeleton	  in	  cilia-­‐related	  processes	  
The	  regulation	  of	  actin	  dynamics	  is	  also	  considered	  a	  major	  ciliogenesis	  driver	  
in	  cycling	  cells	  (Pitaval	  et	  al.,	  2010).	  Processes	  such	  as	  cilia	   initiation,	  elongation	  and	  
maintenance	   or	   cell	   proliferation	   and	   migration	   are	   intrinsically	   linked	   to	   actin	  
dynamics.	  Furthemore,	  genes	  involved	  in	  neural	  tube	  defects	  (NTD)	  such	  as	  Abelson-­‐
related	  gene	   (Arg)	   (Koleske	  et	  al.,	  1998),	  Vinculin	   (Vcl)	   (Xu	  et	  al.,	  1998)	  and	  Shroom	  
(Shrm)	  (Hildebrand	  and	  Soriano,	  1999)	  have	  a	  role	  in	  the	  actin	  cytoskeleton	  dynamics.	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A.	  Cilia	  initiation	  
Actin	   dynamics	   coordinate	   several	   processes	   that	   are	   crucial	   for	   ciliogenesis	  
(Figure	   I	   13).	   Placing	   the	  MC	   to	   the	   appropriate	   area	   at	   the	   cell	   cortex	   is	   an	   actin-­‐
dependent	  process	  (Euteneuer	  and	  Schliwa,	  1985).	  After	  that,	  focal	  adhesion	  proteins	  
anchor	  the	  basal	  body	  to	  the	  underlying	  actin	  cytoskeleton	  (Antoniades	  et	  al.,	  2014)	  
followed	  by	  local	  removal	  of	  the	  actin	  (Francis	  et	  al.,	  2011)	  and	  the	  elongation	  of	  the	  
axoneme.	  	  
After	   the	   basal	   body	   docking,	   a	   reduction	   in	   cortical	   actin	  might	   potentially	  
promote	   ciliogenesis,	   as	   there	   would	   be	   no	   physical	   restriction	   to	   prevent	   cilium	  
growth.	   Supporting	   this	   hypothesis,	   several	   studies	   have	   found	   that	   changes	   in	   the	  
Figure	   I	   12.	   F-­‐actin	   formation	   dynamics.	   The	   formation	   of	   the	   remodeled	   actin	   is	   achieved	   by	   the	  
polymerization	  activity	  of	  Arp2/3	  acting	  downstream	  of	  active	  Rac.	  The	  accumulation	  of	  polymerized	  F-­‐
actin	   poses	   a	   stimulatory	   factor	   in	   the	   phosphatase	   activity	   of	   SSH	   (Slingshot	   homologue	   1	  
phosphatase),	   which	   leads	   to	   net	   dephosphorylation	   and	   activation	   of	   cofilin.	   Hereon,	   the	   actin-­‐
severing	   function	   of	   cofilin	  maintains	   the	   flexibility	   of	   remodeled	   actin	   and	   enables	   regeneration	   of	  
free	  monomeric	  actin	  for	  further	  polymerization.	  LIMK:	  LIM	  domain	  kinase	  1.	  Scheme	  by	  (Chiu,	  Patel,	  
Shaw,	  Bamburg,	  &	  Klip,	  2010).	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actin	   network	   architecture,	   induced	   either	   chemically	   or	   genetically,	   promote	  
ciliogenesis	  or	  affect	  cilia	  length	  (Drummond	  et	  al.,	  2018;	  Hernandez-­‐Hernandez	  et	  al.,	  
2013;	  Kang	  et	  al.,	  2015;	  Kim	  et	  al.,	  2015;	  Kim	  et	  al.,	  2010).	  	  
	  
	  
B.	  Cilia	  length	  
Interfering	   with	   actin	   dynamics	   through	   CytB	   has	   been	   demonstrated	   to	  
promote	  ciliogenesis	  (Cao	  et	  al.,	  2012).	  How	  actin	  regulates	  cilium	  length	  is	  less	  clear.	  
One	  hypothesis	   is	   that	  cortical	  actin	  stretches	  the	  ciliary	  necklace	  to	  prevent	  vesicle	  
trafficking	   and	   anterograde	   transport	   to	   grow	   the	   ciliary	   shaft.	   Alternatively,	   actin	  
may	   serve	   as	   a	   constricting	   force	   that	   promotes	   ectocytosis	   and	   cilium	   tip	   scission	  
preventing	  the	  axoneme	  from	  growing	  too	  long	  (Nager	  et	  al.,	  2017;	  Phua	  et	  al.,	  2017).	  
In	   the	   same	  way,	   actin	   surrounding	   the	   basal	   body	  might	   provide	   the	   relaxation	  or	  
constriction	  to	  either	  allow	  or	  restrict	  the	  axoneme	  growth,	  respectively.	  	  
Figure	  I	  13.	  Diverse	  roles	  of	  cytoplasmic	  actin	  cytoskeleton	  in	  ciliogenesis.	  Cellular	  actin	  and	  myosins	  
mediate	  accumulation	  and	  fusion	  of	  vesicles	  to	  form	  the	  ciliary	  vesicle,	  mother	  centriole	  (MC)	  location	  
to	   the	   cell	   cortex,	   basal	   body	   (BB)	   anchoring	   and	  docking	   to	   the	  apical	   surface,	   ciliary	   function	  and	  
formation	  maintenance	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C.	  Cell	  proliferation	  
During	   mitosis,	   the	   actin	   cytoskeleton	   must	   rearrange	   and	   localize	   to	   the	  
cortical	  plasma	  membrane	   in	  early	  mitotic	  phases	  and	  to	   the	  contractile	   ring	  during	  
cytokinesis	   (Heng	   and	   Koh,	   2010).	   This	   recruitment	   of	   actin	   and	   actin	   regulatory	  
proteins	   to	   the	   cell	   cortex	   during	   mitosis	   is	   essential	   for	   the	   interaction	   between	  
astral	  microtubules	  and	  cortical	  actin,	  which	  is	  believed	  to	  be	  important	  in	  regulating	  
mitotic	   spindle	   orientation	   (Rankin	   and	  Wordeman,	   2010).	   The	   role	   of	   actin	   and	   its	  
regulatory	  proteins	  in	  these	  processes	  ranges	  from	  regulating	  centrosome	  separation	  
(Cao	  et	  al.,	  2010)	   to	  proper	  spindle	  assembly	  and	  orientation	  (Woolner	  et	  al.,	  2008)	  
and	   to	   elongate	   kinetochore	   microtubules.	   Numerical	   and	   structural	   centriole	  
aberrations	  can	  also	  perturb	  the	  formation	  and	  the	  function	  of	  cilia.	  
	  
1.4	  LUZP1	  
The	   leucine-­‐zipper	   motif	   containing	   protein	   LUZP1	   has	   been	   identified	   as	   a	  
nuclear	   protein	   mainly	   expressed	   in	   the	   brain.	   In	   addition	   to	   three	   leucine	   zipper	  
motifs	   located	  at	   the	  N-­‐terminus,	   it	  contains	  three	  nuclear	   localization	  signals	  and	  a	  
large	   number	   of	   putative	   Ser/Thr	   phosphorylation	   sites	   (Sun	   et	   al.,	   1996).	  
Interestingly,	  mutations	   in	   Luzp1	   resulted	   in	   cardiovascular	   defects	   and	   cranial	  NTD	  
(Figure	  I	  14),	  demonstrating	  its	  crucial	  role	  in	  embryonic	  heart	  and	  brain	  development	  
(Hsu	  et	  al.,	  2008;	  Lee	  et	  al.,	  2001;	  Sun	  et	  al.,	  1996).	  Remarkably,	  ectopic	  Shh	  signalling	  
was	   observed	   in	   the	   dorsal	   lateral	   neuroepithelium	   of	   the	   NTD	   Luzp-­‐/-­‐	   mice,	  
suggesting	   that	   LUZP1	   might	   have	   a	   role	   in	   Shh	   signalling	   (Hsu	   et	   al.,	   2008).	   In	  
humans,	  specific	  mutations	  in	  LUZP1	  have	  not	  yet	  been	  reported.	  However	  deletions	  
of	   chromosome	   1p36,	   including	   the	   complete	   deletion	   of	   LUZP1,	   lead	   to	   the	   1p36	  
deletion	   syndrome	   that	   affects	   approximately	   1	   in	   5,000	   newborns	   (Zaveri	   et	   al.,	  
2014).	   The	   symptoms	   include	   developmental	   delay,	   intellectual	   disability,	   seizures,	  
vision	  problems,	  hearing	   loss,	  short	  stature,	  distinctive	  facial	   features,	  brain	  defects,	  
orofacial	   clefting,	   congenital	   heart	   defects,	   cardiomyopathy,	   and	   renal	   anomalies.	  
Although	  the	  exact	  contribution	  of	  LUZP1	   in	  the	  pathogenesis	  of	  the	  1p36	  syndrome	  
is	   unknown,	   it	   has	   been	   proposed	   to	   contribute	   to	   the	   development	   of	   the	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cardiovascular	   malformations.	   In	   spite	   of	   the	   phenotypic	   overlaps	   and	   the	   Shh	  
signalling	   defects	   observed	   in	   Luzp1-­‐/-­‐	  mice,	   a	   link	   between	   LUZP1	   and	   ciliogenesis,	  
until	  this	  work	  had	  not	  been	  previously	  investigated.	  	  
	  
Figure	   I	   14.	   Cranial	   and	   cardiovascular	   defects	   in	   Luzp1-­‐/-­‐	  mutant	   embryos.	   (A)	   Exencephaly	   (black	  
arrow)	  was	  visible	  in	  42	  %	  of	  the	  Luzp1-­‐/-­‐	  but	  not	  in	  WT	  embryos.	  Dotted	  lines	  indicate	  the	  open	  neural	  
tube	  from	  midbrain	  to	  hindbrain	  at	  E9.5.	  (B)	  Ventriculoarterial	  connection	  is	  revealed	  by	  inserting	  blue	  
dye	   into	   the	   right	   ventricle	   (RV)	   of	   neonate	  pups.	   In	  WT,	   dye	   flows	   from	  RV	   to	   only	   the	  pulmonary	  
trunk	  (PT).	  One	  of	  the	  three	  types	  of	  connection	  defects	  that	  are	  present	  in	  Luzp1-­‐/-­‐	  pups	  is	  ventricular	  
septal	  defect	  (VSD,	  right	  pannel)	  where	  dye	  pours	  into	  the	  left	  ventricle	  (LV)	  before	  entering	  the	  great	  
arteries.	  AO:	  aorta.	  RA:	  right	  atrium.	  Scale	  bar:	  1	  mm.	  Image	  adapted	  from	  {Hsu,	  2008	  #115}.	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2.1	  Hypothesis	  
TBS	  is	  an	  autosomal	  dominant	  genetic	  disease	  caused	  by	  mutations	  in	  SALL1	  
(Botzenhart	  et	  al.,	  2007;	  Kohlhase	  et	  al.,	  1998)	  that	  in	  most	  of	  the	  cases	  lead	  to	  the	  
expression	   of	   SALL1	   truncated	   proteins.	   Although	   the	   genetic	   cause	   of	   TBS	   is	  well	  
defined,	   the	   cellular	   and	  molecular	  mechanisms	  mediating	   TBS	   are	   still	   undefined.	  
TBS	  is	  characterized	  by	  the	  presence	  of	  imperforate	  anus,	  dysplastic	  ears,	  thumb	  and	  
heart	   malformations,	   and	   renal	   impairment,	   among	   other	   symptoms.	   Intriguingly,	  
these	  features	  are	  commonly	  reported	  in	  a	  variety	  of	  diseases,	  collectively	  known	  as	  
ciliopathies,	   caused	   by	   defects	   in	   the	   primary	   cilia	   formation	   or	   primary	   cilia-­‐
dependent	   signalling	   (Hildebrandt	   et	   al.,	   2011).	   Depending	   on	   the	   underlying	  
mutation,	  ciliopathies	  present	  a	  broad	  spectrum	  of	  phenotypes,	  ranging	  from	  cystic	  
kidneys	   to	  polydactyly,	  obesity	  and	  heart	   failure.	  These	  coincidental	   features	  could	  
suggest	   similar	   molecular	   causes	   between	   ciliopathies	   and	   TBS,	   but	   a	  
characterization	  of	  primary	  cilia	   formation	  and	   function	  has	  not	  been	  yet	   reported	  
for	  TBS.	  Therefore,	  we	  hypothesized	  that	  defects	  in	  primary	  cilia	  formation	  and/or	  
function	  might	  be	  contributing	  factors	  in	  TBS.	  	  
	  
Hypothesis	  
SALL1	  has	  a	  role	  in	  primary	  cilia	  formation	  and	  function	  that	  might	  contribute	  to	  the	  
etiology	  of	  TBS.	  Specifically,	  truncated	  SALL1	  might	   interphere	  with	  cilia	  formation	  
and/or	  Shh	  signalling,	  leading	  to	  TBS.	  
	  
2.2	  Objectives	  
In	   order	   to	   prove	   this	   hypothesis,	   we	   proposed	   as	   a	   general	   objective	   to	  
study	   the	   cellular	   and	   molecular	   mechanisms	   mediating	   TBS.	   In	   particular,	   we	  
defined	  the	  following	  specific	  aims:	  
	  
1.	  To	  analyse	  the	  role	  of	  SALL1	  in	  cilia	  formation	  and	  function.	  
We	  obtained	  TBS	  patient-­‐derived	  cells	  and	  generated	  TBS-­‐model	  cell	  lines	  to	  
analyse	  the	  effect	  of	  SALL1	  truncations	  on	  cilia	  formation	  and	  cilia	  function.	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2.	   To	   identify	   the	   cellular	   and	  molecular	  mechanisms	  mediating	   the	   cilia	   defects	  
observed	  in	  TBS.	  
	  In	  order	   to	   identify	   candidate	  proteins	   that	  might	  mediate	   the	   cilia-­‐related	  
aberrations	   detected	   in	   TBS,	  we	   employed	   the	   BioID	  method	   to	   identify	   potential	  
SALL1	  interactors.	  Some	  promising	  centrosome	  and/or	  cilia-­‐related	  candidates	  were	  
further	  characterized	  in	  the	  context	  of	  TBS.	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3.1	  Cell	  culture	  	  
Human	   control	   and	   TBS-­‐derived	   primary	   fibroblasts,	   mouse	   embryonic	   fibroblasts	  
(MEF),	   U2OS	   (ATCC	   HTB-­‐96),	   HEK	   293FT	   (Invitrogen)	   and	   mouse	   Shh-­‐LIGHT2	   cells	  
(Taipale	  et	  al.,	  2000)	  were	  cultured	  at	  37°C	  and	  5%	  CO2	  in	  Dulbecco’s	  modified	  Eagle	  
medium	   (DMEM)	   supplemented	  with	  10%	   fetal	   bovine	   serum	   (FBS,	  Gibco)	   and	  1%	  
penicillin/streptomycin	   (Gibco).	   Mouse	   IMCD3	   (Inner	   Medullary	   Collecting	   Duct-­‐3)	  
and	   human	   TERT-­‐RPE1	   cells	   (telomerase	   reverse	   transcriptase-­‐retinal	   pigment	  
epithelial	  1,	  TCC	  CRL-­‐4000)	  were	  cultured	  in	  DMEM:F12	  (Gibco)	  supplemented	  with	  
10%	   FBS	   and	   1%	   penicillin	   and	   streptomycin.	   Dermal	   fibroblasts	   carrying	   a	   SALL1	  
c.995delC	   mutation	   (SALL1c.995delC),	   that	   produce	   a	   truncated	   protein	  
p.Pro332Hisfs*10	   (SALL1332),	   were	   derived	   from	   a	   male	   TBS	   individual	   OX3335	  
(TBS332,	   herein)	   (Botzenhart	   et	   al.,	   2007;	   Furniss	   et	   al.,	   2007).	   Dermal	   fibroblasts	  
carrying	   the	   SALL1	   pathogenic	   variant	   c.826C>T	   (SALL1c.826C>T),	   that	   produce	   a	  
truncated	   protein	   p.Arg275*	   (SALL1275	   herein),	   were	   derived	   from	   a	   male	   TBS	  
individual	  UKTBS#3	   (TBS275)	   (Bozal-­‐Basterra	   et	   al.,	   2018).	  Human	  neonatal	   foreskin	  
fibroblasts	   (HFF;	   ATCC	   CRL-­‐2429)	   and	   adult	   female	   dermal	   fibroblasts	   (ESCTRL#2)	  
from	  healthy	  donors	  were	  used	  as	  controls.	  We	  derived	  MEFs	   from	  wild-­‐type	  (WT)	  
and	  three	  heterozygous	  embryos	  carrying	  the	  Sall1-­‐∆Zn2-­‐10	  mutant	  allele	  (Kiefer	  et	  
al.,	  2003).	  All	  the	  embryos	  were	  at	  stage	  E13.	  WT	  and	  mutant	  alleles	  were	  detected	  
by	   PCR	   genotyping	   using	   established	   methods.	   Cultured	   cells	   were	   maintained	  
between	  10	  and	  20	  passages,	  tested	  for	  senescence	  by	  γ-­‐H2AX	  staining,	  and	  grown	  
until	   confluence	   (6-­‐well	   plates	   for	   RNA	  extraction	   and	  Western	  blot	   assays;	   10	   cm	  
dishes	  for	  pulldowns).	  Cells	  were	  treated	  with	  Cytochalasin	  B	  (CytB;	  Sigma,	  20	  µM)	  
for	  30	  minutes	  to	  stimulate	  actin	  polymerization	  and	  with	  the	  proteasome	  inhibitor	  
MG132	   (Calbiochem,	   5	   µM)	   for	   24	   hours.	   Cells	   were	   transfected	   using	   calcium	  
phosphate	  method,	  with	   the	  exception	  of	  primary	   fibroblasts	   (Lipofectamine	  3000;	  
Invitrogen).	  To	  induce	  primary	  cilia,	  cells	  were	  starved	  for	  24	  hours	  (DMEM,	  0%	  FBS,	  
1%	   penicillin	   and	   streptomycin).	   In	   the	   case	   of	   HEK	   293FT	   cells,	   we	   followed	   the	  
conditions	  previously	  reported	  (Boldt	  et	  al.,	  2016).	  The	  use	  of	  human	  samples	  in	  this	  
study	   was	   approved	   by	   the	   institutional	   review	   board	   (Ethics	   Committee	   at	   CIC	  
bioGUNE)	   and	   appropriate	   informed	   consent	   was	   obtained	   from	   human	   subjects.	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Work	  with	  mouse	  embryos	  to	  derive	  MEFs	  was	  approved	  by	  the	  University	  of	  Saint	  
Louis.	  All	  experiments	  conform	  to	  the	  relevant	  regulatory	  standards.	  
	  
3.2	  SALL1	  proximity	  proteomics	  
Using	   the	   BioID	   method	   (Roux	   et	   al.,	   2012)	   proteins	   in	   close	   proximity	   to	  
SALL1	  were	  biotinylated	  by	  fusion	  to	  a	  promiscuous	  form	  of	  the	  enzyme	  BirA	  (BirA*)	  
and	  isolated	  by	  streptavidin-­‐bead	  pulldowns	  (Figure	  M	  1).	  	  
	  
Myc-­‐BirA*-­‐SALL1c.826C>T	  (BirA*-­‐SALL1826)	  or	  Myc–BirA*-­‐SALL1FL	  (BirA*-­‐SALL1FL)	  
were	  transfected	  in	  HEK	  293FT	  cells	  (5x	  10	  cm	  dishes	  per	  condition).	  24	  hours	  after	  
transfection,	  medium	  was	  supplemented	  with	  biotin	  at	  50	  μM.	  Cells	  were	  collected	  
after	  48	  hours,	  washed	  3	  times	  on	  ice	  with	  cold	  phosphate	  buffered	  saline	  (PBS)	  and	  
scraped	  in	  lysis	  buffer	  [8	  M	  urea,	  1%	  SDS,	  1x	  protease	  inhibitor	  cocktail	  (Roche),	  1x	  
PBS;	   1	   ml	   per	   10	   cm	   dish].	   At	   room	   temperature,	   samples	   were	   sonicated	   and	  
cleared	   by	   centrifugation.	   Cell	   lysates	   were	   incubated	   overnight	   with	   40	   µl	   of	  
equilibrated	  NeutrAvidin-­‐agarose	  beads	  (Thermo	  Scientific).	  Beads	  were	  subjected	  to	  
stringent	  washes	  using	  the	  following	  washing	  buffers	  (WB),	  all	  prepared	  in	  PBS:	  WB1	  
(8	  M	  urea,	  0.25%	  SDS);	  WB2	  (6	  M	  Guanidine-­‐HCl);	  WB3	  (6.4	  M	  urea,	  1	  M	  NaCl,	  0.2%	  
SDS),	  WB4	  (4	  M	  urea,	  1	  M	  NaCl,	  10%	  isopropanol,	  10%	  ethanol	  and	  0.2%	  SDS);	  WB5	  
M	  1.	   Schematic	   representation	   of	   the	   BioID	  method.	   Figure	   adapted	   from	   (Roux,	   Kim,	   Raida,	   &	  
Burke,	   2012).	   Only	   those	   proteins	   in	   close	   proximity	   to	   SALL1-­‐BirA	   fusions	   will	   be	   labelled	   with	  
biotin	  and	  captured	  by	  streptavidin”	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(8	  M	  urea,	  1%	  SDS);	  and	  WB6	  (2%	  SDS).	  For	  elution	  of	  biotinylated	  proteins,	  beads	  
were	   heated	   at	   99°C	   in	   50	  µl	   of	   Elution	   Buffer	   (4x	   Laemmli	   buffer,	   100	  mM	  DTT).	  
Beads	   were	   separated	   by	   centrifugation	   (18000	   x	   g,	   5	   minutes)	   or	   alternatively	  
removed	   by	   centrifugation	   through	   a	   0.8	   µm	   filter	   (Vivaspin,	   Sartorius).	   Samples	  




3.3	  Mass	  spectrometry	  	  
Three	   independent	   pulldown	   experiments	   were	   analysed	   by	   MS.	   Samples	  
eluted	   from	   the	  NeutrAvidin	   beads	  were	   separated	   in	   SDS-­‐PAGE	   and	   stained	  with	  
Brilliant	   Blue	   G-­‐Colloidal	   Concentrate	   (Sigma)	   according	   to	   manufacturer’s	  
instructions.	  The	  entire	  gel	  lanes	  were	  excised,	  divided	  into	  pieces	  and	  distained,	  and	  
proteins	  were	  reduced	  and	  alkylated	  before	  being	  in-­‐situ	  digested	  with	  trypsin.	  The	  
resulting	   peptide	   mixtures	   were	   extracted,	   concentrated	   and	   analysed	   using	   and	  
EASY	   nLC	   system	   (Proxeon).	   Peptide	   ionization	   was	   performed	   on	   a	   Proxeon	   ion	  
source	   and	   sprayed	   directly	   into	   the	   mass	   spectrometer	   (Q-­‐Exactive,	   Thermo	  
Scientific).	   MaxQuant	   software	   (version	   1.4.0.3)	   was	   used	   for	   the	   processing	   and	  
analysis	   of	   recorded	   LC-­‐MS/MS	   raw-­‐files	   using	   default	   parameters	   applying	   a	   1%	  
false	  discovery	  rate	  at	  both	  peptide	  and	  protein	  levels.	  Label-­‐free	  quantitation	  (LFQ)	  
based	   on	   summed	   extracted	   peptide	   ion	   chromatograms	  was	   used	   for	   identifying	  
differentially	  interacting	  proteins.	  	  
The	   lists	  of	  proteins	   identified	  by	  LC-­‐MS/MS	  were	  analysed	  as	   follows:	  only	  
proteins	   identified	   by	  more	   than	   1	   peptide	   and	  present	   in	   at	   least	   two	  out	   of	   the	  
three	  experiments	  were	  considered	  for	  analysis.	  Protein	  IDs	  were	  ranked	  according	  
to	   the	   number	   of	   peptides	   found	   and	   their	   corresponding	   intensities.	   Hits	   were	  
classified	   into	   those	   that	   interact	   with	   both	   FL	   and	   truncated	   SALL1275	   or	   those	  
interacting	  preferentially	  with	  one	  or	   the	  other.	  A	   threshold	  of	   two-­‐fold	   change	   in	  
iBAQ	   value	   (intensity-­‐based	   absolute	   quantification)	   was	   considered	   significant.	  
Calculation	   was	   done	   taking	   into	   account	   a	   baseline	   for	   each	   experiment,	   which	  
corresponds	  to	  the	  minimum	  value	  of	  iBAQ	  registered	  for	  every	  specific	  sample.	  
Gene	   ontology	   (GO)	   term	   enrichment	   was	   analysed	   using	   g:Cocoa,	   a	   tool	  
Materials	  and	  Methods	  
	   62	  
integrated	   in	   the	  g:Profiler	  web	   server	   (Reimand	  et	   al.,	   2016).	  GO	  enrichment	  was	  
obtained	  by	  calculating	  –log10	  of	  the	  P-­‐value.	  
	  
3.4	  GFP	  pulldowns	  
All	  steps	  were	  performed	  at	  4oC.	  Transfected	  HEK	  293FT	  cells	  were	  collected	  
after	  48	  hours,	  washed	  3	  times	  with	  1x	  PBS	  and	  lysed	  in	  1	  ml	  of	  lysis	  buffer	  [25	  mM	  
Tris-­‐HCl	   pH	   7.5,	   150	   mM	   NaCl,	   1	   mM	   EDTA,	   1%	   NP-­‐40,	   0.5%	   Triton	   X-­‐100,	   5%	  
glycerol,	   protease	   inhibitors	   (Roche)].	   Lysates	   were	   kept	   on	   ice	   for	   30	   minutes	  
vortexing	  every	  5	  minutes	  and	  spun	  down	  at	  25,000	  x	  g	  for	  20	  minutes.	  After	  saving	  
40	   μl	   of	   supernatant	   (input),	   the	   rest	   was	   incubated	   overnight	   with	   30	   μl	   of	   pre-­‐
washed	  GFP-­‐Trap	  resin	  (Chromotek)	  in	  a	  rotating	  wheel.	  Beads	  were	  washed	  5	  times	  
for	  5	  minutes	  each	  with	  WB	  (25	  mM	  Tris-­‐HCl	  pH	  7.5,	  300	  mM	  NaCl,	  1	  mM	  EDTA,	  1%	  
NP-­‐40,	   0.5%	   Triton	   X-­‐100,	   5%	   glycerol).	   Beads	  were	   centrifuged	   at	   2,000	   x	   g	   for	   2	  
minutes	  after	  each	  wash.	  For	  elution,	  samples	  were	  boiled	  for	  5	  minutes	  at	  95oC	  in	  
2x	  Laemmli	  buffer.	  
	  
3.5	  Immunoprecipitation	  
	   All	  steps	  were	  performed	  at	  4oC.	  Cells	  were	  collected	  after	  48	  hours,	  washed	  
3	  times	  with	  1x	  PBS	  and	  lysed	  in	  1	  ml	  of	  lysis	  buffer	  [20	  mM	  Tris-­‐HCl	  pH	  7.5,	  137	  mM	  
NaCl,	   2	   mM	   EDTA,	   1%	   NP-­‐40,	   5%	   glycerol,	   protease	   inhibitor	   mixture	   (Roche)].	  
Lysates	   were	   processed	   as	   described	   for	   GFP	   pulldowns.	   Lysates	   were	   incubated	  
overnight	  with	  1	  µg	  of	  CCP110	  or	  CEP97	  antibody	  (Proteintech)	  and	  for	  additional	  4	  
hours	   with	   40	   μl	   of	   pre-­‐washed	   Protein	   G	   Sepharose	   4	   Fast	   Flow	   beads	   (GE	  
Healthcare)	  in	  a	  rotating	  wheel.	  Beads	  were	  washed	  5	  times	  for	  5	  minutes	  each	  with	  
WB	   (10	  mM	  Tris-­‐HCl	   pH	   7.5,	   137	  mM	  NaCl,	   1	  mM	  EDTA,	   1%	   Triton	   X-­‐100).	   Beads	  
were	   centrifuged	  at	  2,000	   x	   g	   for	  2	  minutes	   after	   each	  wash.	   For	  elution,	   samples	  
were	  boiled	  for	  5	  minutes	  at	  95oC	  in	  2x	  Laemmli	  buffer.	  
	  
3.6	  Western	  blot	  analysis	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Cells	  were	  lysed	  in	  cold	  RIPA	  buffer	  or	  weak	  buffer	  (10	  mM	  PIPES	  pH	  6.8,	  100	  
mM	  NaCl,	  1	  mM	  EGTA,	  3	  mM	  MgCl2,	  300	  mM	  sucrose,	  0.5	  mM	  DTT,	  1%	  Triton	  X-­‐100)	  
supplemented	  with	   1x	   protease	   inhibitor	   cocktail	   (Roche),	   and	   also	   in	   some	   cases	  
with	   PhosphoStop	   1x	   (Roche).	   Lysates	   were	   kept	   on	   ice	   for	   30	  minutes	   vortexing	  
every	   5	  minutes	   and	   then	   cleared	  by	   centrifugation	   (25,000	   x	   g,	   20	  minutes,	   4oC).	  
Supernatants	  were	   collected	  and	  protein	   contents	  were	  quantified	  by	  BCA	  protein	  
quantification	  assay	  (Pierce).	  After	  SDS-­‐PAGE	  and	  transfer	  to	  nitrocellulose	  or	  PVDF,	  
membranes	  were	  blocked	  in	  5%	  milk,	  or	  in	  5%	  BSA	  (Bovine	  Serum	  Albumin,	  Fraction	  
V,	  Sigma)	   in	  1x	  PBS	  0.1%	  Tween-­‐20.	   In	  general,	  primary	  antibodies	  were	   incubated	  
overnight	   at	   4°C	   and	   secondary	   antibodies	   for	   1	   hour	   at	   room	   temperature.	  
Antibodies	  used:	  CCP110	  (Proteintech,	  1:1000),	  CEP97	  (Proteintech,	  1:1000),	  LUZP1	  
(Sigma,	  1:1000),	  GLI3	   (R&D,	  1:1000),	  FLNA	  (Cell	  Signalling,	  1:1000),	  vinculin	   (Sigma,	  
1:1000)	   Cofilin	   (Cell	   Signalling	   Technology,	   1:1000),	   phospho-­‐cofilin	   (Cell	   Signalling	  
Technology,	   1:1000),	   Rac1	   and	   pRac1	   (Cell	   Signalling	   Technology,	   1:1000),	   Arp3	  
(Machesky	  et	  al.,	  1997),	  1:1000),	  Biotin-­‐HRP	  (Cell	  Signalling	  Technology,	  1:2000),	  GFP	  
(Roche,	  1:1000),	  HA	  (Sigma,	  1:1000),	  GFP	  (Roche,	  1:1000),	  tubulin-­‐HRP	  (Proteintech,	  
1:2000),	  GAPDH	  (Proteintech,	  1:1000),	  Actin	   (Sigma,	  1:1000).	  Anti-­‐SALL1	  antibodies	  
were:	  R&D,	  1:1000,	  detects	  SALL1FL	  protein;	  anti-­‐SALL1	   (Kiefer	  et	  al.,	  2002)	  detects	  
the	  N-­‐terminal	  part	  of	  both	  truncted	  SALL1	  and	  SALL1FL	  (check	  antibody	  specificity	  in	  
Figure	   R	   1A	   and	   Figure	   R	   1B).	   Secondary	   antibodies	   were	   HRP-­‐conjugated	   anti-­‐
mouse	   or	   anti-­‐rabbit	   (Jackson	   Immunoresearch).	   Proteins	   were	   detected	   using	  
Clarity	   ECL	   (BioRad)	   or	   Super	   Signal	  West	   Femto	   (Pierce).	   Quantification	   of	   bands	  
was	   performed	   using	   ImageJ	   software	   and	   normalized	   against	   actin,	   GAPDH	   or	  
tubulin	  levels.	  At	  least	  three	  independent	  blots	  were	  quantified	  per	  experiment.	  	  
	  
3.7	  Immunostaining	  
	   hTERT-­‐RPE,	   U2OS	   cells,	   Shh-­‐LIGHT2	   cells,	   HEK	   293FT	   cells	   and	   primary	  
fibroblasts	   from	   control	   and	   TBS	   individuals	   were	   seeded	   on	   11	   mm	   coverslips	  
(15,000-­‐50,000	   cells	   per	  well	   on	   a	   24	  well-­‐plate).	   HEK	   293FT	   cells	   were	   plated	   on	  
coverslips	   coated	   with	   0.01%	   poly-­‐L-­‐lysine	   (Sigma)	   to	   enhance	   adhesion.	   After	  
washing	   3	   times	   with	   cold	   1x	   PBS,	   cells	   were	   fixed	   with	   methanol	   100%	   for	   10	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minutes	  at	  -­‐20oC	  or	  with	  4%	  PFA	  supplemented	  with	  0.1%	  Triton	  X-­‐100	  in	  PBS	  for	  15	  
minutes	  at	  RT	  or	  pre-­‐permeabilized	  for	  2	  min	  in	  PTEM	  buffer	  (20	  mM	  PIPES	  pH	  6.8,	  
0.2	  %	  Triton	  X-­‐100,	  10	  mM	  EGTA	  and	  1	  mM	  MgCL2	  (Tanos	  et	  al.,	  2013)	  and	  fixed	  for	  
10	  min	  with	  4%	  PFA	  for	  centrosomal	  staining.	  Then,	  coverslips	  were	  washed	  3	  times	  
with	  1x	  PBS.	  Blocking	  was	  performed	  for	  1	  hour	  at	  37oC	   in	  blocking	  buffer	   (BB:	  2%	  
fetal	  calf	  serum,	  1%	  BSA	  in	  1x	  PBS).	  Primary	  antibodies	  were	  incubated	  overnight	  at	  
4oC	  and	  cells	  were	  washed	  with	  1x	  PBS	  3	  times.	  To	  label	  the	  ciliary	  axoneme	  and	  the	  
basal	   body/pericentriolar	   region,	   we	   used	   mouse	   antibodies	   against	   acetylated	  
alpha-­‐tubulin	   (Santa	  Cruz	  Biotechnologies,	  1:160)	  and	  gamma-­‐tubulin	   (Proteintech,	  
1:160)	   and	   rabbit	   antibodies	   against	   ARL13B	   (Proteintech)	   and	   pericentrin	   (1:160;	  
Covance).	   Other	   antibodies:	   mouse	   anti-­‐SALL1	   (R&D,	   1:100);	   rabbit	   anti-­‐CCP110	  
(Proteintech,	  1:100);	  rabbit	  anti-­‐CEP97	  (Proteintech,	  1:100);	  mouse	  monoclonal	  anti-­‐
CEP164	   (Genetex,	  1:100);	   rabbit	  anti-­‐ODF2	   (Atlas,	  1:100)	  and	  mouse	  anti-­‐phospho-­‐
Histone	   H2A.X	   (Millipore;	   1:500),	   anti-­‐LUZP1	   (Sigma,	   1:100),	   anti-­‐vinculin	   (Sigma,	  
1:200)	  and	  anti-­‐actin	  (Sigma,	  1:500).	  
	   Donkey	   anti-­‐mouse,	   anti-­‐rabbit	   or	   anti-­‐rat	   secondary	   antibodies	   (Jackson	  
Immunoresearch)	   conjugated	   to	   Alexa	   488	   or	   Alexa	   568	   (1:200),	   GFP	   booster	  
(Chromotek,	   1:500)	   and	   Alexa	   568-­‐conjugated	   phalloidin	   (Invitrogen	   1:500),	   were	  
incubated	   for	   1	   hour	   at	   37oC,	   followed	  by	  nuclear	   staining	  with	  DAPI	   (10	  minutes,	  
300	  ng/ml	   in	  PBS;	  Sigma).	  Transfected	  HEK	  293FT	  cells	  with	  Myc-­‐BirA*-­‐SALL1c.826C>T	  
or	  Myc-­‐BirA*-­‐SALL1FL	  were	  incubated	  with	  50	  µM	  biotin	  for	  24	  hours,	  washed,	  fixed,	  
and	   stained	   with	   Alexa	   594-­‐conjugated	   Streptavidin	   (1:100,	   Jackson	  
Immunoresearch).	  Fluorescence	  imaging	  was	  performed	  using	  an	  upright	  fluorescent	  
microscope	  (Axioimager	  D1,	  Zeiss)	  or	  a	  confocal	  microscope	  (Leica	  SP2)	  with	  40x	  or	  
63x	  objectives.	  Cilia	  frequency	  was	  obtained	  dividing	  the	  number	  of	  total	  cilia	  by	  the	  
number	  of	  nuclei	  on	  each	  micrograph.	  Number	  of	  cells	  per	  micrograph	  was	  similar	  in	  
both	   control	   and	   experimental	   conditions.	   For	   cilia	   measurements	   and	   counting,	  
primary	   cilia	   from	   at	   least	   fifteen	   different	   fluorescent	   micrographs	   from	   each	  
experimental	   condition	  were	  analysed	  using	   the	   ruler	   tool	   from	  Adobe	  Photoshop.	  
To	  obtain	  the	  level	  of	  fluorescence	  in	  a	  region,	  mean	  intensity	  or	  corrected	  total	  cell	  
fluorescence	   (CTCF)	   was	   calculated	   as	   described	   (McCloy	   et	   al.,	   2014),	   using	  
parameters	  obtained	  by	  ImageJ.	  	  
Materials	  and	  Methods	  
	   65	  
	  
3.8	  qPCR	  analysis	  
TBS332,	  control	   fibroblasts,	  and	  Shh-­‐LIGHT2	  cells	  were	  starved	  for	  24	  hours	  
with	   or	   without	   purmorphamine	   treatment	   (5	   µM;	   ChemCruz)	   to	   induce	   Shh	  
signalling	  pathway.	  Total	  RNA	  was	  obtained	  with	  EZNA	  Total	  RNA	  Kit	   (Omega)	  and	  
quantified	   by	   Nanodrop	   spectrophotometer.	   cDNAs	   were	   prepared	   using	   the	  
SuperScript	   III	   First-­‐Strand	   Synthesis	   System	   (Invitrogen)	   in	   10	   µl	   volume	   per	  
reaction.	   Human	   LUZP1,	   GLI1,	   PTCH1,	   GAPDH,	   and	   mouse	   Gli1,	   Ptch1,	   and	   Rplp0	  
primers	  were	  tested	  for	  efficiency	  and	  products	  checked	  for	  correct	  size	  before	  being	  
used	   in	   test	   samples.	   qPCR	   was	   done	   using	   PerfeCTa	   SYBR	   Green	   SuperMix	   Low	  
(Quantabio)	  or	  Mi-­‐Hot	  Taq	  Mix	  (Metabion)	  adding	  20x	  Evagreen	  (Biotium).	  Reactions	  
were	  performed	  in	  10	  µl,	  adding	  1	  µl	  of	  cDNA	  and	  0.5	  µl	  of	  each	  primer	  (10	  µM),	  in	  a	  
CFX96	  thermocycler	  (BioRad)	  using	  the	  following	  protocol:	  95°C	  for	  10	  minutes	  and	  
40	  cycles	  of	  95°C	  for	  10	  seconds	  and	  55-­‐60°C	  for	  30	  seconds.	  Melting	  curve	  analysis	  
was	   performed	   for	   each	   pair	   of	   primers	   between	   65°C	   and	   95°C,	   with	   0.5°C	  
temperature	   increments	   every	   5	   seconds.	   Relative	   gene	   expression	   data	   were	  
analysed	  using	  the	  ΔΔCt	  method.	  Reactions	  were	  done	  in	  triplicates	  and	  results	  were	  
derived	   from	   at	   least	   three	   independent	   experiments	   normalized	   to	   GAPDH	   and	  
Rplp0	   and	   presented	   as	   relative	   expression	   levels.	   Primer	   sequences:	   GLI1-­‐F:	   5'-­‐
AGCCTTCAGCAATGCCAGTGAC-­‐3';	   GLI1-­‐R:	   5'-­‐GTCAGGACCATGCACTGTCTTG-­‐3';	  
PTCH1-­‐F:	   5'-­‐CTCATATTTGCCTTCG-­‐3';	   PTCH1-­‐R:	   5'-­‐TCTCCAATCTTCTGGCGAGT-­‐3',	  
LUZP1-­‐F:	   5´-­‐GGAATCGGGTAGGAGACACCA-­‐3´;	   LUZP1-­‐R:	   5´-­‐
TTCCCAGGCAGTTCAGACGGA-­‐3;	  GAPDH-­‐F:	  5'-­‐AGCCACATCGCTCAGACAC-­‐3';	  GAPDH-­‐R:	  
5'-­‐GCCCAATACGACCAAATCC-­‐3';	   Gli1-­‐F:	   5'-­‐AGCCTTCAGCAATGCCAGTGAC-­‐3';	   Gli1-­‐R:	  
5'-­‐GTCAGGACCATGCACTGTCTTG-­‐3';	   Ptch1-­‐F:	   5'-­‐AAGCCGACTACATGCCAGAG-­‐3';	  
Ptch1-­‐R:	   5'-­‐TGATGCCATCTGCGTCTACCAG-­‐3',	   Rplp0-­‐F:	   5'-­‐
ACTGGTCTAGGACCCGAGAAG-­‐3';	  Rplp0-­‐R:	  5'-­‐CTCCCACCTTGTCTCCAGTC-­‐3'.	  
	  
3.9	  CRISPR-­‐Cas9	  genome	  editing	  
CRISPR-­‐Cas9	  targeting	  of	  SALL1	  locus	  was	  performed	  to	  generate	  a	  HEK	  293FT	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cell	   line	   carrying	   a	   TBS-­‐like	   allele.	   We	   used	   online	   resources	   (CRISPRdesign	   and	  
CRISPOR)	   to	   search	   for	   high-­‐scoring	   sites	   in	   proximity	   to	   the	   site	   mutated	   in	   the	  
TBS332	  fibroblasts.	  We	  chose	  the	  highest	  scoring	  sgRNA	  target	  to	  design	  our	  vectors.	  
All	  constructs	  were	  confirmed	  by	  sequencing	  and	  cloning.	  Transient	  transfection	  and	  
puromycin	  selection	  was	  followed	  by	  single-­‐cell	  cloning	  and	  screening.	  After	  CRISPR-­‐
Cas9	  mediated	  cutting,	  we	  selected	  a	  clone	  that	  gave	  rise	  to	  a	  single	  base	   insertion	  
(SALL1c.1003dup)	  and	  the	  SALL1p.Ser335Lysfs*20	  protein	  (SALL1335),	  hereinafter	  referred	  to	  as	  
293335.	   Presence	   of	   the	   truncated	   protein	   was	   confirmed	   by	   Western	   blot.	   This	  
mutation	   was	   heterozygous	   as	   confirmed	   by	   Sanger	   sequencing	   of	   a	   pooled	  
mutant/WT	   amplicon,	   as	   well	   as	   individual	   sequencing	   of	   TOPO-­‐cloned	   amplicons,	  
where	  both	  mutant	  and	  WT	  clones	  were	  detected.	  	  
	   Using	  the	  same	  online	  resources,	  we	  chose	  6	  of	  the	  highest	  scoring	  off-­‐target	  
sites	   for	   additional	   analysis	   (mm2_exon_SALL1P1_chrX_49432372;	  
mm4_exon_NACA_chr12_57110706;	  
mm4_intergenic_CDCA7L|RAPGEF5_chr7_22092853;	   mm4_intergenic_RNU6-­‐
996P|AL162389.1_chr9_110472444;	   mm4_exon_LEMD2_chr6_33744586;	  
mm4_exon_GPRIN2_chr10_46999700).	  Using	  genomic	  DNA	  from	  our	  targeted	  clone	  
as	   template,	  we	  performed	  PCR	  and	  Sanger	   sequencing.	   In	  all	   cases,	  no	  mutations	  
were	  found.	  	  
The	  mouse	  Luzp1	  locus	  was	  targeted	  in	  NIH3T3-­‐based	  Shh-­‐LIGHT2	  fibroblasts	  
(Taipale	  et	  al.,	  2000)	  (kind	  gift	  from	  A.	  McGee,	  Imperial	  College).	  Cas9	  was	  introduced	  
into	   Shh-­‐LIGHT2	   cells	   by	   lentiviral	   transduction	   (Lenti-­‐Cas9-­‐blast;	   Addgene	   #52962;	  
kind	   gift	   from	   F.	   Zhang,	   MIT)	   and	   selection	   with	   blasticidin	   (5	   µg/ml).	   Two	   high-­‐
scoring	   sgRNAs	   were	   selected	   (http://crispr.mit.edu/)	   to	   target	   near	   the	   initiation	  
codon	   (sg2:	  CTTAAATCGCAGGTGGCGGT_TGG;	   sg3:	  CTTCAATCTTCAGTACCCGC_TGG).	  
These	  sequences	  were	  cloned	  into	  px459	  2.0	  (Addgene	  #62988;	  kind	  gift	  of	  F.	  Zhang,	  
MIT),	   for	   expressing	   both	   sgRNAs	   and	   additional	   Cas9	   with	   puromycin	   selection.	  
Transfections	   were	   performed	   in	   Shh-­‐LIGHT2/Cas9	   cells	   with	   Lipofectamine	   3000	  
(Thermo).	  24	  hours	  after	  transfection,	  transient	  puromycin	  selection	  (0.5	  µg/ml)	  was	  
applied	   for	   48	   hours	   to	   enrich	   for	   transfected	   cells.	   Cells	   were	   plated	   at	   clonal	  
density,	  and	  well-­‐isolated	  clones	  were	  picked	  and	  propagated	   individually.	  Western	  
blotting	  was	  used	  to	  identify	  clones	  lacking	  Luzp1	  expression.	  Further	  propagation	  of	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a	  selected	  clone	  (#6)	  was	  carried	  out	  with	  G418	  (0.4	  mg/ml)	  and	  zeocin	  (0.15	  mg/ml)	  
selection	  to	  maintain	  expression	  of	   luciferase	  reporters.	  Genotyping	  was	  performed	  
using	   genomic	   PCR	   (MmLuzp1_geno_F:	   5'-­‐GTTGCCAAAGAAGGTTGTGGATGCC-­‐3’;	  
MmLuzp1_geno_R:	   5'-­‐CGTAAGGTTTTCTTCCTCTTCAAGTTTCTC-­‐3’)	   and	   revealed	   a	  
homozygous	   deletion	   of	   bases	   between	   the	   two	   sgRNA	   target	   sites,	   predicting	   a	  
frame-­‐shifted	  truncated	  protein	  (MAELTNYKDAASNRY*),	  and	  resulting	  in	  a	  null	  Luzp1	  
allele	   (Luzp1-­‐/-­‐	   cells).	   A	   rescue	   cell	   line	   was	   generated	   by	   transducing	   Shh-­‐LIGHT2	  
Luzp1	   KO	   clone	   #6	  with	   a	   lentiviral	   expression	   vector	   carrying	   EFS-­‐LUZP1-­‐YFP-­‐P2A-­‐
blastR,	   with	   a	   positive	   population	   selected	   by	   fluorescence-­‐activated	   cell	   sorting	  
(+LUZP1	  cells).	  A	  similar	  approach	  was	  used	  for	  disrupting	  LUZP1	  in	  human	  HEK	  293FT	  
cells,	   using	   sgRNAs	   targeting	   sequences	   located	   in	   exon	   1,	   namely	   sg1:	  
CTTAAACCGCAAGTGGCGGC_TGG	   and	   sg2:	   AAGCCGCCGCCTTGATGAGT_TGG.	   A	  
knockout	  clone,	  called	  293LUZP1	  KO,	  was	  selected	  by	  absence	  of	  LUZP1	  signal	  in	  western	  
blots.	  
	  
3.10	  Plasmid	  construction	  
A	   FL	   human	   SALL1	   clone	   was	   used	   for	   high-­‐fidelity	   PCR	   amplification	   and	  
subcloning	   into	   EYFP-­‐N1	   (Clontech)	   as	   truncated	   (SALL1826-­‐YFP)	   or	   FL	   versions	  
(SALL1FL-­‐YFP).	  Clones	  were	  validated	  by	  Sanger	  sequencing	  and	  correspond	  to	  current	  
annotations	  (NCBI	  RefSequence:	  NM_002968.2).	  EYFP	  was	  exchanged	  for	  two	  copies	  
of	  HA	  tag	  to	  build	  SALL1FL-­‐2xHA.	  For	  BioID	  vectors,	  Ac5-­‐STABLE2-­‐neo	  (Gonzalez	  et	  al.,	  
2011)	  was	  modified	  to	  contain	  a	  CAG	  promoter,	  a	  Myc-­‐tagged	  version	  of	  BirA	  (R118G,	  
human	  codon-­‐optimized),	  and	  a	  multiple	  cloning	  site	   into	  which	  SALL1826	  or	  SALL1FL	  
was	   inserted	   (Roux	   et	   al.,	   2012).	   Lentiviral	   expression	   vectors	   were	   prepared	   in	  
Lentilox-­‐GFS-­‐IRESpuro,	  a	  derivative	  of	  LL3.7	   (GFS=GFP-­‐FLAG-­‐STREP)	   (Rubinson	  et	  al.,	  
2003).	  	  
The	  human	  LUZP1	  ORF	  was	  amplified	  by	  high-­‐fidelity	  PCR	  (Platinum	  SuperFi;	  
Thermo)	   from	  hTERT-­‐RPE1	   cDNA	   and	   cloned	   to	   generate	  CB6-­‐GFP-­‐LUZP1.	   This	  was	  
used	  as	  a	  source	  clone	  to	  generate	  additional	  variants	   (CB6-­‐HA-­‐LUZP1,	  CMV-­‐LUZP1-­‐
YFP,	  CMV-­‐LUZP1-­‐2xHA).	  The	  LUZP1-­‐YFP	  lentiviral	  expression	  vector	  was	  generated	  by	  
replacing	  Cas9	  in	  Lenti-­‐Cas9-­‐blast	  (Addgene	  #52962).	  All	  constructs	  were	  verified	  by	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Sanger	  sequencing.	  
	  
3.11	  SALL1	  silencing	  	  
	   A	  human	  SALL1	  target	  sequence	  (5’-­‐CTGCTATTTGTATTGTGCTTT-­‐3’;	  based	  on	  
validated	   Mission	   shRNA	   TRCN0000003958;	   Sigma/Merck)	   was	   cloned	   into	   the	  
inducible	   shRNA	   vector	   Tet-­‐pLKO-­‐puro	   (Addgene	   #21915)	   (Wiederschain	   et	   al.,	  
2009).	  Lentivirus	  was	  produced	  in	  HEK	  293FT	  cells	  and	  used	  to	  transduce	  and	  stably	  
select	  HEK	  293FT	  cells	  using	  puromycin	  (1	  µg/ml).	  SALL1	  silencing	  was	  induced	  for	  72	  
hours	  using	  doxycycline	  (1	  µg/ml).	  
	  
3.12	  Lentiviral	  transduction	  
	   Lentiviral	   expression	   constructs	   were	   packaged	   using	   psPAX2	   and	   pVSVG	  
(Addgene)	   in	   HEK	   293FT	   cells,	   and	   lentiviral	   supernatants	  were	   used	   to	   transduce	  
TBS-­‐derived	   human	   cells,	   Shh-­‐LIGHT2	   and	   hTERT-­‐RPE1	   cells.	   Stable-­‐expressing	  
populations	   were	   selected	   using	   puromycin	   (1	   µg/ml).	   For	   primary	   fibroblasts,	  
lentiviral	  supernatants	  were	  concentrated	  100-­‐fold	  before	  use	  (Lenti-­‐X	  concentrator,	  
Clontech).	  
	  
3.13	  Luciferase	  assays	  
	   Firefly	   luciferase	   expression	   was	   measured	   using	   the	   Dual-­‐Luciferase	  
Reporter	  Assay	  System	  (Promega)	  according	  to	  the	  manufacturer's	   instructions.	  For	  
each	   construct,	   luciferase	   activity	   upon	   purmorphamine	   treatment	  was	   divided	   by	  
the	   activity	   of	   cells	   before	   treatment	   induction	   to	   obtain	   the	   fold	   change	   value.	  
Luminescence	   was	   measured	   and	   data	   were	   normalized	   to	   the	   Renilla	   luciferase	  
readout.	  Experiments	  were	  performed	  with	  both	  biological	  and	  technical	  replicates.	  
	  
3.14	  Fluorescence-­‐activated	  cell	  sorting	  	  
To	  evaluate	  apoptosis,	  Shh-­‐LIGHT2	  cells	  were	  washed	  with	  1x	  PBS	  and	  then	  
stained	  with	   Annexin	   V	   (BD	   Biosciences)	   and	  DRAQ7	   (Biostatus	   Ltd).	   For	   cell	   cycle	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analysis,	   Shh-­‐LIGHT2	   cells	  were	  washed	  with	   cold	   PBS	   and	   fixed	  with	   70%	  ethanol	  
overnight.	   Cells	   were	   then	   washed	   twice	   with	   PBS	   and	   resuspended	   in	   PBS	  
containing	  5  μg/ml	  propidium	  iodide	  (PI)	  and	  100  μg/ml	  RNase	  A	  (Sigma-­‐Aldrich,	  St.	  
Louis,	  MO,	  USA).	  A	  total	  of	  20,000	  events	  were	  counted	  for	  each	  sample.	  Data	  were	  
collected	  on	  a	  Fluorescence-­‐activated	  Cell	  Sorting	  (FACS)	  Canto	  (BD	  Biosciences)	  and	  
were	  analysed	  using	  FlowJo	  software	  (www.flowjo.com).	  
	  
3.15	  Proliferation	  assay	  
5×103	  cells	  were	  plated	  in	  triplicate	  in	  12-­‐well	  dishes.	  24	  hours	  later,	  the	  cells	  
were	  considered	  day	  0	  (t0)	  and	  were	  fixed	  in	  formalin	  10%	  for	  15	  minutes.	  The	  same	  
procedure	  was	   performed	   after	   3	   and	   6	   days.	   Cell	   proliferation	  was	  measured	   by	  
staining	   with	   crystal	   violet	   (0.1%	   in	   20%	   methanol)	   for	   45	   minutes	   at	   RT.	   After	  
washing	   3	   times	   with	   water,	   all	   samples	   were	   air	   dried.	   The	   precipitate	   was	  
solubilized	  in	  10%	  acetic	  acid	  for	  20	  minutes	  at	  RT	  and	  the	  absorbance	  was	  measured	  
at	  595	  nm.	  For	  each	  timepoint,	  4	  biological	  replicates	  were	  measured.	  	  
	  
	  
3.16	  Wound-­‐healing	  assay	  
Shh-­‐LIGHT2	   control,	   Luzp1-­‐/-­‐	  mutant	   cells	   and	   Luzp1-­‐/-­‐	   cells	   transduced	  with	  
LUZP1	  (+LUZP1	  cells)	  were	  grown	  in	  24-­‐well	  plates	  and	  a	  scratch	  (wound)	  was	  done	  
using	  a	  20	  µm	  pipette	  tip.	  Subsequently,	  medium	  was	  changed	  to	  remove	  detached	  
and	  dead	  cells.	  Pictures	  were	  taken	  at	  three	  different	  positions	  per	  sample	  and	  three	  
biological	   replicates	  were	  analysed	  of	  each.	  The	  scratch	  width	  was	  measured	  using	  
ImageJ	  Fiji.	  	  
	  
3.17	  Filopodia	  quantification	  
Filopodia	  were	  quantified	  by	  staining	  cells	  with	  Alexa	  594-­‐conjugated	  wheat	  
germ	   agglutinin	   (WGA)	   and	   using	   FiloQuant,	   a	   plugin	   for	   the	   ImageJ	   software	  
(Jacquemet	  et	  al.,	  2017).	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3.18	  Statistical	  analysis	  
Statistical	   analysis	  was	   performed	   using	  GraphPad	   6.0	   software.	   Data	  were	  
analysed	  by	  Shapiro-­‐Wilk	  normality	  test	  and	  Levene´s	  test	  of	  variance.	  We	  used	  two	  
tailed	  unpaired	  Student´s	  t-­‐test	  or	  Mann	  Whitney-­‐U	  tests	  for	  comparing	  two	  groups,	  
One-­‐way	  ANOVA	  or	  Kruskall-­‐Wallis	   and	   the	   corresponding	  post-­‐hoc	   tests	   for	  more	  
than	  two	  groups	  and	  two-­‐way	  ANOVA	  for	  comparing	  more	  than	  one	  variable	  in	  more	  
than	   two	   groups.	   P	   values	  were	   represented	   by	   asterisks	   as	   follows:	   (*)	   P-­‐value	   <	  
0.05;	  (**)	  P-­‐value	  <	  0.01;	  (***)	  P-­‐value	  <	  0.001;	  (****)	  P-­‐value	  <	  0.0001.	  Differences	  
were	  considered	  significant	  when	  P	  <	  0.05.	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4.1	  Objective	  1:	  the	  role	  of	  SALL1	  in	  cilia	  formation	  and	  function	  
4.1.1	   Truncated	   SALL1	   abnormally	   recruits	   SALL1FL	   to	   the	   cytoplasm	   in	   TBS	  
fibroblasts	  
It	   has	   been	   reported	   that	   the	   presence	   of	   truncated	   SALL1	   protein	   is	  
sufficient	   to	   cause	   TBS-­‐like	   phenotype	   in	   a	   mouse	   model	   (Kiefer	   et	   al.,	   2008).	   In	  
humans,	   a	   truncated	   SALL1	   protein	   was	   observed	   in	   B-­‐cells	   derived	   from	   a	   TBS	  
individual	  (Kiefer	  et	  al.,	  2008),	  but	  its	  presence	  in	  fibroblasts	  has	  not	  been	  reported.	  
We	  obtained	  dermal	  fibroblasts	  derived	  from	  a	  male	  TBS332	  individual	  (see	  Materials	  
and	  Methods)	  (Botzenhart	  et	  al.,	  2007;	  Furniss	  et	  al.,	  2007).	  It	  was	  previously	  shown	  
that	  mRNA	  from	  the	  truncated	  allele	  was	  expressed	  in	  TBS332	  fibroblasts	  (Furniss	  et	  
al.,	   2007),	   therefore	   we	   checked	   for	   the	   presence	   of	   truncated	   SALL1	   protein	   by	  
Western	   blot.	   For	   that,	   we	   took	   advantage	   of	   distinct	   antibodies	   recognizing	  
different	  epitopes	  of	  SALL1	   (see	  Materials	  and	  Methods;	  Figure	  R	  1A	  and	  Figure	  R	  
1B),	   which	   allowed	   us	   to	   distinguish	   SALL1FL	   from	   the	   truncated	   forms.	   Using	   an	  
antibody	   directed	   against	   the	   N-­‐terminal	   portion	   of	   SALL1,	   a	   truncated	   protein	   of	  
about	  62	  kDa	  was	  identified	  in	  TBS332	  cells	  but	  not	  in	  control	  fibroblasts	  (HFF)	  (Figure	  
R	   1C).	   Furthermore,	   SALL1FL	   protein	  was	   less	   abundant	   in	   the	   TBS332	   compared	   to	  
control	   HFF	   fibroblasts.	   As	   previously	   reported,	   the	   observed	   size	   of	   SALL1	   by	  
Western	  blot	  is	  higher	  than	  expected	  (Kiefer	  et	  al.,	  2008).	  	  
FL	   SALL1	   proteins	   (SALL1FL)	   are	   normally	   enriched	   in	   the	   nucleus,	   while	  
truncated	   forms	   have	   been	   observed	   in	   both	   nucleus	   and	   cytoplasm	   (Sato	   et	   al.,	  
2004;	   Sweetman	   et	   al.,	   2003).	   These	   studies	   used	   overexpression	   of	   truncated	  
murine	  or	  chicken	  forms	  of	  Sall1,	  which	  induced	  a	  mislocalization	  of	  the	  SALL1FL	  into	  
the	  cytoplasm,	   likely	  due	  to	  the	  interaction	  of	  the	  different	  SALL1	  proteins	  through	  
their	   glutamine-­‐rich	   domains	   (Sato	   et	   al.,	   2004;	   Sweetman	   et	   al.,	   2003).	   We	  
therefore	   analysed	   whether	   the	   reported	   change	   in	   localization	   of	   endogenous	  
SALL1	   was	   also	   occurring	   in	   human	   TBS332-­‐derived	   cells.	   By	   immunofluorescence,	  
TBS332-­‐derived	   fibroblasts	   presented	   abnormal	   cytoplasmic	   staining	   of	   SALL1FL	  
(Figure	  R	  1D).	  We	  quantified	  the	  fluorescence	  intensity	  of	  SALL1FL	   in	  the	  nuclei	  and	  
cytoplasm	   in	   both	   control	   and	   TBS332	   human	   fibroblasts.	   SALL1FL	   intensity	   was	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Figure	   R	   1.	   Truncated	   SALL1	   expressed	   in	   TBS	   individualss	   disrupts	   the	   localization	   of	   SALL1WT	  
protein.	  (A)	  Western	  blot	  analysis	  of	  total	   lysates	  of	  HEK	  293FT	  cells	  transfected	  with	  SALL1c.826C>T-­‐
YFP	  (SALL1275-­‐YFP)	  or	  SALL1FL-­‐YFP	  (SALL1FL–YFP).	  Samples	  were	  run	  in	  duplicate	  on	  the	  same	  gel	  and	  
probed	   against	   SALL1	   using	   two	   different	   antibodies.	   Anti-­‐SALL1	   antibody	   from	   R&D	   specifically	  
recognizes	   SALL1FL	   (asterisk),	   but	   not	   the	   truncated	   form	   (black	   arrowhead),	   while	   anti-­‐SALL1	   N-­‐
terminal	   specific	   detects	   both.	   (B)	   Western	   blot	   analysis	   of	   HEK	   293FT	   lysates	   expressing	   SALL1	  
specific	   shRNA	   under	   the	   control	   of	   a	   doxycycline	   inducible	   promoter.	   Cells	   were	   subjected	   to	  
doxycycline	   (+)	   or	   DMSO	   treatment	   (-­‐)	   for	   72h.	   SALL1FL	   protein	   was	   detected	   using	   anti-­‐SALL1	  
antibody	   from	  R&D	  (asterisk)	  and	  GAPDH	  was	  used	  as	  a	   loading	  control.	  TBS332	  dermal	   fibroblasts	  
express	   truncated	  SALL1	  protein	   (SALL1∆995C).	   (C)	  Western	  analysis	  of	   control	  HFF	  or	  TBS332	  human	  
fibroblast	  lysates	  shows	  loss	  of	  the	  wild-­‐type	  protein	  (asterisk)	  and	  expression	  of	  a	  truncated	  protein	  
of	  62	  kDa	  (arrowhead)	  recognized	  by	  SALL1	  specific	  antibodies	  in	  TBS-­‐derived	  fibroblasts.	  Molecular	  
weight	   markers	   (kDa)	   are	   shown	   to	   the	   right	   in	   A,	   B	   and	   C.	   (D)	   Confocal	   micrographs	   showing	  
SALL1FL	  detected	  by	  FL	  specific	  antibodies	  (R&D)	  in	  control	  HFF	  or	  TBS332	  fibroblasts,	  shown	  as	  black	  
and	   white	   images.	   Nuclei	   were	   counterstained	   with	   DAPI	   (represented	   by	   yellow	   circles).	   (E)	  
Graphical	   representation	   of	   three	   independent	   experiments	   showing	   the	   ratio	   between	   the	  
fluorescence	  quantification	  of	  the	  levels	  of	  SALL1FL	  in	  the	  nucleus	  or	  cytoplasm	  of	  control	  HFF	  (n=40	  
cells;	  blue	  circles)	  or	  TBS332-­‐derived	  fibroblasts	  (n=36	  cells;	  orange	  triangles)	  and	  the	  area	  in	  µm2	  of	  
control	  (n=33	  cells,	  blue	  circles)	  or	  TBS332	  (n=33	  cells,	  orange	  triangles)	  (F).	  P-­‐values	  were	  calculated	  
with	   the	   Mann-­‐Whitney	   two-­‐tailed	   test.	   Median	   and	   interquartile	   range	   of	   the	   median	   are	  
represented.	  Scale	  bars,	  10	  µm.	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significantly	  lower	  in	  the	  nuclei,	  while	  significantly	  higher	  in	  the	  cytoplasm	  of	  TBS332	  
fibroblasts	   leading	   to	  a	  decrease	   in	   the	  nuclear/cytoplasmic	   ratio	   (Figure	  R	  1E).	  No	  
significant	  differences	   in	  nuclei	  or	  cytoplasm	  size	  were	   found	  between	  control	  and	  
TBS	  fibroblasts,	  indicating	  that	  the	  changes	  in	  intensity	  are	  not	  due	  to	  differences	  in	  
size	  (Figure	  R	  1F).	  	  
To	   check	   whether	   the	   presence	   of	   the	   truncated	   protein	   in	   human	   cells	   is	  
sufficient	   to	   produce	   the	   localization	   change	   of	   SALL1FL,	   we	   chose	   a	   mutation	  
(SALL1c.826C>T)	   that	  encodes	   for	  SALL1p.Arg275*	   (SALL1275,	  herein)	  and	   that	   it	  has	  been	  
reported	  in	  several	   independent	  TBS	  individuals	  (Botzenhart	  et	  al.,	  2007),	  making	  it	  
the	   most	   common	   allele	   in	   this	   rare	   syndrome.	   Therefore,	   U2OS	   cells	   were	  
transiently	   transfected	   with	   SALL1FL-­‐2xHA	   (SALL1FL-­‐2xHA),	   with	   SALL1c.826C>T-­‐YFP	  
(SALL1275-­‐YFP)	  or	  with	  a	  combination	  of	  both.	  As	  expected,	  SALL1275-­‐YFP	  localization	  
was	   diffuse	   in	   the	   nucleus	   and	   cytoplasm	   (Figure	   R	   2A),	  while	   SALL1FL	   localization	  
was	   limited	   to	   the	   nuclei	   in	   a	   typical	   pattern	   of	   subnuclear	   spots	   (Figure	   R	   2B).	  
However,	   in	   the	   presence	   of	   SALL1275,	   SALL1FL	   changed	   its	   localization	   and	  
colocalized	   with	   SALL1275	   (Figure	   R	   2C).	   All	   together,	   these	   findings	   imply	   that	  
SALL1275	   compromises	   SALL1FL	   localization	  by	   recruiting	   it	   to	   the	   cytoplasm	   in	   TBS-­‐
derived	  fibroblasts.	  In	  addition,	  these	  results	  further	  support	  the	  conclusion	  that	  the	  
expression	  of	  the	  truncated	  form	  is	  crucial	  in	  the	  pathogenesis	  of	  TBS	  in	  humans	  
	  
4.1.2	  SALL1	  localizes	  to	  the	  primary	  cilia	  
	  	   Intrigued	   by	   the	   overlapping	   phenotypic	   characteristics	   between	   TBS	  
individuals	   and	   ciliopathies	   (polydactyly,	   imperforate	   anus,	   hearing	   loss	   and	  
polycystic	  kidneys),	  we	  further	  explored	  the	  subcellular	  localization	  of	  SALL1	  in	  cells	  
that	  are	  able	  to	  develop	  cilia	  and	  checked	  whether	  it	  localizes	  at	  the	  centrosome	  or	  
ciliary	  shaft.	  For	  this	  purpose,	  we	  chose	  human	  fibroblast	  HEK	  293FT	  and	  the	  murine	  
cell	  lines	  IMCD3	  and	  NIH	  3T3.	  Immunofluorescence	  staining	  was	  performed	  on	  cells	  
that	  had	  been	  starved	  for	  48h.	  In	  addition	  to	  the	  reported	  localization	  of	  SALL1FL	  in	  
the	  nuclei,	  we	  detected	  the	  remarkable	  presence	  of	  SALL1FL	  in	  the	  ciliary	  axoneme	  of	  
HEK	   293FT	   cells,	   determined	   by	   co-­‐staining	   with	   a	   monoclonal	   antibody	   against	  
ARL13B	   (ciliary	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shaft)	  (Figure	  R	  3A).	  SALL1	  was	  also	  present	  in	  the	  nuclei	  and	  the	  ciliary	  shaft	  of	  the	  
inner	  medullar	   conducting	   duct	   cell	   line	   IMCD3,	   in	   a	   pattern	   that	  was	   surprisingly	  
reminiscent	   of	   intrafragellar	   transport	   proteins	   (Figure	   R	   3B),	   and	   of	   the	   mouse-­‐
derived	  NIH	  3T3	  cells	  (Figure	  R	  3C).	  	  
	  
Whereas	  SALL1FL	  was	  localized	  to	  the	  nuclei	  and	  ciliary	  shaft	  in	  human	  control	  
fibroblasts	   (Figure	   R	   4A),	   it	   was	   diffusely	   observed	   in	   the	   nucleus,	   cytoplasm	   and	  
ciliary	   shaft	   in	   TBS332	   patient-­‐derived	   fibroblasts	   (Figure	   R	   4B).	  When	   SALL1	   signal	  
was	  quantified	  exclusively	  along	  the	  cilia,	  SALL1FL	  was	  less	  present	  in	  the	  ciliary	  shaft	  
of	  TBS332	  fibroblasts	  compared	  to	  control-­‐derived	  fibroblasts	  (Figure	  R	  4C).	  Together,	  
Figure	  R	  2.	  Truncated	  SALL1	  interacts	  with	  SALL1FL	  in	  the	  cytoplasm.	  (A-­‐C)	  Confocal	  micrographs	  of	  
U2OS	  cells	   transfected	  with	  SALL1c.826C>T-­‐YFP	   (SALL1275-­‐YFP)	   (A),	  SALL1FL-­‐2xHA	   (SALL1FL–2xHA)	   (B)	  or	  
both	   (C).	   SALL1FL-­‐2xHA	   is	   in	   purple,	   SALL1275-­‐YFP	   in	   green	   and	   nuclei	   in	   blue	   (DAPI).	   SALL1FL	   is	  
recognized	  with	  FL	  specific	  antibodies	  (R&D)	  that	  do	  not	  recognize	  SALL1275,	  which	  localizes	  diffusely	  
thorough	   nucleus	   and	   cytoplasm	   (A).	   SALL1FL	   exhibits	   a	   nuclear	   pattern	   (B)	   that	   is	   impaired	  when	  
SALL1275	  is	  present	  (C).	  Black	  and	  white	  images	  show	  the	  single	  purple	  (A'-­‐C'),	  green	  (A''-­‐C'')	  and	  blue	  
channels	  (A´´´-­‐C´´´).	  Images	  were	  taken	  with	  a	  Zeiss	  Axioimager	  D1,	  63x	  objective.	  Scale	  bar,	  10	  µm.	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these	   results	   imply	   that	   endogenous	   SALL1FL	   might	   be	   a	   ciliary	   protein	   and	   that	  
truncated	  SALL1	  might	  disrupt	  its	  localization	  in	  a	  dominant-­‐negative	  manner.	  
	  
4.1.3	  TBS-­‐derived	  cells	  show	  increased	  cilia	  frequency	  and	  length	  
Based	  on	   the	   localization	  of	  SALL1FL	   to	   the	  ciliary	   shaft	  and	   the	  overlapping	  
symptoms	   between	   TBS	   and	   ciliopathies,	   we	   hypothesized	   that	   primary	   cilia	  
formation	  might	   be	   altered	   in	   TBS	   cells.	   To	   test	   this	   hypothesis,	   we	   checked	   cilia	  
assembly	  and	  disassembly	  in	  fibroblasts	  derived	  from	  both	  control	  (HFF)	  and	  TBS332.	  
Primary	   cilia	   assembly	   was	   promoted	   by	   starving	   cells	   at	   high	   confluency	   for	   48	  
Figure	   R	   3.	   SALL1FL	   localizes	   to	   cilia	   shaft	   in	   human	   and	  mouse	   cell	   lines.	  Confocal	  micrographs	  
show	  SALL1FL	  localizing	  to	  the	  nucleus	  and	  primary	  cilia	  of	  HEK	  293FT	  (A),	  IMCD3	  (B)	  and	  NIH	  3T3	  (C)	  
cells.	   SALL1	   stained	   in	   green	   (middle	   panels)	   and	   microtubule	   axoneme	   and	   basal	   body	   using	  
acetylated	  alpha	   tubulin	  and	  gamma	  tubulin	   (AcGT),	   respectively,	  or	  primary	  cilia	  using	  ARL13B	   in	  
purple.	  Black	  and	  white	   images	  show	  the	  single	  green	  and	  purple	  channels.	  Confocal	   images	  were	  
taken	  with	  a	  Leica	  SP2	  confocal	  microscope.	  Scale	  bar,	  5µm.	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hours,	  whereas	  cilia	  disassembly	  was	  induced	  by	  adding	  complete	  media	  to	  ciliated	  
cells	  previously	  subjected	  to	  serum	  starvation.	  We	  quantified	  frequency	  of	  ciliation	  
and	   primary	   cilia	   length	   at	   all	   mentioned	   timepoints.	   TBS	   fibroblasts	   showed	   a	  
significantly	   higher	   frequency	   of	   primary	   cilia	   formation	   when	   the	   cells	   were	   not	  
subjected	  to	  starvation	  (Figure	  R	  5A-­‐C).	  7.9%	  of	  the	  control	  cells	  vs	  24.7%	  of	  the	  TBS	  
cells	  exhibited	  a	  primary	  cilium	  in	  cycling	  conditions	  (Figure	  R	  5C).	  TBS	  cells	  were	  also	  
significantly	  more	   ciliated	   than	   control	   fibroblasts	   upon	   48	   hours	   of	   starvation.	   In	  
those	  conditions,	  36.1%	  of	  the	  control	  cells	  vs	  78.8%	  of	  the	  TBS	  fibroblasts	  displayed	  
a	   primary	   cilium.	   In	   addition,	   TBS	   cells	  were	   significantly	  more	   ciliated	   30	  minutes	  
and	  2h	  after	  serum	  induction	  (Figure	  R	  5C).	  Whereas	  100%	  of	  the	  control	  cells	  had	  
completely	  dismantled	  their	  cilia	  24h	  after	  inducing	  cilia	  disassembly,	  12%	  of	  the	  TBS	  
fibroblasts	   were	   still	   ciliated	   (data	   not	   shown).	   Furthermore,	   primary	   cilia	   in	   TBS	  
Figure	   R	   4.	   SALL1FL	   localizes	   to	   cilia	   shaft	   and	   its	   levels	   are	   reduced	   in	   TBS332cells.	   Confocal	  
micrographs	   show	   SALL1FL	   localizing	   to	   the	   nucleus	   and	   primary	   cilia	   of	   human	   control	   dermal	  
fibroblasts	  (A)	  and	  diffusely	  thorough	  nucleus	  and	  cytoplasm	  of	  TBS332	  dermal	  fibroblasts	  (B).	  SALL1	  is	  
stained	   in	  green	   (middle	  panels)	  and	  primary	  cilia	  using	  ARL13B	   in	  purple	   (right	  panels).	  Black	  and	  
white	   images	   show	   the	   single	   green	   and	   purple	   channels.	   (C)	   Bar	   graph	   representing	   SALL1FL	  
fluorescent	  signal	  at	  the	  ciliary	  shaft	  of	  control	  (blue	  bar)	  and	  TBS332	  fibroblasts	  (orange	  bar).	  SALL1FL	  
levels	  were	  significantly	  reduced	  at	  the	  ciliary	  shaft	  of	  TBS332	  fibroblasts	  (1278	  ±	  151.3;	  n=129;	  three	  
independent	   experiments)	   compared	   to	   control	   (2240	   ±	   177.3;	   n=108;	   three	   independent	  
experiments).	   Black	   and	   white	   images	   show	   the	   single	   green	   and	   purple	   channels.	   P-­‐values	   were	  
calculated	  with	  the	  two-­‐tailed	  unpaired	  Student´s	  t-­‐test.	  Mean	  and	  standard	  error	  of	  the	  mean	  (SEM)	  
are	  represented.	  Confocal	  images	  were	  taken	  with	  a	  Leica	  SP2	  confocal	  microscope.	  Scale	  bar,	  5µm.	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were	  significantly	  longer	  upon	  48	  hours	  of	  starvation	  compared	  to	  control	  (average	  
3.2	   µm	   in	   control	   vs	   3.7	   µm	   in	   TBS)	   (Figure	   R	   5A-­‐B	   and	   Figure	   R	   5D).	   Cilia	   were	  
significantly	   longer	   in	  TBS	   than	   in	   control	   cells	   at	   all	   the	   studied	   timepoints	  during	  
cilia	  disassembly	   (30	  minutes	  with	  complete	  medium:	  average	  2.6	  µm	  in	  control	  vs	  
3.7	  µm	  in	  TBS;	  2	  hours	  with	  complete	  medium:	  1.9	  µm	  in	  control	  vs	  3	  µm	  in	  TBS).	  The	  
observed	   increase	   in	   cilia	   frequency	   after	   the	   addition	   of	   complete	   medium	   in	  
Figure	  R	  5.	  TBS332	  cells	  show	  aberrant	  cilia	  frequency	  and	  length.	  (A,B)	  Micrographs	  of	  control	  HFF	  
(A)	  or	  TBS332cells.	  (B)	  analysed	  during	  cilia	  assembly	  and	  disassembly.	  Cilia	  were	  visualized	  by	  ARL13B	  
(purple),	  basal	  body	  by	  pericentrin	  (green)	  and	  nuclei	  by	  DAPI	  (blue).	  (C,D)	  Graphical	  representation	  
of	  cilia	  frequency	  (C)	  and	  cilia	  length	  (D)	  measured	  in	  control	  HFF	  (blue	  dots,	  n=58	  cilia)	  or	  TBS332	  cells	  
(orange	  triangles,	  n=116	  cilia)	  from	  three	  independent	  experiments.	  Cells	  that	  underwent	  48	  hours	  
of	  starvation	  were	  compared	  to	  non-­‐starved	  cells.	  After	  starvation,	  cells	  were	  supplied	  with	  serum	  
for	  30	  minutes	  or	  2	  hours	  (n=21-­‐30	  micrographs	  for	  all	  the	  cases).	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control	  cells	   is	  consistent	  with	  a	   reported	  reciliation	  wave	  during	   the	   first	  hours	  of	  
cilia	  disassembly	  (Spalluto	  et	  al.,	  2013).	  These	  results	  show	  that	  TBS	  cells	  have	  longer	  
and	  more	  abundant	  primary	  cilia	  compared	  to	  control	  cells	  in	  all	  tested	  conditions.	  
As	  mentioned	  previously,	  it	  has	  been	  reported	  that	  the	  presence	  of	  truncated	  
SALL1	  protein	  is	  sufficient	  to	  cause	  TBS-­‐like	  phenotype	  in	  a	  mouse	  model	  (Kiefer	  et	  
al.,	  2008).	  Confluent	  HFF	  control	  cells	  (Figure	  R	  6A)	  or	  hTERT-­‐RPE1	  cells	  (Figure	  R	  6C)	  
stably	   transduced	   with	   lentiviral	   GFS-­‐SALL1c.826C>T	   (GFS-­‐SALL1275)	   displayed	   longer	  
cilia	   than	   those	   stable	   for	  GFS	   alone	   (GFS)	   (Figure	   R	   6B	   and	   Figure	   R	   6D),	   further	  
confirming	  that	  the	  presence	  of	  a	  truncated	  form	  of	  SALL1	   is	  sufficient	  to	  promote	  
longer	   cilia.	   Taken	   together,	   these	   results	   suggest	   that	   truncated	   SALL1	   can	   affect	  
cilia	  frequency,	  as	  well	  as	  the	  dynamics	  of	  cilia	  assembly	  and	  disassembly.	  
Figure	  R	  6.	  Cells	  overexpressing	  truncated	  SALL1	  show	  aberrant	  cilia	   length.	  (A,C)	  Micrographs	  
of	   HFF	   control	   (A)	   and	   RPE1	   cells	   (C)	   infected	   with	   lentivirus	   expressing	   GFS	   alone	   (GFS,	   left	  
panels)	  or	  GFS-­‐SALL1c.826C>T	  (GFS-­‐SALL1275,	  right	  panels).	  Cilia	  were	  visualized	  by	  ARL13B	  and	  basal	  
body	  by	  pericentrin	  (per,	  purple)	  and	  nuclei	  by	  DAPI	  (blue).	  Yellow	  arrowheads	  point	  at	  the	  cilia	  
(B,D)	  Graphical	  representation	  of	  cilia	  length	  in	  control	  (B)	  and	  RPE1	  cells	  (D)	  corresponding	  to	  (A)	  
and	   (C)	   infected	  with	   GFS	   (blue	   circles,	   control	   n=25;	   RPE1	   n=43	   cilia)	   or	   GFS-­‐SALL1275	   (orange	  
triangles:	  control	  n=26;	  RPE1	  n=36	  cilia).	  Graphs	  represent	  Mean	  and	  SEM	  of	  three	  independent	  
experiments.	   P-­‐values	  were	   calculated	   using	   two-­‐tailed	   unpaired	   Student´s	   t-­‐test.	   Scale	   bars,	   5	  
µm..	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4.1.4	  TBS-­‐derived	  cells	  exhibit	  aberrant	  Sonic	  Hedgehog	  signalling	  
It	   is	   well	   established	   that	   Shh	   signal	   transduction	   is	   dependent	   on	   the	  
presence	   of	   functional	   primary	   cilia	   in	  mammals	   (Huangfu	   et	   al.,	   2003;	   Yin	   et	   al.,	  
2009).	   Therefore,	   we	   examined	   whether	   Shh	   signalling	   is	   compromised	   in	   TBS332	  
cells.	  Cells	  were	  starved	   for	  24	  hours	  and	   incubated	   in	   the	  presence	  or	  absence	  of	  
purmorphamine	   (a	   Smoothened	   agonist)	   for	   24	   or	   48	   hours	   to	   activate	   the	   Shh	  
pathway.	  mRNA	  expression	  of	  two	  Shh	  target	  genes	  (GLI1	  and	  PTCH1)	  was	  quantified	  
by	   qRT-­‐PCR	   (Figure	   R	   7A	   and	   Figure	   R	   7B).	   We	   found	   that,	   after	   induction	   by	  
purmorphamine	   for	  24	  or	  48	  hours,	   the	   fold-­‐activation	  GLI1	   and	  PTCH1	  expression	  
levels	  in	  TBS	  cells	  was	  higher	  than	  in	  control	  HFF	  cells.	  	  
GLI3	  is	  the	  transcription	  factor	  that	  is	  primarily	  responsible	  for	  repression	  of	  
Shh	   target	   genes,	   and	  Gli3	  mutants	   exhibit	   polydactyly	  because	   they	   lack	   the	  GLI3	  
repressor	  (Hill	  et	  al.,	  2009;	  Litingtung	  et	  al.,	  2002).	  The	  proteolytic	  processing	  event	  
that	   produces	   GLI3	   repressor	   depends	   on	   primary	   cilia	   (Huangfu	   et	   al.,	   2003).	   To	  
further	   study	   the	   role	   of	   SALL1	   truncations	   in	   Shh	   signalling,	   we	   analysed	   GLI3	  
processing	  by	  Western	  blot	  analysis	  using	  total	  lysates	  extracted	  from	  control	  HFF	  vs	  
TBS332	   fibroblasts	   (Figure	  R	  7C).	  We	   found	   that	   the	   increase	  of	  GLI3-­‐A:GLI3-­‐R	   ratio	  
upon	   purmorphamine	   treatment	   is	   significantly	   higher	   in	   TBS332	   cells	   compared	   to	  
control	   fibroblasts	   (Figure	  R	  7C	  and	  Figure	  R	  7D).	  We	  also	  examined	  the	  effects	  of	  
truncated	  SALL1	  on	  Shh	  signalling	  using	  Shh-­‐LIGHT2	  cells	  (Taipale	  et	  al.,	  2000).	  These	  
are	   NIH3T3	  mouse	   embryonic	   fibroblasts	   that	   carry	   an	   incorporated	   Shh	   reporter	  
(firefly	   luciferase	   under	   control	   of	   Gli3-­‐responsive	   promoter).	   We	   observed	  
aberrations	   in	   Shh	   signalling	   in	   Shh-­‐LIGHT2	   cells	   stably	   expressing	  GFS-­‐SALL1c.826C>T	  
(SALL1275)	   vs	   controls	   (Figure	   R	   7E).	   Like	   TBS-­‐derived	   cells,	   Shh-­‐LIGHT2	   cells	  
overexpressing	  SALL1275	   show	  oversensitivity	   to	  Shh	   induction	  compared	   to	  control	  
cells	   (2.3	   fold-­‐induction	   in	   control	   cells	   vs	   3.9	   fold-­‐induction	   in	   cells	   expressing	  
SALL1275).	  Defects	   in	  PTCH1	  and	  GLI1	  gene	  expression	  (endogenous,	  or	  via	  reporter	  
assay)	  and	  impaired	  GLI3	  processing	  confirm	  that	  truncated	  SALL1	  proteins	  found	  in	  
TBS	  might	  cause	  not	  only	  defects	  in	  ciliogenesis,	  but	  also	  in	  Shh	  signalling.	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Figure	  R	  7.	  TBS332	  	  fibroblasts	  show	  aberrant	  SHH	  signaling.	  (A,B)	  Graphical	  representation	  of	  the	  
fold	  change	  in	  the	  expression	  of	  GLI1	  (A)	  and	  PTCH1	  (B)	  obtained	  by	  qPCR	  from	  control	  HFF	  (n=4;	  
blue	   bars)	   or	   TBS332	   (n=4;	   orange	   bars)	   treated	   (+)	   or	   not	   (-­‐)	   with	   purmorphamine	   for	   the	  
indicated	   times.	   Numerical	   quantification	   of	   fold	   activation	   is	   indicated	   below	   the	   graphs.	   (C)	  
Western	  blot	  analysis	  of	  lysates	  from	  control	  ESCTRL#2	  and	  TBS332.	  Samples	  were	  probed	  against	  
GLI3	   that	   detects	   both	   GLI3	   activating	   form	   (GLI3-­‐A)	   and	   GLI3	   repressive	   form	   (GLI3-­‐R)	   and	  
GAPDH	  was	  used	  as	  loading	  control.	  Molecular	  weight	  markers	  (kDa)	  are	  shown	  to	  the	  right.	  (D)	  
Graphical	  representation	  of	  fold	  activation	  obtained	  in	  (C)	  by	  calculating	  the	  GLI3-­‐A:GLI3-­‐R	  ratio	  in	  
control	   and	   TBS332	   fibroblasts.	   Data	   from	   at	   least	   3	   independent	   experiments	   is	   shown,	   using	  
ESCTRL#2	  (control;	  n=3;	  blue	  bars)	  and	  TBS332	  (n=5;	  orange	  bars).	  (E)	  Graphical	  representation	  of	  
fold	   change	   in	   luciferase	   activation	   when	   Shh-­‐LIGHT2	   control	   cells	   (n=8;	   blue	   bars)	   or	   cells	  
expressing	  the	  mutated	  form	  GFS-­‐SALL1c.826C>T	  (GFS-­‐SALL1275;	  n=8;	  orange	  bars)	  are	  treated	  (+)	  or	  
not	   (-­‐)	  with	  purmorphamine.	  All	  graphs	  represent	   the	  Mean	  and	  SEM.	  P-­‐values	  were	  calculated	  
with	  the	  two-­‐tailed	  unpaired	  Student´s	  t-­‐test.	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4.1.5	  New	  TBS-­‐derived	  cell	  line	  exhibits	  cilia	  alterations	  
	   To	  further	  verify	  the	  ciliogenesis	  defects	  previously	  observed	  in	  TBS	  cells,	  we	  
analysed	   SALL1	   levels	   and	   ciliogenesis	   in	   fibroblasts	   derived	   from	   an	   additional	  
individual	   referred	   to	   as	   TBS275	   (Figure	  R	   8A).	  Of	   note,	   this	   is	   the	   same	   truncation	  
that	   is	   used	   in	   our	   exogenous	   expression	   constructs	   (i.e.	   SALL1c.826C>T	   or	   SALL1275).	  
Individual	   TBS275	   displayed	   the	   characteristic	   triad	   of	   TBS	   symphtoms	   (imperforate	  
anus,	   thumb	   and	   ear	   malformations),	   in	   addition	   to	   kidney,	   heart	   and	   hearing	  
problems.	  When	  analysing	  TBS275	  cells,	  we	  observed	  a	  decrease	  in	  SALL1FL	  compared	  
to	   control	   ESCTRL#2	   cells	   and	   the	   presence	   of	   a	   new	   band	   of	   about	   42	   kDa,	  
consistent	  with	  a	  truncated	  SALL1	  protein	  (Figure	  R	  8B).	  Interestingly,	  localization	  of	  
SALL1FL	   was	   also	   altered	   in	   human	   TBS275	   cells	   (Figure	   R	   8C	   and	   Figure	   R	   8D).	   To	  
check	   whether	   the	   presence	   of	   the	   truncated	   protein	   in	   primary	   human	   cells	   is	  
sufficient	   to	   produce	   the	   localization	   change	   of	   SALL1FL,	   ESCTRL#2	   or	   TBS275	   cells	  
were	  transiently	  transfected	  with	  SALL1FL-­‐YFP.	  SALL1FL-­‐YFP	  localization	  was	  limited	  to	  
the	  nuclei	  in	  control	  fibroblasts	  (Figure	  R	  8E)	  while	  its	  localization	  was	  diffuse	  in	  the	  
nucleus	  and	  cytoplasm	  in	  TBS275	  cells	  (Figure	  R	  8F).	  Furthermore,	  when	  compared	  to	  
control	   HFF	   or	   ESCRTL#2,	   TBS275	   cells	   displayed	   longer	   and	  more	   abundant	   cilia	   in	  
confluent	  starved	  conditions,	  similar	  to	  what	  was	  observed	   in	  TBS332	  cells	   (Figure	  R	  
9A-­‐C).	  Thus,	  truncated	  SALL1	  is	  detected	  in	  TBS275	  cells	  and	  leads	  to	  altered	  SALL1FL	  
localization,	   likely	   through	   its	   recruitment	   to	   the	   cytoplasm.	   As	   a	   result,	   the	  
truncated	  SALL1,	  SALL1FL,	  or	  both	  could	  potentially	  interact	  and	  interfere	  with	  other	  
proteins.	  
	  
4.1.6	  TBS-­‐mimicking	  cell	  line	  exhibits	  aberrant	  ciliogenesis	  
Fibroblasts	   derived	   from	   two	   different	   TBS	   individuals	   displayed	   altered	  
frequency	   of	   ciliogenesis	   and	   longer	   cilia	  with	   respect	   to	   control	   cells.	   To	   confirm	  
these	  results,	  we	  attempted	  to	  generate	  a	  TBS-­‐like	  mutation	  in	  HEK	  293FT	  to	  assess	  
the	   cilia	   phenotype.	   In	   addition,	   in	   this	   way	   we	   could	   confirm	   that	   the	   observed	  
differences	   in	   ciliogenesis	   were	   not	   dependent	   on	   the	   genetic	   background	   of	   the	  
cells,	  since	  the	  TBS-­‐like	  model	  cell	  line	  could	  be	  compared	  with	  the	  parental	  cells.	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Figure	  R	  8.	  SALL1	  characterization	   in	  fibroblasts	  derived	  from	  an	  additional	  TBS	   individual.	   (A)	  
Clinical	   findings	   of	   the	   individual	   TBS275.	   (B)	   Western	   blot	   analysis	   of	   lysates	   from	   control	  
ESCTRL#2	  and	  TBS275.	  Samples	  were	  run	  in	  duplicate	  on	  the	  same	  gel	  and	  probed	  against	  SALL1FL	  
(asterisk,	   R&D	   antibody)	   or	   against	   SALL1275	   (black	   arrowhead,	   N-­‐terminal	   specific	   antibody)	  
(Kiefer,	  McDill,	  Yang,	  &	  Rauchman,	  2002).	  TBS275	  cells	  encoded	  a	   truncated	  protein	  of	  about	  48	  
kDa	   that	   positively	   reacts	   against	   SALL1	   antibody.	   Vinculin	   and	   GAPDH	   were	   used	   as	   loading	  
controls.	   Molecular	   weight	   markers	   (kDa)	   are	   shown	   to	   the	   right.	   (C,D)	   Confocal	   micrographs	  
showing	  in	  green	  endogenous	  SALL1FL	  localization	  in	  control	  ESCTRL#2	  (C)	  or	  TBS275	  fibroblasts	  (D)	  
detected	  by	  FL	   specific	  antibody	   (R&D).	   Scale	  bar,	  5	  µm.	   (E,F)	  Confocal	  micrographs	   showing	   in	  
green	   SALL1FL-­‐YFP	   localization	   in	   control	   ESCTRL#2	   and	   TBS275	   fibroblasts.	   Actin	  was	   labeled	   by	  
phalloidin	  (purple),	  DAPI	  was	  used	  to	  counterstain	  the	  nuclei	   (blue)	  and	  black	  and	  white	   images	  
show	  the	  single	  green	  channel	  (C´,	  D´,	  E´and	  F´).	  Yellow	  circles	  idicate	  the	  nuclei.	  Scale	  bar,	  5	  µm.	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Figure	   R	   9.	   TBS275	   fibroblasts	   exhibit	   cilia	   anomalies.	   (A)	   Immunofluorescence	   micrographs	  
showing	  cilia	  marked	  with	  acetylated	  alpha	  tubulin	  and	  basal	  body	  marked	  with	  gamma	  tubulin	  
(AcGT,	   purple)	   and	   nuclei	   counterstained	   with	   DAPI	   (blue)	   in	   control	   HFF	   or	   ESCTRL#2	   (upper	  
panels)	   vs	   TBS332	   or	   TBS275	   (lower	   panels).	   Pictures	   were	   taken	   using	   an	   Axioimager	   D1	  
fluorescence	  microscope,	   Zeiss	   with	   a	   63x	   objective.	   Scale	   bar,	   5	   µm.	   AcTub:	   acetylated	   alpha	  
tubulin;	   G-­‐Tub:	   gamma	   tubulin.	   (B)	   Graphical	   representation	   of	   cilia	   frequency	   of	   micrographs	  
shown	  in	  (A).	  HFF	  (n=18)	  and	  ESCTRL#2	  (n=20),	  blue	  dots;	  TBS332	  (n=20)	  and	  TBS275	  (n=19),	  orange	  
triangles.	  (C)	  Graphical	  representation	  of	  cilia	  length	  measurements	  of	  micrographs	  shown	  in	  (A).	  
HFF	   (n=22)	   and	   ESCTRL#2	   (n=21),	   blue	   dots;	   TBS332	   (n=39)	   and	   TBS275	   (n=51),	   orange	   triangles.	  
Three	  independent	  experiments	  were	  pooled	  together.	  The	  graphs	  represent	  the	  Mean	  and	  SEM.	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We	   used	   CRISPR-­‐Cas9	   method	   to	   target	   the	   SALL1	   locus	   in	   the	   “hotspot”	  
region,	   to	   approximate	   the	   mutation	   seen	   in	   TBS275	   and	   TBS332	   fibroblasts.	   We	  
isolated	  and	  characterized	  a	  clone	  that	  is	  heterozygous	  for	  SALL1	  mutation	  (293335),	  
with	   a	   sequence-­‐verified	   single	   base	   insertion	   that	   leads	   to	   a	   frameshift	   and	   a	  
truncated	   protein.	   Using	   extracts	   from	   this	   clone	   and	   WT	   parental	   cells,	   we	  
confirmed	  the	  protein	  truncation	  by	  Western	  blot	  (Figure	  R	  10A).	  
In	   the	   293335	   cells,	   we	   observed	   a	   dramatic	   decrease	   in	   SALL1FL	   protein	  
compared	  to	  unmodified	  cells	  (293WT)	  and	  the	  presence	  of	  a	  new	  band	  of	  about	  48	  
kDa	  that	  shows	  reactivity	  with	  SALL1	  antibody.	   Interestingly,	   localization	  of	  SALL1FL	  
changed	   in	   293335	   cells.	   Whereas	   SALL1FL	   is	   nuclear	   in	   293WT	   cells,	   it	   is	   diffusely	  
localized	   throughout	   the	  nucleus	   and	   the	   cytoplasm	   in	   293335	   cells	   (Figure	  R	   10B).	  
Upon	  starvation	  and	  in	  confluent	  conditions,	  cilia	  were	  significantly	  more	  abundant	  
in	   293335	   cells	   (average	   26%)	   than	   in	   293WT	   cells	   (average	   7%)	   (Figure	   R	   10B	   and	  
Figure	   R	   10C).	   Furthermore,	   293335	   cells	   displayed	   longer	   cilia	   (average	   7.0	   µm)	  
compared	  to	  293WT	  (average	  5.1	  µm)	  (Figure	  R	  10B	  and	  Figure	  R	  10D).	  These	  results	  
confirmed	  that	  the	  TBS-­‐mimicking	  cell	  line	  that	  we	  generated	  reproduced	  the	  ciliary	  
phenotype	  found	  in	  human	  TBS	  fibroblasts	  
	  
	  
4.1.7	  Cells	  derived	  from	  Sall1∆Zn2-­‐10	  mouse	  embryos	  exhibit	  aberrant	  ciliogenesis	  
Our	  analysis	  in	  TBS-­‐derived	  fibroblasts	  and	  in	  human	  cell	  lines,	  either	  genome-­‐
edited	   or	   exogenously	   expressing	   a	   mutated	   form	   of	   SALL1,	   show	   coincident	  
phenotypes	   in	   the	   length	   and	   frequency	   of	   primary	   cilia.	   To	   further	   confirm	   these	  
results,	  we	  also	  examined	   cells	   from	  a	  TBS	  animal	  model	  previously	   characterized.	  
Sall1-­‐∆Zn2-­‐10	  mice	  mimic	  a	  hotspot	  mutation	  shown	  to	  cause	  TBS,	  and	  they	  produce	  a	  
truncated	  protein	   lacking	  all	   the	   zinc	   finger	  motifs,	  except	   for	   the	  N-­‐terminal	  C2HC	  
finger	   (Kiefer	  et	  al.,	  2003).	  We	  cultured	  MEFs	   from	  tissues	  derived	   from	  E13	  Sall1-­‐
∆Zn2-­‐10	   mice	   and	   analysed	   cilia	   formation	   in	   those	   MEFs.	   After	   confirming	   the	  
genotype	   by	   PCR	   (Figure	   R	   11A),	   we	   analysed	   ciliogenesis	   in	   WT	   (Sall1+/+)	   and	  
heterozygous	  MEFs	  (Sall1+/∆).	   In	  agreement	  with	  our	  previous	  results,	  Sall1+/∆	  MEFs	  
displayed	  more	  abundant	   (pooled	  average	  59%)	  and	   longer	  cilia	   (pooled	  average	  1	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µm)	  than	  Sall1+/+	  (average	  14%	  and	  0,7	  µm,	  respectively),	  both	  in	  starved	  conditions	  
(Figures	   R	   11B-­‐D).	   These	   results	   confirmed	   that	  MEFs	   derived	   from	   a	   mouse	   TBS	  
model	  reproduced	  the	  ciliary	  phenotype	  found	  in	  human	  TBS	  fibroblasts.	  	  
Figure	  R	   10.	   Truncated	   SALL1	   leads	   to	   TBS-­‐like	   cilia	   phenotype	   in	   genetically	  modified	   cells.	   (A)	  
Western	   blot	   analysis	   of	   lysates	   from	  wild-­‐type	  HEK	   293FT	   cells	   (293WT)	   or	   CRISPR/Cas9-­‐modified	  
cells	  (293335)	  to	  mimic	  a	  TBS	  mutation	  in	  SALL1	  gene	  (SALL1c.1003dup).	  A	  truncated	  protein	  of	  about	  48	  
kDa	  was	   identified	   in	  293335	  cells	  by	  SALL1	  antibody	   (SALL1p.Ser335Lysfs*20;	  black	  arrowhead).	  Asterisk	  
indicates	  SALL1FL.	  GAPDH	  was	  used	  as	  a	  loading	  control.	  Molecular	  weight	  markers	  (kDa)	  are	  to	  the	  
right.	  (B)	  Immunofluorescence	  micrographs	  showing	  the	  subcellular	  distribution	  of	  SALL1FL	  in	  293WT	  
or	  293335	  cells	  using	  a	  specific	  antibody	  (green).	  In	  purple,	  ARL13B	  marks	  the	  primary	  cilium	  (yellow	  
arrowheads)	  and	   in	  blue,	  DAPI	  the	  nuclei.	  Yellow	  circles	  delimitate	  the	  nuclei	  and	  black	  and	  white	  
images	   show	   the	   single	   green	   channel.	   Scale	   bar,	   5	   µm.	   (C,D)	   Graphical	   representation	   of	   cilia	  
frequency	  (C)	  and	  cilia	  length	  measurements	  (D)	  of	  micrographs	  shown	  in	  (B).	  Cilia	  frequency,	  n=11	  
micrographs;	  cilia	   length,	  n=38	  cilia	   in	  293WT	  cells	   (blue	  dots)	  and	  n=48	  cilia	   in	  293335	  cells	   (orange	  
trinagles).	  Three	   independent	  experiments	  were	  pooled	  together.	  The	  graphs	  represent	  the	  Mean	  
and	  SEM.	  P-­‐values	  were	  calculated	  using	  two-­‐tailed	  unpaired	  Student´s	  t-­‐test.	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Figure	  R	  11.	  Cells	  derived	  from	  Sall1+/∆	  mouse	  embryos	  exhibit	  cilia	  defects.	  (A)	  PCR	  genotyping	  
of	   MEFs	   derived	   from	   wild-­‐type	   homozygous	   (Sall1+/+)	   or	   Sall1∆Zn2-­‐10	   heterozygous	   embryos	  
(Sall1+/∆).	   (B)	  Micrographs	  of	  Sall1+/+	  and	  Sall1+/∆	  MEFs	  analysed	  during	  cilia	  assembly.	  Cilia	  were	  
visualized	   by	   acetylated	   alpha-­‐tubulin	   and	   gamma-­‐tubulin	   (AcGT,	   purple)	   and	   nuclei	   were	  
counterstained	  with	   DAPI	   (blue).	   (C,D)	   Graphical	   representation	   of	   cilia	   frequency	   (C)	   and	   cilia	  
length	   (D)	  measured	   in	   Sall1+/+	   (n=	   38	   cilia	   and	   24	  micrographs,	   for	   cilia	   length	   and	   frequency,	  
respectively;	  blue	  circles)	  and	  Sall1+/∆	  MEFs	  in	  (B)	  (n=37-­‐45	  cilia	  and	  n=16-­‐38	  micrographs	  for	  cilia	  
length	  and	   frequency,	   respectively;	  orange	   triangles).	  Scale	  bar,	  1	  µm.	  P-­‐values	  were	  calculated	  
using	  One	  way	  ANOVA	  and	  Dunn's	  Multiple	  Comparison	  post-­‐hoc	  test.	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4.2	   Objective	   2:	   Identification	   of	   the	   cellular	   and	   molecular	  
mechanisms	  mediating	  the	  cilia	  defects	  observed	  in	  TBS.	  
	  
	  4.2.1	  Proximity	  proteomics	  of	  SALL1	  identifies	  interactions	  with	  cilia	  regulators	  
	   The	  BioID	  method	  (Roux	  et	  al.,	  2012)	  relies	  on	  a	  mutant	  BirA	  enzyme	  (BirA*)	  
that	  has	  a	  relaxed	  specificity	  and	  is	  able	  to	  biotinylate	  any	  free	  lysine	  ε-­‐amino	  group	  
present	   in	   proteins	  within	   a	   radius	   between	   10	   and	   20	   nm	   (Kim	   et	   al.,	   2014;	   Van	  
Itallie	  et	  al.,	  2013).	  When	  fused	  to	  SALL1275	  or	  SALL1FL,	  BirA*	  can	  biotinylate	  proximal	  
proteins	   that	  either	   interact	  directly	  with	   them	  or	  are	  closely	  associated	   in	  protein	  
complexes	  (see	  Materials	  and	  Methods,	  Figure	  M1).	  	  
	   Myc-­‐BirA*-­‐SALL1c.826C>T	   (BirA*-­‐SALL1275)	   or	   Myc-­‐BirA*-­‐SALL1FL	   (BirA*-­‐
SALL1FL)	  plasmids	  were	  transfected	  in	  HEK	  293FT	  cells.	  Staining	  of	  transfected	  cells	  to	  
visualize	   biotinylated	   proteins	   revealed	   that,	   as	   expected,	   BirA*-­‐SALL1275	   localized	  
diffusely	   throughout	   the	   nucleus	   and	   cytoplasm,	   whereas	   BirA*-­‐SALL1FL	   localized	  
primarily	  in	  the	  nucleus,	  enriched	  in	  subnuclear	  domains	  (Figure	  R	  12A	  and	  Figure	  R	  
12B).	  Total	  lysates	  from	  BirA*-­‐SALL1275	  or	  BirA*-­‐SALL1FL-­‐transiently	  transfected	  cells	  
were	   subjected	   to	   NeutrAvidin	   pulldown	   and	   isolated	   proteins	   were	   analysed	   by	  
liquid	   chromatography	   tandem	   mass	   spectrometry	   (LC-­‐MS/MS).	   In	   addition	   to	  
almost	  all	  known	  interactors	  of	  SALL1,	  such	  as	  NuRD	  complex	  components	  (HDAC1,	  
HDAC2,	  RbAp46,	  MTA1,	  MTA2,	  MBD3,	  CHD4	  and	  CHD3)	  (Xue	  et	  al.,	  1998)	  candidates	  
with	  exclusive	  or	  enriched	  proximity	  to	  SALL1275	  vs	  SALL1FL	  were	  identified.	  A	  total	  of	  
1032	  or	  665	  proteins	  were	  found	  in	  at	  least	  two	  out	  of	  three	  experiments	  done	  with	  
BirA*-­‐SALL1275	  or	  BirA*-­‐SALL1FL,	  respectively	  (Figure	  R	  12C).	  	  
	  
Out	   of	   those	   proteins,	   744	   in	   the	   SALL1275	   and	   123	   in	   the	   SALL1FL	  
subproteome	  were	  significantly	  enriched	  at	   least	  2-­‐fold	  change	  with	  respect	  to	  the	  
other	   subproteome	   in	   at	   least	   2	   out	   of	   3	   experiments	   based	   on	   label-­‐free	   protein	  
quantitation	   (Figure	   R	   13A	   and	   Appendix	   I).	   With	   the	   purpose	   of	   obtaining	   a	  
functional	   overview	   of	   the	   main	   pathways	   associated	   to	   SALL1275,	   a	   comparative	  
Gene	   Ontology	   (GO)	   analysis	   was	   performed,	   comparing	   Cellular	   Component,	  
Molecular	   Function	   and	   Biological	   Process	   fields	   (Figure	   R	   13B-­‐D).	   In	   the	   Cellular	  
G 
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Component	   domain,	   a	   shift	   towards	   “cytoplasm”,	   “actin	   cytoskeleton"	   and	  
"microtubule	  cytoskeleton”	  was	  observed	   in	  the	  SALL1275	  proteome	   (Figure	  R	  13B).	  
Intriguingly,	  the	  “centrosome”	  GO	  term	  is	  found	  exclusively	  in	  the	  SALL1275	  proteome	  
(Appendix	   1).	  With	   respect	   to	  Molecular	   Function,	   SALL1275	   showed	  enrichment	   in	  
cytoplasmic	   proteins	   ("actin	   binding",	   "microtubule	   binding"	   and	   "ATPase"	   or	  
"helicase	   activity"	   terms;	   (Figure	   R	   13C).	   In	   the	   category	   of	   Biological	   Process,	  
SALL1275	  subproteome	  shows	  enrichment	  in	  the	  categories	  "cell	  cycle",	  "cytoskeleton	  
organization"	  and	  "cellular	  response	  to	  stress"	  (Figure	  R	  13D).	  	  
	  
Interestingly,	   among	   genes	   included	   in	   the	   centrosome	   category	   term	   we	  
found	  CCP110	  and	  CEP97,	   two	  proteins	  that	   function	  together	  to	  block	  ciliogenesis	  
(Spektor	   et	   al.,	   2007).	   The	   role	   described	   for	   these	   proteins	   in	   cilia	   formation	   is	  
compatible	  with	   the	  phenotype	  observed	   in	  TBS	   fibroblasts,	   therefore	  we	   selected	  
them	  for	  further	  study.	  
	  
Figure	  R	  12.	  Differential	   interactors	  for	  truncated	  SALL1	  and	  SALL1FL.	   (A,B)	  Confocal	  micrographs	  
showing	  transient	  expression	  of	  transfected	  BirA*-­‐SALL1FL	  (A)	  or	  BirA*-­‐SALL1c.826C>T	  (BirA*-­‐SALL1275)	  
(B)	  detected	  by	  fluorescence	  streptavidin	  in	  green.	  Nuclei	  are	  marked	  by	  DAPI	  in	  blue.	  Single	  green	  
channels	   are	   shown	   in	   black	   an	   white	   (A´,B´).	   Scale	   bar,	   5	   µm.	   (C)	   Venn	   diagram	   showing	   the	  
distribution	  of	  the	   identified	  candidates	  by	  MS	  analysis.	  665	  and	  1032	  proteins	  were	  found	   in	  the	  
close	   proximity	   of	   SALL1FL	   and	   SALL1p.Arg275*	   (SALL1275),	   respectively,	   in	   at	   least	   2	   independent	  
experiments.	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Figure	  R	  13.	  GO	  term	  analysis	  of	  the	  truncated	  SALL1	  vs	  the	  SALL1FL	  subproteomes.	  (A)	  Volcano	  
plot	  representing	  the	  distribution	  of	  the	  candidates	  identified	  by	  proximity	  proteomics	  in	  at	  least	  
two	   out	   of	   three	   independent	   experiments.	   Proteins	   with	   2	   or	   more	   than	   2-­‐fold	   change	   in	  
intensity	  with	  respect	  to	  the	  wild	  type	  proteome	  (log2	  ≥	  1)	  were	  considered	  as	  SALL1
275-­‐associated	  
candidates	   (orange	  dots).	   Proteins	  with	   less	   than	  2	   fold	   change	   in	   intensity	  with	   respect	   to	   the	  
wild-­‐type	  protein	   (log2	  ≤	  1)	  were	  considered	  as	  SALL1
FL	  associated	  candidates	   (blue	  dots).	   (B-­‐D)	  
Graphical	   representation	   of	   the	   -­‐log10	   of	   the	   P-­‐value	   for	   each	   of	   the	   represented	   Cellular	  
Component	   (B),	   Molecular	   Function	   (C)	   or	   Biological	   Process	   (D)	   GO	   terms	   in	   the	   BirA*-­‐
SALL1p.Arg275*proteome	   (SALL1275).	   MT:	   microtubules;	   Extracell.:	   Extracellular;	   Cell.	   response	   to	  
stress:	   cellular	   response	   to	   stress;	   Comp.	   org.	   and	   biogenesis:	   component	   organization	   and	  
biogenesis;	   Local.	   and	   transport:	   localization	   and	   transport;	   Macromol.	   complex	   as.:	  
macromolecular	   complex	   assembly;	   Protein	   compl.	   sub.	   org.:	   protein	   complex	   subunit	  
organization.	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4.2.2	  CCP110	  and	  CEP97	  interact	  with	  truncated	  SALL1	  
We	  confirmed	  CCP110	  and	  CEP97	  among	  the	  most	  enriched	  proteins	   in	   the	  
subproteome	   biotinylated	   by	   BirA*	   when	   fused	   to	   SALL1275	   by	   independent	   BioID	  
experiments	  analysed	  by	  Western	  blot	  using	   specific	   antibodies	   (Figure	  R	  14A	  and	  
Figure	  R	  14B).	  	  
	  
	  
Most	   cases	   of	   TBS	   exhibit	   a	   monoallelic	   truncation	   of	   SALL1,	   with	   likely	  
presence	  of	  both	   truncated	  and	  FL	   forms	  of	   SALL1.	   These	  proteins	   can	  homo-­‐	  and	  
heterodimerize,	   leading	   to	   aberrant	   complexes.	   To	   characterize	   the	   interaction	   of	  
CCP110	   and	   CEP97	  with	   SALL1,	  we	   performed	   pulldowns	  with	   tagged	   SALL1FL-­‐YFP,	  
with	   SALL1275-­‐YFP,	   or	   with	   a	   combination	   of	   both	   in	   HEK	   293FT	   cells.	   Our	   results	  
showed	  that	  both	  endogenous	  CCP110	  and	  CEP97	  were	  able	  to	  bind	  to	  both	  SALL1FL	  
Figure	  R	  14.	  CCP110	  and	  CEP97	  are	   in	   close	  proximity	   to	   truncated	  SALL1.	   (A,B)	  Western	  blot	  
analysis	  of	  BioID,	  biotin	  pulldowns	  (PD)	  of	  HEK	  293FT	  cells	  expressinng	  Myc-­‐tagged	  BirA*-­‐SALL1FL	  
or	  BirA*-­‐SALL1p.Arg275*	  (BirA*-­‐SALL1275).	  Specific	  antibodies	  against	  the	  endogenous	  proteins	  CEP97	  
(A)	   or	   CCP110	   (B)	   were	   used.	   Actin	  was	   used	   as	   loading	   control.	   Biotin	   antibody	   detected	   the	  
most	  biotinylated	  proteins	   in	  the	   inputs	  and	  pulldowns,	  which	  are	  the	  self-­‐biotinylated	  forms	  of	  
BirA*-­‐SALL1FL	  (asterisks)	  and	  BirA*-­‐SALL1275	  (black	  arrowhead),	  as	  well	  as	  other	  interactors	  in	  the	  
pulldowns.	   White	   arrowheads	   indicate	   actin	   signal	   from	   previous	   probing.	   Blots	   shown	   are	  
representative	  of	  three	  independent	  experiments.	  Molecular	  weight	  markers	  (kDa)	  are	  shown	  to	  
the	  right.	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and	  SALL1275,	  with	  preferential	  binding	  to	  the	  truncated	  SALL1275	  protein,	  confirming	  
our	  MS	   results	   (Figure	  R	   15A,	   lanes	   6	   and	   7).	   The	   binding	   to	   SALL1275	   persisted	   in	  
presence	   of	   overexpressed	   SALL1FL	   (Figure	   R	   15A,	   lane	   8),	   indicating	   that	   the	  
heterodimerization	   of	   the	   truncated	   and	   FL	   forms	   does	   not	   inhibit	   the	   interaction	  
with	   CCP110	   and	   CEP97.	   Note	   that	   SALL1275-­‐YFP	   can	   interact	  with	   SALL1FL-­‐HA	   (HA	  
panel,	  lane	  8),	  as	  it	  was	  previously	  suggested	  in	  mice	  (Sato	  et	  al.,	  2004).	  We	  further	  
demonstrated	   the	   specificity	   of	   the	   interaction	   between	   SALL1	   and	   CCP110	   and	  
CEP97	  by	  performing	  the	  reciprocal	  experiment	  (Figure	  R	  15B	  and	  Figure	  R	  15C).	  Our	  
results	  showed	  that	  SALL1275	  was	  able	  to	  immunoprecipitate	  with	  both	  CCP110	  and	  
CEP97	  using	  specific	  antibodies	  against	  the	  last	  two	  proteins.	  These	  results	  support	  
the	  notion	  that	  the	  truncated	  form	  of	  SALL1,	  either	  by	  itself	  or	  in	  complex	  with	  the	  
FL	   form,	   can	   bind	   and	   perhaps	   sequester	   or	   inhibit	   the	   important	   cilia	   regulatory	  
factors	  CCP110	  and	  CEP97,	  leading	  to	  cilia	  defects.	  
	  
4.2.3	  CCP110	  and	  CEP97	  dynamics	  are	  altered	  in	  TBS	  fibroblasts	  	  
One	   key	   event	   in	   ciliogenesis	   is	   the	   depletion	   of	   CCP110	   and	   its	   partner	  
CEP97	   from	   the	   distal	   end	   of	   the	  MC,	   promoting	   the	   ciliary	   activating	   program	   in	  
somatic	   cells	   (Goetz	   et	   al.,	   2012;	   Kleylein-­‐Sohn	  et	   al.,	   2007;	   Prosser	   and	  Morrison,	  
2015;	   Spektor	   et	   al.,	   2007;	   Tsang	   et	   al.,	   2008).	   Our	   data	   suggest	   that	   CCP110	  
interacts	  with	  SALL1275,	  as	  well	  as	  with	  the	  complex	  between	  SALL1275	  and	  SALL1FL,	  
and	   that	   TBS	   fibroblasts	   display	   higher	   cilia	   formation	   rates	   compared	   to	   control	  
cells.	  Based	  on	  these	  results,	  we	  hypothesized	  that	  CCP110	  and	  CEP97	  might	  suffer	  
premature	  displacements	  from	  the	  MC	  in	  TBS.	  In	  order	  to	  check	  this	  hypothesis,	  we	  
analysed	   their	   centrosomal	   localization	   in	   primary	   TBS332	   fibroblasts	   by	  
immunofluorescence.	   CCP110	   was	   present	   at	   the	   MC	   in	   a	   higher	   proportion	   of	  
control	  cells	  (74%)	  than	  TBS332	  (36%)	  (Figure	  R	  16A	  and	  Figure	  R	  16B).	  Furthermore,	  
CEP97	  was	  present	  at	  the	  MC	  in	  78%	  of	  the	  control	  cells	  while	  in	  33%	  of	  the	  TBS332	  
cells	  (Figure	  R	  16C	  and	  Figure	  R	  16D).	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Figure	  R	  15.	  CCP110	  and	  CEP97	  interact	  with	  truncated	  SALL1.	  (A)	  Western	  blot	  of	  inputs	  or	  GFP-­‐
Trap	  pulldowns	  (GFP	  trap)	  performed	  in	  HEK	  293FT	  cells	  transfected	  with	  SALL1FL-­‐YFP	  (lanes	  1	  and	  
6),	   SALL1c.826C>T-­‐YFP	   (SALL1275-­‐YFP;	   lanes	   2	   and	   7),	   SALL1275-­‐YFP	   together	   with	   SALL1FL-­‐2xHA	  
(SALL1FL-­‐HA;	   lanes	   3	   and	   8),	   SALL1FL-­‐HA	   together	   with	   YFP	   alone	   (lanes	   4	   and	   9)	   or	   YFP	   alone	  
(lanes	  5	  and	  10).	  Endogenous	  CCP110	  and	  CEP97	  were	  detected	  with	  specific	  antibodies.	  GAPDH	  
was	  used	  as	  loading	  control.	  Numbers	  under	  CCP110	  and	  CEP97	  panels	  result	  from	  dividing	  band	  
intensities	  of	  each	  lane	  by	  lane	  1	  for	  the	  inputs	  or	  by	  lane	  6	  for	  the	  pulldowns.	  (B,C)	  Western	  blot	  
of	   inputs	  and	  CCP110	   (B)	  or	  CEP97	   (C)	   immunoprecipitations	   (IP)	  performed	   in	  HEK	  293FT	   cells	  
transfected	  with	  SALL1275-­‐YFP	  or	  YFP	  alone.	  Endogenous	  CCP110	  and	  CEP97	   in	  the	   IP	   interacted	  
with	   conjugating	   G	   sepharose	   beads	   linked	   to	   specific	   antibodies.	   GAPDH	  was	   used	   as	   loading	  
control.	  Molecular	  weight	  markers	   (kDa)	  are	  shown	  to	   the	   right.	  One	  asterisk	   indicates	  SALL1FL-­‐
YFP,	  one	  black	  arrowhead	  SALL1275-­‐YFP	  and	  two	  black	  arrowheads	  YFP	  alone.	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Notably,	  10%	  of	  the	  TBS	  cells	  displayed	  multiple	  foci	  or	  more	  diffuse	  labeling	  
of	   CCP110	   around	   the	   centrioles,	   suggesting	   an	   alteration	   of	   CCP110	   dynamics	  
(Figure	  R	  17).	  Therefore,	  the	  disruption	  in	  the	   localization	  of	  CCP110	  and	  CEP97	  by	  
the	   truncated	   SALL1	  or	   by	   the	  presence	  of	   the	   aberrant	   complex	  between	   SALL1FL	  
and	  SALL1	  truncations,	  are	  potential	  mechanisms	  by	  which	  CCP110/CEP97	  might	  be	  
depleted	  from	  the	  MC,	  leading	  to	  a	  higher	  frequency	  of	  ciliogenesis	  in	  TBS	  cells.	  	  
Figure	   R	   16.	   TBS332	   cells	   show	   changes	   in	   the	   localization	   of	   CCP110	   and	   CEP97.	   (A,C)	  
Immunofluorescence	  micrographs	   of	   cycling	   human-­‐derived	   fibroblasts	   stained	  with	   antibodies	  
against	   endogenous	   CCP110	   (A)	   or	   CEP97	   (C)	   (green,	   yellow	   arrowheads),	   CEP164	   to	   label	   the	  
mother	  centriole	  (MC,	  purple)	  and	  counterstained	  with	  DAPI	  to	  label	  the	  nuclei	  (blue).	  Black	  and	  
white	   images	   show	   the	   single	   green	   and	   purple	   channels.	   Note	   the	   different	   distribution	   of	  
CCP110	   and	   CEP97	   to	   the	   MC	   in	   TBS332	   compared	   to	   control	   HFF	   fibroblasts.	   (B,D)	   Graphical	  
representation	  of	  the	  percentage	  of	  cells	  showing	  the	  presence	  of	  CCP110	  or	  CEP97	  at	  the	  MC	  per	  
micrograph	   corresponding	   to	   the	   experiments	   in	   (A)	   and	   (C),	   respectively;	   n=30	   micrographs.	  
Three	  independent	  experiments	  were	  pooled	  together.	  Pictures	  were	  taken	  using	  an	  Axioimager	  
D1	  fluorescence	  microscope,	  Zeiss,	  with	  a	  63x	  objective.	  Scale	  bar,	  1	  µm.	  P-­‐values	  were	  calculated	  
with	  the	  two-­‐tailed	  unpaired	  Student´s	  t-­‐test.	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In	  addition,	  we	  tried	  to	  confirm	  these	  aberrations	  in	  CCP110	  dynamics	  in	  TBS	  
model	  cell	   lines	  that	  displayed	  ciliogenesis	  defects:	   the	  TBS-­‐mimicking	  cell	   line	  that	  
we	  had	  generated	  (293335	  cells)	  and	  in	  heterozygous	  MEFs	  derived	  from	  Sall1-­‐∆Zn2-­‐10	  
mice	  embryos	  (Sall1+/∆	  cells).	  CCP110	  foci	  were	  absent	  or	  reduced	  at	  the	  MC	  in	  89%	  
of	  the	  293335	  cells	  (Figure	  R	  18A	  and	  Figure	  R	  18B)	  and	  in	  around	  67%	  of	  the	  Sall1+/∆	  
MEFs	  in	  non	  starved	  conditions	  (Figure	  R	  18C	  and	  Figure	  R	  18D).	  Taken	  together,	  our	  
results	   indicate	   that	   the	   presence	   of	   truncated	   SALL1	   is	   sufficient	   to	   promote	  
changes	   in	  cilia	   length	  and	  CCP110	   localization	  when	  compared	  to	  a	  control	  of	   the	  
same	  genetic	  background.	  Moreover,	  we	  show	  here	  that	  both	  the	  TBS-­‐mimicking	  cell	  
line	  that	  we	  generated	  and	  MEFs	  derived	  from	  a	  mouse	  TBS	  model	  reproduced	  the	  
ciliary	  phenotype	  found	  in	  human	  TBS	  fibroblasts.	  
Figure	  R	  17.	  CCP110	  localizes	  aberrantly	  in	  multiple	  foci	  in	  TBS332	  cells.	  Representative	  fluorescence	  
micrograph	  of	  a	  control	  (A)	  and	  a	  TBS332	  centrosome	  (B)	  showing	  CCP110	  (green,	  yellow	  arrowheads)	  
in	  a	  cloudy	  pattern	  around	  the	  mother	  centriole	  marked	  by	  CEP164	  (purple).	  10%	  of	  the	  TBS332	  cells	  
show	  multiple	  centrioles.	  Black	  and	  white	  images	  show	  the	  single	  green	  and	  purple	  channels.	  Pictures	  
were	  taken	  using	  a	  Zeiss	  Axioimager	  D1,	  63x	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Figure	  R	  18.	  CCP110	  and	  CEP97	  dynamics	  are	  altered	  in	  a	  TBS	  model	  cell	  line	  and	  Sall1+/∆	  mouse	  
embryonic	   cells.	   (A)	   Immunofluorescence	   micrographs	   of	   HEK	   293FT	   cells	   (293WT)	   or	  
CRISPR/Cas9-­‐modified	   cells	   (293335)	   to	   mimic	   a	   TBS	   mutation	   in	   SALL1	   gene	   (SALL1c.1003dup)	  
showing	   CCP110	   foci	   (green),	   centrosomes	   (gTub,	   purple)	   and	   DAPI	   (blue).	   Scale	   bar,	   1	   µm.	  
Pictures	  were	  taken	  using	  an	  Axioimager	  D1	  fluorescence	  microscope,	  Zeiss	  with	  a	  63x	  objective.	  
(B)	   Graphical	   representation	   of	   the	   percentage	   of	   cells	   showing	   CCP110	   in	   two	   foci	   per	  
micrograph	   in	   293WT	   or	   293335	   cells,	   corresponding	   to	   the	   experiment	   in	   (A).	   (C)	  
Immunofluorescence	  micrographs	   of	   Sall1+/+	   and	   Sall1+/∆	  MEFs	   showing	   CCP110	   foci	   (green),	   in	  
the	  centrosomes	  labelled	  with	  gamma	  tubulin	  (purple)	  and	  nuclei	  (DAPI,	  blue).	  Scale	  bar,	  0.5	  µm.	  
Cells	   that	  underwent	  48	  hours	  of	   starvation	  were	  compared	   to	  non-­‐starved	  cells.	  Pictures	  were	  
taken	   using	   a	   Deltavision	   fluorescence	   microscope,	   GE	   Healthcare	   Life	   Sciences,	   with	   a	   60x	  
objective.	  (D)	  Graphical	  representation	  of	  the	  percentage	  of	  cells	  showing	  CCP110	  in	  two	  foci	   in	  
Sall1+/+	  and	  Sall1+/∆	  MEFs	   in	  (C)	   (n>10).	  The	  graphs	  represent	  the	  Mean	  and	  SEM.	  P-­‐values	  were	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4.2.4	  SALL1	  interacts	  with	  LUZP1	  
	  
	   As	  previously	  described,	  we	  found	  that	  truncated	  forms	  of	  SALL1	  present	   in	  
TBS	   individuals	   aberrantly	   interact	   with	   cytoplasmic	   proteins.	   Interestingly,	   in	  
addition	   to	   CCP110	   and	   CEP97,	   we	   found	   LUZP1	   among	   the	   20	   most	   enriched	  
proteins	   in	   the	   SALL1275	   subproteome	   (Appendix	   I).	  We	   confirmed	   this	   finding	   by	  
independent	   BioID	   experiments	   analysed	   by	   Western	   blot	   using	   a	   LUZP1	   specific	  
antibody.	   Myc-­‐BirA*-­‐SALL1c.826C>T	   (BirA*-­‐SALL1275)	   or	   Myc-­‐BirA*-­‐SALL1FL	   (BirA*-­‐
SALL1FL)	  plasmids	  were	  transfected	  in	  HEK	  293FT	  cells	  and	  lysates	  were	  subjected	  to	  
NeutrAvidin	  pulldown.	  We	  exclusively	  found	  LUZP1	  in	  the	  pulldown	  of	  BirA*-­‐SALL1275	  
(Figure	  R	  19),	  suggesting	  that	  LUZP1	  is	  in	  close	  proximity	  and	  a	  potential	  interactor	  of	  
SALL1275.	  	  
	   	  
Figure	  R	  19.	  LUZP1	  is	  in	  close	  proximity	  to	  truncated	  SALL1.	  Western	  blot	  analysis	  of	  BioID,	  biotin	  
pulldown	  (PD)	  of	  HEK	  293FT	  cells	  transfected	  with	  Myc-­‐tagged	  BirA*-­‐SALL1p.Arg275*	   (BirA*-­‐SALL1275)	  
or	   BirA*-­‐SALL1FL.	   A	   specific	   antibody	   against	   the	   endogenous	   LUZP1	   protein	   was	   used.	   Biotin	  
antibody	  detected	  the	  most	  strongly	  biotinylated	  proteins	   in	   the	   inputs	  and	  pulldowns,	  which	  are	  
the	  self-­‐biotinylated	  form	  of	  BirA*-­‐SALL1FL	  (asterisk)	  or	  BirA*-­‐SALL1275	  (black	  arrowhead),	  as	  well	  as	  
other	  interactors	  in	  the	  pulldowns.	  White	  arrowheads	  indicate	  LUZP1	  and	  actin	  signal	  from	  previous	  
probing	  of	  the	  same	  membrane.	  Molecular	  weight	  markers	  (kDa)	  are	  shown	  to	  the	  right.	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To	   further	   characterize	   the	   interaction	  of	   LUZP1	  with	   SALL1,	  we	  performed	  
pulldowns	   with	   tagged	   SALL1275-­‐YFP	   in	   HEK	   293FT	   cells.	   Our	   results	   showed	   that	  
endogenous	   LUZP1	   was	   able	   to	   bind	   to	   SALL1275,	   confirming	   our	   proximity	  
proteomics	  data	  (Figure	  R	  20,	  lane	  6).	  The	  binding	  to	  SALL1275	  persisted	  in	  presence	  
of	   overexpressed	   SALL1FL	   (Figure	   R	   20,	   lane	   9),	   indicating	   that	   the	   possible	  
heterodimerization	   of	   the	   truncated	   and	   FL	   forms	   does	   not	   inhibit	   the	   interaction	  
with	   LUZP1.	   LUZP1	   also	   binds	   SALL1FL	   when	   overexpressed	   alone,	   although	   to	   a	  
lesser	   extent	   (Figure	   R	   20,	   lane	   7).	   These	   results	   support	   the	   notion	   that	   the	  
truncated	  form	  of	  SALL1	  expressed	  in	  TBS	  individuals,	  either	  by	  itself	  or	   in	  complex	  
with	  the	  FL	  form,	  can	  bind	  to	  LUZP1.	  	  
	  
Figure	  R	  20.	  LUZP1	  interacts	  with	  truncated	  SALL1.	  Western	  blot	  of	  inputs	  or	  GFP-­‐Trap	  pulldowns	  
performed	   in	   HEK	   293FT	   cells	   transfected	   with	   SALL1c.826C>T-­‐YFP	   (SALL1275-­‐YFP;	   lanes	   1	   and	   6),	  
SALL1FL-­‐YFP	   (lanes	  2	  and	  7),	  YFP	  alone	   (lanes	  3	  and	  8),	  SALL1275-­‐YFP	   together	  with	  SALL1FL-­‐2xHA	  
(SALL1FL-­‐HA;	  lanes	  4	  and	  9)	  or	  SALL1FL-­‐HA	  together	  with	  YFP	  alone	  (lanes	  5	  and	  10).	  Endogenous	  
LUZP1	  was	  detected	  with	   a	   specific	   antibody.	  Numbers	  under	   LUZP1	  panel	   result	   from	  dividing	  
band	  intensities	  of	  each	  pulldown	  by	  their	  respective	  input	  levels.	  One	  asterisk	  indicates	  SALL1FL-­‐
YFP,	  one	  black	  arrowhead	  SALL1275-­‐YFP	  and	   two	  black	  arrowheads	  YFP	  alone.	  Molecular	  weight	  
markers	   (kDa)	   are	   shown	   to	   the	   right.	   Actin	   was	   used	   as	   loading	   control.	   Blots	   shown	   are	  
representative	  of	  three	  independent	  experiments.	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4.2.5	  LUZP1	  localizes	  to	  centrosome	  and	  is	  altered	  in	  TBS	  fibroblasts	  	  
	   In	  order	  to	  further	  study	  the	  role	  that	  LUZP1	  might	  have	  in	  TBS,	  we	  checked	  
its	  subcellular	  localization	  in	  fibroblasts	  derived	  from	  two	  TBS	  individuals	  (TBS332	  and	  
TBS275;	  see	  Materials	  and	  Methods)	  (Furniss	  et	  al.,	  2007)	  as	  well	  as	  control	  fibroblasts	  
(ESCTRL2).	  Our	  results	  showed	  that,	  in	  non	  starved	  conditions,	  LUZP1	  was	  present	  in	  
4	  foci	  per	  centrosome	  in	  91%	  of	  the	  control	  cells	   (Figure	  R	  21A	  and	  Figure	  R	  21D),	  
detected	  by	  gamma	  tubulin)	  whereas	  only	  three	  foci	  were	  present	  in	  at	  least	  50%	  of	  
the	  TBS	  cells	   (Figure	  R	  21A-­‐D,	  3	   foci	  per	  centrosome).	  Upon	  starvation,	  one	  of	   the	  
LUZP1	   foci	   disappeared	   from	   the	   MC	   in	   100%	   of	   both	   the	   control	   and	   TBS	   cells	  
(Figure	  R	  21B-­‐D,	  3	  foci	  per	  centrosome).	  These	  findings	  suggest	  that	  LUZP1	  removal	  
from	  the	  centrosome	  might	  be	  necessary	  for	  ciliogenesis	  and	  that	  this	  phenomenon	  
is	  somehow	  altered	  in	  TBS	  cells. Based	  on	  its	  localization	  at	  the	  centrosome	  and	  the	  
defects	  in	  ciliogenesis	  previously	  observed	  in	  TBS	  cells,	  we	  hypothesized	  that	  LUZP1	  
might	  have	  a	  role	   in	  cilia	   formation.	  To	  prove	  this	  hypothesis,	  we	  used	  Shh-­‐LIGHT2	  
cells	   (Taipale	   et	   al.,	   2000).	   Using	   CRISPR/Cas9	   gene	   editing	   directed	   to	   exon	   1	   of	  
murine	   Luzp1,	  we	   generated	   Shh-­‐LIGHT2	  mouse	   fibroblasts	   null	   for	   Luzp1	   (Luzp1-­‐/-­‐	  
cells)	   and	   Luzp1-­‐/-­‐	   cells	   rescued	   by	   the	   expression	   of	   human	   LUZP1-­‐YFP	   (+LUZP1	  
cells).	  First,	  we	  characterized	  LUZP1	  expression	   in	  WT,	  Luzp1-­‐/-­‐	  and	  +LUZP1	  cells	  by	  
immunofluorescence	  and	  Western	  blot,	  confirming	  the	  lack	  of	  LUZP1	  signal	  in	  Luzp1-­‐
/-­‐	  cells	   (Figure	  R	  22A	  and	  Figure	  R	  22B,	  respectively).	   In	  agreement	  with	  what	  was	  
observed	  in	  TBS	  cells,	  LUZP1	  localized	  in	  four	  foci,	  two	  per	  centriole,	  in	  both	  WT	  and	  
+LUZP1	  cells	  (Figure	  R	  22C).	  As	  expected,	  LUZP1	  was	  absent	  from	  the	  centrosome	  in	  
Luzp1-­‐/-­‐	  cells.	  
As	   observed	   in	   human	   cells,	   we	   found	   by	   immunofluorescence	   in	  WT	   cells	  
that	  LUZP1	  was	  also	  depleted	  in	  one	  of	  the	  centrioles	  upon	  starvation	  (Figure	  R	  23A	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Figure	   R	   21.	   TBS	   cells	   show	   changes	   in	   LUZP1	   localization	   at	   the	   centrosome.	   (A,B,C)	  
Immunofluorescence	  micrographs	   of	   non	   starved	   and	   starved	   human-­‐derived	   control	   ESCTRL#2	  
(A),	   TBS332	   fibroblasts	   (B)	   and	   TBS275	   fibroblasts	   (C)	   stained	   with	   antibodies	   against	   endogenous	  
LUZP1	  (green,	  yellow	  arrowheads)	  and	  acetylated	  alpha	  and	  gamma	  tubulin	  to	   label	  the	  cilia	  and	  
centrosomes,	  respectively	  (AcGT,	  purple).	  Black	  and	  white	  images	  show	  the	  single	  green	  channel.	  
Note	  the	  lack	  of	  one	  LUZP1	  foci	  in	  TBS332	  and	  TBS275	  compared	  to	  control	  ESCTRL2	  fibroblasts	  in	  non	  
starved	   conditions.	   Scale	   bars,	   5	   µm.	   (D)	   Graphical	   representation	   of	   the	   percentage	   of	   cells	  
showing	  the	  presence	  of	  LUZP1	  at	  the	  centrosome	  in	  3	  or	  4	  foci	  per	  micrograph,	  corresponding	  to	  
the	   experiments	   in	   (A),	   (B)	   and	   (C);	   n=30	   micrographs.	   Three	   independent	   experiments	   were	  
pooled	  together.	  Scale	  bar,	  5	  µm.	  Images	  were	  taken	  with	  a	  Zeiss	  Axioimager	  D1,	  63x	  objective.	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Figure	  R	  22.	  LUZP1	  is	  missing	  from	  the	  centrosome	  in	  Shh-­‐LIGHT2	  cells	  lacking	  Luzp1.	  (A)	  LUZP1	  
antibody	  validation.	   Immunofluorescence	  micrographs	  of	  Shh-­‐LIGHT2	  cells	  (WT),	  Luzp1	  depleted	  
Shh-­‐LIGHT2	   cells	   (Luzp1-­‐/-­‐)	   and	   Luzp1	   cells	   rescued	   with	   LUZP1	   (+LUZP1	   cells)	   stained	   with	   a	  
specific	  antibody	  against	  endogenous	  LUZP1	  (Sigma,	  green)	  and	  counterstained	  with	  DAPI	  (blue).	  
Single	  green	  channel	   is	  shown	   in	  black	  and	  white.	  Note	  the	   lack	  of	  LUZP1	   in	  Luzp1-­‐/-­‐	  cells.	  Scale	  
bar,	  10	  µm.	  (B)	  Western	  blot	  analysis	  of	  total	  lysates	  of	  WT,	  Luzp1-­‐/-­‐	  cells	  and	  +LUZP1	  cells.	  Anti-­‐
LUZP1	  antibody	  from	  Sigma	  specifically	  recognizes	  LUZP1	  and	  GAPDH	  was	  used	  as	  loading	  control.	  
(C)	   Immunofluorescence	  micrographs	   of	  WT,	   Luzp1-­‐/-­‐	   and	   +LUZP1	   cells	   stained	  with	   antibodies	  
against	  endogenous	  LUZP1	  (green)	  and	  gamma	  tubulin	  (purple).	  Single	  green	  and	  purple	  channels	  
are	   shown	   in	  black	  and	  white.	  Note	   the	   lack	  of	   LUZP1	   in	  Luzp1-­‐/-­‐	   cells.	   Scale	  bar,	  2.5	  µm.	  gTub:	  
gamma	  tubulin.	  
	  
	   	   	   Results	  	  
	   103	  
	  
4.2.6	  LUZP1	  localizes	  to	  actin	  and	  the	  midbody	  and	  is	  altered	  in	  TBS	  
fibroblasts	  	  
	  
In	  addition	  to	  localize	  to	  the	  centrosome,	  we	  also	  detected	  LUZP1	  in	  the	  actin	  
fibers	  (Figure	  R	  24A).	   Interestingly,	  LUZP1	  levels	  were	  reduced	  in	  TBS	  cells	  and	  this	  
reduction	  was	  accompanied	  by	  decreased	  actin	  filaments	  compared	  with	  control,	  as	  
shown	  by	  phalloidin	  staining	  (Figures	  24A-­‐C).	  Moreover,	  LUZP1	  was	  also	  detected	  in	  
the	  midbody	  (Figure	  R	  24D).	  The	  midbody	  is	  an	  organelle	  formed	  at	  the	  intercellular	  
bridge	  in	  the	  last	  phase	  of	  citokinesis	  that	  recruits	  crucial	  proteins	  for	  the	  abscission	  
between	  the	  dividing	  cells	  (D'Avino	  and	  Capalbo,	  2016).	  	  
	  
Figure	  R	   23.	   LUZP1	   is	   depleted	   from	   the	   centrosome	   in	   Shh-­‐LIGHT2	   cells	   upon	   starvation.	   (A)	  
Immunofluorescence	  micrographs	  of	  non	  starved	  and	  starved	  Shh-­‐LIGHT2	  cells	  (WT)	  stained	  with	  
antibodies	  against	  endogenous	  LUZP1	  (green),	  gamma	  tubulin	  (gTub,	  purple)	  and	  counterstained	  
with	  DAPI	  (blue).	  Black	  and	  white	  images	  show	  the	  single	  green	  and	  purple	  channels.	  Scale	  bar,	  5	  
µm.	  (B)	  Graphical	  representation	  of	  the	  percentage	  of	  non	  starved	  vs	  starved	  Shh-­‐LIGHT2	  control	  
cells	   (WT)	  with	  4	  LUZP1	  foci	   in	   (A).	  n>7	  micrographs.	  Graphs	  represent	  Mean	  and	  SEM	  of	   three	  
independent	  experiments.	  Pictures	  were	  taken	  using	  a	  Leica	  SP2	  confocal	  microscope,	  with	  a	  63x	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TBS	  cells	  also	  showed	  reduced	  sensitiveness	  to	  a	  F-­‐actin	  depolymerizing	  drug,	  
CytB.	   When	   induced	   with	   CytB,	   control	   cells	   lost	   shape	   and	   detached	   more	  
dramatically	   than	   TBS	   cells	   (Figure	   R	   25).	  
Figure	   R	   24.	   A	   reduction	   in	   LUZP1	   is	   accompanied	   by	   a	   decrease	   in	   F-­‐actin	   in	   TBS	   cells.	   (A)	  
Immunofluorescence	  micrographs	  of	  human-­‐derived	  control	  ESCTRL#2,	  TBS332	  and	  TBS275	  fibroblasts	  
stained	  with	  an	  antibody	  against	  endogenous	  LUZP1	  (green),	  phalloidin	  to	  label	  F-­‐actin	  (purple),	  and	  
counterstained	  with	  DAPI	  to	  label	  the	  nuclei	  (blue).	  Note	  the	  reduction	  in	  LUZP1	  and	  F-­‐actin	  levels	  in	  
TBS332	  and	  TBS275	  compared	  to	  control	  fibroblasts.	  Scale	  bar,	  10	  µm.	  (B,C)	  Graphical	  representation	  
of	  the	  LUZP1	  (B)	  and	  F-­‐actin	  (C)	  mean	  intensity,	  corresponding	  to	  the	  experiments	  shown	  in	  (A);	  n≥6	  
micrographs.	   (D)	   Immunofluorescence	  micrographs	   of	   two	   dividing	   Shh-­‐LIGHT2	   cells	   stained	  with	  
antibodies	   against	   endogenous	   LUZP1	   (green),	   F-­‐Actin	   (purple)	   to	   label	  microtubules	   and	  DAPI	   to	  
label	  the	  nuclei	  (blue).	  Note	  the	  presence	  of	  LUZP1	  in	  the	  midbody	  (yellow	  arrowhead).	  Scale	  bar,	  30	  
µm.	   Black	   and	   white	   images	   show	   the	   single	   green	   and	   purple	   channels.	   Three	   independent	  
experiments	   were	   pooled	   together.	   P-­‐values	   were	   calculated	   using	   One	   way	   ANOVA	   and	   Dunn's	  
Multiple	  Comparison	  post-­‐hoc	  test.	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LUZP1	  exhibited	  accumulation	  in	  clumps	  in	  control	  cells	  upon	  CytB	  treatment	  
while	   it	   did	   not	   show	   significant	   changes	   in	   TBS	   cells	   (compare	   Figure	   R	   25	   with	  
Figure	  R	  24A).	  These	  results	  indicate	  that	  actin	  cytoskeleton	  might	  be	  altered	  in	  TBS	  
cells,	  which	  is	  in	  agreemnet	  with	  the	  higher	  ciliation	  rates	  they	  exhibit.	  	  
	  We	  also	  observed	  a	  reduction	  in	  F-­‐actin	  (labeled	  by	  phalloidin)	  in	  the	  Luzp1-­‐/-­‐	  
cells	   compared	   to	   WT,	   which	   was	   recovered	   in	   +LUZP1	   cells	   (Figure	   R	   26).	  
Furthermore,	  LUZP1	  levels	  and	  filamentous	  actin	  were	  diminished	  in	  WT	  fibroblasts	  
upon	  starvation	  (Figure	  R	  27A	  and	  Figure	  R	  27B).	  These	  results	  suggest	  that	  LUZP1	  
might	  be	  a	  F-­‐actin	  stabilizing	  protein	  and	  that	  starvation	  triggers	  both	  LUZP1	  and	  F-­‐
Figure	   R	   25.	   TBS	   cells	   are	   more	   sensitive	   to	   Cytochalasin	   B	   treatment.	   Immunofluorescence	  
micrographs	  of	  control	  and	  TBS332	  cells	  treated	  with	  cytochalasin	  B	  (CytB)	  and	  stained	  with	  LUZP1	  
(green),	  phalloidin	   to	   label	   F-­‐actin	   (purple)	   and	  DAPI	   to	   counterstain	   the	  nuclei	   (blue).	  Note	   that	  
TBS332	  are	  less	  sensitive	  to	  CytB	  treatment	  than	  control.	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actin	   reduction.	   Consistent	   with	   the	   observed	   reduction	   of	   F-­‐actin,	   Luzp1-­‐/-­‐	   cells	  
showed	  reduced	  sensitivity	  to	  CytB,	  as	  previously	  noted	  in	  TBS	  cells	  (Figure	  R	  28).	  	  
Although	  LUZP1	  levels	  were	  reduced	  in	  TBS	  cells	  by	  immunofluorescence,	  no	  
transcriptional	  changes	  were	  detected	  in	  LUZP1	  expression	  between	  control	  and	  TBS	  
samples	  by	  RT-­‐qPCR	   (Figure	  R	  29A).	  However,	  we	   confirmed	  a	   reduction	   in	   LUZP1	  
total	  levels	  in	  TBS	  cells	  compared	  to	  control	  cells	  by	  western	  blot	  (0.8	  vs	  1	  folds,	  lane	  
1	  vs	  4,	  respectively;	  Figure	  R	  29B).	  These	  results	  suggest	  that	  truncated	  SALL1	  might	  
	  Figure	  R	  26.	  The	  lack	  of	  Luzp1	  is	  accompanied	  by	  a	  decrease	  in	  F-­‐actin	  in	  Shh-­‐LIGHT2	  cells.	  (A)	  
Immunofluorescence	  micrographs	   of	   Shh-­‐LIGHT2	   cells	   (WT),	   Luzp1	   depleted	   Shh-­‐LIGHT2	   cells	  
(Luzp1-­‐/-­‐)	  and	  Luzp1-­‐/-­‐	  cells	  rescued	  with	  Luzp1-­‐YFP	  (+LUZP1).	  Cells	  were	  stained	  with	  an	  antibody	  
against	  endogenous	  LUZP1	  (green),	  phalloidin	  to	  detect	  F-­‐actin	  (purple),	  and	  counterstained	  with	  
DAPI	   (blue).	   Single	   green	   and	   purple	   channels	   are	   shown	   in	   black	   and	  white.	   Note	   the	   lack	   of	  
LUZP1	  and	  reduction	  of	  F-­‐actin	  in	  Luzp1-­‐/-­‐	  cells.	  Scale	  bar,	  10	  µm.	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Figure	  R	  27.	  A	  reduction	  in	  LUZP1	  is	  linked	  to	  a	  decrease	  in	  F-­‐actin	  in	  cells	  upon	  starvation.	  (A)	  
Immunofluorescence	  micrographs	  of	  non	  starved	  and	  starved	  Shh-­‐LIGHT2	  WT	  cells	  stained	  with	  
antibodies	   against	   endogenous	   LUZP1	   (green),	   phalloidin	   to	   detect	   F-­‐actin	   (purple)	   and	  
counterstained	  with	  DAPI	  (blue).	  Single	  green	  and	  purple	  channels	  are	  shown	  in	  black	  and	  white.	  
Scale	  bar,	  5	  µm.	  (B)	  Graphical	  representation	  of	  the	  LUZP1	  or	  phalloidin	  mean	  intensity	  as	  shown	  
in	  (A).	  Pictures	  were	  taken	  using	  a	  confocal	  microscope,	  Leica	  SP2,	  with	  a	  63x	  objective.	  Graphs	  
represent	   Mean	   and	   SEM	   of	   three	   independent	   experiments	   pooled	   together.	   P-­‐values	   were	  
calculated	  using	  One	  way	  ANOVA	  and	  Bonferroni	  post-­‐hoc	  test.	  
	  
Figure	   R	   28.	   Luzp1	   depleted	   cells	   are	   more	   sensitive	   to	   Cytochalasin	   B	   treatment.	  
Immunofluorescence	  micrographs	   of	   Shh-­‐LIGHT2	   cells	   (WT)	   and	   Shh-­‐LIGHT2	   cells	   lacking	   Luzp1	  
(Luzp1-­‐/-­‐)	   treated	  with	  cytochalasin	  B	   (CytB)	  and	  stained	  with	  phalloidin	   to	   label	  F-­‐actin	   (purple)	  
and	   with	   DAPI	   to	   label	   the	   nuclei	   (blue).	   Note	   that	   Luzp1-­‐/-­‐	   cells	   are	   less	   sensitive	   to	   CytB	  
treatment	  than	  WT	  cells.	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Figure	  R	  29.	  Truncated	  SALL1	  leads	  to	  LUZP1	  destabilization	  and	  degradation.	  (A)	  Quantification	  of	  
LUZP1	   expression	   by	   qPCR	   in	   ESCTRL2	   (control)	   vs	   TBS332	   and	   TBS275	   cells	   pooled	   together	   (TBS).	  
Graphs	   represent	  Mean	   and	   SEM	   from	  5	   independent	   experiments.	   P-­‐value	  was	   calculated	  using	  
the	  Mann	  Whitney	   test;	   ns:	   no	   significant.	   (B)	   Representative	  Western	   blot	   of	   ESCTRL2	   (Control)	  
and	   TBS332	   total	   cell	   lysates	   treated	   or	   not	  with	  MG132	   (2	   or	   5	   µM).	   A	   specific	   antibody	   against	  
LUZP1	  detected	  endogenous	   LUZP1	   and	  GAPDH	  was	  used	   as	   loading	   control.	  Numbers	  on	   top	  of	  
LUZP1	  panel	   represent	   the	  number	   lanes.	  Numbers	  under	   LUZP1	  panel	   result	   from	  dividing	  band	  
intensities	  of	   each	   lane	  by	   control	  without	  MG132	   treatment	   (lane	  1).	  Note	   the	  more	  prominent	  
increase	  of	  LUZP1	  levels	  in	  TBS332	  cells	  upon	  MG132	  treatment	  (lanes	  2	  and	  3	  vs	  lanes	  5	  and	  6).	  (C)	  
Representative	  western	   blot	   of	   total	   lysates	   of	   HEK	   293FT	   cells	   transfected	  with	   SALL1c.826C>T-­‐YFP	  
(SALL1275-­‐YFP;	  lanes	  1	  and	  3)	  or	  YFP	  alone	  (lanes	  2	  and	  4)	  treated	  (+)	  or	  not	  (-­‐)	  with	  the	  proteasome	  
inhibitor	  MG132.	  Note	  an	   increase	   in	  LUZP1	   in	   the	  presence	  of	  MG132	   (+MG132)	  when	  SALL1275-­‐
YFP	   was	   transfected.	   Specific	   antibodies	   against	   LUZP1,	   GFP	   and	   GAPDH	   were	   used.	   Molecular	  
weight	  markers	   (kDa)	  are	  shown	  to	   the	   right.	   (D)	  Graphical	   representation	  of	   the	   fold	  changes	  of	  
LUZP1/GAPDH	  ratios	  obtained	  in	  (C)	  for	  HEK	  293FT	  cells	  transfected	  with	  SALL1c.826C>T-­‐YFP	  (SALL1275-­‐
YFP;	   orange	   dots)	   or	   YFP	   alone	   (blue	   dots)	   treated	   (+)	   or	   not	   (-­‐)	   with	   the	   proteasome	   inhibitor	  
MG132.	  Data	   from	  at	   least	   three	   independent	   experiments	   pooled	   together	   are	   shown.	   P-­‐values	  
were	  calculated	  using	  two-­‐tailed	  unpaired	  Student´s	  t-­‐test.	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modulate	  LUZP1	  stability.	  In	  order	  to	  understand	  these	  changes,	  we	  analysed	  LUZP1	  
levels	   after	   treatment	  with	  MG132,	   a	   known	   inhibitor	   of	   the	   proteasome,	   both	   in	  
control	   and	   TBS	   cells.	   LUZP1	   levels	   were	   increased	   to	   a	   higher	   extent	   in	   TBS	  
compared	   to	   control	   cells	   (Figure	   R	   29B,	   +MG132).	   Moreover,	   we	   confirmed	   the	  
reduction	   of	   LUZP1	   levels	   in	   HEK	   293FT	   cells	   overexpressing	   truncated	   SALL1	  
(SALL1275-­‐YFP)	  compared	  to	  the	  control	  cells	  overexpressing	  YFP	  alone	  (Figure	  R	  29C	  
and	  Figure	  R	  29D).	  An	   increase	  in	  LUZP1	  accumulation	  upon	  MG132	  treatment	  was	  
also	   observed	   in	   HEK	   293FT	   cells	   overexpressing	   SALL1275-­‐YFP	   compared	   to	   their	  
controls	   overexpressing	   YFP.	   These	   results	   suggest	   that	   truncated	   SALL1	   leads	   to	  
LUZP1	  instability	  and	  degradation.	  
	  
4.2.7	  LUZP1	  interacts	  with	  actin	  and	  centrosome-­‐associated	  proteins	  
LUZP1	   localization	   in	   human	   cells	   suggested	   a	   relation	   of	   this	   protein	   with	  
actin	   and	   centrosome-­‐related	   proteins.	   First,	   the	   association	   between	   LUZP1	   and	  
actin-­‐related	  proteins	  was	  supported	  by	  the	  binding	  of	  LUZP1-­‐YFP	  to	  beta	  actin	  and	  
filamin	   A,	   FLNA	   (Figure	   R	   30A).	   The	   link	   between	   LUZP1	   and	   actin	   was	   further	  
demonstrated	  by	  treating	  HEK	  293FT	  cells	  with	  CytB.	  LUZP1	  levels	  were	  increased	  in	  
HEK	   293FT	   cells	   treated	   with	   CytB	   as	   shown	   by	   Western	   blot	   (Figure	   R	   30B	   and	  
Figure	   R	   30C).	   This	   result	   might	   indicate	   that,	   when	   actin	   depolymerization	   is	  
induced,	  LUZP1	  becomes	  more	  soluble	  to	  the	  extraction	  buffer.	  
	  
Next,	   we	   found	   that	   the	   two	   major	   ciliogenesis	   suppressors,	   CCP110	   and	  
CEP97,	   interact	   with	   LUZP1-­‐YFP,	   either	   in	   WT	   HEK	   293FT	   cells	   or	   in	   293335	   SALL1	  
mutant	  cells	  (Figure	  R	  31A,	  lanes	  5	  and	  7,	  respectively).	  As	  shown	  before	  in	  both,	  TBS	  
cells	  and	  HEK	  293FT	  cells	  overexpressing	  SALL1275	   (Figure	  R	  29B	  and	  Figure	  R	  29C),	  
LUZP1	  input	  levels	  were	  reduced	  in	  total	  extracts	  of	  293335	  compared	  with	  WT	  cells	  
(Figure	  R	  31A,	  Input,	  lane	  1	  vs	  lane	  3),	  leading	  to	  less	  CCP110	  and	  CEP97	  interacting	  
with	  LUZP1	  in	  those	  cells	  in	  the	  pulldowns.	  	  
Furthermore,	   we	   found	   LUZP1	   interacting	   with	   the	   centrosomal	   proteins	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CCP110	   and	   CEP97	   by	   immunoprecipitating	   endogenous	   LUZP1	   and	   CEP97,	  
respectively	   (Figure	   R	   31B	   and	   Figure	   R	   31C).	   These	   results	   confirm	   that,	   in	  
agreement	   with	   the	   localization	   of	   the	   protein	   to	   the	   actin	   cytoskeleton	   and	   the	  
centrosome,	   LUZP1	   interacts	   with	   components	   of	   both	   cellular	   structures	   and	  
further	  support	  the	  notion	  that	  the	  presence	  of	  truncated	  SALL1	  leads	  to	  a	  reduction	  
in	  the	  total	  levels	  of	  LUZP1.	  
	  
4.2.8	  LUZP1	  plays	  a	  role	  in	  primary	  cilia	  formation	  
In	  view	  of	  LUZP1	   localization	  to	  the	  centrosome	  and	   its	   interaction	  with	  the	  
centrosome-­‐related	  proteins	  CCP110	  and	  CEP97,	  we	  hypothesized	  that	  LUZP1	  might	  
have	  a	  role	  in	  cilia	  formation.	  To	  analyse	  this	  posibility,	  WT,	  Luzp1-­‐/-­‐	  and	  +LUZP1	  cells	  
were	   plated	   at	   equal	   densities	   and	   promoted	   either	   to	   ciliate	   for	   48h	   by	   serum	  
withdrawal	   (−FBS),	  or	  to	  reabsorb	  their	  cilia	  by	  serum	  replenishment	  for	  4h	  (+FBS).	  
We	   quantified	   ciliation	   rates	   and	   primary	   cilia	   length	   at	   all	  mentioned	   timepoints.	  
Figure	  R	  30.	  LUZP1	  interacts	  with	  actin-­‐related	  proteins.	  (A)	  Western	  blot	  of	  inputs	  or	  GFP-­‐Trap	  
pulldowns	   performed	   in	   HEK	   293FT	   cells	   transfected	  with	   LUZP1-­‐YFP	   (LUZP1-­‐YFP)	   or	   YFP	  alone	  
(YFP).	  Specific	  antibodies	  against	  the	  endogenous	  actin	  and	  filamin	  A	  (FLNA)	  proteins	  were	  used.	  
GFP	  antibody	  detected	  LUZP1-­‐YFP	  (black	  arrowhead)	  and	  YFP	  alone	  (two	  white	  arrowheads).	  (B)	  
Western	  blot	  of	   total	   cell	   lysates	   from	  3	   independent	  experiments	   in	  HEK	  293FT	   treated	  or	  not	  
with	  Cytochalasin	  B	  (CytB).	  Note	  the	  increase	  in	  LUZP1	  levels	  upon	  actin	  polymerization	  blockage	  
with	  CytB.	  Endogenous	  LUZP1	  was	  detected	  by	  a	  specific	  antibody	  against	  LUZP1	  and	  GAPDH	  was	  
used	  as	  loading	  control.	  (C)	  Graphical	  representation	  of	  LUZP1	  vs	  GAPDH	  band	  intensities	  in	  (B).	  
Graphs	  represent	  Mean	  and	  SEM	  of	  three	  independent	  experiments.	  P-­‐value	  was	  calculated	  using	  
two	  tailed	  unpaired	  Student´s	  t-­‐test.	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Luzp1-­‐/-­‐	  fibroblasts	  displayed	  higher	  ciliation	  rate	  (60%)	  than	  WT	  (10.5%)	  and	  
+LUZP1	  (22.2%)	  when	  the	  cells	  were	  not	  subjected	  to	  starvation	  (Figure	  R	  32A	  and	  
Figure	  R	  32B).	  However,	  Luzp1-­‐/-­‐	  cells	  were	  not	  significantly	  more	  ciliated	  than	  WT	  or	  
+LUZP1	  fibroblasts	  upon	  48	  hours	  of	  starvation	  (Figure	  R	  32B).	   In	  addition,	  primary	  
cilia	   in	   Luzp1-­‐/-­‐	   cells	  were	   significantly	   longer	   than	   in	   non-­‐starved	  WT	   cycling	   cells;	  
under	  48	  hours	  of	  starvation,	  the	  differences	  among	  WT,	  Luzp1-­‐/-­‐	  and	  +LUZP1	  were	  
not	  significant.	  In	  the	  case	  of	  cilia	  length,	  Luzp1-­‐/-­‐	  and	  +LUZP1	  cells	  behaved	  similarly	  
(no	   starvation:	   average	   3.0	   µm	   in	   Luzp1-­‐/-­‐	   cells	   and	   2.9	   µm	   in	   +LUZP1	   cells;	   48h	  
starvation:	   average	   4.1	   µm	   in	   Luzp1-­‐/-­‐	   cells	   and	   4.8	   µm	   in	   +LUZP1	   cells;	   4h	   upon	  
disassembly	   induction:	  3	  µm	   in	  Luzp1-­‐/-­‐	   cells	  and	  2.9	  µm	   in	  +LUZP1	  cells)	   (Figure	  R	  
32A	  and	  Figure	  R	  32C).	   These	   results	   confirm	   that	   Luzp1-­‐/-­‐	   cells	  display	   longer	  and	  
more	  abundant	  primary	  cilia	  compared	  to	  WT	  cells	  in	  cycling	  conditions	  and	  indicate	  
that	  LUZP1	  might	  affect	  primary	  cilia	  dynamics.	  This	  phenotype,	  partially	  rescued	  by	  
	  
	  the	  expression	  of	  LUZP1,	  is	  reminiscent	  of	  the	  phenotype	  described	  in	  TBS	  cells.	  	  
To	   check	   whether	   the	   overexpression	   of	   LUZP1	   is	   sufficient	   to	   rescue	   the	  
higher	  ciliation	  rates	  and	  repress	  ciliogenesis	  in	  primary	  human	  TBS	  cells,	  TBS275	  cells	  	  
Figure	  R	  31.	  LUZP1	  interacts	  with	  centrosome-­‐related	  proteins.	  (A)	  Western	  blot	  of	  inputs	  (lines	  
1	  to	  4)	  and	  GFP-­‐Trap	  pulldowns	  (lines	  5	  to	  8)	  performed	  in	  WT	  HEK	  293FT	  cells	  (293)	  or	  in	  293335	  
SALL1	  mutant	  cells	  transfected	  with	  LUZP1-­‐YFP	  (lanes	  1,3,5	  and	  7)	  or	  YFP	  alone	  (lanes	  2,4,	  6	  and	  
8).	   Endogenous	   CEP97	   and	   CCP110	   were	   detected	   with	   specific	   antibodies.	   Numbers	   under	  
CCP110	   and	   CEP97	   panels	   result	   from	   dividing	   band	   intensities	   of	   each	   pulldown	   by	   their	  
respective	  input	  levels.	  GAPDH	  was	  used	  as	  loading	  control.	  (B,C)	  Western	  blot	  of	  representative	  
immunoprecipitation	  (IP)	  assays	  using	  LUZP1	  and	  CEP97	  specific	  antibodies	  to	  pull	  down	  CCP110	  
and	   LUZP1	   endogenous	   proteins,	   respectively.	   Rabbit	   immunoglobulins	   (IgGs)	   were	   used	   as	  
immuno recipitati n	   control .	   GAPDH	   was	   used	   as	   loading	   control.	   Blots	   shown	   here	   are	  
representative	  of	  three	  independent	  experiments.	  Molecular	  weight	  markers	  (kDa)	  are	  shown	  to	  
the	  right.	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were	  ransiently	  transfected	  with	  YFP	  (Figure	  33A)	  or	  LUZP1-­‐YFP	   (Figure	  33B).	  None	  
of	   the	   TBS275	   cells	   transfected	   with	   LUZP1-­‐YFP	   were	   ciliated	   (yellow	   arrowhead)	  
(Figure	   33C)	   whereas	   the	   surrounding	   non	   transfected	   cells	   displayed	   cilia	   (white	  
arrowheads).	   In	  contrast,	  most	  non-­‐transfected	  surrounding	  cells,	  as	  well	  as	  TBS275	  
cells	  overexpressing	  YFP	  were	  ciliated.	  Thus,	  these	  results	  confirm	  that	  LUZP1	  might	  
be	  a	  potential	  primary	  cilium	  repressor	  and	  suggest	  that	  the	  TBS	  phenotype	  might	  be	  
partially	   caused	   by	   the	   reduction	   in	   LUZP1	   levels.
Figure	   R	   32.	   Luzp1-­‐/-­‐	   cells	   show	   aberrant	   cilia	   frequency	   and	   length.	   (A)	   Micrographs	   of	   Shh-­‐
LIGHT2	  cells	  (WT),	  Shh-­‐LIGHT2	  cells	  lacking	  Luzp1	  (Luzp1-­‐/-­‐)	  and	  Luzp1-­‐/-­‐	  cells	  rescued	  with	  human	  
LUZP1-­‐YFP	   (+LUZP1)	   analysed	   in	   cycling	   conditions	   (non	   starved),	   or	   during	   cilia	   assembly	   (48h	  
starved)	   and	   disassembly	   (4h	   refed).	   Cilia	   were	   visualized	   by	   acetylated	   alpha	   tubulin	   (AcTub,	  
purple),	  basal	  body	  by	  gamma	  tubulin	  (g-­‐tub,	  green)	  and	  nuclei	  by	  DAPI	  (blue).	  Scale	  bar,	  2.5	  µm.	  
(B,C)	  Graphical	  representation	  of	  percentage	  of	  ciliated	  cells	  (B)	  and	  cilia	   length	  (C)	  measured	  in	  
WT	  (blue	  circles,	  n>34	  cilia),	  Luzp1-­‐/-­‐	  (orange	  circles,	  n>44	  cilia)	  or	  +LUZP1	  cells	  (green	  circles,	  n>30	  
cilia)	   from	   three	   independent	   experiments.	   Cells	   that	   underwent	   48	   hours	   of	   starvation	   were	  
compared	  to	  non-­‐starved	  cells.	  After	  starvation,	  cells	  were	  supplied	  with	  serum	  for	  4	  hours	  (n=21-­‐
30	   micrographs	   for	   all	   the	   cases).	   Pictures	   were	   taken	   using	   an	   Axioimager	   D1	   fluorescence	  
microscope,	   Zeiss	  with	   a	   63x	  objective.	  Graphs	   represent	  Mean	  and	   SEM	  of	   three	   independent	  
experiments.	  P-­‐values	  were	  calculated	  using	  One	  way	  ANOVA	  and	  Bonferroni	  post-­‐hoc	  test	  or	  two	  
tailed	  unpaired	  Student´s	  t-­‐test.	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Figure	   R	   33.	   Luzp1	   expression	   is	   sufficient	   to	   repress	   ciliogenesis	   in	   TBS	   cells.	   (A,B)	  
Representative	  micrographs	  of	   ciliated	  TBS275	   cells	   showing	   in	   green	  YFP	   (A)	   or	  LUZP1-­‐YFP	   	   (B).	  
Cilia	  were	  visualized	  by	  acetylated	  alpha	  tubulin	  (AcTub,	  purple),	  and	  nuclei	  by	  DAPI	  (blue).	  Note	  
the	  lack	  of	  cilia	  in	  cells	  overexpressing	  LUZP1-­‐YFP.	  Yellow	  arrowheads	  point	  at	  a	  magnified	  region	  
shown	   in	   black	   and	   white	   in	   the	   upper	   left	   panel.	  White	   arrowheads	   point	   at	   the	   cilia	   of	   the	  
LUZP1-­‐YFP	  non	  transfected	  cells.	  Scale	  bar,	  10	  µm.	  Pictures	  were	  taken	  using	  an	  Axioimager	  D1	  
Zeiss	   fluorescence	   microscope,	   with	   a	   63x	   objective.	   (C)	   Graph	   represents	   the	   percentage	   of	  
ciliated	   cells	   in	   cells	   overexpressing	   YFP	   (orange	   dots,	   n=34)	   or	   LUZP1-­‐YFP	   (green	   dots,	   n=10).	  
Mean	  and	  SEM	  of	  three	  independent	  experiments	  are	  shown.	  P-­‐values	  were	  calculated	  using	  the	  
two	  tailed	  unpaired	  Student´s	  t-­‐test.	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4.2.9	  Luzp1-­‐/-­‐	  cells	  exhibit	  aberrant	  Sonic	  Hedgehog	  signalling	  
In	  view	  of	  the	  previously	  observed	  ciliogenesis	  defects,	  we	  examined	  whether	  
Shh	  signalling	   is	  compromised	   in	  Luzp1-­‐/-­‐	   cells.	  Cells	  were	  starved	   for	  24	  hours	  and	  
incubated	   in	   the	   presence	   or	   absence	   of	   purmorphamine	   for	   6	   or	   24	   hours	   to	  
activate	  the	  Shh	  pathway.	  mRNA	  expression	  of	  two	  Shh	  target	  genes	  (Gli1	  and	  Ptch1)	  
was	  quantified	  by	  qRT-­‐PCR	  (Figure	  R	  34A	  and	  Figure	  R	  34B).	  We	  found	  that	  the	  basal	  
Gli1	  and	  Ptch1	  expression	   levels	   in	  Luzp1-­‐/-­‐	   cells	  were	  higher	   than	   in	  WT	  cells	   (Gli1	  
1.5	  fold	  and	  Ptch1	  2.3	  fold	  increase	  in	  Luzp1-­‐/-­‐	  vs	  WT	  cells	  without	  purmorphamine).	  
Upon	  induction	  by	  purmorphamine	  for	  24	  hours,	  WT	  cells	  increased	  significantly	  the	  
expression	  of	   both	   targets,	  while	   Luzp1-­‐/-­‐	   cells	   did	  not,	   indicating	   the	   incapacity	  of	  
Luzp1-­‐/-­‐	  to	  respond	  to	  Shh	  signalling	  induction.	  To	  further	  study	  the	  role	  of	  LUZP1	  in	  
Shh	   signalling,	   we	   analysed	   GLI3	   processing	   by	   Western	   blot	   using	   total	   lysates	  
extracted	  from	  WT	  vs	  Luzp1-­‐/-­‐	  cells.	  Without	  purmorphamine	  induction,	  we	  found	  a	  
significantly	  higher	  ratio	  of	  GLI3	  activating	  form	  vs	  GLI3	  repressive	  form	  (GLI3-­‐A:GLI3-­‐
R)	   in	   Luzp1-­‐/-­‐	   cells	   compared	   to	  WT	   (2.9	   fold	   increase	   in	   Luzp1-­‐/-­‐	   cells	  vs	   1	   foldWT)	  
(Figure	  R	  34C).	  After	  induction,	  the	  values	  were	  similar	  for	  Luzp1-­‐/-­‐	  and	  WT	  cells.	  We	  
also	  examined	  the	  effects	  of	  lacking	  Luzp1	  on	  Shh	  signalling	  by	  measuring	  the	  activity	  
of	   a	   Shh	   luciferase	   reporter	   activity	   (Figure	   R	   34D).	   Prior	   to	   purmorphamine	  
treatment,	  Luzp1-­‐/-­‐	  cells	  showed	  higher	  Shh	  activity	  compared	  to	  control	  or	  +LUZP1	  
cells,	  as	  observed	  in	  TBS-­‐derived	  cells.	  (1.6	  fold-­‐activity	  in	  Luzp1-­‐/-­‐	  vs	  0.5	  fold-­‐activity	  
in	   +LUZP1	   cells	   or	   1	   fold-­‐activity	   in	  WT	   cells).	   However,	   the	   induction	   capacity	   of	  
Luzp1-­‐/-­‐	  cells	  upon	  purmorphamine	  treatment	  is	  reduced	  compared	  to	  WT	  or	  +LUZP1	  
cells.	  Altogether,	   the	  observed	  defects	   in	  Ptch1	   and	  Gli1	   gene	  expression,	   reduced	  
GLI3	   processing	   and	   Shh	   reporter	   missregulation	   confirm	   a	   role	   for	   LUZP1	   in	   Shh	  
signalling.	  
	  
4.2.10	  LUZP1	  regulates	  cell	  proliferation	  
In	  the	  course	  of	  our	  centrosome	  studies	  in	  Luzp1-­‐/-­‐	  cells,	  immunofluorescence	  
microscopy	  revealed	  a	  striking	  phenotype:	  Luzp1	  depletion	  resulted	  in	  the	  presence	  
of	  more	   than	   four	  centrioles	   in	  Luzp1-­‐/-­‐	   cells	   (Figure	  R	  35A	  and	  Figure	  R	  35B).	  This	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phenotype	  was	   rescued	   in	  +LUZP1	  cells,	   suggesting	   that	   lacking	  Luzp1	  might	  affect	  
centrosome	  amplification.	  The	  presence	  of	  multiple	  centrioles	  was	  further	  verified	  in	  
293LUZP1	  KO	  cells	  (Figure	  R	  35C).	  	  
Figure	  R	  34.	   Luzp1-­‐/-­‐	   cells	  display	  aberrant	  Shh	   signaling.	   (A,B)	  Graphical	   representation	  of	   the	  
fold	  change	   in	   the	  expression	  of	  Gli1	   (n=5)	   (A)	  and	  Ptch1	   (n=7)	   (B)	  obtained	  by	  qPCR	  from	  Shh-­‐
LIGHT2	  cells	  (WT;	  blue	  dots)	  or	  Shh-­‐LIGHT2	  cells	  lacking	  Luzp1	  (Luzp1-­‐/-­‐;	  orange	  dots),	  treated	  (+)	  
or	   not	   (-­‐)	  with	  purmorphamine	   for	   24	  hours.	   (C)	  Western	  blot	   analysis	   of	   lysates	   from	  WT	  and	  
Luzp1-­‐/-­‐	  cells.	  Samples	  were	  probed	  with	  an	  anti-­‐GLI3	  antibody	  that	  detects	  both	  GLI3	  activating	  
form	   (GLI3-­‐A)	   and	  GLI3	   repressive	   form	   (GLI3-­‐R),	   and	  GAPDH	  was	   used	   as	   loading	   control.	   The	  
ratio	   of	   activating:repressing	   forms	   of	   GLI3	   (A:R	   ratio)	   was	   calculated	   using	   image	   analysis	   to	  
quantitate	  the	  intensity	  of	  the	  bands,	  and	  is	  indicated	  at	  the	  bottom.	  The	  value	  of	  the	  WT,	  non-­‐
induced	   sample	   was	   taken	   as	   1.	   Molecular	   weight	   markers	   (kDa)	   are	   shown	   to	   the	   right.	   (D)	  
Graphical	   representation	   of	   fold	   change	   activation	   of	   a	   Shh	   luciferase	   reporter	   when	  WT	   cells	  
(n>7;	  blue	  dots),	  Luzp1-­‐/-­‐	  cells	  (n>7;	  orange	  dots)	  or	  +LUZP1	  cells	  (n=4;	  green	  dots)	  were	  treated	  or	  
not	  (-­‐)	  with	  purmorphamine	  for	  6	  or	  24	  hours.	  All	  graphs	  represent	  the	  Mean	  and	  SEM.	  P-­‐values	  
were	   calculated	   using	   two	   tailed	   unpaired	   Student´s	   t-­‐test	   or	   One	  way	   ANOVA	   and	   Bonferroni	  
post-­‐hoc	  test.	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Aberrant	   centriole	   numbers	   could	   result	   from	   defects	   in	   the	   control	   of	   the	  
cell	   cycle,	   failure	   in	  cytokinesis	  or,	  alternatively,	   cell	   fusion.	  FACS	  analysis	  detected	  
more	   apoptotic	   cells	   among	   the	   Luzp1-­‐/-­‐	   cell	   population	   by	   co-­‐staining	   cells	   with	  
DRAQ7	   and	   Annexin	   V	   (Figure	   R	   36A	   and	   Figure	   R	   36B)	   but	   it	   did	   not	   reveal	  
significant	   changes	   in	   cell	   cycle	   (Figure	   R	   36C).	   In	   addition,	   nuclear	   size	   was	  
significantly	   increased	   in	   Luzp1-­‐/-­‐	   cells	  and	   it	  was	   rescued	   in	  +LUZP1	  cells	   (Figure	  R	  
37A),	   suggesting	   that	   the	   presence	   of	   multiple	   centrioles	   might	   not	   be	   a	  
consequence	  of	  cell-­‐cycle	  deregulation	  in	  Luzp1-­‐/-­‐	  cells,	  but	  it	  might	  be	  derived	  from	  
defects	   in	  cytokinesis.	   In	   line	  with	  this,	  Luzp1-­‐/-­‐	  cells	  exhibited	  a	  significant	  delay	   in	  
proliferation	   at	   day	   3	   and	   6	   after	   seeding,	   compared	   to	  WT	   cells	   (Figure	   R	   37B).	  
+LUZP1	  cells	  partially	  rescued	  proliferation	  impairment	  (Figure	  R	  37B,	  green	  line).	  
4.2.11	  LUZP1	  affects	  actin	  polymerization	  
Based	  on	  the	  actin	  fibers	  reduction	  observed	  in	  Luzp1-­‐/-­‐	  cells	  and	  
that	   the	   loss	  
Figure	  R	  35.	  Luzp1-­‐/-­‐	  cells	  display	  multiple	  centrioles.	  (A)	  Micrographs	  showing	  centrioles	  in	  wild-­‐
type	   Shh-­‐LIGHT2	   cells	   (WT),	   Shh-­‐LIGHT2	   cells	   lacking	   Luzp1	   (Luzp1-­‐/-­‐)	   and	   Luzp1-­‐/-­‐	   cells	   rescued	  
with	   Luzp1-­‐YFP	   (+LUZP1)	   analysed	   during	   cycling	   conditions.	   Centrioles	  were	   visualized	   using	   a	  
gamma	  tubulin	  antibody	  (gTub,	  purple,	  yellow	  arrowheads)	  and	  nuclei	  were	  counterstained	  using	  
DAPI	  (blue).	  Scale	  bar,	  5	  µm.	  (B)	  Graphical	  representation	  of	  the	  percentage	  of	  cells	  that	  exhibit	  
more	   than	   4	   centrioles	   in	   (A).	  WT,	   n=37,	   blue	   dots;	   Luzp1-­‐/-­‐,	   n=38,	   orange	   dots;	  +LUZP1,	   n=35,	  
green	  dots.	  P-­‐values	  were	  calculated	  using	  Kruskall	  Wallis	  and	  Dunn's	  multiple	  comparisons	  tests.	  
(C)	  Graphical	  representation	  of	  the	  percentage	  of	  cells	  that	  exhibit	  more	  than	  4	  centrioles	  in	  wild-­‐
type	  HEK	  293FT	  (293WT)	  and	  HEK	  293FT	  cells	  lacking	  LUZP1	  (293LUZP1	  KO).	  The	  graphs	  represent	  the	  
Mean	  and	  SEM.	  P-­‐values	  were	  calculated	  using	  Mann	  Whitney	  test.	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Figure	   R	   37.	   Luzp1-­‐/-­‐	   cells	   exhibit	   cell	   division	   defects.	   (A)	   Graphical	   representation	   of	   nuclear	  
area	  of	  Shh-­‐LIGHT2	  WT	  (n=178;	  blue	  dots),	  Luzp1-­‐/-­‐	  (n=185;	  orange	  dots)	  and	  +LUZP1	  cells	  (n=90;	  
green	  dots).	  P-­‐values	  were	  calculated	  using	  Kruskall	  Wallis	  and	  Dunn's	  multiple	  comparisons	  tests.	  
(B)	   Graphical	   representation	   of	   fold	   change	   in	   cell	   proliferation	   of	  WT	   (n=5;	   blue	   line),	   Luzp1-­‐/-­‐	  
(n=5;	  orange	  line)	  and	  +LUZP1	  cells	  (n=5;	  green	  line).	  The	  graphs	  represent	  the	  Mean	  and	  SEM.	  P-­‐
values	  were	  calculated	  using	  Two	  way	  ANOVA	  and	  Sidak's	  multiple	  comparisons	  test.	  
	  
Figure	  R	  36.	  Increased	  apoptosis	  in	  Luzp1-­‐/-­‐	  cells.	  (A)	  Graphical	  representation	  of	  the	  percentage	  
of	  Shh-­‐LIGHT2	  WT	  cells	  (blue	  dots)	  and	  Shh-­‐LIGHT2	  cells	  Luzp1-­‐/-­‐	  cells	  (orange	  dots)	  in	  G0/G1,	  S	  or	  
G2/M	   phases.	   P-­‐values	   were	   calculated	   using	   Two	   way	   ANOVA.	   (B)	   Representative	   profiles	   of	  
FACS	  analysis	  of	  apoptosis	   in	  WT	  and	  Luzp1-­‐/-­‐	  cells.	  Q2	  and	  Q4	  point	  at	  early	  and	   late	  apoptosis	  
cells	   (blue	   and	   purple	   dots,	   respectively).	   (C)	   Graphical	   representation	   of	   the	   results	   of	   flow	  
cytometry	  (FACS)	  analysis	  to	  determine	  the	  percentage	  of	  apoptotic	  cells	  in	  WT	  and	  Luzp1-­‐/-­‐	  cells	  
in	  (B)	  (n=4).	  P-­‐value	  was	  calculated	  using	  Mann	  Whitney	  test.	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of	  ARP3	  has	  been	  previously	  shown	  to	  increase	  axoneme	  length	  in	  htRPE	  cells	  (Kim	  
et	  al.,	  2010),	  we	  aimed	  to	  characterize	  their	  actin	  polymerization	  state	  by	  assessing	  
ARP3	  and	  cofilin	   levels	   in	   those	  cells	  by	  Western	  blot.	  The	  decrease	   in	  ARP3	   levels	  
(Figure	  R	  38A	  and	  Figure	  R	  38B)	  was	  accompanied	  by	  an	  increase	  in	  phosphorylated	  
cofilin	   in	   Luzp1-­‐/-­‐	   cells	   (Figure	  R	  38C	  and	  Figure	  R	  38D).	  Of	  note,	  we	  also	  analysed	  
Rac1	  activation	  by	  phosphorylation	  (pRAC1	  vs	  RAC1),	  but	  we	  did	  not	  find	  significant	  
differences	  between	  Luzp1-­‐/-­‐	  and	  WT	  cells	  (Figure	  R	  38E	  and	  Figure	  R	  38F).	  	  
4.2.12	  LUZP1	  interferes	  with	  cell	  migration	  
Based	   on	   the	   neural	   tube	   closure	   defects	   that	   Luzp1	   KO	   mice	   display,	  
together	  with	  the	  relevance	  of	  actin	  cytoskeleton	  dynamics	  for	  proper	  cell	  migration	  
in	   the	   neural	   tube	   closure	   process	   (Cabrera	   et	   al.,	   2004;	   Copp	   et	   al.,	   2003;	  
Wallingford,	  2005),	  we	  analysed	  cell	  migration	  rates	  in	  Luzp1-­‐/-­‐	  cells	  using	  a	  wound-­‐
healing	   assay.	   This	   assay	   typically	   measures	   migration	   of	   cells	   by	   measuring	   the	  
closure	  of	  a	   standard	  scratch	   in	   time.	  We	   found	   that	  Luzp1-­‐/-­‐	   cells	  had	  significantly	  
faster	  migratory	  capacity	  compared	  to	  WT	  cells	  (Figure	  R	  39A	  and	  Figure	  R	  39B).	  This	  
phenotype	  was	  rescued	  in	  +LUZP1	  cells.	  To	  migrate,	  a	  cell	  must	  coordinate	  a	  number	  
of	   different	   inputs	   into	   appropriate	   cellular	   responses.	   The	   cell	   must	   polarize	   and	  
extend	   lamellipodial	   and/or	   filopodial	   protrusions.	   Vinculin	   and	   phalloidin	   staining	  
revealed	  a	  different	  migration	  pattern,	  where	  Luzp1-­‐/-­‐	   cells	   form	  more	   lamellipodia	  
and	  more	   focal	   adhesions	   than	  WT	   in	   the	   front	   of	  migrating	   cells	   (Figure	   R	   39C).	  
Filopodia	  and	  filopodia-­‐like	  protrusions	  are	  prominent	  features	  of	  migrating	  cells	   in	  
vitro	   (Jacquemet	   et	   al.,	   2013;	   Paul	   et	   al.,	   2015;	   Petrie	   and	   Yamada,	   2012).	   In	  
concordance	  with	   their	   increased	  migration	   capacity,	   Luzp1-­‐/-­‐	   cells	   displayed	  more	  
filopodia	  than	  WT	  cells	  (Figure	  R	  39D).	  	  
In	   a	  migrating	   cell,	   the	   activities	   of	   the	   different	   Rho	  GTPases	   and/or	   their	  
effector	  pathways	  must	  be	  coordinated	  in	  a	  temporal	  and	  spatial	  manner	  to	  control	  
cytoskeletal	  dynamics.	   In	  fact,	  the	  contractile	  force	   is	  generated	  by	  the	  actomyosin	  
contractility	   through	   myosin	   light	   chain	   2	   (MLCII)	   phosphorylation	   by	   ROCK.	   To	  
deepen	   in	   the	   understanding	   of	   the	   migratory	   phenotype	   shown	   in	   Luzp1-­‐/-­‐	   cells,	  
MLCII	  phosphorylation	  was	  assessed	  on	  those	  cells.	  However,	  our	  antibody	  did	  not	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Figure	  R	  38.	  Defects	  in	  F-­‐actin	  formation	  in	  Luzp1-­‐/-­‐	  cells.	  (A,C,E)	  Representative	  western	  blot	  of	  
total	  lysates	  of	  Shh-­‐LIGHT2	  WT	  and	  Luzp1-­‐/-­‐	  cells.	  Note	  a	  reduction	  in	  ARP3	  (A)	  and	  an	  increase	  in	  
phosphorylated	   cofilin	   (p-­‐Cofilin)	   (C)	   in	   Luzp1-­‐/-­‐	   cells.	   No	   significant	   changes	   were	   observed	   in	  
phosphorylated	   Rac1	   (pRac1)	   (E).	   	   Specific	   antibodies	   against	   ARP3,	   cofilin,	   phospho-­‐cofilin,	  
pRac1,	  Rac1	  actin	  and	  GAPDH	  were	  used.	  Molecular	  weight	  markers	  (kDa)	  are	  shown	  to	  the	  right.	  
(B,D,F)	  Graphical	  representation	  of	  the	  fold	  change	  of	  ARP3/GAPDH	  ratios	  obtained	  in	  (A),	  the	  p-­‐
cofilin/Cofilin	  ratios	  obtained	  in	  (C)	  and	  the	  pRac1/Rac1	  ratios	  obtained	  in	  (E).	  Data	  from	  at	  least	  
three	  independent	  experiments	  pooled	  together	  are	  shown.	  P-­‐values	  were	  calculated	  using	  two-­‐
tailed	  unpaired	  Student´s	  t-­‐test.	  ns:	  no	  significant.	  
	  
Results	  	  
	   120	  
	  
Figure	   R	   39.	   Luzp1-­‐/-­‐	   cells	   display	   cell	   migration	   defects.	   (A)	   Representative	   bright-­‐field	  
micrographs	  of	  the	  wound	  healing	  assays	  performed	  on	  Shh-­‐LIGHT2	  WT,	  Luzp1-­‐/-­‐	  and	  Luzp1-­‐/-­‐	  cells	  
rescued	  with	  Luzp1-­‐YFP	  (+LUZP1).	  The	  horizontal	  yellow	  lines	  represent	  the	  wound	  boundary;	  “a”	  
and	   “b”	   are	   the	   distances	   between	   wound	   boundaries	   just	   after	   wound	   was	  made	   (0h)	   and	   6	  
hours	  later	  (6h),	  respectively.	  (B)	  Quantification	  of	  wound	  healing	  in	  (A)	  calculated	  by	  subtracting	  
distance	  “b”	  to	  distance	  “a”	  and	  dividing	  the	  result	  by	  6	  hours	  (n>8).	  Data	  were	  analysed	  by	  One	  
way	  ANOVA	  and	  Bonferroni	  post-­‐hoc	  test.	  (C)	  Micrographs	  of	  WT	  and	  Luzp1-­‐/-­‐	  cells	  during	  wound-­‐
healing	  assay.	  Focal	  adhesions	  were	  detected	  by	  vinculin	  antibody	   (green),	   F-­‐actin	  by	  phalloidin	  
(purple)	   and	   nuclei	   by	   DAPI	   (blue).	   Yellow	   arrowheads	   point	   at	   lamellipodia.	   Black	   and	   white	  
images	  show	  the	  single	  green	  and	  purple	  channels.	  Scale	  bar,	  10	  µm.	  (D)	  Upper	  panel:	  example	  of	  
filopodia	  detection	  by	  Filoquant	  plugin	  for	  ImageJ	  (in	  purple)	  from	  an	  original	  picture	  (in	  black	  and	  
white).	   Lower	   panel:	   graphical	   representation	   of	   filopodia	   number	   of	  WT	   (n=7;	   blue	   dots)	   and	  
Luzp1-­‐/-­‐	   cells	   (n=7;	   orange	   dots).	   Pictures	   were	   taken	   using	   an	   Axioimager	   D1	   fluorescence	  
microscope,	   Zeiss	  with	  a	  63x	  objective.	  P-­‐values	  were	   calculated	  using	  Mann	  Whitney	   test.	   The	  
graphs	  represent	  the	  Mean	  and	  SEM.	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detect	   neither	   the	   total	   nor	   the	   phosphorylated	   form	   of	   the	   protein	   (data	   not	  
shown).	   Although	   further	   research	   is	   needed,	   the	   previously	   observed	   increase	   in	  
cofilin	   phosphorylation	   might	   indicate	   an	   enhancement	   in	   cell	   contractibility	   in	  
Luzp1-­‐/-­‐	  cells	  (Mseka	  and	  Cramer,	  2011;	  Wiggan	  et	  al.,	  2012).	  
Taken	   together,	   this	   data	   reveal	   a	   mechanism	   through	   which	   LUZP1	   may	  
coordinate	  actin	  cytoskeleton	  mechanics	  in	  cell	  migration	  via	  actin	  dynamics.	  
	  
	  	   122	  
	  	   123	  
	  
	  
Chapter	  5:	  Discussion	  
	  	   124	  
	  
Discussion	  
	   125	  
5.1	  The	  role	  of	  SALL1	  in	  primary	  cilia	  formation	  and	  function	  	  
Townes-­‐Brocks	  Syndrome	  (TBS)	  is	  a	  rare	  disease	  characterized	  by	  a	  spectrum	  
of	  malformations	  in	  digits,	  ears,	  heart	  and	  kidneys.	  The	  phenotypes	  observed	  in	  TBS	  
individuals	  fall	  within	  the	  spectrum	  of	  those	  observed	   in	  ciliopathies.	  This	   led	  us	  to	  
speculate	   that	   defective	   regulation	   of	   cilia	   function	   and/or	   formation	   might	   be	  
contributing	  factors	  in	  the	  TBS-­‐related	  limb,	  ear,	  heart,	  anus	  and	  kidney	  phenotypes.	  
Our	   work	   provides	   mechanistic	   connection	   between	   truncated	   SALL1	   and	  
aberrations	   in	   primary	   cilia,	   offering	   insights	   into	   the	   regulation	   of	   cilia	   formation	  
and	   function	   with	   respect	   to	   TBS	   etiology.	   In	   addition	   to	   its	   function	   as	   a	  
transcription	   factor	   in	   the	   nucleus,	   SALL1	  mutations,	   especially	   those	   found	   in	   the	  
hotspot	  (Figure	  I	  2)	  that	  generate	  mislocalized	  truncated	  proteins	  (Botzenhart	  et	  al.,	  
2007),	   may	   lead	   to	   aberrant	   cilia	   function.	   Four	   lines	   of	   evidence	   support	   our	  
conclusions.	   First,	   SALL1FL	   localized	   to	   primary	   cilia	   in	   several	   cell	   types;	   Second,	  
while	  control	  fibroblasts	  display	  primary	  cilia	  at	  a	  normal	  length	  and	  rates,	  TBS	  cells	  
display	  significantly	  longer	  and	  more	  abundant	  cilia;	  Third,	  signalling	  through	  primary	  
cilia	   is	   functionally	   defective	   in	   TBS332	   and	   in	   Shh-­‐LIGHT2	   cells	   that	   exogenously	  
express	   the	   mutated	   form	   SALL1332;	   Forth,	   proteins	   necessary	   for	   primary	   cilia	  
formation	  and	  function	  show	  aberrant	  dynamics	  in	  TBS332-­‐derived	  fibroblasts,	  in	  the	  
293335	  TBS	  model	  cell	  line,	  and	  in	  Sall1+/∆	  MEFs.	  	  
	  
5.1.1	  Aberrant	  interactions	  of	  truncated	  SALL1	  
The	  presence	  of	   truncated	   SALL1	   in	   the	   cytoplasm	  and	   its	   capacity	   to	   form	  
inappropriate	  protein	  interactions	  may	  underlie	  TBS	  malformations.	  This	  hypothesis	  
relies	  on	  the	  presence	  of	  the	  truncated	  form,	  which	  we	  were	  able	  to	  detect	  in	  TBS-­‐
derived	   dermal	   fibroblasts	   and	   in	   a	   genome-­‐edited	   kidney-­‐derived	  model	   cell	   line	  
(293335).	  In	  all	  these	  cases,	  the	  observed	  sizes	  of	  FL	  SALL1	  and	  its	  truncated	  forms	  are	  
higher	   than	   their	   expected	  molecular	   weight	   as	   shown	   by	  Western	   blot.	   This	   has	  
been	   previously	   observed	   (Kiefer	   et	   al.,	   2008)	   and	   might	   be	   consistent	   with	  
differential	  SALL1	  binding	  to	  SDS	  detergent	  or	  with	  the	  presence	  of	  excessive	  proline	  
residues	   that	   might	   cause	   structural	   rigidity	   to	   the	   primary	   sequence,	   thereby	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decreasing	   the	   electrophoretic	   mobility.	   Alternatively,	   posttranslational	  
modifications	  may	  also	  account	  for	  variations	  in	  the	  expected	  molecular	  weight.	  
	  By	   examining	   dermal	   fibroblasts,	   which	   display	   primary	   cilia	   and	   are	  
competent	  for	  Shh	  signalling,	  we	  show	  that	  truncated	  SALL1	  has	  multiple	  effects	  on	  
cilia	   formation	   and	   function.	   This	   might	   be	   the	   result	   of	   the	   dominant-­‐negative	  
binding	   and	   displacement	   of	   cilia-­‐related	   factors	   by	   the	   truncated	   forms	   of	   SALL1,	  
alone	   or	   in	   complex	   with	   SALL1FL.	   Notwithstanding,	   some	   aspects	   of	   the	   disease	  
might	   result	   from	   the	   sequestration	   of	   SALL1FL	   to	   the	   cytoplasm,	   which	   might	  
interfere	   with	   the	   transcriptional	   role	   of	   SALL1	   in	   the	   nucleus	   and	   alter	   cilia	  
formation	   and	   function	   through	   aberrant	   regulation	   of	   downstream	   genes.	  
Furthermore,	   other	   SALL	   proteins	   (SALL2,	   SALL3,	   SALL4)	   may	   also	   heterodimerize	  
with	   truncated	   SALL1	   (Kiefer	   et	   al.,	   2003)	   and	   thus	   contribute	   to	   the	  TBS	  etiology.	  
Furthermore,	  mouse	   studies	   that	   combine	  mutations	   in	  multiple	   Sall	   genes	   report	  
phenotypes	   including	  digit	  and	   limb	  malformations,	   Shh	  signalling	  aberrations,	  and	  
neural	  tube	  defects,	  suggestive	  of	  cilia	  malfunction	  (Bohm	  et	  al.,	  2008;	  Kawakami	  et	  
al.,	  2009).	   Interestingly,	   it	  has	  been	   reported	   that	  heterozygous	  deletions	  of	  SALL1	  
(i.e.,	   haploinsufficiency)	   lead	   to	   a	   milder	   form	   of	   TBS	   than	   that	   associated	   with	  
truncated	  variants	  in	  the	  hot	  spot	  region	  (Borozdin	  et	  al.,	  2006).	  This	  might	  indicate	  
that	  there	  is	  a	  certain	  dosage	  effect	  contributing	  to	  TBS	  phenotype.	  How	  a	  reduction	  
or	   loss	  of	   SALL1FL	   contributes	   to	  TBS	  etiology	  and	   cilia	   formation	   is	  highly	   relevant	  
and	  remains	  a	  subject	  for	  future	  research.	  
	  	  
5.1.2	  Novel	  SALL1	  localization	  along	  the	  ciliary	  shaft	  
Extensive	  studies	  on	  SALL1	  uncovered	  its	  role	  as	  a	  transcriptional	  regulator	  at	  
the	  nuclei	  (Kiefer	  et	  al.,	  2002;	  Netzer	  et	  al.,	  2006;	  Netzer	  et	  al.,	  2001;	  Nishinakamura	  
et	  al.,	  2001;	  Sweetman	  et	  al.,	  2003).	  However,	   the	  presence	  of	  SALL1FL	  at	   the	  cilia,	  
and	   its	   displacement	   to	   the	   cytoplasm	   by	   the	   truncated	   form,	   may	   also	   be	   a	  
contributing	   factor	   in	   TBS	  malformations.	   The	   partial	   removal	   of	   SALL1FL	   from	   the	  
cilia	  might	  interfere	  with	  its	  potential	  function	  at	  this	  organelle.	  Further	  investigation	  
would	  be	  needed	  to	  unveil	  the	  mechanism	  by	  which	  a	  transcription	  factor	  like	  SALL1,	  
described	   to	   localize	   mainly	   to	   the	   nuclei,	   is	   also	   found	   at	   the	   ciliary	   shaft.	   The	  
Discussion	  
	   127	  
observations	   that	   a	   nuclear	   transport	   system	   is	   involved	   in	   ciliary	   targeting,	   that	  
many	   nucleoporins	   (Nups)	   are	   localized	   at	   ciliary	   base	   and	   that	   the	   ciliary	   base	  
contains	  a	  barrier	  comparable	  to	  that	  of	  nuclear	  pores,	   led	  to	  hypothesize	  that	  the	  
ciliary	  base	  may	  contain	  a	  nuclear	  pore-­‐like	  structure	   (Kee	  et	  al.,	  2012;	  Obado	  and	  
Rout,	  2012;	  Takao	  and	  Verhey,	  2016).	  Nevertheless,	  other	  studies,	   including	  super-­‐
resolution	   imaging,	   revealed	   that	   the	  ciliary	  diffusion	  barrier	   is	  mechanistically	  and	  
structurally	  distinct	  from	  those	  of	  the	  nuclear	  pore	  complex	  (Breslow	  et	  al.,	  2013;	  Del	  
Viso	  et	   al.,	   2016;	   Lin	   et	   al.,	   2013;	  Obado	  and	  Rout,	   2016).	   Therefore,	   it	   is	   possible	  
that	   Nups	   form	   a	   different	   type	   of	   diffusion	   barrier	   at	   ciliary	   base,	   which	   could	  
explain	  why	  canonical	  nuclear	   localization	   signals	   (NLS)	  do	  not	   function	  as	  a	   ciliary	  
targeting	   signal.	   It	   is	   also	   possible	   that	   the	   cilia	   may	   contain	   additional	   diffusion	  
mechanisms	  that	  need	  to	  be	  overcome	  to	  enter	  the	  ciliary	  shaft.	  For	  instance,	  it	  has	  
been	  reported	  that	  other	  transcription	  factors	  such	  as	  GLI	  proteins	  contain	  a	  ciliary	  
localization	  sequence	  (Santos	  and	  Reiter,	  2014).	  This	  sequence	  may	  bind	  a	  factor	  or	  
factors	  that	  help	  GLI	  proteins	  in	  crossing	  the	  diffusion	  barrier	  at	  the	  ciliary	  base	  in	  a	  
passive	   or	   active	   way.	   Like	   in	   the	   case	   of	   GLI2,	   it	   is	   possible	   that	   a	   cytoplasmic	  
microtubule	  network	  might	  be	  required	  for	  ciliary	  targeting	  of	  nuclear	  proteins	  such	  
as	  SALL1	  (Kim	  et	  al.,	  2009).	  
Also,	   future	   studies	  will	   be	   necessary	   to	   examine	   levels	   and	   localization	   of	  
other	   SALL	   proteins	   in	   ciliated	   cells	   and	   tissues.	   Cells	   or	   tissues	   derived	   from	   Sall	  
knock-­‐out	  mice	  vs	  WT	  mice	  would	  be	  interesting	  models	  to	  asses	  the	  localization	  of	  
SALL	   proteins	   at	   the	   cilia.	   SALL1	   transcriptional	   regulation	   by	   the	   Shh	   signalling	  
pathway	   adds	   further	   complexity	   (Kawakami	   et	   al.,	   2009;	   Koster	   et	   al.,	   1997)	   and	  
raises	   the	   possibility	   of	   feedback	   control,	   a	   common	   theme	   in	   Shh	   pathway	  
regulation	  (e.g.	  PTCH1,	  GLI1).	  
	  
	  5.1.3	  Primary	  cilia	  aberrations	  in	  TBS-­‐derived	  cells	  
In	  this	  work,	  we	  provided	  evidences	  that	  truncated	  SALL1	  results	  in	  aberrant	  
cilia	   formation	   and	   function.	   Furthermore,	   primary	   cilia	   of	   TBS	   fibroblasts	   took	  
longer	  to	  be	  reabsorbed	  than	  those	  of	  control	  cells	  once	  serum	  was	  added	  to	  starved	  
cells.	  The	  presence	  of	  longer	  cilia	  in	  TBS-­‐derived	  fibroblasts	  is	  consistent	  with	  other	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studies	  in	  which	  ciliary	  length	  is	  coincident	  to	  phenotypes	  shown	  by	  TBS	  individuals.	  
For	   instance,	  cells	  derived	  from	  a	  Kif7	  mutant	  mice	  exhibited	  polydactyly	  displayed	  
elongated	  cilia	  (He	  et	  al.,	  2014;	  Liem	  et	  al.,	  2009;	  Tunovic	  et	  al.,	  2015).	  Although	  not	  
observed	   in	   all	   individuals,	   TBS	   can	   lead	   to	  polycystic	   kidneys.	  Consistently,	   kidney	  
epithelial	   cells	   derived	   from	   a	   mouse	   model	   of	   nephronophthisis	   that	   develops	  
polycystic	  kidney	  disease	  exhibit	  abnormally	  longer	  cilia	  (Smith	  et	  al.,	  2006;	  Sohara	  et	  
al.,	   2008).	   Notably,	   a	   recent	   study	   concluded	   that	   the	   reduction	   of	   ciliary	   length	  
using	   R-­‐roscovitine	   or	   S-­‐CR8	   drugs,	   attenuated	   cystic	   disease	   progression	   in	   these	  
mice	  (Husson	  et	  al.,	  2016),	  suggesting	  that	  cilia-­‐altering	  therapies	  may	  be	  beneficial	  
to	  TBS	  individuals.	  
	  
5.1.4	  Shh	  signalling	  aberrations	  and	  TBS	  
Since	  we	  found	  that	  TBS-­‐derived	  cells	  had	  longer	  and	  more	  abundant	  primary	  
cilia	   than	   control	   cells,	   it	  was	  not	  unexpected	   to	  observe	  defects	   in	   Shh	   signalling,	  
due	   to	   its	   dependence	   on	   intact	   cilia.	   The	   characteristic	   triad	   of	   TBS	   symptoms	  
includes	   digit	   malformations,	   misshapen	   outer	   ears	   and	   hearing	   problems,	   and	  
gastrointestinal	  anomalies,	  phenotypes	   that	  might	  be	  consistent	  with	  Shh	  signaling	  
missregulation.	  TBS332-­‐derived	  cells	  were	  hypersensitive	  to	  Shh	  pathway	  stimulation.	  
Increased	   Shh	   activity	   or	   expansion	   of	   the	   domain	   of	   expression	   of	   Shh	   in	   the	  
developing	   limb	   bud	   can	   cause	   pre-­‐axial	   polydactyly	   in	  mice,	   chick	   and	   humans,	   a	  
phenotype	   commonly	   seen	   in	   TBS	   individuals	   (Lettice	   et	   al.,	   2003;	   Masuya	   et	   al.,	  
1995;	   Yang	   et	   al.,	   1997).	   In	   addition,	   Shh	   signalling	   defects	   may	   underlie	   the	  
pathogenesis	  of	  human	  anorectal	  malformations	   in	  TBS	   individuals.	  For	   instance,	   it	  
has	   been	   shown	   that	   Gli2-­‐/-­‐	   mice	   exhibit	   imperforate	   anus,	   whereas	   Gli3-­‐/-­‐	   mice	  
display	  less	  severe	  anal	  stenosis	  (Mo	  et	  al.,	  2001),	  both	  of	  which	  are	  observed	  in	  TBS.	  
In	   humans,	   some	   individuals	   with	   Pallister-­‐Hall	   syndrome	   (PHS	   [MIM:	   165240]),	  
which	  is	  caused	  by	  mutations	  in	  GLI3	  (GLI-­‐Kruppel	  family	  member	  3	  [MIM:165240]),	  
also	  exhibit	  anorectal	  malformations,	   such	  as	   imperforate	  anus	   (Kang	  et	  al.,	  1997).	  
On	  the	  other	  hand,	  ear	  defects	  in	  TBS	  individuals	  include	  dysplastic	  ears,	  congenital	  
sensorineural	   and/or	   conductive	   hearing	   loss.	   Developmental	   pathways	   governing	  
human	  outer	  ear	  morphology	  are	   largely	  unexplored,	  but	  Shh	  signalling	  might	  be	  a	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contributing	  factor	  to	  TBS	  hearing	  problems	  since	  it	  has	  been	  demonstrated	  that	  Shh	  
influences	  proper	  development	  of	  the	  cochlea	  and	  sensory	  epithelium	  in	  mice,	  and	  
for	  auditory	  function	  in	  humans	  (Driver	  et	  al.,	  2008).	  
	  
5.2	  Cilia	  and	  actin-­‐related	  proteins	  as	  mediators	  of	  TBS	  
5.2.1	  CCP110	  and	  CEP97,	  candidate	  mediators	  of	  TBS	  etiology	  	  
	   Our	   BioID	   experiments	   showed	   an	   enrichment	   of	   ciliary/centrosomal	  
proteins	  among	  the	  potential	  interactors	  of	  truncated	  SALL1275,	  which	  may	  underlie	  
the	  observed	  ciliary	  defects.	  Approximately	  6%	  of	  the	  verified	  ciliary	  genes	  (and	  18%	  
of	  the	  potential	  ones)	  previously	  identified	  by	  the	  SYSCILIA	  Consortium	  (van	  Dam	  et	  
al.,	   2013)	   were	   found	   as	   SALL1275-­‐specific	   proximal	   interactors	   in	   at	   least	   2	  
experiments.	   In	   addition,	   6.5%	  of	   the	   SALL1275-­‐specific	   list	  was	   present	   among	   the	  
384	   centrosome-­‐localized	   proteins	   identified	   by	   the	   Human	   Protein	   Atlas	   project	  
based	   on	   subcellular	   localization	   (Uhlen	   et	   al.,	   2015).	   Among	   the	   cilia-­‐related	  
candidates	  we	  selected	  CCP110	  and	  CEP97,	  two	  of	  the	  hits	  from	  our	   list,	  which	  are	  
important	  negative	  regulators	  of	  ciliogenesis	  (Goetz	  and	  Anderson,	  2010;	  Kohlmaier	  
et	  al.,	  2009;	  Schmidt	  et	  al.,	  2009;	  Spektor	  et	  al.,	  2007).	  The	  removal	  of	  CCP110	  and	  
CEP97	   is	  a	  key	  early	  event	   in	  ciliogenesis:	  depletion	  of	  CCP110	  and	  CEP97	   leads	   to	  
the	   premature	   formation	   of	   aberrant	   cilia	   while	   their	   overexpression	   blocks	  
ciliogenesis.	  Consistently	  with	  the	  observed	  higher	  frequency	  of	  primary	  cilia	  in	  TBS-­‐
derived	   cells,	   our	   experiments	   show	   that	   CCP110	   and	   CEP97	   are	   more	   often	  
depleted	   from	   MCs	   in	   TBS332	   cells	   compared	   to	   controls.	   While	   some	   studies	  
demonstrated	   that	   removal	   of	   CCP110	   was	   sufficient	   to	   induce	   ectopic	   cilia	  
formation	  (Spektor	  et	  al.,	  2007;	  Tsang	  et	  al.,	  2008),	  others	  reported	  that	  its	  depletion	  
promoted	  abnormal	  elongation	  of	  non-­‐docked	  centriolar	  microtubules	  (Franz	  et	  al.,	  
2013;	   Schmidt	   et	   al.,	   2009).	   A	   recent	   publication	   suggested	   a	   dual	   and	   context-­‐
dependent	  role	  of	  CCP110	  in	  cilia	  formation	  relying	  on	  the	  proteins	  interacting	  with	  
CCP110	   in	   a	   determined	   subcellular	   environment	   (Yang	   et	   al.,	   2016).	   Importantly,	  
consistent	  with	  altered	   levels	  of	  CCP110	  at	   the	  MC	   in	  TBS332	   cells,	  Ccp110	  KO	  mice	  
exhibited	   a	   spectrum	  of	   developmental	   phenotypes	   including	   preaxial	   polydactyly,	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heart	   malformations	   and	   cleft	   palate	   among	   others.	   Understanding	   the	   exact	  
contribution	   of	   CCP110	   and	   its	   protein	   interaction	   network	   in	   the	   context	   of	   TBS,	  
which	   may	   function	   in	   a	   tissue-­‐	   or	   organ-­‐dependent	   manner,	   would	   be	   of	   high	  
relevance.	  	  
	  
5.2.2	  LUZP1,	  another	  potential	  mediator	  of	  TBS	  etiology	  that	   localizes	  to	  the	  cilia	  
and	  actin	  cytoskeleton	  
Applying	   the	   BioID	   method,	   we	   also	   found	   LUZP1	   as	   a	   truncated	   SALL1	  
interactor.	  It	  was	  previously	  described	  that	  LUZP1	  localized	  in	  the	  nuclei,	  which	  is	  in	  
line	   with	   the	   presence	   of	   three	   nuclear	   localization	   signals	   in	   its	   sequence.	  
Immunohistochemistry	   using	   an	   antibody	   against	   the	   N-­‐terminal	   part	   of	   LUZP1	  
showed	  the	  expression	  of	  LUZP1	  mainly	  in	  the	  mouse	  brain	  (Lee	  et	  al.,	  2001;	  Sun	  et	  
al.,	   1996).	  However,	   although	  we	   also	  detected	   LUZP1	   in	   the	  nuclei	   of	  mouse	   and	  
human	  cells	  (see	  Figure	  R	  25),	  we	  observed	  by	  immunofluorescence	  using	  a	  LUZP1-­‐
specific	   antibody	   a	   prominent	   localization	   of	   LUZP1	   to	   the	   actin	   cytoskeleton	   and	  
centrosomes,	  both	   in	  human	  and	  mouse	   cells.	   This	   localization	   correlates	  with	   the	  
one	  described	   in	  the	  Human	  Protein	  Atlas	  website,	  where	  a	  different	  antibody	  was	  
used,	   and	   is	   consistent	   with	   our	   finding	   that	   LUZP1	   interacts	   with	   actin	   and	  
centrosome-­‐related	   proteins	   (Figure	   R30	   and	   Figure	   R	   31).	   Furthermore,	   an	  
independent	   study	   using	   the	   BioID	   assay	   identified	   LUZP1	   as	   an	   interactor	   of	  
centriole-­‐related	  proteins	  such	  as	  PCM1	  (Gupta	  et	  al.,	  2015).	  Discrepancies	  in	  LUZP1	  
localization	   might	   be	   due	   to	   the	   use	   of	   different	   techniques,	   as	  
immunohistochemistry	   (Lee	   et	   al.,	   2001;	   Sun	   et	   al.,	   1996)	   vs	   immunofluorescence	  
(this	   study)	  and/or	   the	  use	  of	  different	  antibodies,	  directed	  against	   the	  N-­‐terminal	  
part	  of	  the	  protein	  (Lee	  et	  al.,	  2001;	  Sun	  et	  al.,	  1996)	  or	  against	   its	  C-­‐terminal	  part	  
(Sigma,	   this	   study).	   Further	   investigation	   will	   be	   necessary	   to	   examine	   the	  
localization	  and	  role	  of	  LUZP1	  in	  the	  nucleus.	  
	  
5.2.3	  LUZP1	  is	  altered	  in	  TBS-­‐derived	  cells	  
Here	   we	   found	   that	   truncated	   SALL1	   interacts	   with	   LUZP1,	   stimulating	   its	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degradation.	   The	   exact	  mechanism	  by	  which	   the	   aberrant	   complex	  with	   truncated	  
SALL1	   stimulates	   LUZP1	  depletion,	  both	  at	   the	  centrosome	  and	  actin	   cytoskeleton,	  
requires	  further	  investigation.	  Importantly,	  we	  detected	  an	  increase	  in	  LUZP1	  levels	  
upon	   proteasome	   inhibitor	   MG132	   treatment	   in	   control	   cells	   (Figure	   R	   29),	  
suggesting	   that	  LUZP1	  degradation	   is	  proteasome-­‐mediated.	  We	  could	  hypothesize	  
that	   LUZP1	   interaction	   with	   truncated	   SALL1	   leads	   to	   LUZP1	   posttranslational	  
modifications,	  such	  as	  ubiquitylation,	  and	  its	  subsequent	  degradation.	  
Based	  on	  its	  localization,	  we	  hypothesized	  that	  LUZP1	  has	  a	  function	  on	  cilia	  
and	  cytoskeletal	  organization.	  Both	  Luzp1-­‐/-­‐	   and	  TBS	  cells	   showed	  a	   reduction	   in	  F-­‐
actin	   accompanied	   by	   an	   increase	   in	   ciliation.	   Whether	   cilia	   dependent	   signalling	  
influences	  the	  actin	  cytoskeleton	  or	  vice	  versa	  remains	  to	  be	  elucidated.	  In	  this	  line,	  
it	  has	  been	  recently	  reported	  that	  the	  axoneme	  length	  control	  can	  influence	  primary	  
cilia–mediated	   Shh	   signalling,	   independently	   of	   cilia	   frequency	   (Drummond	   et	   al.,	  
2018).	  What	  mediates	  the	  increase	  in	  Shh	  signalling	  in	  longer	  axonemes	  is	  unknown.	  
Based	  on	  these	  results,	  we	  suggest	  that	  the	  reduction	  in	  actin	  fibres	  might	  contribute	  
to	   the	  higher	  cilia	  abundance,	   longer	  cilia	  and	   increased	  Shh	  signalling	  observed	   in	  
TBS	   cells.	   Together	   with	   the	   impairment	   of	   ciliogenesis	   in	   TBS275	   cells	   transiently	  
transfected	   with	   LUZP1-­‐YFP,	   these	   results	   suggest	   a	   role	   for	   LUZP1	   as	   a	   cilia	  
repressor	  factor	  and	  a	  stabilizer	  of	  actin	  cytoskeleton.	  	  
	  
5.2.4	  LUZP1	  as	  an	  integrator	  of	  actin	  and	  primary-­‐cilium	  dynamics	  
As	   mentioned	   in	   the	   introduction,	   actin	   dynamics	   coordinate	   several	  
processes	   that	   are	   crucial	   for	   ciliogenesis	   (Figure	   I	   13).	   Placing	   the	   MC	   to	   the	  
appropriate	   area	   at	   the	   cell	   cortex,	   basal	   body	   docking	   and	   the	   elongation	   of	   the	  
axoneme	  are	  all	  actin-­‐dependent	  processes.	  Interfering	  with	  actin	  dynamics	  through	  
CytB	   has	   been	  demonstrated	   to	   promote	   ciliogenesis	   (Cao	   et	   al.,	   2012).	   The	   exact	  
implication	  of	  LUZP1	  as	  an	  integrator	  of	  actin	  and	  primary	  cilia	  dynamics	  needs	  to	  be	  
more	  extensively	  examined.	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A.	  The	  role	  of	  LUZP1	  in	  neural	  tube	  closure	  and	  cardiac	  defects	  
Several	   studies	   have	   implicated	   cilia	   in	   the	   etiology	   of	   neural	   tube	   closure	  
defects	   (Wallingford,	   2005).	   These	   studies	   emphasize	   the	   tight	   links	   between	   cell	  
fate	  and	  cytoskeletal	  organization.	  Shh	  signalling,	  a	  pathway	  involved	  in	  neural	  tube	  
closure	   that	   relies	   on	   the	   presence	   of	   functional	   cilia,	   is	   aberrant	   in	   TBS	   patient-­‐
derived	   fibroblasts.	   Interestingly,	   ectopic	   Shh	   expression	   was	   observed	   in	   the	  
neuroepithelium	   of	   the	   NTD	   Luzp1	   KO	   mouse	   hindbrain	   (Hsu	   et	   al.,	   2008).	   In	  
concordance	   with	   these	   results,	   we	   also	   showed	   aberrant	   Shh	   signalling	  
accompanied	   by	   longer	   cilia	   in	   Luzp1-­‐/-­‐	   cells.	   Our	   results,	   together	   with	   others,	  
indicate	  that	  LUZP1	  is	  therefore	  pivotal	  to	  the	  maintenance	  of	  a	  gradient	  expression	  
of	  Shh	  such	  that	  cranial	  neural	  tube	  closure	  may	  be	  achieved.	  Hsu	  et.	  al.	  noted	  that	  
the	  NTD	  in	  Luzp1	  KO	  embryos	  with	  exencephaly	  may	  be	  caused	  by	  failure	  in	  bending	  
at	   the	   dorsolateral	   hinge	   point	   and	   that	   the	   dorsolateral	   neural	   folds	   was	   convex	  
instead	  of	  the	  concave	  morphology	  observed	  in	  WT	  embryos	  (Hsu	  et	  al.,	  2008).	  It	  has	  
been	  reported	  that	  changes	  in	  apical	  actin	  architecture	  are	  required	  to	  convert	  cells	  
from	   columnar	   to	   wedge-­‐shaped,	   subsequently	   forcing	   neural	   folds	   during	   the	  
proper	   formation	   of	   the	   neural	   tube	   (Sadler	   et	   al.,	   1982).	   Thus,	   it	   is	   tempting	   to	  
hypothesize	   that	   there	   might	   be	   defects	   in	   actin	   distribution	   at	   the	   neural	   tube	  
folding	  in	  Luzp1	  KO	  mice	  
In	   addition	   to	   NTDs,	   loss-­‐of-­‐function	   mouse	   models	   of	   Luzp1	   phenocopy	  
other	   features	   of	   human	   ciliopathies	   commonly	   found	   in	   TBS	   patients,	   such	   as	  
cardiac	  malformations	  (Kohlhase,	  1993).	  Congenital	  heart	  disease	   is	  present	   in	  50%	  
of	   the	   TBS	   patients	  with	   the	   common	   p.Arg275*	   allele	   (Kohlhase	   et	   al.,	   2003)	   and	  
12%-­‐25%	  of	  patients	  with	  other	  SALL1	  pathogenic	  variants	  (Botzenhart	  et	  al.,	  2007;	  
Botzenhart	   et	   al.,	   2005;	   Surka	   et	   al.,	   2001).	   Cardiac	   defects	   include	   atrial	   or	  
ventricular	  septal	  defect,	  which	   is	  also	  present	   in	   loss-­‐of-­‐function	  mouse	  models	  of	  
Luzp1.	  Whether	  the	  differential	  interaction	  of	  the	  diverse	  SALL1	  pathogenic	  variants	  
with	   LUZP1	   is	   responsible	   for	   the	   differences	   in	   prevalence	   of	   cardiac	   defects	  
remains	   unknown.	   Interestingly,	   it	   has	   been	   reported	   that	   Sall1	   expression	   is	   very	  
prominent	  in	  the	  developing	  brain	  (Buck	  et	  al.,	  2001)	  and	  that	  compound	  Sall1/Sall4	  
mutant	  mice	  show	  NTD	  and	  cardiac	  problems	  (Bohm	  et	  al.,	  2008).	  All	  together,	  these	  
evidences	  could	  suggest	  a	  cross	  talk	  between	  Sall1	  and	  Luzp1	  during	  brain	  and	  heart	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development.	  
	  
B.	  LUZP1	  has	  a	  role	  in	  cell	  division	  	  
	  We	   observed	   that	   Luzp1-­‐/-­‐	   cells	   exhibited	  multiple	   centrioles,	   larger	   nuclei,	  
decreased	  cell	  proliferation	  and	   increased	  apoptosis,	  which	  might	  be	   indicating	  cell	  
division	  failure	  due	  to	  reduced	  actin	  cytoskeleton.	  In	  concordance	  with	  these	  results,	  
elevated	  apoptosis	  was	  also	  observed	   in	  the	  neuroepithelium	  of	  the	  NTD	  Luzp1	  KO	  
mouse	  hindbrain	  (Hsu	  et	  al.,	  2008).	  
Moreover	   we	   found	   that	   LUZP1	   localizes	   not	   only	   to	   centrioles	   and	   actin	  
cytoskeleton,	  but	  also	  to	  the	  midbody	  in	  dividing	  cells	  (Figure	  R	  24D).	  The	  midbody,	  
an	   organelle	   formed	   at	   the	   intercellular	   bridge	   in	   the	   last	   phase	   of	   citokinesis,	  
recruits	   crucial	   proteins	   for	   the	   abscission	   between	   the	   dividing	   cells	   (D'Avino	   and	  
Capalbo,	  2016).	  One	  hypothesis	  about	  the	  role	  of	  the	  postmitotic	  midbody	  remnant	  
in	  the	  extracellular	  milieu	   is	   that	   it	  might	  be	  crucial	   for	  cell	   fate	  (Chen	  et	  al.,	  2013;	  
Dionne	   et	   al.,	   2015).	   In	   fact,	   Rubio-­‐Bernabé	   et.	   al.	   recently	   reported	   that	   the	  
midbody	   promotes	   ciliogenesis	   in	   polarized	   epithelial	   cells	   (Bernabe-­‐Rubio	   et	   al.,	  
2016).	  Understanding	  the	  role	  of	  LUZP1	  in	  the	  midbody	  would	  be	  of	  major	  interest.	  
	  
C.	  LUZP1	  affects	  actin	  polymerization	  and	  cell	  migration	  
Two	  main	   actin	   binding	   complexes/proteins	   control	   the	   polymerization	   and	  
depolymerization	   of	   the	   actin	   fibers	   in	   cells:	   the	   Arp2/3	   complex	   and	   cofilin.	   It	   is	  
known	   that	   Arp2/3	   and	   cofilin	   work	   synergistically	   in	   such	   a	   way	   that	   the	   newly	  
polymerized	   filaments	   from	   cofilin-­‐generated	   barbed	   ends	   are	   ATP-­‐rich	   filaments	  
that	   promote	   the	   nucleation	   and	   branching	   activity	   of	   the	   Arp2/3	   complex	  
(DesMarais	  et	  al.,	  2004).	  In	  this	  regard,	  we	  observed	  a	  reduction	  in	  ARP3	  and	  in	  non-­‐
phosphorylated	   (or	  active	  cofilin)	   in	  Luzp1-­‐/-­‐	  cells	  compared	  to	  WT	  cells,	   suggesting	  
that	  actin	  polymerization	  might	  be	  diminished	  (Figure	  R	  38).	  The	  reduction	   in	  actin	  
polymerization	   might	   lead	   to	   a	   negative	   feedback	   over	   SSH1.	   As	   a	   result,	  
phosphorylated	  (or	  inactive)	  cofilin	  levels	  would	  increase	  followed	  by	  actin	  turnover	  
suppression	  and	  repression	  of	  de	  novo	  actin	  filament	  growth	  in	  Luzp1-­‐/-­‐	  cells	  (Figure	  
D1).	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Although	  stress	  fibres	  contribute	  to	  cell	  shape	  and	  adhesion,	  their	  exact	  role	  
in	   cell	  migration	  has	  been	   less	   conclusively	  demonstrated.	   Stress	   fibres	   are	   absent	  
from	   several	   highly	   motile	   cells,	   such	   as	   leukocytes	   (Valerius	   et	   al.,	   1981)	   and	  
Dictyostelium	   discoideum	   amoeba	   (Rubino	   et	   al.,	   1984).	   These	   observations,	  
together	   with	   the	   lack	   of	   stress	   fibres	   in	   cells	   implanted	   in	   a	   three-­‐dimensional	  
environment	  led	  to	  suggest	  that	  they	  are	  not	  essential	  for	  cell	  migration	  (Burridge	  et	  
al.,	   1988).	   Indeed,	   stress	   fibres	  might,	  under	   certain	   conditions,	   inhibit	   rather	   than	  
drive	  cell	  motility.	  (Badley	  et	  al.,	  1980;	  Cramer	  et	  al.,	  1997;	  Herman	  et	  al.,	  1981).	  In	  
fact,	   it	  has	  been	  reported	  that	  an	   increase	   in	  actin	  fibres	   is	   linked	  to	   lower	  motility	  
(Kemp	  and	  Brieher,	  2018).	  These	  findings	  match	  our	  observations	  that	  Luzp1-­‐/-­‐	  cells	  
that	  contain	  less	  stress	  fibres	  were	  more	  motile	  than	  WT	  cells	  (Figure	  R	  39).	  
Figure	  D	  1.	  F-­‐actin	   formation	  dynamics	   in	  Luzp1-­‐/-­‐	  cells.	   In	   the	  absence	  of	  LUZP1,	  Arp2/3	   levels	  
are	  reduced,	   leading	  to	  diminished	  F-­‐actin	  polymerization.	  The	  reduction	  of	  polymerized	  F-­‐actin	  
decreases	   the	   phosphatase	   activity	   of	   SSH	   (Slingshot	   homologue	   1),	   which	   leads	   to	   net	  
phosphorylation	   and	   deactivation	   of	   cofilin.	   Therefore,	   the	   actin-­‐severing	   function	   of	   cofilin	  
impedes	   the	   flexibility	   of	   remodeled	   actin	   and	   the	   regeneration	   of	   free	   monomeric	   actin	   for	  
further	  polymerization.	  Compare	  with	  the	  WT	  scenario	  in	  Figure	  I	  12	  in	  the	  Introduction	  section.	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Importantly,	   cells	   use	   many	   proteins	   to	   regulate	   actin	   assembly	   and	   cell	  
migration.	   Actin-­‐related	   proteins	   act	   synergistically	   to	   maintain	   a	   pool	   of	  
unpolymerized	   actin	   monomers,	   nucleate,	   elongate	   and	   cap	   actin	   filaments,	  
promote	  dissociation	  of	  Pi	  from	  ADP-­‐Pi-­‐subunits,	  sever	  actin	  filaments,	  and	  crosslink	  
filaments	   into	   higher	   order	   structures.	   Despite	   our	   promising	   preliminary	   results,	  
further	  analysis	  of	  other	  proteins	  implied	  in	  the	  regulation	  of	  actin	  dynamics	  such	  as	  
profilins	  or	  Rho	  GTPases	  would	  be	  necessary	  to	  draw	  robust	  conclusions	  about	  the	  
function	  of	  LUZP1	  in	  the	  integration	  of	  this	  complex	  actin	  network.	  
	  
	  
5.3	  Concluding	  remarks	  
The	   results	   obtained	   thoroughout	   this	   thesis	   work	   confirm	   our	   initial	  
hypothesis	   and	   demonstrate	   that	   TBS	   is	   a	   ciliopathy-­‐like	   disease,	   with	   symptoms	  
caused	  by	  truncated	  SALL1	  interfering	  with	  the	  normal	  function	  of	  cilia/centrosomal-­‐
related	  proteins	   such	  as	  CPP110,	  CEP97	  and	  LUZP1.	  Our	   findings	  also	   indicate	   that	  
LUZP1	   is	   a	   novel	   actin	   and	   centrosome-­‐related	   protein	   that	   might	   facilitate	   actin	  
polymerization	  and	  repress	  ciliogenesis.	  Cells	  adapt	  to	  new	  environments,	  like	  serum	  
starvation,	   through	   coordinated	   changes	   in	   gene	   expression,	   cytoskeletal	  
rearrangements,	   and	   cilia	   signalling.	   This	   integrated	   response	   requires	   signal	  
transduction	   relays	   that	   communicate	   the	   cytoplasmic	   actin	   polymerization	   status	  
with	   cilia	   and	   nucleus.	   Here,	   we	   propose	   that	   LUZP1	  might	   act	   as	   a	   nexus	   in	   this	  
complex	  intracellular	  network,	  and	  that	  truncated	  SALL1	  disrupts	  this	  network	  in	  TBS	  
patients.	  
The	   ciliopathies	   are	   an	   increasingly	   recognized	   class	   of	   human	   genetic	  
disorders,	   and	   our	   work	   provides	   a	   framework	   for	   understanding	   TBS	   and	   the	  
contributing	  role	   that	  primary	  cilia	  might	  play	   in	   the	  pathology	  of	   the	  disease.	  This	  
does	  not	  rule	  out	  a	  disruption	  in	  the	  nuclear	  role	  of	  SALL1,	  or	  dominant	  interactions	  
with	   other	   SALL	   family	   proteins.	   Different	   alleles	   may	   exhibit	   different	   strengths,	  
depending	  on	  interactors,	  and	  genetic,	  environmental,	  or	  stochastic	  modifiers	  might	  
influence	  the	  phenotypic	  spectrum	  in	  TBS	  individuals	  (Botzenhart	  et	  al.,	  2007;	  Kiefer	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et	  al.,	  2003).	  Defining	  to	  which	  degree	  primary	  cilia	  and	  other	  factors	  are	  implicated	  






Figure	   D	   2.	   Final	   model.	   The	   presence	   of	   truncated	   SALL1	   underlies	   cilia	   and	   actin	  
malformations	   in	  TBS	   through	  the	  sequestration	  of	  key	   regulatory	   factors	  CCP110,	  CEP97	  and	  
LUZP1.	   In	   control	   cells	   (left),	   SALL1FL	   is	  mainly	   nuclear	   and	   CCP110/CEP97	   complex	   and	   LUZP1	  
localize	  to	  the	  mother	  (MC)	  and	  daughter	  centrioles	  inhibiting	  cilia	  formation.	  LUZP1	  localizes	  also	  
to	   F-­‐actin.	  Upon	   starvation,	   the	  CCP110/CEP97	   complex	   and	  one	   LUZP1	   foci	   are	  depleted	   from	  
the	  MC,	   which	   will	   allow	   the	   formation	   of	   the	   primary	   cilia.	   By	   contrast,	   in	   TBS	   cells	   (right)	   a	  
truncated	   form	   of	   SALL1	   (SALL1MUT),	   together	   with	   sequestered	   SALL1FL,	   localizes	   to	   the	  
cytoplasm,	   where	   it	   interacts	   with	   LUZP1	   and	   the	   CCP110/CEP97	   complex,	   leading	   to	   their	  
degradation.	  As	  a	   result,	   the	   frequency	  of	   cilia	   formation	   increases,	  and	  cilia	  are	   longer	   than	   in	  
control	   cells.	   Problems	   in	   cilia	   formation	   are	   accompanied	   by	   SHH	   signaling	   alterations	   in	   TBS	  
cells.	  
	  
	  	   137	  
	  
Chapter	  6:	  Conclusions	  
	  	   138	  
Conclusions	  	  
	   139	  
Chapter	  6:	  Conclusions	  
	  
The	  results	  obtained	  along	  this	  thesis	  lead	  to	  the	  following	  conclusions:	  
	  
1.	   SALL1FL	   is	   a	   nuclear	   and	   a	   ciliary	   protein	   and	   truncated	   SALL1	   disrupts	   its	  
localization	  to	  the	  cytoplasm	  in	  a	  dominant-­‐negative	  manner.	  
2.	   TBS	   patients-­‐derived	   fibroblasts	   display	   longer	   and	   more	   abundant	   cilia	   than	  
control	  fibroblasts	  and	  we	  reproduced	  those	  cilia	  defects	  in	  the	  following	  TBS	  model	  
cell	  lines,	  eventhough	  they	  express	  different	  pathogenic	  variants:	  
a.	   Fibroblasts	   from	   a	   new	   TBS	   patient	   with	   the	   pathogenic	   SALL1c.826C>T	  
variant.	  
b.	  A	  HEK	  293FT	  TBS-­‐mimicking	  cell	  line	  generated	  by	  CRISPR/Cas9	  technology.	  
c.	  Sall1∆Zn2-­‐10	  mouse	  embryonic	  fibroblasts.	  
3.	  TBS	  patients-­‐derived	  fibroblasts	  present	  Shh	  signalling	  aberrations.	  
4.	  Truncated	  SALL1	  interacts	  with	   the	  centrosome	  negative	  regulators	  CCP110	  and	  
CEP97	   and	   with	   LUZP1	   and	   they	   are	   prematurely	   depleted	   from	   the	   mother	  
centriole	  in	  TBS	  cells.	  
5.	   LUZP1	   localizes	   to	   the	   centrosome	   and	   interacts	  with	   the	   centrosomal	  CCP110	  
and	  CEP97	  negative	  regulators.	  
6.	  LUZP1	  is	  a	  cilia	  negative	  regulator	  implicated	  in	  Shh	  signalling.	  
7.	  LUZP1	  is	  an	  actin-­‐stabilizing	  protein	  reduced	  in	  TBS	  cells.	  
8.	  Truncated	  SALL1	  leads	  to	  proteasome-­‐mediated	  LUZP1	  degradation.	  
9.	   The	   lack	   of	   LUZP1	   leads	   to	   cell	   proliferation	   and	   cell	   migration	   defects,	  
presumably,	  through	  the	  regulation	  of	  actin	  dynamics,	  although	  further	  confirmation	  
is	  needed.	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Appendix	  I.	  List	  of	  proteins	   identified	  by	  BioID	  significantly	  enriched	  at	   least	  2-­‐fold	   in	  the	  SALL1275	  subproteome	  with	  respect	  to	  the	  SALL1FL	  

















2751/FL1	   2752/FL2	   2753/FL3	  
average	  
ratio	  
Kinesin-­‐1	  heavy	  chain	   KIF5B	   11709000000	   606220000	   511450000	   849090	   7218600	   12139000	   13790.1	   84.0	   42.1	   4638.7	  
Band	  4.1-­‐like	  protein	  2	   EPB41L2	   9153200000	   820650000	   607080000	   849090	   1656200	   1318000	   10780.0	   495.5	   460.6	   3912.0	  
La-­‐related	  protein	  1	   LARP1	   7294500000	   780580000	   731460000	   849090	   13451000	   1318000	   8591.0	   58.0	   555.0	   3068.0	  
Ataxin-­‐2-­‐like	  protein	   ATXN2L	   5667700000	   587370000	   551100000	   849090	   1656200	   1318000	   6675.0	   354.6	   418.1	   2482.6	  
LIM	  domain	  and	  actin-­‐binding	  protein	  1	   LIMA1	   5427600000	   409460000	   151410000	   849090	   1656200	   1318000	   6392.3	   247.2	   114.9	   2251.5	  
C-­‐Jun-­‐amino-­‐terminal	  kinase-­‐interacting	  protein	  4	   SPAG9	   4649500000	   309140000	   213600000	   849090	   1656200	   1318000	   5475.9	   186.7	   162.1	   1941.5	  
Transforming	  acidic	  coiled-­‐coil-­‐containing	  protein	  2	   TACC2	   1210600000	   97675	   5250100000	   849090	   1656200	   1318000	   1425.8	   0.1	   3983.4	   1803.1	  
Afadin	   AFDN	   5893400000	   787430000	   533810000	   1252800	   24483000	   16236000	   4704.2	   32.2	   32.9	   1589.7	  
Protein	  PRRC2C	   PRRC2C	   3348400000	   226490000	   159440000	   849090	   8260200	   1318000	   3943.5	   27.4	   121.0	   1364.0	  
Unconventional	  myosin-­‐VI	   MYO6	   3306000000	   49963000	   55756000	   849090	   1656200	   1318000	   3893.6	   30.2	   42.3	   1322.0	  
STE20-­‐like	  serine/threonine-­‐protein	  kinase	   SLK	   2997300000	   104840000	   116620000	   849090	   1656200	   1318000	   3530.0	   63.3	   88.5	   1227.3	  
A-­‐kinase	  anchor	  protein	  12	   AKAP12	   2996700000	   31117000	   29249000	   849090	   1656200	   1318000	   3529.3	   18.8	   22.2	   1190.1	  
Condensin	  complex	  subunit	  2	   NCAPH	   2720900000	   194050000	   146540000	   849090	   1656200	   1318000	   3204.5	   117.2	   111.2	   1144.3	  
Nuclear	  pore	  complex	  protein	  Nup153	   NUP153	   2707900000	   227690000	   202280000	   849090	   31717000	   1318000	   3189.2	   7.2	   153.5	   1116.6	  
Band	   4.1-­‐like	   protein	   3;Band	   4.1-­‐like	   protein	   3,	   N-­‐
terminally	  processed	   EPB41L3	   29726000000	   3655200000	   3149500000	   42213000	   14779000	   1318000	   704.2	   247.3	   2389.6	   1113.7	  
Kinesin-­‐like	  protein	  KIF11	   KIF11	   2560700000	   275980000	   129340000	   849090	   1656200	   1318000	   3015.8	   166.6	   98.1	   1093.5	  
Protein	  4.1	   EPB41	   15927000000	   2467300000	   2539500000	   32127000	   22276000	   1318000	   495.8	   110.8	   1926.8	   844.4	  
Eukaryotic	  translation	  initiation	  factor	  4B	   EIF4B	   10168000000	   1908100000	   1582800000	   144740000	   1656200	   1318000	   70.3	   1152.1	   1200.9	   807.8	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Leucine	  zipper	  protein	  1	   LUZP1	   1966700000	   98882000	   13908000	   849090	   1656200	   1318000	   2316.2	   59.7	   10.6	   795.5	  
Deubiquitinating	  protein	  VCIP135	   VCPIP1	   1753000000	   241760000	   130240000	   849090	   37476000	   30738000	   2064.6	   6.5	   4.2	   691.8	  
Zinc	  finger	  RNA-­‐binding	  protein	   ZFR	   1740000000	   15838000	   77089000	   849090	   17753000	   8659500	   2049.3	   0.9	   8.9	   686.3	  
AP2-­‐associated	  protein	  kinase	  1	   AAK1	   1582200000	   159580000	   81009000	   849090	   1656200	   1318000	   1863.4	   96.4	   61.5	   673.7	  
Unconventional	  myosin-­‐Ib	   MYO1B	   1633100000	   29252000	   15461000	   849090	   1656200	   1318000	   1923.4	   17.7	   11.7	   650.9	  
RalBP1-­‐associated	  Eps	  domain-­‐containing	  protein	  1	   REPS1	   1537400000	   129480000	   61728000	   849090	   1656200	   1318000	   1810.6	   78.2	   46.8	   645.2	  
Epidermal	  growth	  factor	  receptor	  substrate	  15	   EPS15	   1504700000	   92475000	   70919000	   849090	   1656200	   1318000	   1772.1	   55.8	   53.8	   627.3	  
Eukaryotic	  translation	  initiation	  factor	  4	  gamma	  3	   EIF4G3	   1423700000	   155810000	   60176000	   849090	   1656200	   1318000	   1676.7	   94.1	   45.7	   605.5	  
Phosphatase	  and	  actin	  regulator	  4	   PHACTR4	   1403600000	   88402000	   75011000	   849090	   1656200	   1318000	   1653.1	   53.4	   56.9	   587.8	  
Zinc	  finger	  protein	  1	  homolog	   ZFP1	   95968000	   2567800000	   1858200	   849090	   1656200	   1318000	   113.0	   1550.4	   1.4	   555.0	  
Tight	  junction	  protein	  ZO-­‐1	   TJP1	   1361000000	   30492000	   3835100	   849090	   1656200	   1318000	   1602.9	   18.4	   2.9	   541.4	  
GTPase-­‐activating	   protein	   and	   VPS9	   domain-­‐
containing	  protein	  1	   GAPVD1	   1297100000	   102090000	   44285000	   849090	   1656200	   1318000	   1527.6	   61.6	   33.6	   541.0	  
LIM	   and	   calponin	   homology	   domains-­‐containing	  
protein	  1	   LIMCH1	   1275800000	   92159000	   83704000	   849090	   1656200	   1318000	   1502.5	   55.6	   63.5	   540.6	  
Cold	  shock	  domain-­‐containing	  protein	  E1	   CSDE1	   8278500000	   1346800000	   872980000	   90811000	   1656200	   1318000	   91.2	   813.2	   662.4	   522.2	  
Protein	  FAM208A	   FAM208A	   1245900000	   86773000	   58316000	   849090	   18821000	   8954800	   1467.3	   4.6	   6.5	   492.8	  
Zyxin	   ZYX	   1006100000	   247130000	   188000000	   849090	   1656200	   1318000	   1184.9	   149.2	   142.6	   492.3	  
Drebrin	   DBN1	   17878000000	   1455000000	   1099100000	   43988000	   7125700	   1318000	   406.4	   204.2	   833.9	   481.5	  
E3	  ubiquitin-­‐protein	  ligase	  CBL	   CBL	   1200200000	   24400000	   21433000	   849090	   1656200	   1318000	   1413.5	   14.7	   16.3	   481.5	  
Double-­‐stranded	   RNA-­‐specific	   adenosine	  
deaminase	   ADAR	   1219700000	   36809000	   52932000	   849090	   10280000	   33782000	   1436.5	   3.6	   1.6	   480.5	  
Threonine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   TARS	   1187200000	   72096000	   65254000	   849090	   6046800	   18974000	   1398.2	   11.9	   3.4	   471.2	  
Glycogen	  phosphorylase,	  liver	  form;Phosphorylase	   PYGL	   1160300000	   169400000	   103280000	   849090	   27796000	   61182000	   1366.5	   6.1	   1.7	   458.1	  
Microtubule-­‐associated	   protein	   1B;MAP1B	   heavy	  
chain;MAP1	  light	  chain	  LC1	   MAP1B	   7011300000	   617510000	   583360000	   12591000	   1656200	   1318000	   556.9	   372.8	   442.6	   457.4	  
Calpastatin	   CAST	   1139700000	   136980000	   79376000	   849090	   7554500	   7155300	   1342.3	   18.1	   11.1	   457.2	  
Ubiquitin	   carboxyl-­‐terminal	   hydrolase	   15;Ubiquitin	   USP15	   1093700000	   48094000	   30163000	   849090	   1656200	   1318000	   1288.1	   29.0	   22.9	   446.7	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carboxyl-­‐terminal	  hydrolase	  
CD2-­‐associated	  protein	   CD2AP	   8594800000	   944890000	   1500700000	   107830000	   8239300	   1318000	   79.7	   114.7	   1138.6	   444.3	  
Cytoplasmic	  dynein	  1	  light	  intermediate	  chain	  2	   DYNC1LI2	   1084600000	   28880000	   37480000	   849090	   1656200	   1318000	   1277.4	   17.4	   28.4	   441.1	  
A-­‐kinase	  anchor	  protein	  1,	  mitochondrial	   AKAP1	   1064700000	   57823000	   40232000	   849090	   1656200	   1318000	   1253.9	   34.9	   30.5	   439.8	  
G	  protein-­‐regulated	  inducer	  of	  neurite	  outgrowth	  1	   GPRIN1	   1060600000	   47433000	   19152000	   849090	   1656200	   1318000	   1249.1	   28.6	   14.5	   430.8	  
Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  15	   ZC3H15	   1075400000	   15334000	   11771000	   849090	   1656200	   1318000	   1266.5	   9.3	   8.9	   428.2	  
Exocyst	  complex	  component	  3	   EXOC3	   1041000000	   26469000	   43398000	   849090	   1656200	   1318000	   1226.0	   16.0	   32.9	   425.0	  
Eukaryotic	  translation	  initiation	  factor	  5B	   EIF5B	   1011200000	   63131000	   43038000	   849090	   1656200	   1318000	   1190.9	   38.1	   32.7	   420.6	  
DNA	  excision	  repair	  protein	  ERCC-­‐6-­‐like	   ERCC6L	   993640000	   94421000	   32279000	   849090	   1656200	   1318000	   1170.2	   57.0	   24.5	   417.2	  
SH3	  and	  PX	  domain-­‐containing	  protein	  2B	   SH3PXD2B	   1035800000	   10409000	   32122000	   849090	   1656200	   1318000	   1219.9	   6.3	   24.4	   416.9	  
Striatin	   STRN	   1039700000	   25613000	   11479000	   849090	   1656200	   1318000	   1224.5	   15.5	   8.7	   416.2	  
Cullin-­‐4B	   CUL4B	   1054100000	   7359300	   1858200	   849090	   1656200	   1318000	   1241.4	   4.4	   1.4	   415.8	  
Elongation	   factor	   Tu	   GTP-­‐binding	   domain-­‐
containing	  protein	  1	   EFL1	   1030400000	   32579000	   17521000	   849090	   1656200	   1318000	   1213.5	   19.7	   13.3	   415.5	  
Myosin	  phosphatase	  Rho-­‐interacting	  protein	   MPRIP	   990790000	   23770000	   1858200	   849090	   1656200	   1318000	   1166.9	   14.4	   1.4	   394.2	  
Caldesmon	   CALD1	   8226900000	   983800000	   603180000	   64487000	   1656200	   1318000	   127.6	   594.0	   457.6	   393.1	  
Centrosomal	  protein	  of	  170	  kDa	   CEP170	   3813600000	   367050000	   464800000	   6346300	   1656200	   1318000	   600.9	   221.6	   352.7	   391.7	  
Neurabin-­‐2	   PPP1R9B	   950640000	   63141000	   22882000	   849090	   1656200	   1318000	   1119.6	   38.1	   17.4	   391.7	  
Ankyrin-­‐3	   ANK3	   929250000	   38146000	   44672000	   849090	   1656200	   1318000	   1094.4	   23.0	   33.9	   383.8	  
cAMP-­‐dependent	   protein	   kinase	   type	   II-­‐alpha	  
regulatory	  subunit	   PRKAR2A	   947070000	   30167000	   1858200	   849090	   1656200	   1318000	   1115.4	   18.2	   1.4	   378.3	  
RING	  finger	  protein	  214	   RNF214	   952930000	   9682400	   8481100	   849090	   1656200	   1318000	   1122.3	   5.8	   6.4	   378.2	  
Exosome	  component	  10	   EXOSC10	   944910000	   14828000	   1858200	   849090	   1656200	   24799000	   1112.9	   9.0	   0.1	   374.0	  
General	  vesicular	  transport	  factor	  p115	   USO1	   926400000	   19323000	   22428000	   849090	   1656200	   1318000	   1091.1	   11.7	   17.0	   373.2	  
Mitotic	   checkpoint	   serine/threonine-­‐protein	  kinase	  
BUB1	  beta	   BUB1B	   918920000	   11493000	   1858200	   849090	   1656200	   1318000	   1082.2	   6.9	   1.4	   363.5	  
Gamma-­‐adducin	   ADD3	   825080000	   50494000	   57569000	   849090	   1656200	   1318000	   971.7	   30.5	   43.7	   348.6	  
Protein	  AHNAK2	   AHNAK2	   873360000	   4336200	   2857700	   849090	   1656200	   1318000	   1028.6	   2.6	   2.2	   344.5	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Mitochondrial	  antiviral-­‐signalling	  protein	   MAVS	   830810000	   14886000	   42974000	   849090	   1656200	   1318000	   978.5	   9.0	   32.6	   340.0	  
Ankycorbin	   RAI14	   829670000	   20625000	   16988000	   849090	   1656200	   1318000	   977.1	   12.5	   12.9	   334.2	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  1	   PSMD1	   824680000	   48458000	   47978000	   849090	   26832000	   16559000	   971.3	   1.8	   2.9	   325.3	  
Protein	  transport	  protein	  Sec24B	   SEC24B	   750830000	   65537000	   67216000	   849090	   1656200	   1318000	   884.3	   39.6	   51.0	   324.9	  
Desmoglein-­‐2	   DSG2	   753000000	   68337000	   60386000	   849090	   1656200	   1318000	   886.8	   41.3	   45.8	   324.6	  
Dynactin	  subunit	  1	   DCTN1	   780260000	   97675	   65739000	   849090	   1656200	   1318000	   918.9	   0.1	   49.9	   323.0	  
Ras-­‐associated	   and	   pleckstrin	   homology	   domains-­‐
containing	  protein	  1	   RAPH1	   736030000	   91296000	   56299000	   849090	   1656200	   1318000	   866.8	   55.1	   42.7	   321.6	  
WASH	  complex	  subunit	  WASHC2C	   WASHC2C	   787550000	   17047000	   13364000	   849090	   1656200	   1318000	   927.5	   10.3	   10.1	   316.0	  
Testin	   TES	   785720000	   15736000	   15746000	   849090	   1656200	   1318000	   925.4	   9.5	   11.9	   315.6	  
Protein	  numb	  homolog	   NUMB	   787920000	   10453000	   16356000	   849090	   1656200	   1318000	   928.0	   6.3	   12.4	   315.6	  
Regulator	  of	  nonsense	  transcripts	  1	   UPF1	   710550000	   49332000	   74290000	   849090	   1656200	   1318000	   836.8	   29.8	   56.4	   307.7	  
Pleckstrin	   homology	   domain-­‐containing	   family	   A	  
member	  5	   PLEKHA5	   755810000	   10867000	   22078000	   849090	   1656200	   1318000	   890.1	   6.6	   16.8	   304.5	  
WD	  repeat-­‐containing	  protein	  44	   WDR44	   743430000	   37187000	   10070000	   849090	   1656200	   1318000	   875.6	   22.5	   7.6	   301.9	  
Ubiquitin-­‐like	  modifier-­‐activating	  enzyme	  5	   UBA5	   752070000	   6521300	   6574100	   849090	   1656200	   1318000	   885.7	   3.9	   5.0	   298.2	  
ELKS/Rab6-­‐interacting/CAST	  family	  member	  1	   ERC1	   735350000	   30821000	   10893000	   849090	   1656200	   1318000	   866.0	   18.6	   8.3	   297.6	  
Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  23	   PTPN23	   724570000	   27092000	   18386000	   849090	   1656200	   1318000	   853.3	   16.4	   13.9	   294.6	  
Receptor-­‐interacting	   serine/threonine-­‐protein	  
kinase	  1	   RIPK1	   725290000	   12654000	   6508700	   849090	   1656200	   1318000	   854.2	   7.6	   4.9	   288.9	  
Sorting	   nexin-­‐6;Sorting	   nexin-­‐6,	   N-­‐terminally	  
processed	   SNX6	   698520000	   35685000	   22595000	   849090	   1656200	   1318000	   822.7	   21.5	   17.1	   287.1	  
Protein	  NPAT	   NPAT	   690500000	   16046000	   1858200	   849090	   1656200	   1318000	   813.2	   9.7	   1.4	   274.8	  
Trinucleotide	  repeat-­‐containing	  gene	  6B	  protein	   TNRC6B	   654780000	   61300000	   15986000	   849090	   1656200	   1318000	   771.2	   37.0	   12.1	   273.4	  
HCLS1-­‐binding	  protein	  3	   HS1BP3	   684930000	   4220900	   1858200	   849090	   1656200	   1318000	   806.7	   2.5	   1.4	   270.2	  
Sorting	  nexin-­‐9	   SNX9	   625860000	   97566000	   9638000	   849090	   1656200	   1318000	   737.1	   58.9	   7.3	   267.8	  
CTP	  synthase	  1	   CTPS1	   16246000000	   1035000000	   724150000	   129860000	   1656200	   19315000	   125.1	   624.9	   37.5	   262.5	  
Dihydropyrimidinase-­‐related	  protein	  3	   DPYSL3	   652230000	   13739000	   13277000	   849090	   1656200	   1318000	   768.2	   8.3	   10.1	   262.2	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LIM	  domain-­‐containing	  protein	  1	   LIMD1	   642390000	   23691000	   18128000	   849090	   1656200	   1318000	   756.6	   14.3	   13.8	   261.5	  
Segment	  polarity	  protein	  dishevelled	  homolog	  DVL-­‐
2	   DVL2	   600540000	   28373000	   73928000	   849090	   1656200	   1318000	   707.3	   17.1	   56.1	   260.2	  
HBS1-­‐like	  protein	   HBS1L	   543530000	   77295000	   116280000	   849090	   1656200	   1318000	   640.1	   46.7	   88.2	   258.3	  
Nesprin-­‐1	   SYNE1	   322060000	   266080000	   280040000	   849090	   1656200	   1318000	   379.3	   160.7	   212.5	   250.8	  
Zinc	  finger	  FYVE	  domain-­‐containing	  protein	  16	   ZFYVE16	   603520000	   36357000	   25104000	   849090	   1656200	   1318000	   710.8	   22.0	   19.0	   250.6	  
Death-­‐inducer	  obliterator	  1	   DIDO1	   633200000	   64369000	   19633000	   849090	   21122000	   10141000	   745.7	   3.0	   1.9	   250.2	  
Glycylpeptide	  N-­‐tetradecanoyltransferase	  1	   NMT1	   594880000	   45646000	   21714000	   849090	   1656200	   1318000	   700.6	   27.6	   16.5	   248.2	  
Zinc	  finger	  CCCH-­‐type	  antiviral	  protein	  1	   ZC3HAV1	   1136800000	   387180000	   191260000	   3293200	   1656200	   1318000	   345.2	   233.8	   145.1	   241.4	  
Protein	  unc-­‐45	  homolog	  A	   UNC45A	   532250000	   73153000	   36881000	   849090	   1656200	   1318000	   626.8	   44.2	   28.0	   233.0	  
Nucleosome-­‐remodeling	  factor	  subunit	  BPTF	   BPTF	   583790000	   45527000	   1858200	   849090	   11740000	   10560000	   687.5	   3.9	   0.2	   230.5	  
Serine/threonine-­‐protein	   kinase	  
4;Serine/threonine-­‐protein	   kinase	   4	   37kDa	  
subunit;Serine/threonine-­‐protein	   kinase	   4	   18kDa	  
subunit	   STK4	   574430000	   17364000	   1858200	   849090	   1656200	   1318000	   676.5	   10.5	   1.4	   229.5	  
Paxillin	   PXN	   558120000	   3196000	   36674000	   849090	   1656200	   1318000	   657.3	   1.9	   27.8	   229.0	  
La-­‐related	  protein	  4	   LARP4	   570450000	   5300100	   7192700	   849090	   1656200	   1318000	   671.8	   3.2	   5.5	   226.8	  
Protein	  phosphatase	  1	  regulatory	  subunit	  12A	   PPP1R12A	   561760000	   2051000	   17439000	   849090	   1656200	   1318000	   661.6	   1.2	   13.2	   225.4	  
Structural	   maintenance	   of	   chromosomes	   protein	  
4;Structural	  maintenance	  of	  chromosomes	  protein	   SMC4	   557850000	   11547000	   15862000	   849090	   1656200	   1318000	   657.0	   7.0	   12.0	   225.3	  
Phosphatidylinositol	   3,4,5-­‐trisphosphate	   5-­‐
phosphatase	  2	   INPPL1	   564090000	   7397400	   1858200	   849090	   1656200	   1318000	   664.3	   4.5	   1.4	   223.4	  
Protein	  ELYS	   AHCTF1	   1067100000	   38450000	   12737000	   1635200	   8791500	   1318000	   652.6	   4.4	   9.7	   222.2	  
Vesicle-­‐fusing	  ATPase	   NSF	   540510000	   10186000	   30616000	   849090	   4119000	   1318000	   636.6	   2.5	   23.2	   220.8	  
Alanine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   AARS	   514370000	   52521000	   11048000	   849090	   1656200	   1318000	   605.8	   31.7	   8.4	   215.3	  
PERQ	   amino	   acid-­‐rich	  with	   GYF	   domain-­‐containing	  
protein	  2	   GIGYF2	   526640000	   5055200	   22454000	   849090	   1656200	   1318000	   620.2	   3.1	   17.0	   213.4	  
Nuclear	   fragile	   X	   mental	   retardation-­‐interacting	   NUFIP2	   1717100000	   408400000	   258910000	   8709500	   1656200	   1318000	   197.2	   246.6	   196.4	   213.4	  




Paladin	   PALD1	   522360000	   15652000	   16667000	   849090	   1656200	   1318000	   615.2	   9.5	   12.6	   212.4	  
Rap	  guanine	  nucleotide	  exchange	  factor	  6	   RAPGEF6	   525780000	   4773800	   10016000	   849090	   1656200	   1318000	   619.2	   2.9	   7.6	   209.9	  
182	  kDa	  tankyrase-­‐1-­‐binding	  protein	   TNKS1BP1	   513760000	   15902000	   8749800	   849090	   1656200	   1318000	   605.1	   9.6	   6.6	   207.1	  
C-­‐1-­‐tetrahydrofolate	  synthase	   MTHFD1	   518050000	   79397000	   62110000	   849090	   11828000	   30547000	   610.1	   6.7	   2.0	   206.3	  
Ubiquitin	   carboxyl-­‐terminal	   hydrolase	   28;Ubiquitin	  
carboxyl-­‐terminal	  hydrolase	   USP28	   515690000	   67182000	   63992000	   849090	   24960000	   9814500	   607.3	   2.7	   6.5	   205.5	  
Condensin	  complex	  subunit	  3	   NCAPG	   507900000	   11286000	   9409200	   849090	   1656200	   1318000	   598.2	   6.8	   7.1	   204.0	  
FH1/FH2	  domain-­‐containing	  protein	  1	   FHOD1	   501890000	   7720000	   15127000	   849090	   1656200	   1318000	   591.1	   4.7	   11.5	   202.4	  
GRB2-­‐associated-­‐binding	  protein	  1	   GAB1	   445560000	   61494000	   56621000	   849090	   1656200	   1318000	   524.8	   37.1	   43.0	   201.6	  
Ubiquitin-­‐associated	  protein	  2	   UBAP2	   1485000000	   177560000	   216530000	   4460500	   1656200	   1318000	   332.9	   107.2	   164.3	   201.5	  
Neurofilament	  medium	  polypeptide	   NEFM	   15150000000	   388970000	   263240000	   41822000	   1656200	   46243000	   362.2	   234.9	   5.7	   200.9	  
Symplekin	   SYMPK	   500600000	   6936500	   4919300	   849090	   3280900	   4186300	   589.6	   2.1	   1.2	   197.6	  
Apoptotic	   chromatin	   condensation	   inducer	   in	   the	  
nucleus	   ACIN1	   1832300000	   177430000	   52340000	   3471000	   7275400	   1318000	   527.9	   24.4	   39.7	   197.3	  
40S	  ribosomal	  protein	  S3a	   RPS3A	   1203400000	   392270000	   428650000	   41233000	   1656200	   1318000	   29.2	   236.8	   325.2	   197.1	  
Dihydropyrimidinase-­‐related	  protein	  4	   DPYSL4	   486220000	   21668000	   1858200	   849090	   1656200	   1318000	   572.6	   13.1	   1.4	   195.7	  
Septin-­‐9	   SEPT9	   8154100000	   744180000	   516610000	   60703000	   12456000	   1318000	   134.3	   59.7	   392.0	   195.3	  
Neuroblast	   differentiation-­‐associated	   protein	  
AHNAK	   AHNAK	   60113000000	   8788100000	   6493600000	   364080000	   44535000	   30197000	   165.1	   197.3	   215.0	   192.5	  
Vigilin	   HDLBP	   11833000000	   667440000	   461040000	   106410000	   5735300	   1318000	   111.2	   116.4	   349.8	   192.5	  
Alpha-­‐adducin	   ADD1	   480810000	   97675	   11320000	   849090	   1656200	   1318000	   566.3	   0.1	   8.6	   191.6	  
PDZ	  and	  LIM	  domain	  protein	  5	   PDLIM5	   1990200000	   613310000	   625450000	   55318000	   9674400	   1318000	   36.0	   63.4	   474.5	   191.3	  
Rho	  GTPase-­‐activating	  protein	  1	   ARHGAP1	   472990000	   97675	   17915000	   849090	   1656200	   1318000	   557.1	   0.1	   13.6	   190.2	  
ADP-­‐ribosylation	  factor-­‐binding	  protein	  GGA3	   GGA3	   416290000	   57291000	   50384000	   849090	   1656200	   1318000	   490.3	   34.6	   38.2	   187.7	  
Striatin-­‐3	   STRN3	   453870000	   16657000	   17837000	   849090	   1656200	   1318000	   534.5	   10.1	   13.5	   186.0	  
Nestin	   NES	   3097700000	   50433000	   27505000	   6175500	   1656200	   1318000	   501.6	   30.5	   20.9	   184.3	  
Coatomer	  subunit	  beta	   COPB1	   438910000	   43294000	   62120000	   849090	   1656200	   8366100	   516.9	   26.1	   7.4	   183.5	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Transcriptional	  repressor	  CTCF	   CTCF	   462050000	   17991000	   6382400	   849090	   8300200	   6428700	   544.2	   2.2	   1.0	   182.4	  
Hepatocyte	  growth	  factor-­‐regulated	  tyrosine	  kinase	  
substrate	   HGS	   444750000	   14004000	   14082000	   849090	   1656200	   1318000	   523.8	   8.5	   10.7	   181.0	  
Heat	  shock	  70	  kDa	  protein	  4L	   HSPA4L	   456820000	   17179000	   13755000	   849090	   7057400	   7707800	   538.0	   2.4	   1.8	   180.7	  
La-­‐related	  protein	  4B	   LARP4B	   450160000	   10788000	   1858200	   849090	   1656200	   1318000	   530.2	   6.5	   1.4	   179.4	  
Cysteine	   and	   histidine-­‐rich	   domain-­‐containing	  
protein	  1	   CHORDC1	   419460000	   26272000	   24740000	   849090	   1656200	   1318000	   494.0	   15.9	   18.8	   176.2	  
Calmodulin-­‐regulated	  spectrin-­‐associated	  protein	  1	   CAMSAP1	   439080000	   13577000	   1858200	   849090	   1656200	   1318000	   517.1	   8.2	   1.4	   175.6	  
Staphylococcal	  nuclease	  domain-­‐containing	  protein	  
1	   SND1	   427970000	   19100000	   6292600	   849090	   1656200	   3514600	   504.0	   11.5	   1.8	   172.5	  
Protein	  CDV3	  homolog	   CDV3	   1564300000	   362870000	   330140000	   33743000	   1656200	   1318000	   46.4	   219.1	   250.5	   172.0	  
Heterogeneous	   nuclear	   ribonucleoprotein	   U-­‐like	  
protein	  1	   HNRNPUL1	   417400000	   19243000	   12571000	   849090	   1656200	   1318000	   491.6	   11.6	   9.5	   170.9	  
Poly(ADP-­‐ribose)	  glycohydrolase	   PARG	   423640000	   17720000	   1858200	   849090	   4987000	   1318000	   498.9	   3.6	   1.4	   168.0	  
Zinc	  finger	  CCHC	  domain-­‐containing	  protein	  8	   ZCCHC8	   417880000	   10416000	   1858200	   849090	   1656200	   1318000	   492.2	   6.3	   1.4	   166.6	  
5-­‐3	  exoribonuclease	  1	   XRN1	   392150000	   36250000	   20277000	   849090	   1656200	   1318000	   461.8	   21.9	   15.4	   166.4	  
Charged	  multivesicular	  body	  protein	  2b	   CHMP2B	   72550000	   620250000	   502880000	   849090	   19679000	   1318000	   85.4	   31.5	   381.5	   166.2	  
THO	  complex	  subunit	  2	   THOC2	   379820000	   31844000	   31657000	   849090	   1656200	   1318000	   447.3	   19.2	   24.0	   163.5	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  2	   PSMD2	   406790000	   25987000	   14384000	   849090	   4639900	   17716000	   479.1	   5.6	   0.8	   161.8	  
Rho	  GTPase-­‐activating	  protein	  17	   ARHGAP17	   399920000	   12922000	   1858200	   849090	   1656200	   1318000	   471.0	   7.8	   1.4	   160.1	  
NEDD4-­‐binding	  protein	  2	   N4BP2	   392870000	   13312000	   10453000	   849090	   1656200	   1318000	   462.7	   8.0	   7.9	   159.6	  
Calmin	   CLMN	   391950000	   11800000	   8928300	   849090	   1656200	   1318000	   461.6	   7.1	   6.8	   158.5	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  10	   USP10	   1092500000	   241610000	   186580000	   5863900	   1656200	   1318000	   186.3	   145.9	   141.6	   157.9	  
Synergin	  gamma	   SYNRG	   384570000	   13977000	   15275000	   849090	   1656200	   1318000	   452.9	   8.4	   11.6	   157.6	  
Clathrin	  interactor	  1	   CLINT1	   5695800000	   663680000	   583720000	   823730000	   1656200	   9066000	   6.9	   400.7	   64.4	   157.3	  
Filamin-­‐B	   FLNB	   392720000	   35537000	   11678000	   849090	   11594000	   2728400	   462.5	   3.1	   4.3	   156.6	  
Numb-­‐like	  protein	   NUMBL	   350800000	   47322000	   34646000	   849090	   1656200	   1318000	   413.1	   28.6	   26.3	   156.0	  
Endophilin-­‐A2	   SH3GL1	   348120000	   62809000	   24148000	   849090	   1656200	   1318000	   410.0	   37.9	   18.3	   155.4	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Protein	  diaphanous	  homolog	  2	   DIAPH2	   379320000	   17545000	   1858200	   849090	   1656200	   1318000	   446.7	   10.6	   1.4	   152.9	  
Niban-­‐like	  protein	  1	   FAM129B	   380040000	   14190000	   1858200	   849090	   1656200	   1318000	   447.6	   8.6	   1.4	   152.5	  
Protein	  CIP2A	   CIP2A	   354020000	   27929000	   8282300	   849090	   1656200	   1318000	   416.9	   16.9	   6.3	   146.7	  
Lethal(2)	  giant	  larvae	  protein	  homolog	  1	   LLGL1	   358140000	   4843800	   15776000	   849090	   1656200	   1318000	   421.8	   2.9	   12.0	   145.6	  
Centromere/kinetochore	  protein	  zw10	  homolog	   ZW10	   359200000	   10030000	   8716100	   849090	   1656200	   1318000	   423.0	   6.1	   6.6	   145.2	  
Inositol	  polyphosphate	  5-­‐phosphatase	  OCRL-­‐1	   OCRL	   348830000	   97675	   17478000	   849090	   1656200	   1318000	   410.8	   0.1	   13.3	   141.4	  
Serine/threonine-­‐protein	  kinase	  Nek9	   NEK9	   339310000	   7771900	   25165000	   849090	   1656200	   1318000	   399.6	   4.7	   19.1	   141.1	  
Bifunctional	   glutamate/proline-­‐-­‐tRNA	  
ligase;Glutamate-­‐-­‐tRNA	  ligase;Proline-­‐-­‐tRNA	  ligase	   EPRS	   337320000	   31097000	   1858200	   849090	   1656200	   1318000	   397.3	   18.8	   1.4	   139.2	  
Serine/threonine-­‐protein	  phosphatase	  6	   regulatory	  
subunit	  1	   PPP6R1	   315890000	   55343000	   1858200	   849090	   1656200	   1318000	   372.0	   33.4	   1.4	   135.6	  
ATPase	  WRNIP1	   WRNIP1	   340810000	   97675	   6155200	   849090	   1656200	   1318000	   401.4	   0.1	   4.7	   135.4	  
Eukaryotic	  translation	  initiation	  factor	  4	  gamma	  2	   EIF4G2	   2759600000	   295640000	   150110000	   24637000	   1656200	   1318000	   112.0	   178.5	   113.9	   134.8	  
SURP	  and	  G-­‐patch	  domain-­‐containing	  protein	  2	   SUGP2	   335220000	   8600700	   1858200	   849090	   1656200	   1318000	   394.8	   5.2	   1.4	   133.8	  
Peroxisomal	  membrane	  protein	  PEX14	   PEX14	   6906600000	   81993000	   126450000	   27029000	   1656200	   1318000	   255.5	   49.5	   95.9	   133.7	  
Eukaryotic	  translation	  initiation	  factor	  2A	   EIF2A	   3669500000	   413560000	   387080000	   94050000	   7121300	   1318000	   39.0	   58.1	   293.7	   130.3	  
Serine/threonine-­‐protein	  kinase	  Nek1	   NEK1	   321260000	   7032300	   5158500	   849090	   1656200	   1318000	   378.4	   4.2	   3.9	   128.8	  
Focal	  adhesion	  kinase	  1	   PTK2	   306010000	   10325000	   23689000	   849090	   1656200	   1318000	   360.4	   6.2	   18.0	   128.2	  
Palladin	   PALLD	   308320000	   14462000	   16453000	   849090	   1656200	   1318000	   363.1	   8.7	   12.5	   128.1	  
HMG	  box	  transcription	  factor	  BBX	   BBX	   317640000	   97675	   9108000	   849090	   11272000	   1318000	   374.1	   0.0	   6.9	   127.0	  
Serine/threonine-­‐protein	   phosphatase	   PP1-­‐gamma	  
catalytic	   subunit;Serine/threonine-­‐protein	  
phosphatase	   PPP1CC	   309560000	   11027000	   18244000	   849090	   7819600	   1318000	   364.6	   1.4	   13.8	   126.6	  
Protein	  transport	  protein	  Sec16A	   SEC16A	   296590000	   2017400	   29221000	   849090	   1656200	   1318000	   349.3	   1.2	   22.2	   124.2	  
Shootin-­‐1	   CCAR2	   1800500000	   130520000	   83608000	   7838500	   1656200	   1318000	   229.7	   78.8	   63.4	   124.0	  
ATP-­‐binding	  cassette	  sub-­‐family	  F	  member	  1	   ABCF1	   1376900000	   38397000	   12462000	   4011900	   1656200	   2636700	   343.2	   23.2	   4.7	   123.7	  
Transforming	  acidic	  coiled-­‐coil-­‐containing	  protein	  3	   TACC3	   1904100000	   144210000	   74658000	   8477100	   1656200	   1318000	   224.6	   87.1	   56.6	   122.8	  
Golgin	  subfamily	  B	  member	  1	   GOLGB1	   301690000	   4383600	   4166200	   849090	   1656200	   1318000	   355.3	   2.6	   3.2	   120.4	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116	   kDa	   U5	   small	   nuclear	   ribonucleoprotein	  
component	   EFTUD2	   293730000	   12618000	   32152000	   849090	   1656200	   5963300	   345.9	   7.6	   5.4	   119.6	  
Talin-­‐1	   TLN1	   316100000	   11225000	   4572700	   918180	   1656200	   1318000	   344.3	   6.8	   3.5	   118.2	  
SLAIN	  motif-­‐containing	  protein	  2	   SLAIN2	   292080000	   8747900	   1858200	   849090	   1656200	   1318000	   344.0	   5.3	   1.4	   116.9	  
Centriolar	  coiled-­‐coil	  protein	  of	  110	  kDa	   CCP110	   289010000	   97675	   11112000	   849090	   1656200	   1318000	   340.4	   0.1	   8.4	   116.3	  
Inositol	  hexakisphosphate	  kinase	  1	   IP6K1	   288270000	   97675	   7917000	   849090	   1656200	   1318000	   339.5	   0.1	   6.0	   115.2	  
Lipopolysaccharide-­‐responsive	   and	   beige-­‐like	  
anchor	  protein	   LRBA	   276110000	   14329000	   9230200	   849090	   1656200	   1318000	   325.2	   8.7	   7.0	   113.6	  
Septin-­‐2	   SEPT2	   961910000	   59352000	   107420000	   4518600	   1656200	   1318000	   212.9	   35.8	   81.5	   110.1	  
Epidermal	   growth	   factor	   receptor	   substrate	  15-­‐like	  
1	   EPS15L1	   3518400000	   316210000	   286040000	   65324000	   6354600	   1318000	   53.9	   49.8	   217.0	   106.9	  
Round	  spermatid	  basic	  protein	  1-­‐like	  protein	   RSBN1L	   261910000	   6274300	   6344300	   849090	   1656200	   1318000	   308.5	   3.8	   4.8	   105.7	  
ATP-­‐dependent	  RNA	  helicase	  DHX29	   DHX29	   259110000	   14752000	   1858200	   849090	   1656200	   1318000	   305.2	   8.9	   1.4	   105.2	  
Protein	  scribble	  homolog	   SCRIB	   248250000	   24668000	   10100000	   849090	   1656200	   1318000	   292.4	   14.9	   7.7	   105.0	  
Ran	  GTPase-­‐activating	  protein	  1	   RANGAP1	   12032000000	   1116500000	   1058600000	   857520000	   15940000	   4656800	   14.0	   70.0	   227.3	   103.8	  
Torsin-­‐1A-­‐interacting	  protein	  1	   TOR1AIP1	   253600000	   8130500	   8545700	   849090	   1656200	   1318000	   298.7	   4.9	   6.5	   103.4	  
Tubulin	  alpha-­‐1A	  chain	   TUBA1A	   257680000	   32185000	   1858200	   849090	   6468900	   1318000	   303.5	   5.0	   1.4	   103.3	  
Tumor	  suppressor	  p53-­‐binding	  protein	  1	   TP53BP1	   2084800000	   28343000	   75923000	   7311400	   4359200	   6460400	   285.1	   6.5	   11.8	   101.1	  
Protein	  SMG9	   SMG9	   253850000	   97675	   2953900	   849090	   1656200	   1318000	   299.0	   0.1	   2.2	   100.4	  
Probable	  ATP-­‐dependent	  RNA	  helicase	  YTHDC2	   YTHDC2	   249970000	   97675	   2609000	   849090	   1656200	   1318000	   294.4	   0.1	   2.0	   98.8	  
Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  4	   ZC3H4	   244050000	   11334000	   1858200	   849090	   1656200	   1318000	   287.4	   6.8	   1.4	   98.6	  
Rab	  GTPase-­‐activating	  protein	  1-­‐like	   RABGAP1L	   220880000	   23761000	   23799000	   849090	   1656200	   1318000	   260.1	   14.3	   18.1	   97.5	  
Insulin	  receptor	  substrate	  4	   IRS4	   239620000	   97675	   9859600	   849090	   8379600	   1318000	   282.2	   0.0	   7.5	   96.6	  
Unconventional	  myosin-­‐Ie	   MYO1E	   231880000	   13242000	   10524000	   849090	   1656200	   1318000	   273.1	   8.0	   8.0	   96.4	  
Zinc	  finger	  protein	  638	   ZNF638	   380360000	   97675	   10033000	   1388900	   1656200	   1318000	   273.9	   0.1	   7.6	   93.8	  
60	  kDa	  SS-­‐A/Ro	  ribonucleoprotein	   TROVE2	   226550000	   8064500	   8325100	   849090	   1656200	   5352300	   266.8	   4.9	   1.6	   91.1	  
Huntingtin-­‐interacting	  protein	  1	   HIP1	   224960000	   97675	   4220500	   849090	   1656200	   1318000	   264.9	   0.1	   3.2	   89.4	  
Endoribonuclease	  Dicer	   DICER1	   210110000	   97675	   18905000	   849090	   1656200	   1318000	   247.5	   0.1	   14.3	   87.3	  
	   	   	  Appendices	  
	  
	  
Protein	  transport	  protein	  Sec24A	   SEC24A	   209770000	   97675	   15662000	   849090	   1656200	   1318000	   247.1	   0.1	   11.9	   86.3	  
Kinesin	  light	  chain	  1	   KLC1	   3978000000	   54935000	   89433000	   25323000	   1656200	   1318000	   157.1	   33.2	   67.9	   86.0	  
Sorting	  nexin-­‐1	   SNX1	   1199600000	   263030000	   216380000	   47342000	   3890600	   1318000	   25.3	   67.6	   164.2	   85.7	  
Rab	  GTPase-­‐binding	  effector	  protein	  1	   RABEP1	   213850000	   3375300	   2685900	   849090	   1656200	   1318000	   251.9	   2.0	   2.0	   85.3	  
Glomulin	   GLMN	   209260000	   9026600	   1858200	   849090	   1656200	   1318000	   246.5	   5.5	   1.4	   84.4	  
4F2	  cell-­‐surface	  antigen	  heavy	  chain	   SLC3A2	   210230000	   71995000	   86757000	   849090	   22570000	   48847000	   247.6	   3.2	   1.8	   84.2	  
Elongator	  complex	  protein	  4	   ELP4	   148680000	   58916000	   55024000	   849090	   1656200	   1318000	   175.1	   35.6	   41.7	   84.1	  
Replication	  factor	  C	  subunit	  1	   RFC1	   210140000	   30900000	   13855000	   849090	   9482400	   17707000	   247.5	   3.3	   0.8	   83.8	  
Synembryn-­‐A	   RIC8A	   207200000	   97675	   9113100	   849090	   1656200	   1318000	   244.0	   0.1	   6.9	   83.7	  
Transport	  and	  Golgi	  organization	  protein	  6	  homolog	   TANGO6	   207200000	   97675	   6274500	   849090	   1656200	   1318000	   244.0	   0.1	   4.8	   82.9	  
Myosin-­‐9	   MYH9	   9701200000	   1267500000	   955390000	   42470000	   107510000	   183670000	   228.4	   11.8	   5.2	   81.8	  
HAUS	  augmin-­‐like	  complex	  subunit	  6	   HAUS6	   1845300000	   201540000	   130920000	   76277000	   1656200	   1318000	   24.2	   121.7	   99.3	   81.7	  
Microtubule-­‐associated	   protein;Microtubule-­‐
associated	  protein	  4	   MAP4	   47850000000	   5865200000	   4782700000	   299910000	   130060000	   129330000	   159.5	   45.1	   37.0	   80.5	  
Caspase-­‐3;Caspase-­‐3	  subunit	  p17;Caspase-­‐3	  subunit	  
p12	   CASP3	   167960000	   97675	   56992000	   849090	   1656200	   1318000	   197.8	   0.1	   43.2	   80.4	  
Cytoskeleton-­‐associated	  protein	  5	   CKAP5	   4428800000	   700190000	   537220000	   21787000	   37128000	   29903000	   203.3	   18.9	   18.0	   80.0	  
Coatomer	  subunit	  beta	   COPB2	   159000000	   18051000	   50657000	   849090	   1656200	   1318000	   187.3	   10.9	   38.4	   78.9	  
Cytoskeleton-­‐associated	  protein	  4	   CKAP4	   191120000	   13803000	   20858000	   849090	   1656200	   7379800	   225.1	   8.3	   2.8	   78.7	  
Protein	  Shroom2	   SHROOM2	   195300000	   6188800	   1858200	   849090	   1656200	   1318000	   230.0	   3.7	   1.4	   78.4	  
Nuclear	  pore	  complex	  protein	  Nup93	   NUP93	   151350000	   15745000	   60534000	   849090	   1656200	   1318000	   178.2	   9.5	   45.9	   77.9	  
Oxysterol-­‐binding	  protein-­‐related	  protein	  11	   OSBPL11	   170070000	   15390000	   30268000	   849090	   1656200	   1318000	   200.3	   9.3	   23.0	   77.5	  
Src	  substrate	  cortactin	   CTTN	   57414000000	   9708300000	   7164400000	   1730800000	   102100000	   69348000	   33.2	   95.1	   103.3	   77.2	  
Calmodulin-­‐regulated	  spectrin-­‐associated	  protein	  3	   CAMSAP3	   185200000	   20392000	   1858200	   849090	   1656200	   3519800	   218.1	   12.3	   0.5	   77.0	  
Biotin-­‐-­‐protein	   ligase;Biotin-­‐-­‐[methylmalonyl-­‐CoA-­‐
carboxytransferase]	   ligase;Biotin-­‐-­‐[propionyl-­‐CoA-­‐
carboxylase	   [ATP-­‐hydrolyzing]]	   ligase;Biotin-­‐-­‐
[methylcrotonoyl-­‐CoA-­‐carboxylase]	   ligase;Biotin-­‐-­‐ HLCS	   189350000	   343260000	   277090000	   849090	   113120000	   80190000	   223.0	   3.0	   3.5	   76.5	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[acetyl-­‐CoA-­‐carboxylase]	  ligase	  
Drebrin-­‐like	  protein	   DBNL	   3895900000	   154560000	   120190000	   87578000	   1656200	   1318000	   44.5	   93.3	   91.2	   76.3	  
Methionine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   MARS	   190310000	   26404000	   22580000	   849090	   9322000	   16379000	   224.1	   2.8	   1.4	   76.1	  
Secretory	  carrier-­‐associated	  membrane	  protein	  1	   SCAMP1	   182450000	   7759700	   14775000	   849090	   12840000	   1318000	   214.9	   0.6	   11.2	   75.6	  
Zinc	  finger	  protein	  687	   ZNF687	   176750000	   21856000	   10924000	   849090	   1656200	   5328000	   208.2	   13.2	   2.1	   74.5	  
RNA	  polymerase	  II-­‐associated	  protein	  3	   RPAP3	   3009400000	   108230000	   85673000	   32655000	   1656200	   1318000	   92.2	   65.3	   65.0	   74.2	  
Eukaryotic	  translation	  initiation	  factor	  4	  gamma	  1	   EIF4G1	   5930500000	   546240000	   522470000	   31174000	   37287000	   31174000	   190.2	   14.6	   16.8	   73.9	  
TGF-­‐beta-­‐activated	   kinase	   1	   and	   MAP3K7-­‐binding	  
protein	  2	   TAB2	   172710000	   15712000	   10008000	   849090	   1656200	   1318000	   203.4	   9.5	   7.6	   73.5	  
Ankyrin	  repeat	  domain-­‐containing	  protein	  17	   ANKRD17	   388000000	   20248000	   18662000	   2007800	   1656200	   1318000	   193.2	   12.2	   14.2	   73.2	  
Glutamine-­‐-­‐tRNA	  ligase	   QARS	   178140000	   17230000	   16725000	   849090	   3546600	   5792900	   209.8	   4.9	   2.9	   72.5	  
Protein	  SMG7	   SMG7	   169850000	   97675	   15862000	   849090	   1656200	   1318000	   200.0	   0.1	   12.0	   70.7	  
NF-­‐kappa-­‐B	  inhibitor	  epsilon	   NFKBIE	   157850000	   22060000	   16518000	   849090	   1656200	   1318000	   185.9	   13.3	   12.5	   70.6	  
Golgi	  reassembly-­‐stacking	  protein	  2	   GORASP2	   1777100000	   97675	   24509000	   9411300	   1656200	   1318000	   188.8	   0.1	   18.6	   69.2	  
Putative	   RNA	   polymerase	   II	   subunit	   B1	   CTD	  
phosphatase	  RPAP2	   RPAP2	   168960000	   11575000	   1858200	   849090	   1656200	   1318000	   199.0	   7.0	   1.4	   69.1	  
Perilipin-­‐3	   PLIN3	   4505000000	   215540000	   190460000	   433030000	   4270500	   1318000	   10.4	   50.5	   144.5	   68.5	  
Serine/threonine-­‐protein	  phosphatase	  6	   regulatory	  
subunit	  3	   PPP6R3	   3449700000	   86433000	   104610000	   47322000	   1656200	   1318000	   72.9	   52.2	   79.4	   68.2	  
Microtubule-­‐associated	  protein	  tau	   MAPT	   1533800000	   84562000	   22048000	   11385000	   1656200	   1318000	   134.7	   51.1	   16.7	   67.5	  
DNA	   polymerase	   alpha	   catalytic	   subunit;DNA	  
polymerase	   POLA1	   166770000	   97675	   6206300	   849090	   1656200	   1318000	   196.4	   0.1	   4.7	   67.1	  
WW	  domain-­‐containing	  oxidoreductase	   WWOX	   1822200000	   120950000	   162310000	   503870000	   1656200	   1318000	   3.6	   73.0	   123.1	   66.6	  
Zinc	  finger	  protein	  131	   ZNF131	   162160000	   11958000	   1858200	   849090	   1656200	   1318000	   191.0	   7.2	   1.4	   66.5	  
TBC1	  domain	  family	  member	  15	   TBC1D15	   84989000	   74889000	   71434000	   849090	   1656200	   1318000	   100.1	   45.2	   54.2	   66.5	  
Reticulon-­‐4	   RTN4	   7898100000	   276460000	   209580000	   46752000	   14465000	   20055000	   168.9	   19.1	   10.5	   66.2	  
Ataxin-­‐2	   ATXN2	   159970000	   97675	   13024000	   849090	   1656200	   1318000	   188.4	   0.1	   9.9	   66.1	  
Stromal	  membrane-­‐associated	  protein	  1	   SMAP1	   3427300000	   173520000	   70826000	   88160000	   1656200	   1318000	   38.9	   104.8	   53.7	   65.8	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Protein	  SON	   SON	   2472600000	   68825000	   65117000	   17506000	   1656200	   5081300	   141.2	   41.6	   12.8	   65.2	  
LIM	  and	  SH3	  domain	  protein	  1	   LASP1	   959290000	   113370000	   154660000	   118430000	   1656200	   1318000	   8.1	   68.5	   117.3	   64.6	  
Interferon-­‐induced	   protein	   with	   tetratricopeptide	  
repeats	  5	   IFIT5	   159390000	   5687400	   1858200	   849090	   1656200	   1318000	   187.7	   3.4	   1.4	   64.2	  
Tropomodulin-­‐3	   TMOD3	   675810000	   18946000	   17106000	   4021300	   1656200	   1318000	   168.1	   11.4	   13.0	   64.2	  
Protein	   kinase	   C	   and	   casein	   kinase	   substrate	   in	  
neurons	  protein	  2	   PACSIN2	   816140000	   47896000	   11312000	   5290200	   1656200	   1318000	   154.3	   28.9	   8.6	   63.9	  
Vacuolar	   protein	   sorting-­‐associated	   protein	   VTA1	  
homolog	   VTA1	   145640000	   97675	   26227000	   849090	   10145000	   1318000	   171.5	   0.0	   19.9	   63.8	  
Zinc	  finger	  MYM-­‐type	  protein	  4	   ZMYM4	   149640000	   97675	   18672000	   849090	   1656200	   1318000	   176.2	   0.1	   14.2	   63.5	  
Aftiphilin	   AFTPH	   155860000	   7529800	   1858200	   849090	   1656200	   1318000	   183.6	   4.5	   1.4	   63.2	  
Ribosomal	  protein	  S6	  kinase	  alpha-­‐3	   RPS6KA3	   155980000	   97675	   6654700	   849090	   1656200	   1318000	   183.7	   0.1	   5.0	   62.9	  
Serine/threonine-­‐protein	   kinase	   PAK	   2;PAK-­‐
2p27;PAK-­‐2p34	   PAK2	   2406200000	   159830000	   78853000	   79925000	   1656200	   1318000	   30.1	   96.5	   59.8	   62.1	  
GPN-­‐loop	  GTPase	  1	   GPN1	   1213900000	   122190000	   137350000	   251150000	   1656200	   1318000	   4.8	   73.8	   104.2	   60.9	  
Autophagy-­‐related	  protein	  2	  homolog	  B	   ATG2B	   391930000	   11767000	   16610000	   2420500	   1656200	   1318000	   161.9	   7.1	   12.6	   60.5	  
Glucose-­‐6-­‐phosphate	  1-­‐dehydrogenase	   G6PD	   787300000	   5613700	   10987000	   4648800	   1656200	   1318000	   169.4	   3.4	   8.3	   60.4	  
Utrophin	   UTRN	   127880000	   30801000	   13144000	   849090	   1656200	   1318000	   150.6	   18.6	   10.0	   59.7	  
Septin-­‐7	   SEPT7	   2201500000	   189430000	   162200000	   54161000	   1656200	   7353500	   40.6	   114.4	   22.1	   59.0	  
Protein	  diaphanous	  homolog	  1	   DIAPH1	   140340000	   9082200	   1858200	   849090	   1656200	   1318000	   165.3	   5.5	   1.4	   57.4	  
YLP	  motif-­‐containing	  protein	  1	   YLPM1	   1410500000	   228520000	   138680000	   12565000	   6117400	   6829200	   112.3	   37.4	   20.3	   56.6	  
Syntenin-­‐1	   SDCBP	   824970000	   111980000	   83718000	   9249500	   1656200	   7887900	   89.2	   67.6	   10.6	   55.8	  
Sorting	  nexin-­‐2	   SNX2	   360040000	   88029000	   73921000	   6195800	   1656200	   1318000	   58.1	   53.2	   56.1	   55.8	  
Phosphatidylinositol	   5-­‐phosphate	   4-­‐kinase	   type-­‐2	  
gamma	   PIP4K2C	   137290000	   97675	   4588500	   849090	   1656200	   1318000	   161.7	   0.1	   3.5	   55.1	  
TIP41-­‐like	  protein	   TIPRL	   737070	   219700000	   134820000	   9843400	   1656200	   4557500	   0.1	   132.7	   29.6	   54.1	  
Interleukin-­‐1	  receptor-­‐associated	  kinase	  1	   IRAK1	   119170000	   31430000	   1858200	   849090	   1656200	   1318000	   140.4	   19.0	   1.4	   53.6	  
Phenylalanine-­‐-­‐tRNA	  ligase	  beta	  subunit	   FARSB	   573700000	   54861000	   33963000	   3704000	   15661000	   24449000	   154.9	   3.5	   1.4	   53.3	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Fragile	   X	   mental	   retardation	   syndrome-­‐related	  
protein	  2	   FXR2	   110000000	   23382000	   21000000	   849090	   1656200	   1318000	   129.6	   14.1	   15.9	   53.2	  
Ran-­‐binding	  protein	  9	   RANBP9	   127540000	   6848800	   8763000	   849090	   3933600	   1318000	   150.2	   1.7	   6.6	   52.9	  
Nibrin	   NBN	   1312900000	   10431000	   6827500	   9066600	   1656200	   1318000	   144.8	   6.3	   5.2	   52.1	  
Serine/threonine-­‐protein	   phosphatase	   2A	   56	   kDa	  
regulatory	  subunit	  delta	  isoform	   PPP2R5D	   118660000	   12997000	   10720000	   849090	   1656200	   1318000	   139.7	   7.8	   8.1	   51.9	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  3	   PSMD3	   2973000000	   149900000	   106170000	   47240000	   12449000	   1318000	   62.9	   12.0	   80.6	   51.8	  
DBIRD	  complex	  subunit	  CCAR2	   CCAR2	   121740000	   37870000	   74342000	   849090	   16906000	   9751700	   143.4	   2.2	   7.6	   51.1	  
tRNA	  (cytosine(34)-­‐C(5))-­‐methyltransferase	   NSUN2	   124510000	   3906400	   3781600	   849090	   1656200	   1318000	   146.6	   2.4	   2.9	   50.6	  
Ezrin	   EZR	   2721200000	   209720000	   184160000	   22307000	   9171400	   26876000	   122.0	   22.9	   6.9	   50.6	  
Antigen	  KI-­‐67	   MKI67	   2054000000	   54166000	   56927000	   14007000	   15261000	   38049000	   146.6	   3.5	   1.5	   50.6	  
EF-­‐hand	  domain-­‐containing	  protein	  D2	   EFHD2	   228880000	   189360000	   161620000	   39072000	   8836900	   1318000	   5.9	   21.4	   122.6	   50.0	  
Gem-­‐associated	  protein	  5	   GEMIN5	   90337000	   8817100	   49751000	   849090	   1656200	   1318000	   106.4	   5.3	   37.7	   49.8	  
Protein	  phosphatase	  methylesterase	  1	   PPME1	   1375800000	   128320000	   86121000	   223240000	   1656200	   1318000	   6.2	   77.5	   65.3	   49.7	  
Translational	  activator	  GCN1	   GCN1	   653800000	   350950000	   318450000	   5317900	   32155000	   22658000	   122.9	   10.9	   14.1	   49.3	  
E3	   SUMO-­‐protein	   ligase	   RanBP2;Putative	   peptidyl-­‐
prolyl	  cis-­‐trans	  isomerase	   RANBP2	   15311000000	   1659200000	   1575100000	   299510000	   76456000	   22995000	   51.1	   21.7	   68.5	   47.1	  
Biorientation	   of	   chromosomes	   in	   cell	   division	  
protein	  1-­‐like	  1	   BOD1L1	   1099300000	   28430000	   25249000	   10616000	   1656200	   1318000	   103.6	   17.2	   19.2	   46.6	  
mRNA-­‐decapping	  enzyme	  1A	   DCP1A	   549970000	   131520000	   73651000	   191200000	   1656200	   1318000	   2.9	   79.4	   55.9	   46.1	  
DNA	  replication	  licensing	  factor	  MCM6	   MCM6	   110730000	   9777000	   3477200	   849090	   1656200	   19284000	   130.4	   5.9	   0.2	   45.5	  
YTH	  domain	  family	  protein	  2	   YTHDF2	   1472600000	   47546000	   134470000	   264090000	   1656200	   1318000	   5.6	   28.7	   102.0	   45.4	  
Fermitin	  family	  homolog	  2	   FERMT2	   737070	   52429000	   131130000	   849090	   1656200	   1318000	   0.9	   31.7	   99.5	   44.0	  
Aminoacyl	   tRNA	   synthase	   complex-­‐interacting	  
multifunctional	  protein	  2	   AIMP2	   259530000	   14340000	   30319000	   2180400	   1656200	   7373800	   119.0	   8.7	   4.1	   43.9	  
Rab11	  family-­‐interacting	  protein	  1	   RAB11FIP1	   108600000	   97675	   4397700	   849090	   1656200	   1318000	   127.9	   0.1	   3.3	   43.8	  
Bifunctional	   protein	   NCOAT;Protein	   O-­‐
GlcNAcase;Histone	  acetyltransferase	   MGEA5	   102110000	   8564400	   7883500	   849090	   1656200	   1852900	   120.3	   5.2	   4.3	   43.2	  
	   	   	  Appendices	  
	  
	  
Signal	  recognition	  particle	  54	  kDa	  protein	   SRP54	   2065900000	   14939000	   56392000	   27215000	   1656200	   1318000	   75.9	   9.0	   42.8	   42.6	  
Synapse-­‐associated	  protein	  1	   SYAP1	   989570000	   6233100	   33954000	   10137000	   1656200	   1318000	   97.6	   3.8	   25.8	   42.4	  
Ran-­‐specific	  GTPase-­‐activating	  protein	   RANBP1	   737070	   199490000	   95084000	   16068000	   1656200	   17489000	   0.0	   120.5	   5.4	   42.0	  
Phosphatidylinositol-­‐binding	   clathrin	   assembly	  
protein	   PICALM	   927490000	   97608000	   28146000	   20582000	   1656200	   1318000	   45.1	   58.9	   21.4	   41.8	  
Enhancer	  of	  mRNA-­‐decapping	  protein	  4	   EDC4	   614600000	   104030000	   59321000	   40868000	   1656200	   1318000	   15.0	   62.8	   45.0	   41.0	  
Coiled-­‐coil	  domain-­‐containing	  protein	  43	   CCDC43	   27370000	   54203000	   115330000	   849090	   20252000	   1318000	   32.2	   2.7	   87.5	   40.8	  
Coatomer	  subunit	  gamma-­‐2	   COPG2	   6728600000	   2281200000	   1878700000	   151870000	   46221000	   67302000	   44.3	   49.4	   27.9	   40.5	  
Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  7A	   ZC3H7A	   96408000	   7394300	   4392100	   849090	   1656200	   1318000	   113.5	   4.5	   3.3	   40.4	  
Wiskott-­‐Aldrich	  syndrome	  protein	  family	  member	  2	   WASF2	   95668000	   97675	   10089000	   849090	   1656200	   1318000	   112.7	   0.1	   7.7	   40.1	  
Tetratricopeptide	  repeat	  protein	  28	   TTC28	   99563000	   97675	   2974300	   849090	   1656200	   1318000	   117.3	   0.1	   2.3	   39.9	  
Serine/threonine-­‐protein	   phosphatase	   PP1-­‐beta	  
catalytic	   subunit;Serine/threonine-­‐protein	  
phosphatase	   PPP1CB	   96737000	   5623700	   5562300	   849090	   4138100	   1318000	   113.9	   1.4	   4.2	   39.8	  
Disks	  large-­‐associated	  protein	  5	   DLGAP5	   1673600000	   159790000	   191670000	   18328000	   12390000	   13505000	   91.3	   12.9	   14.2	   39.5	  
SCY1-­‐like	  protein	  2	   SCYL2	   1144600000	   36330000	   23484000	   14723000	   1656200	   1318000	   77.7	   21.9	   17.8	   39.2	  
ADP-­‐ribosylation	  factor	  GTPase-­‐activating	  protein	  1	   ARFGAP1	   982620000	   85958000	   48401000	   35822000	   1656200	   1318000	   27.4	   51.9	   36.7	   38.7	  
Protein	  kinase	  C-­‐binding	  protein	  1	   ZMYND8	   1560300000	   177220000	   121220000	   18974000	   15930000	   5440300	   82.2	   11.1	   22.3	   38.5	  
Activator	   of	   90	   kDa	   heat	   shock	   protein	   ATPase	  
homolog	  1	   AHSA1	   2973900000	   479110000	   381580000	   707440000	   5003100	   29345000	   4.2	   95.8	   13.0	   37.7	  
Treacle	  protein	   TCOF1	   1674300000	   18309000	   69461000	   28169000	   23033000	   1318000	   59.4	   0.8	   52.7	   37.6	  
Msx2-­‐interacting	  protein	   SPEN	   1817800000	   132160000	   86320000	   17244000	   45005000	   24368000	   105.4	   2.9	   3.5	   37.3	  
Putative	  ribosomal	  RNA	  methyltransferase	  NOP2	   NOP2	   91927000	   14436000	   6677600	   849090	   5113400	   8932700	   108.3	   2.8	   0.7	   37.3	  
Pre-­‐mRNA-­‐splicing	   factor	   ATP-­‐dependent	   RNA	  
helicase	  PRP16	   DHX38	   91223000	   3198500	   2767800	   849090	   1656200	   1318000	   107.4	   1.9	   2.1	   37.2	  
Nucleolar	  RNA	  helicase	  2	   DDX21	   85120000	   15974000	   1858200	   849090	   1656200	   1318000	   100.2	   9.6	   1.4	   37.1	  
Centrosomal	  protein	  of	  97	  kDa	   CEP97	   872380000	   14546000	   1858200	   8639100	   1656200	   1318000	   101.0	   8.8	   1.4	   37.1	  
Telomere-­‐associated	  protein	  RIF1	   RIF1	   1366200000	   50004000	   38999000	   17735000	   11137000	   1318000	   77.0	   4.5	   29.6	   37.0	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Adenylyl	  cyclase-­‐associated	  protein	  1	   CAP1	   1040700000	   25891000	   41367000	   12108000	   1656200	   5292200	   86.0	   15.6	   7.8	   36.5	  
G	  patch	  domain-­‐containing	  protein	  1	   GPATCH1	   88097000	   5499000	   1858200	   849090	   1656200	   1318000	   103.8	   3.3	   1.4	   36.2	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  4	   PSMD4	   2008400000	   146890000	   104600000	   86870000	   25813000	   1318000	   23.1	   5.7	   79.4	   36.1	  
TGF-­‐beta-­‐activated	   kinase	   1	   and	   MAP3K7-­‐binding	  
protein	  1	   TAB1	   754340000	   19106000	   19416000	   9264200	   1656200	   1318000	   81.4	   11.5	   14.7	   35.9	  
Ubiquitin-­‐associated	  protein	  2-­‐like	   UBAP2L	   3539200000	   390530000	   256930000	   53872000	   26590000	   9582300	   65.7	   14.7	   26.8	   35.7	  
LIM	  and	  cysteine-­‐rich	  domains	  protein	  1	   LMCD1	   644290000	   13014000	   12541000	   7220700	   1656200	   1318000	   89.2	   7.9	   9.5	   35.5	  
Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX46	   DDX46	   1141800000	   39356000	   27711000	   16845000	   2229700	   1318000	   67.8	   17.7	   21.0	   35.5	  
Elongation	  factor	  1-­‐delta	   EEF1D	   774730000	   152820000	   122690000	   76497000	   1656200	   44050000	   10.1	   92.3	   2.8	   35.1	  
Ubiquitin	   carboxyl-­‐terminal	   hydrolase	   14;Ubiquitin	  
carboxyl-­‐terminal	  hydrolase	   USP14	   2625500000	   64787000	   63475000	   153600000	   1656200	   1318000	   17.1	   39.1	   48.2	   34.8	  
Oxysterol-­‐binding	  protein-­‐related	  protein	  6	   OSBPL6	   81819000	   5182600	   5182100	   849090	   1656200	   1318000	   96.4	   3.1	   3.9	   34.5	  
Extended	  synaptotagmin-­‐1	   ESYT1	   67292000	   30256000	   6347500	   849090	   1656200	   1318000	   79.3	   18.3	   4.8	   34.1	  
Ankyrin	  repeat	  and	  SAM	  domain-­‐containing	  protein	  
1A	   ANKS1A	   1519100000	   29782000	   84023000	   74520000	   1656200	   1318000	   20.4	   18.0	   63.8	   34.0	  
Moesin	   MSN	   82828000	   5175800	   1858200	   849090	   1656200	   1318000	   97.5	   3.1	   1.4	   34.0	  






reductase;Oleoyl-­‐[acyl-­‐carrier-­‐protein]	  hydrolase	   FASN	   1277700000	   480180000	   331410000	   13447000	   101400000	   143840000	   95.0	   4.7	   2.3	   34.0	  
Developmentally-­‐regulated	  GTP-­‐binding	  protein	  2	   DRG2	   737740000	   33498000	   31687000	   13633000	   1656200	   1318000	   54.1	   20.2	   24.0	   32.8	  
MAP7	  domain-­‐containing	  protein	  1	   MAP7D1	   76503000	   10421000	   1858200	   849090	   1656200	   1318000	   90.1	   6.3	   1.4	   32.6	  
Tyrosine-­‐-­‐tRNA	   ligase,	   cytoplasmic;Tyrosine-­‐-­‐tRNA	  
ligase,	  cytoplasmic,	  N-­‐terminally	  processed	   YARS	   567400000	   47682000	   1858200	   8459700	   1656200	   1318000	   67.1	   28.8	   1.4	   32.4	  
Transforming	  acidic	  coiled-­‐coil-­‐containing	  protein	  1	   TACC1	   76192000	   10036000	   1858200	   849090	   1656200	   1318000	   89.7	   6.1	   1.4	   32.4	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Nuclear	  pore	  complex	  protein	  Nup214	   NUP214	   4439200000	   460530000	   327940000	   75649000	   23513000	   17357000	   58.7	   19.6	   18.9	   32.4	  
Charged	  multivesicular	  body	  protein	  5	   CHMP5	   888240000	   136180000	   156840000	   28222000	   8868300	   3134000	   31.5	   15.4	   50.0	   32.3	  
Myotubularin-­‐related	  protein	  6	   MTMR6	   469320000	   26560000	   62833000	   14288000	   1656200	   1318000	   32.8	   16.0	   47.7	   32.2	  
Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  G	   EIF3G	   2866400000	   77241000	   37686000	   138590000	   1656200	   1318000	   20.7	   46.6	   28.6	   32.0	  
CREB-­‐regulated	  transcription	  coactivator	  1	   CRTC1	   66758000	   13324000	   11832000	   849090	   1656200	   1318000	   78.6	   8.0	   9.0	   31.9	  
AP-­‐2	  complex	  subunit	  beta	   AP2B1	   76264000	   16638000	   1858200	   849090	   7654300	   1318000	   89.8	   2.2	   1.4	   31.1	  
Arf-­‐GAP	  domain	  and	  FG	  repeat-­‐containing	  protein	  1	   AGFG1	   1545300000	   125190000	   106210000	   385100000	   1656200	   8077200	   4.0	   75.6	   13.1	   30.9	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  CYLD	   CYLD	   73284000	   97675	   8190500	   849090	   1656200	   1318000	   86.3	   0.1	   6.2	   30.9	  
Tyrosine-­‐protein	  phosphatase	  non-­‐receptor	  type	  11	   PTPN11	   9611700000	   552520000	   346870000	   1090700000	   13339000	   8451500	   8.8	   41.4	   41.0	   30.4	  
Protein-­‐methionine	  sulfoxide	  oxidase	  MICAL3	   MICAL3	   69150000	   13948000	   1858200	   849090	   1656200	   1318000	   81.4	   8.4	   1.4	   30.4	  
Proliferation-­‐associated	  protein	  2G4	   PA2G4	   543310000	   43197000	   60961000	   29029000	   1656200	   1318000	   18.7	   26.1	   46.3	   30.4	  
Microtubule-­‐associated	   protein	   1A;MAP1A	   heavy	  
chain;MAP1	  light	  chain	  LC2	   MAP1A	   564070000	   8962500	   1858200	   6922600	   1656200	   1318000	   81.5	   5.4	   1.4	   29.4	  
Dihydropyrimidinase-­‐related	  protein	  2	   DPYSL2	   966390000	   43637000	   19237000	   20551000	   1656200	   1318000	   47.0	   26.3	   14.6	   29.3	  
SUMO-­‐activating	  enzyme	  subunit	  2	   UBA2	   552030000	   25189000	   29554000	   11018000	   1656200	   1318000	   50.1	   15.2	   22.4	   29.2	  
Carboxypeptidase	  D	   CPD	   66286000	   12037000	   1858200	   849090	   1656200	   1318000	   78.1	   7.3	   1.4	   28.9	  
Obg-­‐like	  ATPase	  1	   OLA1	   54054000	   27635000	   8248300	   849090	   1656200	   1318000	   63.7	   16.7	   6.3	   28.9	  
Eukaryotic	   translation	   initiation	   factor	   3	   subunit	  
C;Eukaryotic	   translation	   initiation	   factor	   3	   subunit	  
C-­‐like	  protein	   EIF3C	   661780000	   80199000	   66732000	   10090000	   6784800	   8054900	   65.6	   11.8	   8.3	   28.6	  
Oxysterol-­‐binding	   protein-­‐related	   protein	  
9;Oxysterol-­‐binding	  protein	   OSBPL9	   61219000	   97675	   16841000	   849090	   1656200	   1318000	   72.1	   0.1	   12.8	   28.3	  
Ankyrin	  repeat	  and	  FYVE	  domain-­‐containing	  protein	  
1	   ANKFY1	   61370000	   9927700	   8768900	   849090	   1656200	   1318000	   72.3	   6.0	   6.7	   28.3	  
E3	  ubiquitin-­‐protein	  ligase	  RBBP6	   RBBP6	   410720000	   11144000	   42880000	   9010500	   1656200	   1318000	   45.6	   6.7	   32.5	   28.3	  
Protein	  prune	  homolog	   PRUNE1	   3097200000	   118360000	   65410000	   239700000	   5394300	   1318000	   12.9	   21.9	   49.6	   28.2	  
Aminoacyl	   tRNA	   synthase	   complex-­‐interacting	  
multifunctional	   protein	   1;Endothelial	   monocyte-­‐ AIMP1	   67352000	   6219400	   1858200	   849090	   1656200	   1318000	   79.3	   3.8	   1.4	   28.2	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activating	  polypeptide	  2	  
Cohesin	  subunit	  SA-­‐2	   STAG2	   66694000	   6414300	   1858200	   849090	   1656200	   1318000	   78.5	   3.9	   1.4	   27.9	  
Protein	  PBDC1	   PBDC1	   297780000	   97675	   10135000	   3914600	   1656200	   1318000	   76.1	   0.1	   7.7	   27.9	  
AP-­‐3	  complex	  subunit	  beta-­‐1	   AP3B1	   60549000	   97675	   16239000	   849090	   1656200	   1318000	   71.3	   0.1	   12.3	   27.9	  
Ras	  GTPase-­‐activating	  protein-­‐binding	  protein	  1	   G3BP1	   1004100000	   22822000	   51145000	   32793000	   1656200	   1318000	   30.6	   13.8	   38.8	   27.7	  
Tudor	  domain-­‐containing	  protein	  3	   TDRD3	   63832000	   97675	   10048000	   849090	   1656200	   1318000	   75.2	   0.1	   7.6	   27.6	  
Pachytene	  checkpoint	  protein	  2	  homolog	   TRIP13	   763080000	   41539000	   43820000	   11334000	   4298400	   8004700	   67.3	   9.7	   5.5	   27.5	  
Centromere	  protein	  H	   CENPH	   1018200000	   33830000	   64087000	   77853000	   1656200	   1318000	   13.1	   20.4	   48.6	   27.4	  
Interleukin	  enhancer-­‐binding	  factor	  3	   ILF3	   2508600000	   240570000	   247260000	   33306000	   112380000	   85583000	   75.3	   2.1	   2.9	   26.8	  
Ankyrin	  repeat	  and	  KH	  domain-­‐containing	  protein	  1	   ANKHD1	   888050000	   37717000	   24352000	   24128000	   1656200	   1318000	   36.8	   22.8	   18.5	   26.0	  
WW	   domain-­‐containing	   adapter	   protein	   with	  
coiled-­‐coil	   WAC	   840650000	   74718000	   74237000	   82878000	   6661100	   1318000	   10.1	   11.2	   56.3	   25.9	  
Serine/threonine-­‐protein	  kinase	  WNK1	   WNK1	   1335000000	   28270000	   59841000	   91474000	   1656200	   1318000	   14.6	   17.1	   45.4	   25.7	  
Protein	  DDI1	  homolog	  2	   DDI2	   63026000	   97675	   5391800	   849090	   1656200	   2237400	   74.2	   0.1	   2.4	   25.6	  




formyltransferase	   GART	   53818000	   14553000	   5000700	   849090	   1656200	   1318000	   63.4	   8.8	   3.8	   25.3	  
Paired	  amphipathic	  helix	  protein	  Sin3a	   SIN3A	   870000000	   9876000	   39445000	   21888000	   1656200	   1318000	   39.7	   6.0	   29.9	   25.2	  
General	  transcription	  factor	  3C	  polypeptide	  5	   GTF3C5	   1282700000	   49129000	   54245000	   267630000	   1656200	   1318000	   4.8	   29.7	   41.2	   25.2	  
Double-­‐stranded	   RNA-­‐binding	   protein	   Staufen	  
homolog	  1	   STAU1	   3403000000	   30222000	   34685000	   114160000	   1656200	   1318000	   29.8	   18.2	   26.3	   24.8	  
Centromere	  protein	  F	   CENPF	   12533000	   95868000	   1858200	   849090	   1656200	   1318000	   14.8	   57.9	   1.4	   24.7	  
Elongation	  factor	  1-­‐alpha	  2	   EEF1A2	   979900000	   48216000	   40444000	   15381000	   6378100	   14792000	   63.7	   7.6	   2.7	   24.7	  
28	  kDa	  heat-­‐	  and	  acid-­‐stable	  phosphoprotein	   PDAP1	   737070	   59746000	   49786000	   33327000	   1656200	   1318000	   0.0	   36.1	   37.8	   24.6	  
Protein	  NDRG1	   NDRG1	   2342000000	   30991000	   71192000	   157170000	   7823600	   1318000	   14.9	   4.0	   54.0	   24.3	  
Protein	  LSM14	  homolog	  B	   LSM14B	   690740000	   10934000	   11593000	   12049000	   1656200	   1318000	   57.3	   6.6	   8.8	   24.2	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Catenin	  delta-­‐1	   CTNND1	   704010000	   16951000	   37826000	   20872000	   1656200	   1318000	   33.7	   10.2	   28.7	   24.2	  
Protein	  TALPID3	   KIAA0586	   4421600	   109100000	   1858200	   849090	   1656200	   1318000	   5.2	   65.9	   1.4	   24.2	  
Lamin-­‐B	  receptor	   LBR	   42231000	   27579000	   39584000	   849090	   1656200	   7684700	   49.7	   16.7	   5.2	   23.8	  
Anaphase-­‐promoting	  complex	  subunit	  4	   ANAPC4	   552930000	   29821000	   16737000	   13700000	   1656200	   1318000	   40.4	   18.0	   12.7	   23.7	  
Pre-­‐mRNA-­‐processing-­‐splicing	  factor	  8	   PRPF8	   52297000	   30502000	   13162000	   849090	   3399400	   31087000	   61.6	   9.0	   0.4	   23.7	  
IST1	  homolog	   IST1	   1343400000	   13621000	   1858200	   21968000	   1656200	   1318000	   61.2	   8.2	   1.4	   23.6	  
Coiled-­‐coil	  domain-­‐containing	  protein	  50	   CCDC50	   600230000	   53639000	   1858200	   17252000	   1656200	   1318000	   34.8	   32.4	   1.4	   22.9	  
Myosin-­‐14	   MYH14	   163090000	   20648000	   1858200	   3034600	   1656200	   1318000	   53.7	   12.5	   1.4	   22.5	  
V-­‐type	  proton	  ATPase	  catalytic	  subunit	  A	   ATP6V1A	   232110000	   66438000	   15087000	   14574000	   1656200	   1318000	   15.9	   40.1	   11.4	   22.5	  
Thyroid	  hormone	  receptor-­‐associated	  protein	  3	   THRAP3	   1155200000	   44480000	   22646000	   49428000	   1656200	   1318000	   23.4	   26.9	   17.2	   22.5	  
BAG	  family	  molecular	  chaperone	  regulator	  3	   BAG3	   3474000000	   189680000	   114320000	   139430000	   8312500	   5876200	   24.9	   22.8	   19.5	   22.4	  
ATP-­‐dependent	   RNA	   helicase	   DDX19A;ATP-­‐
dependent	  RNA	  helicase	  DDX19B	   DDX19A	   617410000	   11666000	   1858200	   10749000	   1656200	   1318000	   57.4	   7.0	   1.4	   22.0	  
Histone-­‐lysine	   N-­‐methyltransferase,	   H3	   lysine-­‐36	  
and	  H4	  lysine-­‐20	  specific	   NSD1	   23150000	   61411000	   1858200	   849090	   1656200	   1318000	   27.3	   37.1	   1.4	   21.9	  
Cyclin-­‐K	   CCNK	   3146800000	   132880000	   94985000	   52212000	   52489000	   32927000	   60.3	   2.5	   2.9	   21.9	  
Eukaryotic	  translation	  initiation	  factor	  5	   EIF5	   45909000000	   4006300000	   4070400000	   2090400000	   188960000	   184990000	   22.0	   21.2	   22.0	   21.7	  
Syntaxin-­‐5	   STX5	   593870000	   8278400	   10012000	   11549000	   1656200	   1318000	   51.4	   5.0	   7.6	   21.3	  
Nuclear	   pore	   complex	   protein	   Nup98-­‐
Nup96;Nuclear	   pore	   complex	   protein	  
Nup98;Nuclear	  pore	  complex	  protein	  Nup96	   NUP98	   1001900000	   20431000	   58621000	   140970000	   1656200	   1318000	   7.1	   12.3	   44.5	   21.3	  
Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  D	   PPID	   773090000	   41300000	   27079000	   42109000	   1656200	   1318000	   18.4	   24.9	   20.5	   21.3	  
Ubiquitin	   carboxyl-­‐terminal	   hydrolase	   8;Ubiquitin	  
carboxyl-­‐terminal	  hydrolase	   USP8	   50303000	   97675	   5470100	   849090	   1656200	   1318000	   59.2	   0.1	   4.2	   21.2	  
Ubiquitin-­‐like-­‐conjugating	  enzyme	  ATG3	   ATG3	   558050000	   38430000	   22713000	   25198000	   1656200	   1318000	   22.1	   23.2	   17.2	   20.9	  
Filamin-­‐C	   FLNC	   244000000	   4904900	   6843000	   4488000	   1656200	   1318000	   54.4	   3.0	   5.2	   20.8	  
PDZ	  and	  LIM	  domain	  protein	  4	   PDLIM4	   1180600000	   37392000	   48533000	   381190000	   1656200	   1318000	   3.1	   22.6	   36.8	   20.8	  
Coatomer	  subunit	  gamma-­‐1	   COPG1	   49826000	   5572700	   7124800	   849090	   2637600	   10339000	   58.7	   2.1	   0.7	   20.5	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Tetratricopeptide	  repeat	  protein	  1	   TTC1	   462780000	   28494000	   21404000	   16650000	   1656200	   1318000	   27.8	   17.2	   16.2	   20.4	  
Protein	  misato	  homolog	  1	   MSTO1	   869420000	   18360000	   18087000	   24191000	   1656200	   1318000	   35.9	   11.1	   13.7	   20.2	  
ATP-­‐dependent	   RNA	   helicase	   DDX3X;ATP-­‐
dependent	  RNA	  helicase	  DDX3Y	   DDX3X	   4333200000	   507390000	   531840000	   476460000	   12659000	   47484000	   9.1	   40.1	   11.2	   20.1	  
Tryptophan-­‐-­‐tRNA	   ligase,	   cytoplasmic;T1-­‐TrpRS;T2-­‐
TrpRS	   WARS	   2466400000	   100040000	   45285000	   174080000	   9246500	   1318000	   14.2	   10.8	   34.4	   19.8	  
NSFL1	  cofactor	  p47	   NSFL1C	   1529600000	   42837000	   35508000	   277160000	   1656200	   1318000	   5.5	   25.9	   26.9	   19.4	  
Tetratricopeptide	  repeat	  protein	  4	   TTC4	   402440000	   57573000	   10440000	   25906000	   1656200	   1318000	   15.5	   34.8	   7.9	   19.4	  
COP9	  signalosome	  complex	  subunit	  3	   COPS3	   84387000	   26885000	   26740000	   1594800	   9350500	   12070000	   52.9	   2.9	   2.2	   19.3	  
Signal	  transducing	  adapter	  molecule	  2	   STAM2	   189300000	   7460500	   9872100	   4155800	   1656200	   1318000	   45.6	   4.5	   7.5	   19.2	  
Hsp90	   co-­‐chaperone	   Cdc37;Hsp90	   co-­‐chaperone	  
Cdc37,	  N-­‐terminally	  processed	   CDC37	   793650000	   206470000	   167100000	   119360000	   7798700	   6993100	   6.6	   26.5	   23.9	   19.0	  
Histone	  deacetylase	  complex	  subunit	  SAP130	   SAP130	   861810000	   12148000	   12185000	   17934000	   1656200	   7842900	   48.1	   7.3	   1.6	   19.0	  
U4/U6.U5	  tri-­‐snRNP-­‐associated	  protein	  1	   SART1	   1238500000	   100590000	   39238000	   90594000	   7556300	   1318000	   13.7	   13.3	   29.8	   18.9	  
Pinin	   PNN	   3313400000	   343960000	   141080000	   189600000	   10364000	   34064000	   17.5	   33.2	   4.1	   18.3	  
Eukaryotic	  peptide	  chain	  release	  factor	  subunit	  1	   ETF1	   1409900000	   31170000	   17442000	   62087000	   1656200	   1318000	   22.7	   18.8	   13.2	   18.3	  
Nucleosome	  assembly	  protein	  1-­‐like	  1	   NAP1L1	   4050800000	   243250000	   225730000	   304720000	   7388300	   26515000	   13.3	   32.9	   8.5	   18.2	  
Coatomer	  subunit	  delta	   ARCN1	   2189800000	   66627000	   119470000	   311480000	   1656200	   16259000	   7.0	   40.2	   7.3	   18.2	  
Twinfilin-­‐2	   TWF2	   985920000	   27146000	   34826000	   83790000	   1656200	   1318000	   11.8	   16.4	   26.4	   18.2	  
Host	  cell	  factor	  1	   HCFC1	   43177000	   20556000	   23986000	   849090	   14898000	   11992000	   50.9	   1.4	   2.0	   18.1	  
Transaldolase	   TALDO1	   494400000	   66181000	   42262000	   56893000	   1656200	   7679000	   8.7	   40.0	   5.5	   18.1	  
Pleckstrin	   homology	   domain-­‐containing	   family	   A	  
member	  1	   PLEKHA1	   202220000	   10145000	   1858200	   4342800	   1656200	   1318000	   46.6	   6.1	   1.4	   18.0	  
Splicing	  factor	  3B	  subunit	  1	   SF3B1	   9547400000	   1170400000	   1073300000	   217130000	   226880000	   216370000	   44.0	   5.2	   5.0	   18.0	  
60S	  ribosomal	  protein	  L5	   RPL5	   100970000	   59239000	   17273000	   22390000	   1656200	   1318000	   4.5	   35.8	   13.1	   17.8	  
Pseudouridylate	  synthase	  7	  homolog	   PUS7	   416560000	   54297000	   21188000	   94251000	   1656200	   1318000	   4.4	   32.8	   16.1	   17.8	  
PAS	   domain-­‐containing	   serine/threonine-­‐protein	  
kinase	   PASK	   40763000	   5558800	   1858200	   849090	   1656200	   1318000	   48.0	   3.4	   1.4	   17.6	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T-­‐complex	  protein	  1	  subunit	  alpha	   TCP1	   383120000	   201770000	   130700000	   8175900	   47023000	   83715000	   46.9	   4.3	   1.6	   17.6	  
T-­‐complex	  protein	  1	  subunit	  epsilon	   CCT5	   174620000	   53968000	   25403000	   4472500	   5501100	   10430000	   39.0	   9.8	   2.4	   17.1	  
Uncharacterized	  protein	  C1orf198	   C1orf198	   690220000	   55586000	   13130000	   91012000	   1656200	   1318000	   7.6	   33.6	   10.0	   17.0	  
Tubulin-­‐specific	  chaperone	  cofactor	  E-­‐like	  protein	   TBCEL	   1169400000	   18801000	   26212000	   59748000	   1656200	   1318000	   19.6	   11.4	   19.9	   16.9	  
WD	  repeat	  and	  HMG-­‐box	  DNA-­‐binding	  protein	  1	   WDHD1	   1655000000	   148070000	   119990000	   40550000	   41956000	   21760000	   40.8	   3.5	   5.5	   16.6	  
Splicing	  factor	  45	   RBM17	   2199800000	   34009000	   23373000	   193270000	   1656200	   1318000	   11.4	   20.5	   17.7	   16.6	  
Splicing	  factor	  3A	  subunit	  1	   SF3A1	   5669100000	   250960000	   84416000	   160810000	   20208000	   52016000	   35.3	   12.4	   1.6	   16.4	  
L-­‐aminoadipate-­‐semialdehyde	   dehydrogenase-­‐
phosphopantetheinyl	  transferase	   AASDHPPT	   236960000	   22364000	   19687000	   11563000	   1656200	   1318000	   20.5	   13.5	   14.9	   16.3	  
Alpha-­‐globin	  transcription	  factor	  CP2	   TFCP2	   977680000	   105750000	   78055000	   38325000	   20091000	   4371000	   25.5	   5.3	   17.9	   16.2	  
Importin-­‐9	   IPO9	   33460000	   8223400	   5544700	   849090	   1656200	   1318000	   39.4	   5.0	   4.2	   16.2	  
Alpha-­‐centractin	   ACTR1A	   737070	   13813000	   51423000	   849090	   1656200	   1318000	   0.9	   8.3	   39.0	   16.1	  
Nascent	   polypeptide-­‐associated	   complex	   subunit	  
alpha	   NACA	   1130700000	   43016000	   19644000	   158390000	   1656200	   1318000	   7.1	   26.0	   14.9	   16.0	  
U2	  snRNP-­‐associated	  SURP	  motif-­‐containing	  protein	   U2SURP	   1616600000	   136560000	   170570000	   42807000	   28741000	   31343000	   37.8	   4.8	   5.4	   16.0	  
Vesicle-­‐associated	   membrane	   protein-­‐associated	  
protein	  B/C	   VAPB	   10991000	   32679000	   33020000	   3553600	   1656200	   1318000	   3.1	   19.7	   25.1	   16.0	  
Protein	  FAM208B	   FAM208B	   230260000	   97675	   5870500	   5383000	   1656200	   1318000	   42.8	   0.1	   4.5	   15.8	  
Keratin,	  type	  I	  cytoskeletal	  18	   KRT18	   30679000000	   779470000	   619490000	   6465400000	   25937000	   49744000	   4.7	   30.1	   12.5	   15.8	  
RanBP2-­‐like	   and	   GRIP	   domain-­‐containing	   protein	  
3;RanBP2-­‐like	   and	  GRIP	   domain-­‐containing	   protein	  
4;RANBP2-­‐like	  and	  GRIP	  domain-­‐containing	  protein	  
1;RANBP2-­‐like	  and	  GRIP	  domain-­‐containing	  protein	  
2	   RGPD3	   314610000	   96007000	   70622000	   8877200	   12120000	   19336000	   35.4	   7.9	   3.7	   15.7	  
Nucleosome	  assembly	  protein	  1-­‐like	  4	   NAP1L4	   7963500000	   445910000	   392680000	   773690000	   25024000	   21038000	   10.3	   17.8	   18.7	   15.6	  
Spectrin	  alpha	  chain,	  non-­‐erythrocytic	  1	   SPTAN1	   705150000	   37183000	   33711000	   34088000	   1656200	   9286700	   20.7	   22.5	   3.6	   15.6	  
Signal	   transducer	   and	   activator	   of	   transcription	   1-­‐
alpha/beta	   STAT1	   4336700000	   366020000	   259530000	   143280000	   36255000	   40736000	   30.3	   10.1	   6.4	   15.6	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Heterogeneous	  nuclear	  ribonucleoprotein	  R	   HNRNPR	   1148900000	   221080000	   167060000	   31384000	   43979000	   35698000	   36.6	   5.0	   4.7	   15.4	  
TOM1-­‐like	  protein	  1	   TOM1L1	   255280000	   97675	   7739000	   6414200	   1656200	   1318000	   39.8	   0.1	   5.9	   15.2	  
Protein	  kintoun	   DNAAF2	   366210000	   17307000	   23782000	   21378000	   1656200	   1318000	   17.1	   10.4	   18.0	   15.2	  
Protein	   phosphatase	   inhibitor	   2;Putative	   protein	  
phosphatase	  inhibitor	  2-­‐like	  protein	  3	   PPP1R2	   165910000	   29607000	   99494000	   6499700	   1656200	   54618000	   25.5	   17.9	   1.8	   15.1	  
CCR4-­‐NOT	  transcription	  complex	  subunit	  1	   CNOT1	   35122000	   2652000	   2703900	   849090	   1656200	   1318000	   41.4	   1.6	   2.1	   15.0	  
Upstream-­‐binding	  protein	  1	   UBP1	   405540000	   12572000	   15509000	   14459000	   2714700	   1318000	   28.0	   4.6	   11.8	   14.8	  
Regulation	  of	  nuclear	  pre-­‐mRNA	  domain-­‐containing	  
protein	  2	   RPRD2	   1019300000	   127590000	   71609000	   30459000	   25908000	   12328000	   33.5	   4.9	   5.8	   14.7	  
Exosome	  complex	  exonuclease	  RRP44	   DIS3	   760270000	   41994000	   44406000	   19189000	   22758000	   20505000	   39.6	   1.8	   2.2	   14.5	  
Phosducin-­‐like	  protein	   PDCL	   907980000	   43191000	   15895000	   174310000	   1656200	   1318000	   5.2	   26.1	   12.1	   14.4	  
Plastin-­‐3	   PLS3	   519160000	   102070000	   102650000	   14426000	   21790000	   43668000	   36.0	   4.7	   2.4	   14.3	  
Polyadenylate-­‐binding	  protein	  4	   PABPC4	   17414000	   17504000	   15721000	   849090	   1656200	   1318000	   20.5	   10.6	   11.9	   14.3	  
Bifunctional	   purine	   biosynthesis	   protein	  
PURH;Phosphoribosylaminoimidazolecarboxamide	  
formyltransferase;IMP	  cyclohydrolase	   ATIC	   264220000	   11838000	   11399000	   7626400	   2488800	   3652700	   34.6	   4.8	   3.1	   14.2	  
Serine/threonine-­‐protein	  kinase	  BRSK2	   BRSK2	   30240000	   8807900	   1858200	   849090	   1656200	   1318000	   35.6	   5.3	   1.4	   14.1	  
Transcription	  elongation	  regulator	  1	   TCERG1	   2786700000	   622640000	   365240000	   78145000	   137150000	   196890000	   35.7	   4.5	   1.9	   14.0	  
Asparagine	  synthetase	  [glutamine-­‐hydrolyzing]	   ASNS	   849110000	   21449000	   18425000	   56243000	   1656200	   1318000	   15.1	   13.0	   14.0	   14.0	  
PIH1	  domain-­‐containing	  protein	  1	   PIH1D1	   2352500000	   107120000	   90138000	   103310000	   10397000	   10285000	   22.8	   10.3	   8.8	   13.9	  
Scaffold	  attachment	  factor	  B2	   SAFB2	   416850000	   18436000	   33133000	   88771000	   1656200	   1318000	   4.7	   11.1	   25.1	   13.7	  
Tubulin-­‐specific	  chaperone	  E	   TBCE	   612490000	   8159500	   27775000	   42305000	   1656200	   1318000	   14.5	   4.9	   21.1	   13.5	  
Anamorsin	   CIAPIN1	   5092400000	   305070000	   355650000	   845270000	   17887000	   20543000	   6.0	   17.1	   17.3	   13.5	  
Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  J	   EIF3J	   350990000	   15326000	   8343000	   14270000	   1656200	   1318000	   24.6	   9.3	   6.3	   13.4	  
Mitochondrial	  inner	  membrane	  protein	   IMMT	   25368000	   8478700	   34930000	   849090	   1656200	   6969400	   29.9	   5.1	   5.0	   13.3	  
E3	  ubiquitin-­‐protein	  ligase	  XIAP	   XIAP	   1289000000	   12468000	   9958200	   52131000	   1656200	   1318000	   24.7	   7.5	   7.6	   13.3	  
Echinoderm	  microtubule-­‐associated	  protein-­‐like	  4	   EML4	   16502000	   16996000	   13318000	   849090	   1656200	   1318000	   19.4	   10.3	   10.1	   13.3	  
DNA	  polymerase	  delta	  subunit	  3	   POLD3	   441480000	   27817000	   40928000	   62282000	   16905000	   1318000	   7.1	   1.6	   31.1	   13.3	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Calponin-­‐2	   CNN2	   85498000	   57392000	   4528600	   82212000	   1656200	   1318000	   1.0	   34.7	   3.4	   13.0	  
ATP-­‐dependent	  RNA	  helicase	  DDX42	   DDX42	   1803200000	   109140000	   72964000	   57792000	   19761000	   36789000	   31.2	   5.5	   2.0	   12.9	  
Serpin	  H1	   SERPINH1	   107880000	   18619000	   11760000	   4174300	   1656200	   8623800	   25.8	   11.2	   1.4	   12.8	  
Protein	  EMSY	   EMSY	   1955000000	   143360000	   72931000	   55541000	   65523000	   72541000	   35.2	   2.2	   1.0	   12.8	  
RNA	  polymerase-­‐associated	  protein	  RTF1	  homolog	   RTF1	   371650000	   7989900	   40978000	   180930000	   1656200	   1318000	   2.1	   4.8	   31.1	   12.7	  
Coronin-­‐1B	   CORO1B	   1285000000	   215460000	   142830000	   199240000	   13328000	   9362600	   6.4	   16.2	   15.3	   12.6	  
Heat	  shock	  protein	  105	  kDa	   HSPH1	   2753000000	   43369000	   102460000	   114840000	   6410000	   14579000	   24.0	   6.8	   7.0	   12.6	  
Insulin-­‐like	  growth	  factor	  2	  mRNA-­‐binding	  protein	  2	   IGF2BP2	   578630000	   16088000	   1858200	   21726000	   1656200	   1318000	   26.6	   9.7	   1.4	   12.6	  
Serine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   SARS	   69922000	   27885000	   24813000	   55340000	   1656200	   1318000	   1.3	   16.8	   18.8	   12.3	  
PDZ	  and	  LIM	  domain	  protein	  7	   PDLIM7	   409350000	   12880000	   12985000	   21440000	   1656200	   1318000	   19.1	   7.8	   9.9	   12.2	  
Heterogeneous	  nuclear	  ribonucleoprotein	  D-­‐like	   HNRNPDL	   790620000	   48463000	   45581000	   175580000	   1656200	   17688000	   4.5	   29.3	   2.6	   12.1	  
Nuclear	  protein	  localization	  protein	  4	  homolog	   NPLOC4	   386430000	   31704000	   21204000	   361990000	   1656200	   1318000	   1.1	   19.1	   16.1	   12.1	  
Switch-­‐associated	  protein	  70	   SWAP70	   15438000	   15390000	   33894000	   14113000	   1656200	   1318000	   1.1	   9.3	   25.7	   12.0	  
T-­‐complex	  protein	  1	  subunit	  theta	   CCT8	   80377000000	   18651000000	   17353000000	   5650700000	   1785400000	   1551100000	   14.2	   10.4	   11.2	   12.0	  
RNA-­‐binding	  protein	  Raly	   RALY	   324210000	   22885000	   34494000	   39679000	   17383000	   1318000	   8.2	   1.3	   26.2	   11.9	  
Protein	  Spindly	   SPDL1	   30908000	   28379000	   34895000	   589130000	   3300400	   1318000	   0.1	   8.6	   26.5	   11.7	  
Filamin-­‐A	   FLNA	   30763000000	   14129000000	   12686000000	   2178100000	   1286100000	   1281000000	   14.1	   11.0	   9.9	   11.7	  
Melanoma-­‐associated	  antigen	  D2	   MAGED2	   1887500000	   55258000	   89017000	   86586000	   14669000	   9692000	   21.8	   3.8	   9.2	   11.6	  
Lamin-­‐B1	   LMNB1	   611610000	   205070000	   263520000	   112690000	   8040800	   82753000	   5.4	   25.5	   3.2	   11.4	  
Dynamin-­‐1-­‐like	  protein	   DNM1L	   22167000	   97675	   10392000	   849090	   1656200	   1318000	   26.1	   0.1	   7.9	   11.4	  
Eukaryotic	   translation	   initiation	   factor	   2	   subunit	  
3;Putative	   eukaryotic	   translation	   initiation	   factor	   2	  
subunit	  3-­‐like	  protein	   EIF2S3	   737070	   23804000	   25800000	   12500000	   1656200	   1318000	   0.1	   14.4	   19.6	   11.3	  
Polyadenylate-­‐binding	  protein-­‐interacting	  protein	  1	   PAIP1	   290100000	   97675	   14527000	   12672000	   1656200	   1318000	   22.9	   0.1	   11.0	   11.3	  
Insulin-­‐like	  growth	  factor	  2	  mRNA-­‐binding	  protein	  1	   IGF2BP1	   3262500000	   422820000	   333600000	   300030000	   22457000	   83662000	   10.9	   18.8	   4.0	   11.2	  
Bcl-­‐2-­‐associated	  transcription	  factor	  1	   BCLAF1	   802370000	   12044000	   23668000	   97658000	   1656200	   1318000	   8.2	   7.3	   18.0	   11.1	  
BRCA2	  and	  CDKN1A-­‐interacting	  protein	   BCCIP	   653370000	   21141000	   24728000	   23303000	   14445000	   6753000	   28.0	   1.5	   3.7	   11.1	  
Coatomer	  subunit	  alpha;Xenin;Proxenin	   COPA	   25961000	   97675	   15864000	   849090	   9629500	   7465800	   30.6	   0.0	   2.1	   10.9	  
	   	   Appendices	  
	  
ADP-­‐ribosylation	  factor-­‐binding	  protein	  GGA1	   GGA1	   22451000	   97675	   8128500	   849090	   1656200	   1318000	   26.4	   0.1	   6.2	   10.9	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  12	   PSMD12	   1471400000	   1500500	   19941000	   89318000	   1656200	   1318000	   16.5	   0.9	   15.1	   10.8	  
KH	   domain-­‐containing,	   RNA-­‐binding,	   signal	  
transduction-­‐associated	  protein	  1	   KHDRBS1	   214170000	   97675	   29870000	   23335000	   10055000	   1318000	   9.2	   0.0	   22.7	   10.6	  
Nuclear	  migration	  protein	  nudC	   NUDC	   29029000000	   4247800000	   3294800000	   2255000000	   407670000	   404660000	   12.9	   10.4	   8.1	   10.5	  
Annexin	  A5;Annexin	   ANXA5	   10707000	   70289000	   125290000	   849090	   4335900	   56928000	   12.6	   16.2	   2.2	   10.3	  
Synaptic	  vesicle	  membrane	  protein	  VAT-­‐1	  homolog	   VAT1	   21974000	   65986000	   12535000	   849090	   18421000	   9239400	   25.9	   3.6	   1.4	   10.3	  
Heat	  shock	  70	  kDa	  protein	  4	   HSPA4	   1178300000	   151740000	   117990000	   52925000	   20993000	   92695000	   22.3	   7.2	   1.3	   10.3	  
Peroxiredoxin-­‐6	   PRDX6	   737070	   45990000	   43276000	   172240000	   1656200	   14696000	   0.0	   27.8	   2.9	   10.2	  
Acyl-­‐coenzyme	   A	   thioesterase	   1;Acyl-­‐coenzyme	   A	  
thioesterase	  2,	  mitochondrial	   ACOT1	   35846000	   32400000	   10949000	   12609000	   1656200	   1318000	   2.8	   19.6	   8.3	   10.2	  
Guanine	   nucleotide-­‐binding	   protein	   G(k)	   subunit	  
alpha;Guanine	   nucleotide-­‐binding	   protein	   G(s)	  
subunit	   alpha	   isoforms	   short;Guanine	   nucleotide-­‐
binding	   protein	   G(i)	   subunit	   alpha-­‐2;Guanine	  
nucleotide-­‐binding	   protein	   G(i)	   subunit	   alpha-­‐
1;Guanine	   nucleotide-­‐binding	   protein	   G(o)	   subunit	  
alpha;Guanine	   nucleotide-­‐binding	   protein	   G(olf)	  
subunit	   alpha;Guanine	   nucleotide-­‐binding	   protein	  
G(t)	   subunit	   alpha-­‐2;Guanine	   nucleotide-­‐binding	  
protein	   G(t)	   subunit	   alpha-­‐3;Guanine	   nucleotide-­‐
binding	   protein	   G(t)	   subunit	   alpha-­‐1;Guanine	  
nucleotide-­‐binding	   protein	   G(s)	   subunit	   alpha	  
isoforms	  XLas	   GNAI3	   18897000	   97675	   10948000	   849090	   1656200	   1318000	   22.3	   0.1	   8.3	   10.2	  
Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  M	   EIF3M	   22828000	   2872600	   3152300	   849090	   2585100	   1318000	   26.9	   1.1	   2.4	   10.1	  
Annexin	  A6;Annexin	   ANXA6	   737070	   20339000	   22325000	   849090	   1656200	   1318000	   0.9	   12.3	   16.9	   10.0	  
Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX41	   DDX41	   99520000	   10954000	   1858200	   4521500	   1656200	   1318000	   22.0	   6.6	   1.4	   10.0	  
RuvB-­‐like	  2	   RUVBL2	   1522500000	   16003000	   63186000	   83260000	   7724500	   6728700	   18.3	   2.1	   9.4	   9.9	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Serine	   hydroxymethyltransferase,	  
mitochondrial;Serine	  hydroxymethyltransferase	   SHMT2	   737070	   42823000	   17669000	   849090	   1656200	   6184700	   0.9	   25.9	   2.9	   9.9	  
RNA-­‐binding	  protein	  12	   RBM12	   659800000	   97675	   8816300	   29193000	   1656200	   1318000	   22.6	   0.1	   6.7	   9.8	  
Nucleoprotein	  TPR	   TPR	   604920000	   17984000	   25528000	   27745000	   4439800	   7364400	   21.8	   4.1	   3.5	   9.8	  
Signal	  recognition	  particle	  subunit	  SRP72	   SRP72	   375510000	   12950000	   18546000	   51684000	   1656200	   1318000	   7.3	   7.8	   14.1	   9.7	  
H/ACA	  ribonucleoprotein	  complex	  non-­‐core	  subunit	  
NAF1	   NAF1	   84853000	   4330300	   1858200	   3378800	   1656200	   1318000	   25.1	   2.6	   1.4	   9.7	  
Nuclear-­‐interacting	  partner	  of	  ALK	   ZC3HC1	   394730000	   8013700	   5923100	   19967000	   1656200	   1318000	   19.8	   4.8	   4.5	   9.7	  




carboxylase	   PAICS	   2500600000	   530460000	   569190000	   120160000	   133860000	   140700000	   20.8	   4.0	   4.0	   9.6	  
Heterogeneous	  nuclear	  ribonucleoprotein	  K	   HNRNPK	   67156000	   40946000	   1858200	   32962000	   1656200	   1318000	   2.0	   24.7	   1.4	   9.4	  
Nuclear	  pore	  glycoprotein	  p62	   NUP62	   1054600000	   7050500	   6845100	   56428000	   1656200	   1318000	   18.7	   4.3	   5.2	   9.4	  
U5	   small	   nuclear	   ribonucleoprotein	   200	   kDa	  
helicase	   SNRNP200	   228300000	   45452000	   55599000	   10045000	   22458000	   17514000	   22.7	   2.0	   3.2	   9.3	  
Uncharacterized	  protein	  CXorf57	   CXorf57	   55489000	   5991300	   9797800	   2441800	   1656200	   6331700	   22.7	   3.6	   1.5	   9.3	  
Immunoglobulin-­‐binding	  protein	  1	   IGBP1	   520250000	   10802000	   21557000	   107000000	   1656200	   1318000	   4.9	   6.5	   16.4	   9.2	  
Plasminogen	   activator	   inhibitor	   1	   RNA-­‐binding	  
protein	   SERBP1	   12756000000	   507360000	   494520000	   768620000	   164560000	   61771000	   16.6	   3.1	   8.0	   9.2	  
HIV	  Tat-­‐specific	  factor	  1	   HTATSF1	   1847400000	   200220000	   114950000	   154570000	   54645000	   9524500	   12.0	   3.7	   12.1	   9.2	  
Phosphoribosyl	  pyrophosphate	  synthase-­‐associated	  
protein	  2	   PRPSAP2	   15797000	   14066000	   1858200	   849090	   1656200	   3296400	   18.6	   8.5	   0.6	   9.2	  
Microtubule-­‐associated	   protein	   RP/EB	   family	  
member	  2	   MAPRE2	   3653100000	   518670000	   334150000	   323510000	   157250000	   25655000	   11.3	   3.3	   13.0	   9.2	  
N6-­‐adenosine-­‐methyltransferase	  70	  kDa	  subunit	   METTL3	   95547000	   31778000	   31707000	   123970000	   11656000	   1318000	   0.8	   2.7	   24.1	   9.2	  
Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  D	   EIF3D	   266820000	   15626000	   17281000	   54385000	   1656200	   1318000	   4.9	   9.4	   13.1	   9.2	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Vimentin	   VIM	   31943000000	   1760000000	   2503400000	   1669700000	   352010000	   785990000	   19.1	   5.0	   3.2	   9.1	  
Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX6	   DDX6	   720930000	   13592000	   11137000	   71173000	   1656200	   1318000	   10.1	   8.2	   8.4	   8.9	  
Zinc	  finger	  CCCH	  domain-­‐containing	  protein	  11A	   ZC3H11A	   9200300000	   1270700000	   846170000	   425730000	   488970000	   384760000	   21.6	   2.6	   2.2	   8.8	  
Cell	  division	  cycle	  protein	  27	  homolog	   CDC27	   354010000	   8353600	   1858200	   17850000	   1656200	   1318000	   19.8	   5.0	   1.4	   8.8	  
Arginine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   RARS	   566770000	   665920000	   420120000	   109410000	   48439000	   57312000	   5.2	   13.7	   7.3	   8.8	  
Ubiquitin	   carboxyl-­‐terminal	   hydrolase	   7;Ubiquitin	  
carboxyl-­‐terminal	  hydrolase	   USP7	   624130000	   52224000	   42059000	   29279000	   17163000	   23022000	   21.3	   3.0	   1.8	   8.7	  
AP-­‐3	  complex	  subunit	  delta-­‐1	   AP3D1	   16632000	   8013000	   1858200	   849090	   1656200	   1318000	   19.6	   4.8	   1.4	   8.6	  
BRISC	  and	  BRCA1-­‐A	  complex	  member	  1	   BABAM1	   361950000	   97675	   23725000	   47653000	   1656200	   1318000	   7.6	   0.1	   18.0	   8.6	  
Serine/threonine-­‐protein	   phosphatase	   PP1-­‐alpha	  
catalytic	   subunit;Serine/threonine-­‐protein	  
phosphatase	   PPP1CA	   319360000	   23963000	   7370300	   58539000	   1656200	   1318000	   5.5	   14.5	   5.6	   8.5	  
DnaJ	  homolog	  subfamily	  C	  member	  13	   DNAJC13	   18202000	   4210200	   1858200	   849090	   1656200	   1318000	   21.4	   2.5	   1.4	   8.5	  
Cyclin-­‐dependent	   kinase	   11B;Cyclin-­‐dependent	  
kinase	  11A	   CDK11B	   2056400000	   27094000	   1858200	   271260000	   1656200	   1318000	   7.6	   16.4	   1.4	   8.4	  
SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	  
regulator	  of	  chromatin	  subfamily	  E	  member	  1	   SMARCE1	   1701100000	   7148100	   13524000	   124950000	   4966900	   1318000	   13.6	   1.4	   10.3	   8.4	  
Small	  acidic	  protein	   SMAP	   74302000	   54726000	   70684000	   8390100	   17750000	   5303700	   8.9	   3.1	   13.3	   8.4	  
YEATS	  domain-­‐containing	  protein	  2	   YEATS2	   1984000000	   43628000	   54381000	   92069000	   20819000	   42672000	   21.5	   2.1	   1.3	   8.3	  
Charged	  multivesicular	  body	  protein	  4b	   CHMP4B	   1333500000	   27192000	   24819000	   295610000	   17266000	   1318000	   4.5	   1.6	   18.8	   8.3	  
COP9	  signalosome	  complex	  subunit	  5	   COPS5	   436890000	   9250700	   7026000	   31734000	   1656200	   1318000	   13.8	   5.6	   5.3	   8.2	  
T-­‐complex	  protein	  1	  subunit	  delta	   CCT4	   123270000	   108080000	   83327000	   6982600	   36375000	   23473000	   17.7	   3.0	   3.5	   8.1	  
PDZ	  and	  LIM	  domain	  protein	  1	   PDLIM1	   9214900000	   1995300000	   2024800000	   1049000000	   281580000	   251560000	   8.8	   7.1	   8.0	   8.0	  
26S	  protease	  regulatory	  subunit	  8	   PSMC5	   450810000	   23864000	   1858200	   56485000	   1656200	   1318000	   8.0	   14.4	   1.4	   7.9	  
ATP-­‐binding	  cassette	  sub-­‐family	  E	  member	  1	   ABCE1	   17630000	   97675	   3455200	   849090	   1656200	   1318000	   20.8	   0.1	   2.6	   7.8	  
ADP-­‐sugar	  pyrophosphatase	   NUDT5	   130120000	   388680000	   458910000	   10759000	   77073000	   78695000	   12.1	   5.0	   5.8	   7.7	  
Mitotic	  checkpoint	  protein	  BUB3	   BUB3	   737070	   15010000	   17965000	   4832800	   1656200	   1318000	   0.2	   9.1	   13.6	   7.6	  
Plasma	   membrane	   calcium-­‐transporting	   ATPase	   ATP2B1	   13803000	   8528600	   1858200	   849090	   1656200	   1318000	   16.3	   5.1	   1.4	   7.6	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1;Plasma	  membrane	  calcium-­‐transporting	  ATPase	  4	  
Calmodulin-­‐regulated	  spectrin-­‐associated	  protein	  2	   CAMSAP2	   15689000	   4551100	   1858200	   849090	   1656200	   1318000	   18.5	   2.7	   1.4	   7.5	  
PC4	  and	  SFRS1-­‐interacting	  protein	   PSIP1	   228830000	   21238000	   16533000	   28576000	   11093000	   1318000	   8.0	   1.9	   12.5	   7.5	  
Serine/arginine-­‐rich	  splicing	  factor	  11	   SRSF11	   11834000	   10380000	   8100300	   849090	   1656200	   3665400	   13.9	   6.3	   2.2	   7.5	  
Pericentriolar	  material	  1	  protein	   PCM1	   214190000	   97675	   12544000	   16970000	   1656200	   1318000	   12.6	   0.1	   9.5	   7.4	  
Bromodomain-­‐containing	  protein	  4	   BRD4	   622630000	   38129000	   28978000	   32731000	   44728000	   12883000	   19.0	   0.9	   2.2	   7.4	  
WD	   repeat	   domain	   phosphoinositide-­‐interacting	  
protein	  2	   WIPI2	   737070	   26925000	   6309000	   849090	   1656200	   1318000	   0.9	   16.3	   4.8	   7.3	  
Exportin-­‐5	   XPO5	   11058000	   12171000	   1858200	   849090	   1656200	   1318000	   13.0	   7.3	   1.4	   7.3	  
Peptidyl-­‐prolyl	   cis-­‐trans	   isomerase	   FKBP4;Peptidyl-­‐
prolyl	   cis-­‐trans	   isomerase	   FKBP4,	   N-­‐terminally	  
processed	   FKBP4	   1282700000	   57244000	   48197000	   70232000	   42543000	   23108000	   18.3	   1.3	   2.1	   7.2	  
Calponin-­‐3	   CNN3	   10088000000	   1711900000	   1647700000	   1355900000	   289410000	   201180000	   7.4	   5.9	   8.2	   7.2	  
BRCA1-­‐associated	  protein	   BRAP	   151410000	   5875300	   5165500	   10964000	   1656200	   1318000	   13.8	   3.5	   3.9	   7.1	  
Tubulin	  alpha-­‐4A	  chain	   TUBA4A	   254900000	   32025000	   32944000	   29812000	   6178100	   4370700	   8.6	   5.2	   7.5	   7.1	  
Cyclin-­‐dependent	  kinase	  2	   CDK2	   410940000	   49592000	   18685000	   129080000	   13079000	   1318000	   3.2	   3.8	   14.2	   7.1	  
Double-­‐strand	  break	  repair	  protein	  MRE11	   MRE11	   3072900000	   395960000	   422060000	   257830000	   114920000	   73574000	   11.9	   3.4	   5.7	   7.0	  
Insulin-­‐like	  growth	  factor	  2	  mRNA-­‐binding	  protein	  3	   IGF2BP3	   256350000	   27358000	   24890000	   36188000	   3110400	   4886700	   7.1	   8.8	   5.1	   7.0	  
Pogo	  transposable	  element	  with	  ZNF	  domain	   POGZ	   326430000	   10526000	   1858200	   22702000	   1656200	   20183000	   14.4	   6.4	   0.1	   6.9	  
DNA	  primase	  large	  subunit	   PRIM2	   1298700000	   8382500	   5557800	   113210000	   1656200	   1318000	   11.5	   5.1	   4.2	   6.9	  
Signal	  transducing	  adapter	  molecule	  1	   STAM	   951870000	   10578000	   1858200	   73840000	   1656200	   1318000	   12.9	   6.4	   1.4	   6.9	  
Guanine	  nucleotide-­‐binding	  protein-­‐like	  3	   GNL3	   70538000	   15645000	   1858200	   7182300	   1656200	   1318000	   9.8	   9.4	   1.4	   6.9	  
AP-­‐1	  complex	  subunit	  beta-­‐1	   AP1B1	   364770000	   97675	   22529000	   20899000	   1656200	   7708900	   17.5	   0.1	   2.9	   6.8	  
Dihydrolipoyllysine-­‐residue	   succinyltransferase	  
component	   of	   2-­‐oxoglutarate	   dehydrogenase	  
complex,	  mitochondrial	   DLST	   12297000	   97675	   23491000	   4859000	   1656200	   1318000	   2.5	   0.1	   17.8	   6.8	  
Stromal	  membrane-­‐associated	  protein	  2	   SMAP2	   261070000	   97675	   11658000	   22802000	   1656200	   1318000	   11.4	   0.1	   8.8	   6.8	  
Kanadaptin	   SLC4A1AP	   1894600000	   39209000	   43341000	   116480000	   21097000	   20885000	   16.3	   1.9	   2.1	   6.7	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Poly(U)-­‐binding-­‐splicing	  factor	  PUF60	   PUF60	   702670000	   54195000	   68643000	   72824000	   21045000	   8662600	   9.6	   2.6	   7.9	   6.7	  
Stress-­‐induced-­‐phosphoprotein	  1	   STIP1	   565300000	   21488000	   18737000	   34921000	   7862400	   18200000	   16.2	   2.7	   1.0	   6.7	  
60S	   acidic	   ribosomal	   protein	   P0;60S	   acidic	  
ribosomal	  protein	  P0-­‐like	   RPLP0	   833170000	   108950000	   107500000	   120230000	   9774300	   63097000	   6.9	   11.1	   1.7	   6.6	  
Mitogen-­‐activated	   protein	   kinase	   9;Mitogen-­‐
activated	  protein	  kinase	  10	   MAPK9	   1059800000	   11203000	   7446200	   153090000	   1656200	   1318000	   6.9	   6.8	   5.6	   6.4	  
GTP-­‐binding	  nuclear	  protein	  Ran	   RAN	   737070	   24833000	   159760000	   66123000	   1656200	   36997000	   0.0	   15.0	   4.3	   6.4	  
Negative	  elongation	  factor	  E	   NELFE	   572420000	   63927000	   44036000	   190310000	   14236000	   3777700	   3.0	   4.5	   11.7	   6.4	  
Biliverdin	  reductase	  A	   BLVRA	   90766000	   97675	   8316200	   7127300	   1656200	   1318000	   12.7	   0.1	   6.3	   6.4	  
ATP-­‐citrate	  synthase	   ACLY	   33664000	   25888000	   13216000	   2185400	   8423100	   24617000	   15.4	   3.1	   0.5	   6.3	  
DnaJ	  homolog	  subfamily	  C	  member	  7	   DNAJC7	   554050000	   5750900	   5658900	   49445000	   1656200	   1318000	   11.2	   3.5	   4.3	   6.3	  
Nuclear	  pore	  complex	  protein	  Nup133	   NUP133	   433160000	   7258700	   25972000	   28151000	   7151700	   10379000	   15.4	   1.0	   2.5	   6.3	  
Serine-­‐threonine	  kinase	  receptor-­‐associated	  protein	   STRAP	   4081000000	   290580000	   252030000	   575100000	   42139000	   58045000	   7.1	   6.9	   4.3	   6.1	  
Transcription	  intermediary	  factor	  1-­‐beta	   TRIM28	   7039700000	   283990000	   252600000	   502510000	   160820000	   104260000	   14.0	   1.8	   2.4	   6.1	  
5-­‐3	  exoribonuclease	  2	   XRN2	   6816400	   97675	   13292000	   849090	   4812300	   1318000	   8.0	   0.0	   10.1	   6.0	  
Puromycin-­‐sensitive	  aminopeptidase	   NPEPPS	   12264000	   15226000	   1858200	   849090	   4393600	   29959000	   14.4	   3.5	   0.1	   6.0	  
Hydroxyacyl-­‐coenzyme	   A	   dehydrogenase,	  
mitochondrial	   HADH	   10565000	   97675	   7176600	   849090	   2881800	   1318000	   12.4	   0.0	   5.4	   6.0	  
FACT	  complex	  subunit	  SPT16	   SUPT16H	   108400000	   44250000	   42304000	   7312800	   18709000	   58329000	   14.8	   2.4	   0.7	   6.0	  
Lamina-­‐associated	   polypeptide	   2,	   isoforms	  
beta/gamma;Thymopoietin;Thymopentin	   TMPO	   2473600000	   306500000	   309280000	   276460000	   78723000	   63670000	   8.9	   3.9	   4.9	   5.9	  
Splicing	  factor	  3B	  subunit	  2	   SF3B2	   6279400000	   311360000	   304440000	   800680000	   55736000	   71799000	   7.8	   5.6	   4.2	   5.9	  
Serine/threonine-­‐protein	  phosphatase	  6	   regulatory	  
subunit	  2	   PPP6R2	   801560000	   10739000	   12980000	   601760000	   1656200	   1318000	   1.3	   6.5	   9.8	   5.9	  
Importin-­‐5	   IPO5	   8655600	   33030000	   12202000	   849090	   5048400	   14921000	   10.2	   6.5	   0.8	   5.9	  
Nuclear	  pore	  complex	  protein	  Nup50	   NUP50	   2089900000	   201710000	   267160000	   327790000	   29571000	   62779000	   6.4	   6.8	   4.3	   5.8	  
RNA-­‐binding	  protein	  26	   RBM26	   7138300000	   627450000	   552090000	   495810000	   319300000	   521650000	   14.4	   2.0	   1.1	   5.8	  
Tubulin	  alpha-­‐1B	  chain	   TUBA1B	   63537000000	   7299700000	   7483000000	   6918900000	   1574800000	   2099700000	   9.2	   4.6	   3.6	   5.8	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Kinesin-­‐like	  protein	  KIF1A	   KIF1A	   12726000	   97675	   3025400	   849090	   1656200	   1318000	   15.0	   0.1	   2.3	   5.8	  
Zinc	  finger	  protein	  318	   ZNF318	   1264200000	   100030000	   100280000	   113050000	   33174000	   45476000	   11.2	   3.0	   2.2	   5.5	  
Hepatoma-­‐derived	  growth	  factor	   HDGF	   225550000	   97675	   18747000	   111760000	   1656200	   1318000	   2.0	   0.1	   14.2	   5.4	  
Mediator	  of	  DNA	  damage	  checkpoint	  protein	  1	   MDC1	   4023200000	   793840000	   800170000	   572430000	   177830000	   167640000	   7.0	   4.5	   4.8	   5.4	  
Heterogeneous	  nuclear	  ribonucleoprotein	  Q	   SYNCRIP	   406210000	   37195000	   79118000	   38262000	   11871000	   33489000	   10.6	   3.1	   2.4	   5.4	  
Vinculin	   VCL	   193790000	   14547000	   14297000	   30524000	   1656200	   14983000	   6.3	   8.8	   1.0	   5.4	  
Ribonucleoside-­‐diphosphate	  reductase	  subunit	  M2	   RRM2	   24306000	   2513600	   4113200	   2123500	   1656200	   1318000	   11.4	   1.5	   3.1	   5.4	  
40S	  ribosomal	  protein	  SA	   RPSA	   404720000	   55699000	   45894000	   265320000	   4669200	   18293000	   1.5	   11.9	   2.5	   5.3	  
Parafibromin	   CDC73	   846440000	   13897000	   14347000	   154480000	   1656200	   7080400	   5.5	   8.4	   2.0	   5.3	  
RuvB-­‐like	  1	   RUVBL1	   37936000000	   3625300000	   3320600000	   4259400000	   991680000	   1008200000	   8.9	   3.7	   3.3	   5.3	  
T-­‐complex	  protein	  1	  subunit	  beta	   CCT2	   449950000	   83207000	   57682000	   39732000	   23897000	   55687000	   11.3	   3.5	   1.0	   5.3	  
Protein	  disulfide-­‐isomerase	  A3	   PDIA3	   909490000	   178720000	   203930000	   87149000	   64985000	   77485000	   10.4	   2.8	   2.6	   5.3	  
Pyruvate	  kinase	  PKM	   PKM	   3281700000	   741200000	   805970000	   327590000	   198830000	   404710000	   10.0	   3.7	   2.0	   5.2	  
Peptidylprolyl	   isomerase	   domain	   and	   WD	   repeat-­‐
containing	  protein	  1	   PPWD1	   107150000	   5152800	   1858200	   9761600	   1656200	   1318000	   11.0	   3.1	   1.4	   5.2	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  6	   PSMD6	   28397000	   19171000	   22851000	   15565000	   1656200	   11068000	   1.8	   11.6	   2.1	   5.2	  
Serine/threonine-­‐protein	   phosphatase	  
5;Serine/threonine-­‐protein	  phosphatase	   PPP5C	   737070	   6873700	   13662000	   849090	   1656200	   1318000	   0.9	   4.2	   10.4	   5.1	  
Serine/threonine-­‐protein	  phosphatase	  4	   regulatory	  
subunit	  3A	   SMEK1	   3716100000	   337840000	   221430000	   379760000	   115260000	   84728000	   9.8	   2.9	   2.6	   5.1	  
Elongation	   factor	   1-­‐alpha	   1;Putative	   elongation	  
factor	  1-­‐alpha-­‐like	  3	   EEF1A1	   48440000000	   11085000000	   12165000000	   7991500000	   2365900000	   2663000000	   6.1	   4.7	   4.6	   5.1	  
PDZ	  and	  LIM	  domain	  protein	  3	   PDLIM3	   4955400000	   630370000	   499760000	   1092700000	   138000000	   80819000	   4.5	   4.6	   6.2	   5.1	  
Actin-­‐binding	  protein	  anillin	   ANLN	   3043400000	   223340000	   122340000	   285890000	   97685000	   52771000	   10.6	   2.3	   2.3	   5.1	  
Calcyclin-­‐binding	  protein	   CACYBP	   737070	   211760000	   223470000	   849090	   25008000	   37979000	   0.9	   8.5	   5.9	   5.1	  
F-­‐actin-­‐capping	  protein	  subunit	  alpha-­‐1	   CAPZA1	   267540000	   97675	   10393000	   37713000	   1656200	   1318000	   7.1	   0.1	   7.9	   5.0	  
Inorganic	  pyrophosphatase	   PPA1	   35746000	   14613000	   13050000	   7515500	   1656200	   9393800	   4.8	   8.8	   1.4	   5.0	  
SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐dependent	   SMARCA5	   1774600000	   274280000	   171260000	   220400000	   61707000	   71049000	   8.1	   4.4	   2.4	   5.0	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regulator	  of	  chromatin	  subfamily	  A	  member	  5	  
Cell	  division	  cycle	  5-­‐like	  protein	   CDC5L	   946380000	   41466000	   69487000	   79599000	   70746000	   29676000	   11.9	   0.6	   2.3	   4.9	  
Chloride	  intracellular	  channel	  protein	  1	   CLIC1	   39728000	   75712000	   182390000	   7597000	   13555000	   46077000	   5.2	   5.6	   4.0	   4.9	  
UBX	  domain-­‐containing	  protein	  7	   UBXN7	   779490000	   9964400	   6386900	   93255000	   6673700	   1318000	   8.4	   1.5	   4.8	   4.9	  
CWF19-­‐like	  protein	  1	   CWF19L1	   521940000	   97675	   12959000	   112710000	   1656200	   1318000	   4.6	   0.1	   9.8	   4.8	  
TAR	  DNA-­‐binding	  protein	  43	   TARDBP	   1613500000	   157900000	   166180000	   379630000	   28386000	   35821000	   4.3	   5.6	   4.6	   4.8	  
Glutaredoxin-­‐3	   GLRX3	   208480000	   3337500	   1858200	   19058000	   1656200	   1318000	   10.9	   2.0	   1.4	   4.8	  
Craniofacial	  development	  protein	  1	   CFDP1	   621250000	   92733000	   151670000	   315010000	   118020000	   13294000	   2.0	   0.8	   11.4	   4.7	  
Acyl-­‐CoA	  synthetase	  family	  member	  4	   AASDH	   8323900	   4595800	   1858200	   849090	   1656200	   1318000	   9.8	   2.8	   1.4	   4.7	  
Serine/threonine-­‐protein	  kinase	  38	   STK38	   2379700000	   140870000	   132200000	   488160000	   25985000	   36631000	   4.9	   5.4	   3.6	   4.6	  
Splicing	  factor,	  arginine/serine-­‐rich	  15	   SCAF4	   199850000	   9462000	   5479500	   50139000	   1656200	   1318000	   4.0	   5.7	   4.2	   4.6	  
UV	  excision	  repair	  protein	  RAD23	  homolog	  B	   RAD23B	   229560000	   4110000	   4074200	   27715000	   1656200	   1318000	   8.3	   2.5	   3.1	   4.6	  
Coiled-­‐coil	  domain-­‐containing	  protein	  174	   CCDC174	   762270000	   34433000	   13281000	   351700000	   22588000	   1318000	   2.2	   1.5	   10.1	   4.6	  
Histone-­‐lysine	   N-­‐methyltransferase	   2A;MLL	  
cleavage	  product	  N320;MLL	  cleavage	  product	  C180	   KMT2A	   300650000	   3083300	   2829500	   31037000	   1656200	   1318000	   9.7	   1.9	   2.1	   4.6	  
Transcription	  initiation	  factor	  TFIID	  subunit	  6	   TAF6	   662420000	   97675	   24568000	   73230000	   12348000	   5304900	   9.0	   0.0	   4.6	   4.6	  
Unconventional	  prefoldin	  RPB5	  interactor	  1	   URI1	   7307700	   97675	   6566100	   849090	   1656200	   1318000	   8.6	   0.1	   5.0	   4.5	  
Histone	  acetyltransferase	  type	  B	  catalytic	  subunit	   HAT1	   258560000	   136060000	   127470000	   132500000	   20631000	   25195000	   2.0	   6.6	   5.1	   4.5	  
T-­‐complex	  protein	  1	  subunit	  eta	   CCT7	   326740000	   45271000	   58213000	   32333000	   18901000	   80081000	   10.1	   2.4	   0.7	   4.4	  
Peroxisomal	   multifunctional	   enzyme	   type	   2;(3R)-­‐
hydroxyacyl-­‐CoA	   dehydrogenase;Enoyl-­‐CoA	  
hydratase	  2	   HSD17B4	   4064800	   4597700	   7381600	   849090	   1656200	   1318000	   4.8	   2.8	   5.6	   4.4	  
Signal	  transducer	  and	  activator	  of	  transcription	  3	   STAT3	   2012500000	   8267500	   21593000	   351210000	   1656200	   8968700	   5.7	   5.0	   2.4	   4.4	  
Isocitrate	  dehydrogenase	  [NADP]	  cytoplasmic	   IDH1	   447740000	   5117800	   1858200	   53587000	   1656200	   1318000	   8.4	   3.1	   1.4	   4.3	  
Nuclear	  autoantigenic	  sperm	  protein	   NASP	   13326000000	   2874300000	   1958300000	   1856700000	   858670000	   921890000	   7.2	   3.3	   2.1	   4.2	  
Hsc70-­‐interacting	   protein;Putative	   protein	  
FAM10A4;Putative	  protein	  FAM10A5	   ST13	   163450000	   55213000	   60192000	   43361000	   8675000	   27236000	   3.8	   6.4	   2.2	   4.1	  
Heterogeneous	  nuclear	  ribonucleoprotein	  L	   HNRNPL	   3414400000	   304880000	   450080000	   554340000	   128080000	   120830000	   6.2	   2.4	   3.7	   4.1	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Nuclear	  receptor-­‐binding	  factor	  2	   NRBF2	   200950000	   14512000	   1858200	   99163000	   1656200	   1318000	   2.0	   8.8	   1.4	   4.1	  
5-­‐nucleotidase	  domain-­‐containing	  protein	  1	   NT5DC1	   668960000	   17677000	   17274000	   104430000	   7031100	   5318300	   6.4	   2.5	   3.2	   4.1	  
Poly(rC)-­‐binding	  protein	  2	   PCBP2	   3207700000	   524140000	   611120000	   537630000	   186870000	   187450000	   6.0	   2.8	   3.3	   4.0	  
Heterogeneous	  nuclear	  ribonucleoprotein	  A3	   HNRNPA3	   1942300000	   156260000	   54348000	   875460000	   61316000	   7571000	   2.2	   2.5	   7.2	   4.0	  
Uncharacterized	  protein	  GPALPP1	   GPALPP1	   177440000	   12167000	   1858200	   56093000	   1656200	   1318000	   3.2	   7.3	   1.4	   4.0	  
Apoptosis-­‐inducing	  factor	  1,	  mitochondrial	   AIFM1	   737070	   11338000	   5454100	   849090	   1656200	   1318000	   0.9	   6.8	   4.1	   4.0	  
Heterogeneous	  nuclear	  ribonucleoprotein	  U	   HNRNPU	   4377900000	   883700000	   1071900000	   579190000	   326640000	   678100000	   7.6	   2.7	   1.6	   3.9	  
Aspartate	   aminotransferase,	  
mitochondrial;Aspartate	  aminotransferase	   GOT2	   33220000	   65700000	   70385000	   4032800	   32202000	   66086000	   8.2	   2.0	   1.1	   3.8	  
Ubiquitin-­‐conjugating	  enzyme	  E2	  O	   UBE2O	   5568900	   4063200	   3064300	   849090	   1656200	   1318000	   6.6	   2.5	   2.3	   3.8	  
Calnexin	   CANX	   161860000	   33103000	   19750000	   28381000	   9135400	   9950700	   5.7	   3.6	   2.0	   3.8	  
Vacuolar	   protein	   sorting-­‐associated	   protein	   72	  
homolog	   VPS72	   359360000	   97675	   4799600	   48076000	   1656200	   1318000	   7.5	   0.1	   3.6	   3.7	  
Eukaryotic	  translation	  initiation	  factor	  3	  subunit	  A	   EIF3A	   87568000	   48206000	   7928400	   19196000	   9088600	   8297300	   4.6	   5.3	   1.0	   3.6	  
Protein	  phosphatase	  1G	   PPM1G	   609960000	   83701000	   17607000	   91140000	   25695000	   24530000	   6.7	   3.3	   0.7	   3.6	  
Rac	  GTPase-­‐activating	  protein	  1	   RACGAP1	   206410000	   9350700	   1858200	   57858000	   1656200	   1318000	   3.6	   5.6	   1.4	   3.5	  
Spliceosome	  RNA	  helicase	  DDX39B	   DDX39B	   1674500000	   233360000	   226930000	   284420000	   100380000	   97988000	   5.9	   2.3	   2.3	   3.5	  
DNA	  fragmentation	  factor	  subunit	  alpha	   DFFA	   548620000	   18431000	   12164000	   77391000	   8049500	   11718000	   7.1	   2.3	   1.0	   3.5	  
Protein	  KNL1	   KNL1	   627270000	   22840000	   7775800	   300850000	   9639200	   1318000	   2.1	   2.4	   5.9	   3.5	  
Acidic	   leucine-­‐rich	   nuclear	   phosphoprotein	   32	  
family	  member	  E	   ANP32E	   1101300000	   48194000	   22526000	   167190000	   16160000	   37086000	   6.6	   3.0	   0.6	   3.4	  
Far	  upstream	  element-­‐binding	  protein	  2	   KHSRP	   1135100000	   223090000	   148110000	   172100000	   92329000	   140620000	   6.6	   2.4	   1.1	   3.4	  
Nuclear	  receptor	  coactivator	  6	   NCOA6	   256060000	   3317700	   2672200	   35751000	   3867600	   1318000	   7.2	   0.9	   2.0	   3.3	  
Voltage-­‐dependent	  anion-­‐selective	   channel	  protein	  
1	   VDAC1	   127590000	   30376000	   89437000	   21087000	   35575000	   29215000	   6.1	   0.9	   3.1	   3.3	  
Poly(rC)-­‐binding	  protein	  1	   PCBP1	   2682300000	   1306900000	   1118300000	   1299000000	   294750000	   324170000	   2.1	   4.4	   3.4	   3.3	  
Suppressor	  of	  G2	  allele	  of	  SKP1	  homolog	   SUGT1	   2575600000	   133870000	   938050000	   456810000	   202350000	   258130000	   5.6	   0.7	   3.6	   3.3	  
Polyadenylate-­‐binding	  protein	  1	   PABPC1	   373250000	   260660000	   162780000	   621220000	   40030000	   58143000	   0.6	   6.5	   2.8	   3.3	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Interleukin	  enhancer-­‐binding	  factor	  2	   ILF2	   42930000	   117190000	   119860000	   7644900	   38896000	   101990000	   5.6	   3.0	   1.2	   3.3	  
Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase-­‐like	  4	   PPIL4	   1902600000	   68365000	   27155000	   542950000	   13624000	   21994000	   3.5	   5.0	   1.2	   3.3	  
Lysine-­‐specific	  demethylase	  3B	   KDM3B	   313880000	   3290800	   3886100	   42361000	   1656200	   12067000	   7.4	   2.0	   0.3	   3.2	  
Aconitate	  hydratase,	  mitochondrial	   ACO2	   120180000	   10871000	   31541000	   117800000	   1656200	   14962000	   1.0	   6.6	   2.1	   3.2	  
Kinesin-­‐like	  protein	  KIF23	   KIF23	   516280000	   3520600	   7535900	   162230000	   5214400	   1318000	   3.2	   0.7	   5.7	   3.2	  
Synaptojanin-­‐1	   SYNJ1	   5220400	   3309000	   1858200	   849090	   1656200	   1318000	   6.1	   2.0	   1.4	   3.2	  
ATP-­‐dependent	  RNA	  helicase	  DDX39A	   DDX39A	   56909000	   97675	   7009400	   13996000	   1656200	   1318000	   4.1	   0.1	   5.3	   3.1	  
Importin-­‐7	   IPO7	   654360000	   70481000	   75835000	   113230000	   34774000	   47794000	   5.8	   2.0	   1.6	   3.1	  
Cyclin-­‐dependent	  kinase	  7	   CDK7	   362260000	   97675	   6392600	   80988000	   1656200	   1318000	   4.5	   0.1	   4.9	   3.1	  
Ran-­‐binding	  protein	  3	   RANBP3	   1331600000	   215990000	   166220000	   867360000	   48098000	   49839000	   1.5	   4.5	   3.3	   3.1	  
Heat	  shock	  protein	  HSP	  90-­‐beta	   HSP90AB1	   3949100000	   1779200000	   1835400000	   701690000	   801400000	   1236900000	   5.6	   2.2	   1.5	   3.1	  
Transferrin	   receptor	   protein	   1;Transferrin	   receptor	  
protein	  1,	  serum	  form	   TFRC	   6100200	   97675	   2642500	   849090	   1656200	   1318000	   7.2	   0.1	   2.0	   3.1	  
Four	  and	  a	  half	  LIM	  domains	  protein	  1	   FHL1	   878150000	   47935000	   193020000	   178020000	   51777000	   59480000	   4.9	   0.9	   3.2	   3.0	  
Ubiquitin	  fusion	  degradation	  protein	  1	  homolog	   UFD1	   85487000	   3788700	   1858200	   16022000	   1656200	   1318000	   5.3	   2.3	   1.4	   3.0	  
Eukaryotic	  initiation	  factor	  4A-­‐I	   EIF4A1	   882820000	   233030000	   196920000	   393110000	   42716000	   147890000	   2.2	   5.5	   1.3	   3.0	  
Heterogeneous	  nuclear	  ribonucleoprotein	  A0	   HNRNPA0	   1252000000	   45047000	   54031000	   293250000	   16069000	   28628000	   4.3	   2.8	   1.9	   3.0	  
Putative	   pre-­‐mRNA-­‐splicing	   factor	   ATP-­‐dependent	  
RNA	  helicase	  DHX16	   DHX16	   54510000	   5459200	   1858200	   13013000	   1656200	   1318000	   4.2	   3.3	   1.4	   3.0	  
Heterogeneous	  nuclear	  ribonucleoprotein	  M	   HNRNPM	   3326200000	   778080000	   769530000	   1223600000	   209600000	   316460000	   2.7	   3.7	   2.4	   3.0	  
Polypyrimidine	  tract-­‐binding	  protein	  1	   PTBP1	   1274500000	   257560000	   318940000	   277680000	   85405000	   260190000	   4.6	   3.0	   1.2	   2.9	  
Crk-­‐like	  protein	   CRKL	   444250000	   83862000	   69140000	   499580000	   16131000	   25309000	   0.9	   5.2	   2.7	   2.9	  
Importin	  subunit	  alpha-­‐1	   KPNA2	   91339000	   9761200	   38985000	   16309000	   11512000	   16927000	   5.6	   0.8	   2.3	   2.9	  
Malate	   dehydrogenase,	   mitochondrial;Malate	  
dehydrogenase	   MDH2	   111910000	   60938000	   45095000	   26813000	   16404000	   59730000	   4.2	   3.7	   0.8	   2.9	  
Poly(A)	  polymerase	  alpha	   PAPOLA	   4864600000	   1096000000	   820530000	   1183700000	   431520000	   423270000	   4.1	   2.5	   1.9	   2.9	  
Amyloid	  beta	  A4	  precursor	  protein-­‐binding	  family	  B	  
member	  1	   APBB1	   318420000	   2300000	   5810100	   115360000	   1656200	   1318000	   2.8	   1.4	   4.4	   2.9	  
	   	   	  Appendices	  
	  
	  
Spindle	  and	  kinetochore-­‐associated	  protein	  3	   SKA3	   877150000	   97675	   7620600	   325680000	   1656200	   1318000	   2.7	   0.1	   5.8	   2.8	  
Putative	   pre-­‐mRNA-­‐splicing	   factor	   ATP-­‐dependent	  
RNA	  helicase	  DHX15	   DHX15	   1796300000	   240610000	   174580000	   399750000	   95657000	   114700000	   4.5	   2.5	   1.5	   2.8	  
Heat	  shock	  protein	  HSP	  90-­‐alpha	   HSP90AA1	   575620000	   948010000	   887220000	   105200000	   461700000	   882630000	   5.5	   2.1	   1.0	   2.8	  
Replication	  factor	  C	  subunit	  4	   RFC4	   1510200000	   42723000	   59284000	   392810000	   16748000	   29027000	   3.8	   2.6	   2.0	   2.8	  
Centrosomal	  protein	  of	  44	  kDa	   CEP44	   475010000	   97675	   7868100	   210440000	   1656200	   1318000	   2.3	   0.1	   6.0	   2.8	  
DnaJ	  homolog	  subfamily	  B	  member	  1	   DNAJB1	   2125900000	   186940000	   253970000	   1089800000	   67526000	   71930000	   2.0	   2.8	   3.5	   2.7	  
TATA-­‐binding	  protein-­‐associated	  factor	  2N	   TAF15	   1462400000	   131080000	   109890000	   471520000	   56487000	   39558000	   3.1	   2.3	   2.8	   2.7	  
Heterogeneous	  nuclear	  ribonucleoproteins	  A2/B1	   HNRNPA2B1	   13959000000	   510820000	   721470000	   3204300000	   233110000	   445060000	   4.4	   2.2	   1.6	   2.7	  
Nucleolin	   NCL	   17877000000	   2052800000	   2415800000	   4401900000	   950860000	   1265900000	   4.1	   2.2	   1.9	   2.7	  
Integrin-­‐linked	   kinase-­‐associated	   serine/threonine	  
phosphatase	  2C	   ILKAP	   1420000000	   208710000	   131170000	   392070000	   62715000	   112460000	   3.6	   3.3	   1.2	   2.7	  
Prohibitin	   PHB	   737070	   153970000	   137940000	   849090	   37317000	   44790000	   0.9	   4.1	   3.1	   2.7	  
Phosphoglycerate	  mutase	  1	   PGAM1	   219900000	   355750000	   386780000	   75726000	   106820000	   216210000	   2.9	   3.3	   1.8	   2.7	  
SAP	  domain-­‐containing	  ribonucleoprotein	   SARNP	   115620000	   30214000	   1858200	   32349000	   7207300	   7769900	   3.6	   4.2	   0.2	   2.7	  
Protein-­‐L-­‐isoaspartate(D-­‐aspartate)	   O-­‐
methyltransferase;Protein-­‐L-­‐isoaspartate	   O-­‐
methyltransferase	   PCMT1	   737070	   60144000	   45718000	   849090	   14350000	   15758000	   0.9	   4.2	   2.9	   2.7	  
Alpha-­‐enolase	   ENO1	   3712600000	   1911300000	   1704200000	   859650000	   846010000	   1582200000	   4.3	   2.3	   1.1	   2.6	  
Proliferating	  cell	  nuclear	  antigen	   PCNA	   737070	   31574000	   39825000	   3990300	   6164800	   17370000	   0.2	   5.1	   2.3	   2.5	  
UPF0552	  protein	  ARPIN	   ARPIN	   737070	   164080000	   98048000	   5111400	   32644000	   42456000	   0.1	   5.0	   2.3	   2.5	  
Apoptosis	  inhibitor	  5	   API5	   1932900000	   81480000	   1858200	   376330000	   36361000	   19778000	   5.1	   2.2	   0.1	   2.5	  
DNA-­‐(apurinic	   or	   apyrimidinic	   site)	   lyase;DNA-­‐
(apurinic	  or	  apyrimidinic	  site)	  lyase,	  mitochondrial	   APEX1	   29472000	   6274400	   1858200	   13897000	   1656200	   1318000	   2.1	   3.8	   1.4	   2.4	  
Voltage-­‐dependent	  anion-­‐selective	   channel	  protein	  
2	   VDAC2	   36815000	   86195000	   90425000	   14714000	   41183000	   34023000	   2.5	   2.1	   2.7	   2.4	  
Sex	  comb	  on	  midleg-­‐like	  protein	  2	   SCML2	   3257500000	   512170000	   503640000	   982510000	   306960000	   247450000	   3.3	   1.7	   2.0	   2.3	  
Phosphorylated	  adapter	  RNA	  export	  protein	   PHAX	   1230900000	   88764000	   79471000	   357590000	   38179000	   70847000	   3.4	   2.3	   1.1	   2.3	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Splicing	  factor	  1	   SF1	   2102300000	   265620000	   54193000	   947100000	   62591000	   131690000	   2.2	   4.2	   0.4	   2.3	  
L-­‐lactate	   dehydrogenase	   B	   chain;L-­‐lactate	  
dehydrogenase	   LDHB	   1291600000	   2992400000	   2790900000	   415830000	   1208800000	   2193100000	   3.1	   2.5	   1.3	   2.3	  
Heat	  shock	  70	  kDa	  protein	  6	   HSPA6	   1519700000	   944580000	   679090000	   1315600000	   261950000	   326020000	   1.2	   3.6	   2.1	   2.3	  
PEST	  proteolytic	  signal-­‐containing	  nuclear	  protein	   PCNP	   737070	   608610000	   822020000	   849090	   175920000	   344300000	   0.9	   3.5	   2.4	   2.2	  
DnaJ	  homolog	  subfamily	  C	  member	  9	   DNAJC9	   193430000	   13183000	   1858200	   71652000	   5079400	   1318000	   2.7	   2.6	   1.4	   2.2	  
Exosome	  complex	  component	  RRP45	   EXOSC9	   117880000	   28188000	   10368000	   45485000	   9455700	   10121000	   2.6	   3.0	   1.0	   2.2	  
Protein	  disulfide-­‐isomerase	  A6	   PDIA6	   147340000	   4692600	   25110000	   54703000	   1656200	   25368000	   2.7	   2.8	   1.0	   2.2	  
Pleiotropic	  regulator	  1	   PLRG1	   1379200000	   79756000	   27984000	   532620000	   23350000	   56411000	   2.6	   3.4	   0.5	   2.2	  
Heat	  shock	  70	  kDa	  protein	  1A/1B	   HSPA1A	   37658000000	   17242000000	   16337000000	   15976000000	   7794300000	   8560900000	   2.4	   2.2	   1.9	   2.2	  
Heterogeneous	   nuclear	   ribonucleoprotein	  
A1;Heterogeneous	   nuclear	   ribonucleoprotein	   A1-­‐
like	  2	   HNRNPA1	   7078000000	   1810200000	   1307200000	   2536900000	   700470000	   1207300000	   2.8	   2.6	   1.1	   2.2	  
Proteasome	  activator	  complex	  subunit	  3	   PSME3	   80572000	   97675	   13901000	   18806000	   6080100	   6643000	   4.3	   0.0	   2.1	   2.1	  
Heterogeneous	  nuclear	  ribonucleoprotein	  A/B	   HNRNPAB	   906620000	   19445000	   71816000	   257840000	   26796000	   33588000	   3.5	   0.7	   2.1	   2.1	  
WD	  repeat-­‐containing	  protein	  70	   WDR70	   956670000	   105050000	   151310000	   535140000	   46197000	   65355000	   1.8	   2.3	   2.3	   2.1	  
Serine/threonine-­‐protein	  kinase	  greatwall	   MASTL	   1068400000	   94675000	   68752000	   507020000	   39963000	   36854000	   2.1	   2.4	   1.9	   2.1	  
Heterogeneous	   nuclear	   ribonucleoprotein	  
F;Heterogeneous	   nuclear	   ribonucleoprotein	   F,	   N-­‐
terminally	  processed	   HNRNPF	   160400000	   68369000	   26049000	   67676000	   19418000	   89031000	   2.4	   3.5	   0.3	   2.1	  
Elongation	  factor	  2	   EEF2	   1169300000	   366150000	   451450000	   487510000	   232210000	   205110000	   2.4	   1.6	   2.2	   2.1	  
Creatine	  kinase	  B-­‐type	   CKB	   259330000	   235490000	   296630000	   102510000	   120060000	   177240000	   2.5	   2.0	   1.7	   2.1	  
60	  kDa	  heat	  shock	  protein,	  mitochondrial	   HSPD1	   394820000	   861210000	   820570000	   149000000	   334110000	   927740000	   2.6	   2.6	   0.9	   2.0	  
Tuftelin-­‐interacting	  protein	  11	   TFIP11	   2010400000	   106690000	   121680000	   907960000	   67471000	   54050000	   2.2	   1.6	   2.3	   2.0	  
G	  patch	  domain	  and	  KOW	  motifs-­‐containing	  protein	   GPKOW	   2586200000	   72476000	   25434000	   790270000	   33721000	   46293000	   3.3	   2.1	   0.5	   2.0	  
Eukaryotic	   initiation	   factor	   4A-­‐III;Eukaryotic	  
initiation	  factor	  4A-­‐III,	  N-­‐terminally	  processed	   EIF4A3	   156480000	   17418000	   32051000	   134820000	   8400300	   12649000	   1.2	   2.1	   2.5	   1.9	  
T-­‐complex	  protein	  1	  subunit	  gamma	   CCT3	   423980000	   39449000	   71316000	   429880000	   18575000	   27193000	   1.0	   2.1	   2.6	   1.9	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Replication	   protein	   A	   70	   kDa	   DNA-­‐binding	  
subunit;Replication	   protein	   A	   70	   kDa	   DNA-­‐binding	  
subunit,	  N-­‐terminally	  processed	   RPA1	   2265200000	   217710000	   193870000	   1103300000	   135900000	   94456000	   2.1	   1.6	   2.1	   1.9	  
Rho	  GDP-­‐dissociation	  inhibitor	  1	   ARHGDIA	   737070	   26664000	   35883000	   849090	   11302000	   15741000	   0.9	   2.4	   2.3	   1.8	  
ADP/ATP	   translocase	   2;ADP/ATP	   translocase	   2,	   N-­‐
terminally	  processed	   SLC25A5	   737070	   66944000	   109080000	   849090	   30783000	   48797000	   0.9	   2.2	   2.2	   1.8	  
Zinc	  finger	  protein	  207	   ZNF207	   1400900000	   80703000	   18731000	   548010000	   34113000	   65307000	   2.6	   2.4	   0.3	   1.7	  
DnaJ	  homolog	  subfamily	  C	  member	  8	   DNAJC8	   792050000	   72191000	   21944000	   333860000	   35469000	   31185000	   2.4	   2.0	   0.7	   1.7	  
Sideroflexin-­‐1	   SFXN1	   737070	   18845000	   39019000	   849090	   9084600	   18597000	   0.9	   2.1	   2.1	   1.7	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Townes-­‐Brocks	   Syndrome	   (TBS)	   is	   a	   rare	   disease	   characterized	   by	   a	   spectrum	   of	  
malformations	   in	   digits,	   ears,	   heart	   and	   kidneys,	   symptoms	   that	   are	   also	   found	   in	  
many	   human	   ciliopathies.	   TBS	   patient-­‐derived	   fibroblasts	   display	   longer	   and	  more	  
frequent	  cilia	  compared	  to	  controls.	  TBS	  is	  caused	  by	  mutations	  in	  SALL1	  gene,	  which	  
often	   lead	   to	   expression	   of	   a	   truncated	   protein	   that	   interferes	   with	   the	   normal	  
function	  of	  the	  cell.	  Here,	  we	  show	  that	  truncated	  SALL1	  interacts	  with	  the	  leucine-­‐
zipper	   containing	   protein	   LUZP1,	   leading	   to	   its	   degradation,	   placing	   LUZP1	   as	   a	  
mediator	   of	   TBS	   symptoms.	   We	   demonstrate	   that	   LUZP1	   localizes	   to	   the	  
centrosome,	  actin	  cytoskeleton,	  and	  midbody.	  CRISPR/Cas9-­‐mediated	  loss	  of	  LUZP1	  
in	   mouse	   fibroblasts	   changes	   actin	   dynamics	   and	   cell	   migration,	   while	   facilitating	  
ciliogenesis	  and	  altering	  Sonic	  Hedgehog	  signaling.	  Given	  its	  localization	  to	  both	  actin	  
stress	   fibers	   and	   the	   centrosome,	   LUZP1	   might	   be	   a	   key	   factor	   for	   integrating	  
cytoskeletal	   changes	   to	   cilia	   formation	   and	   function.	   Disruption	   of	   LUZP1	   function	  
may	   be	   a	   contributing	   factor	   to	   TBS,	   opening	   a	   possibility	   for	   pharmacological	  
intervention	  by	  cytoskeletal	  modulators.	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Townes-­‐Brocks	  syndrome	   (TBS)	   is	   characterized	  by	  a	  spectrum	  of	  malformations	   in	  
the	   digits,	   ears,	   and	   kidneys.	   These	   anomalies	   overlap	   those	   seen	   in	   a	   growing	  
number	   of	   ciliopathies,	   which	   are	   genetic	   syndromes	   linked	   to	   defects	   in	   the	  
formation	  or	   function	  of	   the	  primary	   cilia.	   TBS	   is	   caused	  by	  mutations	   in	   the	  gene	  
encoding	  the	  transcriptional	  repressor	  SALL1	  and	  is	  associated	  with	  the	  presence	  of	  a	  
truncated	   protein	   that	   localizes	   to	   the	   cytoplasm.	   Here,	  we	   provide	   evidence	   that	  
SALL1	  mutations	  might	  cause	  TBS	  by	  means	  beyond	   its	   transcriptional	   capacity.	  By	  
using	   proximity	   proteomics,	   we	   show	   that	   truncated	   SALL1	   interacts	   with	   factors	  
related	  to	  cilia	  function,	  including	  the	  negative	  regulators	  of	  ciliogenesis	  CCP110	  and	  
CEP97.	  This	  most	   likely	  contributes	  to	  more	  frequent	  cilia	  formation	   in	  TBS-­‐derived	  
fibroblasts,	   as	   well	   as	   in	   a	   CRISPR/Cas9-­‐generated	   model	   cell	   line	   and	   in	   TBS-­‐
modeled	  mouse	  embryonic	  fibroblasts,	  than	  in	  wild-­‐type	  controls.	  Furthermore,	  TBS-­‐
like	   cells	   show	   changes	   in	   cilia	   length	   and	   disassembly	   rates	   in	   combination	   with	  
aberrant	   SHH	   signalling	   transduction.	   These	   findings	   support	   the	   hypothesis	   that	  
aberrations	   in	   primary	   cilia	   and	   SHH	   signalling	   are	   contributing	   factors	   in	   TBS	  
phenotypes,	   representing	   a	   paradigm	   shift	   in	   understanding	   TBS	   etiology.	   These	  
results	  open	  possibilities	  for	  the	  treatment	  of	  TBS.	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Cellular	   transformation	   and	   cancer	   progression	   is	   accompanied	   by	   changes	   in	   the	  
metabolic	   landscape.	   Master	   co-­‐regulators	   of	   metabolism	   orchestrate	   the	  
modulation	   of	  multiple	  metabolic	   pathways	   through	   transcriptional	   programs,	   and	  
hence	  constitute	  a	  probabilistically	  parsimonious	  mechanism	   for	  general	  metabolic	  
rewiring.	  Here	  we	  show	  that	  the	  transcriptional	  co-­‐activator	  peroxisome	  proliferator-­‐
activated	   receptor	   gamma	   co-­‐activator	   1α	   (PGC1α)	   suppresses	   prostate	   cancer	  
progression	  and	  metastasis.	  A	  metabolic	  co-­‐regulator	  data	  mining	  analysis	  unveiled	  
that	   PGC1α	   is	   downregulated	   in	   prostate	   cancer	   and	   associated	   with	   disease	  
progression.	   Using	   genetically	   engineered	   mouse	   models	   and	   xenografts,	   we	  
demonstrated	   that	   PGC1α	   opposes	   prostate	   cancer	   progression	   and	   metastasis.	  
Mechanistically,	   the	   use	   of	   integrative	  metabolomics	   and	   transcriptomics	   revealed	  
that	   PGC1α	   activates	   an	   oestrogen-­‐related	   receptor	   alpha	   (ERRα)-­‐dependent	  
transcriptional	   program	   to	   elicit	   a	   catabolic	   state	   and	   metastasis	   suppression.	  
Importantly,	   a	   signature	   based	   on	   the	   PGC1α-­‐ERRα	   pathway	   exhibited	   prognostic	  
potential	   in	   prostate	   cancer,	   thus	   uncovering	   the	   relevance	   of	   monitoring	   and	  
manipulating	  this	  pathway	  for	  prostate	  cancer	  stratification	  and	  treatment.	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Maternal	  inflammation	  during	  pregnancy	  can	  have	  detrimental	  effects	  on	  embryonic	  
development	   that	   persist	   during	   adulthood.	   However,	   the	   underlying	  mechanisms	  
and	   insights	   in	   the	   responsible	  cell	   types	  are	  still	   largely	  unknown.	  Here	  we	  report	  
the	  effect	  of	  maternal	   inflammation	  on	   fetal	  microglia,	   the	   innate	   immune	  cells	  of	  
the	  central	  nervous	  system	  (CNS).	  In	  mice,	  a	  challenge	  with	  LPS	  during	  late	  gestation	  
stages	  (days	  15-­‐16-­‐17)	  induced	  a	  pro-­‐inflammatory	  response	  in	  fetal	  microglia.	  Adult	  
whole	   brain	   microglia	   of	   mice	   that	   were	   exposed	   to	   LPS	   during	   embryonic	  
development	   displayed	   a	   persistent	   reduction	   in	   pro-­‐inflammatory	   activation	   in	  
response	   to	   a	   re-­‐challenge	   with	   LPS.	   In	   contrast,	   hippocampal	   microglia	   of	   these	  
mice	   displayed	   an	   increased	   inflammatory	   response	   to	   an	   LPS	   re-­‐challenge.	   In	  
addition,	   a	   reduced	   expression	   of	   brain-­‐derived	   neurotrophic	   factor	   (BDNF)	   was	  
observed	   in	   hippocampal	   microglia	   of	   LPS-­‐offspring.	   Microglia-­‐derived	   BDNF	   has	  
been	  shown	  to	  be	  important	  for	  learning	  and	  memory	  processes.	  In	  line	  with	  these	  
observations,	   behavioral-­‐	   and	   learning	   tasks	   with	   mice	   that	   were	   exposed	   to	  
maternal	   inflammation	   revealed	   reduced	   home	   cage	   activity,	   reduced	   anxiety	   and	  
reduced	   learning	   performance	   in	   a	   T-­‐maze.	   These	   data	   show	   that	   exposure	   to	  
maternal	  inflammation	  during	  late	  gestation	  results	  in	  long	  term	  changes	  in	  microglia	  
responsiveness	   during	   adulthood,	   which	   is	   different	   in	   nature	   in	   hippocampus	  
compared	  to	  total	  brain	  microglia.	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Introducción	  
El	   síndrome	   de	   Townes-­‐Brocks	   (TBS,	   MIM:	   107480)	   se	   caracteriza	   por,	   al	  
menos,	   dos	   de	   estos	   fenotipos	   principales:	   ano	   imperforado,	   orejas	   displásicas	   y	  
malformaciones	   del	   pulgar	   (pulgares	   trifalángicos,	   polidactilia	   preaxial	   e	   hipoplasia	  
del	  pulgar).	  TBS	  también	  suele	  asociarse	  con	  otros	  síntomas	  menos	  frecuentes	  como	  
la	   deficiencia	   auditiva	   neurosensorial	   y/o	   conductiva,	   malformaciones	   del	   pie,	  
insuficiencia	   renal	   (incluyendo	   los	   riñones	  poliquísticos),	   junto	   con	  malformaciones	  
genitourinarias	   y	   cardiopatía	   congenita.	   Aunque	   más	   atípicos,	   también	   se	   puede	  
observar	  disfuncionalidad	  intelectual,	  retrasos	  en	  el	  crecimiento,	  paladar	  hendido	  y	  
defectos	  oculares.	  	  
TBS	   está	   causado	   por	   mutaciones	   en	   el	   gen	   que	   codifica	   el	   represor	  
transcripcional	  SALL1	  que,	  mayoritariamente,	  dan	  lugar	  a	  una	  proteína	  truncada	  que	  
se	   localiza	   en	   el	   citoplasma.	   Existen	   cuatro	   genes	   SALL	   en	   mamíferos,	   SALL1-­‐4.	  
Estudios	  anteriores	  han	  demostrado	  que	   ratones	  con	  mutaciones	  dobles/triples	  en	  
Sall1/Sall2/Sall4	  exhiben	  defectos	  en	  el	  tubo	  neural	  y	  hendidura	  palatina.	  
TBS	  está	   considerada	   como	  una	  enfermedad	  genética	   rara.	   La	   investigación	  
llevada	  a	  cabo	  hasta	  ahora	  se	  ha	  centrado	  en	  la	  función	  de	  SALL1	  en	  el	  núcleo	  y	  en	  la	  
perturbación	  de	  dicha	  función	  nuclear	  en	  la	  regulación	  transcripcional	  como	  posible	  
causas	   de	   TBS.	   Hemos	   observado	   que	   los	   síntomas	   de	   TBS	   se	   incluyen	   dentro	   del	  
espectro	   observado	   en	   una	   clase	   emergente	   de	   enfermedades	   denominadas	  
“ciliopatías”.	   Éstas	   son	   en	   su	   mayoría	   síndromes	   genéticos	   raros	   causados	   por	   la	  
disfunción	  del	  cilio	  primario.	  Los	  cilios	  son	  estructuras	  basadas	  en	  microtúbulos	  que	  
se	  originan	  a	  raíz	  de	  dos	  estructuras	  con	  forma	  de	  barril,	   los	  centríolos.	  Durante	  el	  
desarrollo,	   la	   generación	   e	   interpretación	   de	   gradientes	   morfogénicos	   tales	   como	  
Wnt,	   TGFbeta	   o	   Hedgehog	   (Hh)	   son	   esenciales	   para	   la	   correcta	   formación	   del	  
organismo.	   Entre	   todas	   estas	   funciones,	   la	   vía	   de	   Sonic	   hedgehog	   (Shh)	   juega	   un	  
papel	   importante	   en	   la	   formación	   de	   dígitos	   durante	   el	   desarrollo	   de	   las	  
extremidades.	  Se	  ha	  demostrado	  que	   la	   señalización	  por	  Shh	   requiere	   la	  presencia	  
del	  cilio	  primario	  en	  vertebrados.	  	  
Las	  características	  comunes	  entre	  las	  ciliopatías	  y	  TBS	  podrían	  sugerir	  causas	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moleculares	  similares.	  Por	  lo	  tanto,	  nos	  planteamos	  la	  hipótesis	  de	  que	  defectos	  en	  
la	   formación	   y/o	   función	  de	   los	   cilios	   primarios	  podrían	   contribuir	   al	   desarrollo	  de	  
TBS	  e	   iniciamos	  el	  estudio	  de	   la	   formación	  y	  función	  de	   los	  cilios	  primarios	  en	  TBS.	  
Para	  ello	  nos	  marcamos	  los	  objetivos	  detallados	  a	  continuación.	  
Objetivos	  
1.	  Analizar	  el	  papel	  de	  SALL1	  en	  la	  formación	  y	  función	  de	  los	  cilios.	  	  
Obtuvimos	   células	   derivadas	   de	   pacientes	   con	   TBS	   y	   generamos	   líneas	  
celulares	  modelo	  de	  TBS	  para	  analizar	  el	  efecto	  de	  proteínas	  SALL1	  truncadas	  en	  la	  
ciliogénesis	  y	  la	  función	  de	  los	  cilios.	  	  
2.	   Identificar	   los	  mecanismos	  celulares	  y	  moleculares	  que	  median	   los	  defectos	  de	  
los	  cilios	  observados	  en	  TBS.	  	  
Con	  el	  fin	  de	  identificar	  mediadores	  de	  los	  defectos	  relacionadas	  con	  los	  cilios	  
detectados	  en	  TBS,	  utilizamos	  el	  método	  de	  proteómica	  de	  proximidad,	  BioID,	  para	  
identificar	  interactores	  de	  la	  proteína	  SALL1	  truncada.	  Los	  candidatos	  seleccionados	  
se	  estudiaron	  en	  relación	  con	  los	  cilios	  y/o	  centrosomas	  en	  el	  contexto	  de	  TBS.	  
Materiales	  y	  Métodos	  
El	   trabajo	   aquí	   presentado	   se	   llevó	   a	   cabo	   en	   células	   en	   cultivo,	   tanto	   de	  
líneas	  celulares	  como	  de	  células	  derivadas	  de	  tejidos	  primarios	  de	  ratón	  y	  humano.	  
Además,	   generaron	   líneas	   celulares	   modelo	   mediante	   el	   uso	   de	   la	   tecnología	  
CRISPR/Cas9.	  Por	  otro	  lado,	  se	  emplearon	  técnicas	  de	  biología	  molecular	  tales	  como	  
la	   extracción	   de	   RNA,	   qRT-­‐PCR,	   western	   blot,	   BioID	   e	   immunoprecipitaciones.	  
También	   se	   llevaron	   a	   cabo	   ensayos	   de	   actividad	   reportera,	   de	   espectrometría	   de	  
masas	  así	  como	  análisis	  con	  microscopía	  de	  inmunofluorescencia,	  con	  citometría	  de	  
flujo	  y	  análisis	  de	  proliferación	  y	  migración.	  
Resultados	  
Objetivo	  1.	  Analizar	  el	  papel	  de	  SALL1	  en	  la	  formación	  y	  función	  de	  los	  cilios.	  	  
	  
1.1	   La	   proteína	   SALL1	   truncada	   expresada	   en	   los	   pacientes	   de	   TBS	   altera	   la	  
localización	  subcelular	  de	  full-­‐length	  SALL1.	  
En	   este	   trabajo	   hemos	   caracterizado	   la	   localización	   nuclear	   y	   ciliar	   de	   full-­‐
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length	   SALL1	   (SALL1FL)	   tanto	   en	   células	   humanas	   como	   de	   ratón	   por	  
inmunofluorescencia.	   Sin	   embargo,	   observamos	   que	   en	   células	   derivadas	   de	  
pacientes	  de	  TBS,	  SALL1FL	  se	  localizaba	  difusamente	  entre	  el	  núcleo	  y	  el	  citoplasma,	  
siendo	   su	   expresión	  más	   reducida	   en	   el	   cilio	   comparado	   con	   células	   control.	   Para	  
comprobar	   que	   dicho	   cambio	   en	   la	   localización	   de	   SALL1FL	   estaba	  mediado	   por	   la	  
proteína	  truncada,	  sobrexpresamos	  la	  proteína	  SALL1	  truncada	  junto	  con	  SALL1FL	  en	  
células	   U2OS.	   Corroboramos	   que,	   cuando	   ambas	   formas	   se	   expresaban	   en	  
combinación,	  SALL1FL	  colocalizaba	  con	   la	  proteína	   truncada,	  demostrando	  que	  esta	  
última	  secuestra	  a	  SALL1FL	  del	  núcleo	  y	  la	  arrastra	  al	  citoplasma.	  
	  
1.2	   Los	   fibroblastos	   de	   paciente	   de	   Townes-­‐Brocks	   (TBS)	  muestran	   defectos	   en	   el	  
cilio	  primario	  en	  comparación	  con	  células	  de	  donante	  control.	  
Mediante	   la	   reducción	   de	   nutrientes	   durante	   24	   ó	   48h	   para	   inducir	   la	  
ciliogénesis,	   se	   llevó	   a	   cabo	   la	   visualización	   del	   cilio	   primario	   mediante	  
inmunofluorescencia	   con	   marcadores	   del	   cuerpo	   basal	   y	   del	   axonema	   ciliar.	   Se	  
observó	  que	  los	  fibroblastos	  del	  paciente	  de	  TBS	  muestran	  una	  mayor	  frecuencia	  de	  
ciliación	  así	  como	  cilios	  primarios	  de	  mayor	  longitud	  en	  comparación	  con	  el	  individuo	  
control.	   Estas	   diferencias	   son	   significativas	   en	   todas	   las	   series	   temporales	   de	  
inducción	  de	  la	  ciliogénesis.	  	  
Dado	   que	   la	   vía	   de	   señalización	   de	   Shh	   depende	   de	   la	   presencia	   del	   cilio	  
primario	   funcional,	   analizamos	   cómo	   responden	  a	   la	   activación	  por	   Shh	   las	   células	  
procedentes	   del	   paciente	   de	   TBS	   y	   de	   dos	   individuos	   control.	   Observamos	   que	   la	  
activación	  basal	  de	  la	  vía	  Shh	  era	  significativamente	  menor	  en	  células	  TBS	  que	  en	  las	  
control.	  Sin	  embargo,	  las	  células	  TBS	  mostraban	  hipersensibilidad	  ante	  la	  activación	  
de	  la	  vía	  y,	  como	  consecuencia,	  una	  alteración	  en	  la	  funcionalidad	  del	  cilio	  primario.	  
	  
1.3	   Los	   modelos	   celulares	   de	   TBS	   reproducen	   los	   defectos	   en	   la	   ciliogénesis	  
observados	  en	  las	  células	  derivadas	  de	  TBS.	  
Para	   confirmar	   los	   defectos	   en	   la	   ciliogénesis	   que	   presentaban	   las	   células	  
derivadas	   de	   pacientes	   de	   TBS,	   se	   caracterizaró	   y	   analizó	   la	   ciliogénisis	   en	   los	  
siguientes	  modelos	  celulares	  de	  TBS:	  
• Células	  humanas	  RPEI	  sobrexpresando	  SALL1	  mutada.	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• Células	  derivadas	  del	  modelo	  de	  ratón	  TBS	  (Sall1+/∆).	  
• HEK	   293FT	   modificadas	   con	   la	   tecnología	   CRISPR/Cas9	   para	   generar	   una	  
mutación	  en	  la	  región	  de	  SALL1	  generalmente	  presente	  en	  la	  mayor	  parte	  de	  
los	  pacientes	  de	  TBS	  (293335).	  
En	   todos	   los	   casos,	   los	   citados	   modelos	   celulares	   presentaron	   cilios	   más	  
largos	   y	   un	   mayor	   índice	   de	   ciliación	   en	   comparación	   con	   las	   células	   control,	  
confirmando	   los	   resultados	   previamente	   observados	   en	   células	   derivadas	   de	  
paciente	  de	  TBS.	  
	  
Objetivo	  2.	  Identificar	  los	  mecanismos	  celulares	  y	  moleculares	  que	  median	  
los	  defectos	  de	  los	  cilios	  observados	  en	  TBS.	  	  
	  
2.1	   Análsis	   de	   los	   reguladores	   negativos	   de	   ciliogénesis	   CCP110	   y	   CEP97	   en	   el	  
centriolo	  madre	  de	  fibroblastos	  derivados	  de	  TBS	  y	  fibroblastos	  control.	  
Mediante	   el	   método	   BioID,	   identificamos	   dos	   proteínas	   centrosomales	  
encargadas	   de	   bloquear	   la	   ciliogénesis,	   CEP97	   y	   CCP110,	   que	   se	   encontraron	  
mayoritaria	  o	  exclusivamente	  asociadas	  a	  SALL1	  truncado.	  Dado	  que	  se	  sabe	  que	  la	  
degradación	  de	  CCP110	  y	  CEP97	  en	  el	  centriolo	  madre	  (CM)	  que	  da	  lugar	  al	  cilio	  es	  
determinate	  para	   la	   iniciación	  de	   la	  ciliogénesis,	  analizamos	   la	  expresión	  de	  ambas	  
proteínas	   exclusivamente	   a	  nivel	   del	   CM.	   Los	   resultados	  mostraron	  que	  CCP110	  ni	  
CEP97	  no	  se	   localizan	  en	  CM	  de	   las	  células	  de	  TBS	  en	  un	  porcentaje	  mayor	  que	   las	  
células	   control	   incluso	   antes	   de	   inducir	   la	   ciliogénesis	   y,	   por	   tanto,	   el	   proceso	   de	  
ciliogénesis	   se	   encuentra	   desinhibido.	   Estos	   resultados	   concuerdan	   con	  
experimentos	   previos	   en	   los	   que	   observamos	   una	   formación	   prematura	   de	   cilios	  
primarios	   en	   células	   de	   paciente	   de	   TBS	   en	   comparación	   con	   células	   control.	   La	  
desaparición	  prematura	  de	  CCP110	  del	  CM	  se	  confirmó	  también	  en	  células	  Sall1+/∆	  y	  
en	  293335	  comparadas	  con	  sus	  controles.	  
	  
2.2	  Caracterización	  de	  LUZP1	  en	  células	  TBS.	  
Mediante	   el	   método	   BioID,	   identificamos	   también	   a	   LUZP1	   como	   una	  
proteína	  asociada	  exclusivamente	  a	  SALL1	  truncado.	  La	  función	  molecular	  de	  LUZP1	  
se	   desconocía	   hasta	   este	   trabajo.	   Observamos	   que	   LUZP1	   se	   localiza	   en	   el	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centrosoma,	   en	   el	   citoesqueleto	   de	   actina	   y	   en	   el	   cuerpo	   medio	   o	   midbody.	  
Descubrimos	  que	  la	  degradación	  de	  LUZP1	  en	  el	  CM	  es	  determinate	  para	  la	  iniciación	  
de	   la	   ciliogénesis	   y	   analizamos	   su	  expresión	  en	   células	  de	  pacientes	   TBS	   y	   control.	  
Nuestros	  resultados	  mostraron	  que	  en	  las	  células	  TBS	  LUZP1	  no	  se	  localiza	  en	  el	  CM	  
en	   un	   porcentaje	   mayor	   que	   las	   células	   control	   incluso	   antes	   de	   inducir	   la	  
ciliogénesis	   y,	   por	   tanto,	   el	   proceso	   de	   ciliogénesis	   está	   desinhibido.	   Dada	   la	  
reducción	   tanto	   de	   los	   niveles	   totales	   de	   LUZP1	   como	   de	   fibras	   de	   actina,	   estos	  
resultados	   concuerdan	   con	   experimentos	   previos	   en	   los	   que	   observamos	   una	  
formación	   prematura	   de	   cilios	   primarios	   en	   células	   de	   paciente	   de	   TBS	   en	  
comparación	  con	  células	  control.	  	  
	  
2.3	   Interacción	   de	   la	   proteína	   LUZP1	   con	   proteínas	   centrosomales	   y	   asociadas	   al	  
citoesqueleto	  de	  actina	  
Para	  corroborar	   la	   localización	  observada	  en	  células	  de	  pacientes	  de	  TBS,	  se	  
observó	  mediante	  un	  análisis	  de	  Pull	  Down	  usando	   la	  resina	  GFPtrap	   la	   interacción	  
directa	   de	   LUZP1	   con	   las	   proteínas	   centrosomales	   CCP110	   y	   CEP97	   y	   proteínas	  
relacionadas	  con	  el	  citoesqueleto	  celular	  FLNA	  y	  beta	  actina.	  	  
	  
2.4	  Análisis	  del	  cilio	  primario	  y	  la	  vía	  de	  señalización	  Shh	  en	  fibroblastos	  derivados	  de	  
embriones	  de	  ratón	  en	  ausencia	  de	  LUZP1.	  
Para	   estudiar	   la	   función	   molecular	   de	   Luzp1,	   modificamos	   fibroblastos	  
embrionarios	   de	   ratón	   para	   obtener	   células	   knock	   out	   (Luzp1-­‐/-­‐).	   Tras	   genotipar	  
dichos	   fibroblastos,	   comparamos	   tanto	   la	   longitud	   del	   cilio	   como	   la	   frecuencia	   de	  
ciliación	   con	   células	   de	   ratones	   control	   (Luzp1+/+).	   En	   consistencia	   con	   los	   datos	  
obtenidos	  en	  células	  humanas	  TBS	  en	   las	  que	   los	  niveles	  de	  LUZP1	  se	  encontraban	  
reducidos,	   los	   fibroblastos	   de	   ratones	   Luzp1-­‐/-­‐	   presentaron	   cilios	   más	   largos	   y	   un	  
mayor	  índice	  de	  ciliación	  en	  comparación	  con	  las	  células	  control.	  Estos	  defectos	  en	  la	  
ciliogénesis	   fueron	   rescatados	  mediante	   la	   sobrexpresión	  de	  LUZP1	   humano	  en	   las	  
células	  Luzp1-­‐/-­‐	  (+LUZP1).	  Además,	  se	  observaron	  defectos	  en	  la	  señalización	  de	  la	  vía	  
Shh	  en	  las	  células	  mutantes.	  
	  
2.5	  Análisis	  de	  la	  proliferación,	  migración	  e	  invasión	  celular	  en	  ausencia	  de	  LUZP1.	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Durante	   la	   cuantificación	   de	   los	   cilios,	   se	   observó	   que	   las	   células	   Luzp1-­‐/-­‐	  
presentan	   un	   porcentaje	   significativamente	   mayor	   de	   centriolos	   múltiples	   y	   unos	  
núcleos	   significativamente	   más	   grandes	   respecto	   a	   las	   control.	   Estos	   defectos	  
pueden	  ser	  indicativos	  de	  fallos	  en	  la	  proliferación	  o	  división	  celular.	  Mediante	  cristal	  
violeta,	   se	  observó	  una	  menor	  proliferación	  de	   las	   células	   Luzp1-­‐/-­‐	   en	   comparación	  
con	   las	   células	   Luzp1+/+.	   Curiosamente,	   las	   células	   Luzp1-­‐/-­‐	   mostraron	   una	   mayor	  
capacidad	  de	  migración	  e	  invasión	  celular	  que	  las	  células	  Luzp1+/+.	  Estos	  defectos	  en	  
la	   migración	   e	   invasión	   celular	   fueron	   rescatados	   mediante	   la	   sobrexpresión	   de	  
LUZP1	  en	  las	  células	  Luzp1-­‐/-­‐.	  Por	  último,	  nuestros	  resultados	  preliminares	  mostraron	  
que	   los	   mediadores	   de	   la	   polimerización	   de	   la	   actina	   Arp2/3	   y	   cofilina	   están	  
alterados	  en	  células	  Luzp1-­‐/-­‐.	  
Conclusiones	  
Los	   resultados	   de	   esta	   tesis	   permiten	   concluir	   que	   el	   síndrome	  de	   Townes-­‐
Brocks	  es	  una	  enfermedad	  similar	  a	  las	  ciliopatías,	  cuya	  etiología	  está	  mediada	  por	  la	  
interfencia	  de	  SALL1	  truncado	  con	  la	  red	  citoesqueleto	  de	  actina-­‐cilia	  a	  través	  de	  su	  
interacción	  con	  las	  proteínas	  CCP110,	  CEP97	  y	  LUZP1.	  
Los	  resultados	  de	  esta	  tesis	  permiten	  concluir:	  
	  
	  1.	   SALL1FL	   es	   una	   proteína	   nuclear	   y	   ciliar,	   y	   la	   proteína	   SALL1	   truncada	  
provoca	  su	  localización	  en	  el	  citoplasma	  de	  manera	  dominante-­‐negativa.	  	  
	  
2.	  Los	  fibroblastos	  derivados	  de	  pacientes	  con	  TBS	  muestran	  cilios	  más	  largos	  
y	  más	  abundantes	  que	  los	  fibroblastos	  control	  y	  estos	  defectos	  en	  la	  ciliogénesis	  se	  
han	  reproducido	  en	  las	  siguientes	  líneas	  celulares	  modelo	  de	  TBS,	  aunque	  expresen	  
diferentes	  variantes	  patógenas:	  	  
a.	   Fibroblastos	   de	   un	   nuevo	   paciente	   de	   TBS	   con	   la	   variante	   patológica	  
SALL1c.826C>	  T.	  	  
b.	   Una	   línea	   celular	   modelo	   de	   TBS	   generada	   en	   células	   HEK	   293FT	   por	   la	  
tecnología	  CRISPR/Cas9.	  	  
c.	  Fibroblastos	  embrionarios	  del	  modelo	  de	  TBS	  en	  ratón	  Sall1-­‐∆Zn2-­‐10.	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3.	   Los	   fibroblastos	   derivados	   de	   pacientes	   con	   TBS	   presentan	   defectos	   en	  
señalización	  de	  Shh.	  	  
	  
4.	   La	   proteína	   SALL1	   truncada	   interactúa	   con	   los	   reguladores	   negativos	   del	  
cilio	  primario	  CCP110	  y	  CEP97,	  y	  con	  LUZP1,	  provocando	  su	  desaparición	  	  prematura	  
del	  centríolo	  madre	  en	  las	  células	  TBS.	  	  
	  
5.	  LUZP1	  se	  localiza	  en	  el	  centrosoma	  e	  interactúa	  con	  CCP110	  y	  CEP97.	  	  
	  
6.	   LUZP1	   es	   un	   regulador	   negativo	   de	   la	   ciliogénesis	   implicado	   en	   la	  
señalización	  de	  Shh.	  	  
	  
7.	  LUZP1	  es	  una	  proteína	  estabilizadora	  de	  actina	  reducida	  en	  células	  TBS.	  	  
	  
8.	   La	  presencia	  de	   la	  proteína	   SALL1	   truncada	   conduce	  a	   la	  degradación	  de	  
LUZP1	  mediada	  por	  proteasoma.	  	  
	  
9.	   La	   falta	   de	   LUZP1	   da	   lugar	   a	   defectos	   en	   la	   proliferación	   y	   migración	  
celular,	   presumiblemente,	   a	   través	   de	   la	   regulación	   del	   citoesqueleto	   de	   actina.
	  	   212	  
 
Personal	  resumé	  (CV)	  
	   213	  
Personal	  Resumé	  (CV):	  Laura	  Bozal	  Basterra	  
	  
Avda.	  del	  Ferrocarril,	  4,	  5B	  	   48013	  Bilbao	  (Vizcaya)	  	   	  
+34	  629979926	  lbozal@cicbiogune.es	  
	  
Education	  
01/2015	   -­‐	   12/2018.	   Molecular	   Biology	   and	   Biomedicine	   Ph.D.	   CIC	  
bioGUNE,	  Technology	  Park	  of	  Bizkaia,	  Spain.	  
09/2017	  –	  07/2018	  Teaching	  Training	  M.S.	  Universidad	  Isabel	  I,	  Burgos,	  
Spain.	  
09/2013	  –	  06/2014	  Molecular	  Biology	  and	  Biomedicine	  M.S.	  University	  of	  Basque	  Country	  
(UPV-­‐	  EHU).	  
09/2011	   –	   06/2012	   Erasmus	   Exchange	   Programme.	   University	   of	   Groningen	   (RUG),	   The	  
Netherlands.	  
09/2006	  –	  07/2012	  Bachelor	  of	  Biochemistry,	  BS.	  University	  of	  Navarre,	  Spain.	  	  
09/2006	  –	  07/2012.	  Bachelor	  of	  Biology,	  BS.	  University	  of	  Navarre,	  Spain.	  	  
	  
Research	  experience	  
01/2015-­‐12/2018.	  Molecular	  Biology	  and	  Biomedicine	  Ph.D.	  CIC	  bioGUNE,	  Technology	  Park	  
of	  Bizkaia,	  Spain.	  Supervisor:	  Dr.	  Rosa	  Barrio.	  
04/2017	  –	   07/2017.	   International	   Ph.D.	   Programme	   Internship.	  Memorial	   Sloan	  Kettering	  
Cancer	  Center,	  MSKCC.	  Supervisor:	  Dr.	  Kathryn	  Anderson.	  
01/2013	   –	   12/2014.	   Training	   contract.	   CIC	   bioGUNE,	   Technology	   Park	   of	   Bizkaia,Spain.	  
Supervisor:	  Dr.	  Rosa	  Barrio.	  
09/2011	   –	   07/2012	   Neurophysiology	   Research	   Project.	   University	   Medical	   Center	   of	  
Groningen,	  The	  Netherlands.	  Supervisor:	  Dr.	  Erik	  Bodekke.	  
09/2009	   –	   06/2011	   Cancer	   research	   Project.	   Centro	   de	   investigación	   Médica	   Aplicada	  
(CIMA),	  Pamplona,	  Spain.	  Supervisor:	  Dr.	  Jackeline	  Agorreta	  
	  
Grants	  and	  awards	  
10/2018.	  Outstanding	  Poster	  Presentation	  Award.	  Cilia	  2018	  EMBO	  workshop.	  Copenhague,	  
Denmark.	  
04/2017-­‐07/2017.	   Travel	   Grant:	   3	   month	   International	   PhD	   Programme	   Internship	   in	  
Memorial	  Sloan	  Kettering	  Cancer	  Research	  Center,	  New	  York,	  USA.	  Boehringer	   Ingelheim	  
Fonds.	  Cantidad:	  8680	  €.	  
01/2015-­‐11/2018.	  4-­‐year	  PhD	  Programme	  Grant	  by	  Basque	  Government,	   Spain.	  Cantidad:	  
65.300	  €.	  
09/2011-­‐07/2012.	  Erasmus	  Exchange	  Programme	  Grant	  by	  The	  European	  Commission.	  




Bozal-­‐Basterra,	   L.,	   Gonzalez-­‐Santamarta,	   M.,	   Martín,	   N.,	   Carracedo,	   A.,	   Barrio,	   R.	   and	  
Sutherland,	   J.D.	   (2018)	   LUZP1	   underlies	   primary	   cilia	   and	   actin	   cytoskeleton	   defects	   in	  
Townes-­‐Brocks	  Syndrome.	  The	  Journal	  of	  Cell	  Biology	  (submitted).	  
	  
Bozal-­‐Basterra,	  L.,	  Martín-­‐Ruíz	  I.,	  Pirone,	  L.,	  Liang,	  Y.,	  Sigurðsson,	  JO.,	  Gonzalez-­‐Santamarta,	  
M.,	  Giordano,	  I.,	  Gabicagogeascoa,	  E.,	  de	  Luca,	  A.,	  Rodríguez,	  JA.,	  Wilkie,	  AOM.,	  Kohlhase,	  J.,	  
Eastwood,	  D.,	  Yale,	  C.,	  Olsen,	   JV.,	  Rauchman,	  M.,	  Anderson,	  KV.,	  Sutherland,	   JD.,	  Barrio,	  R.	  
(2018).	   Primary	   cilium	   defects	   are	   contributing	   factors	   in	   Townes-­‐Brocks	   Syndrome.	  
American	  Journal	  of	  Human	  Genetics,	  102	  (2),	  249-­‐265.	  
Personal	  resumé	  (CV)	  
	   214	  
	  
Torrano,	   V.,	   Valcarcel-­‐Jimenez,	   …	   Bozal-­‐Basterra,	   L.,	   et	   al.	   (2016).	   The	   metabolic	   co-­‐
regulator	  PGC1α	  suppresses	  prostate	  cancer	  metastasis.	  Nature	  Cell	  Biology	  (18),	  645-­‐656.	  
	  
Schaafsma,	   W.,	   Bozal-­‐Basterra,	   L.,	   Jacobs,	   S.,	   Brouwer,	   N.,	   Meerlo,	   P.,	   Schaafsma,	   A.,	  
Bodekke,	   E.W.G.M.,	   Eggen,	   B.	   J.	   L.	   (2017).	   Maternal	   inflammation	   induces	   immune	  
activation	  of	  fetal	  microglia	  and	  leads	  to	  disrupted	  microglia	  immune	  responses,	  behavior,	  
and	  learning	  performance	  in	  adulthood.	  Neurobiology	  of	  disease	  (106),	  291-­‐300.	  
	  
Leadership	  experience	  	  
1.	  Supervised	  Master	  Thesis:	  
(2016)	  E.	  Gabikagogeascoa	  	  
(2017)	  M.	  González,	  	  
2.	  Supervised	  Bachelor	  of	  Science	  Thesis	  from:	  	  
(2018)	  A.	  Cenigaonandia.	  
3.	  Supervised	  tecnician	  trainee	  from:	  	  
(2015)	  A.	  Fernández,	  	  
4.	  Supervised	  Erasmus	  internship	  from:	  	  
(2016)	  K.A.	  Haly	  
(2016)	  A.	  de	  Luca.	  
	  
Contributions	  to	  Congresses	  
2/5-­‐10-­‐2016.	  Cilia	  2018,	  EMBO	  workshop,	  Copenhagen,	  Denmark.	  	  
24-­‐27/10/2017.	  1st	  Joint	  Meeting	  SEDB,	  SEG,	  SEBC,	  Gijón.	  Poster	  presentation.	  	  
4/7-­‐10-­‐2016.	  Cilia	  2016,	  EMBO,	  Amsterdam,	  The	  Netherlands.	  Poster	  presentation.	  
10-­‐2013.	   8th	   International	   Conference	   on	   Neural	   Tube	   Defects,	   Austin,	   USA.	   Poster	  
presentation.	  




9/2012-­‐Currently.	  Professional	  winemaker,	  La	  Rioja,	  Spain.	  	  
1/2006-­‐Currently.	   Secretary	   of	   the	   Valjoven	   Young	   Association	   to	   promote	   cultural	  


















	   	  
216	  
